Cytokine mediated CD4+ T-cell dysregulation in early rheumatoid arthritis by Ridgley, Laura Alice
1 
 
Cytokine mediated CD4+ T-cell dysregulation in 
early rheumatoid arthritis  
 
Thesis for the degree of Doctor of Philosophy 
 
 
Laura Alice Ridgley 
Musculoskeletal Research Group,  
Institute of Cellular Medicine,  
Faculty of Medical Sciences, 
 Newcastle University 
 
Supervised by: 
Dr Arthur Pratt 
Dr Amy Anderson  
Dr Ruaidhrí Carmody 
Professor David Young 
Professor John Isaacs 
 
September 2018 
 
 
 
2 
 
 
 
i 
 
Abstract 
 
Background 
A 12-gene signature in CD4+ T-cells had discriminatory utility for early rheumatoid arthritis 
(RA) patients compared with disease controls. This signature is enriched for STAT-3 target 
genes whose expression correlates with paired circulating IL-6. I hypothesise that pre-exposure 
of CD4+ T-cells to IL-6 mediates STAT-3 activation and aberrant effector function following 
T-cell receptor (TCR) stimulation, providing a mechanism of antigen non-specific immune 
dysfunction in early RA.  
Methods 
A model for cytokine pre-exposure was developed, in which naïve (CD45RA+) and antigen 
experienced (CD45RA-) CD4+ T-cells from healthy human donors were cultured with IL-6 and 
equimolar soluble IL-6R for 3 days, before being washed and stimulated with anti-CD3 and 
anti-CD28 for 6 days. RNA was extracted at multiple experimental time-points and global gene 
expression profiling undertaken. Phenotype and proliferation were assessed by flow cytometry, 
measuring cell surface markers and proliferation dyes. Whether the observed consequences of 
IL-6 pre-exposure reflected transcriptional and phenotypic characteristics of CD4+ T-cells 
isolated from patients with early RA was explored.  
Results 
The effects of IL-6 pre-exposure were seen most prominently in naïve CD4+ T-cells, potentially 
related to IL-6 receptor expression. Pre-exposure of healthy control naïve CD4+ T-cells to 
physiological levels of IL-6 caused significant STAT-3 target gene induction, mirroring genes 
previously found to distinguish RA patients from disease controls. Following TCR-stimulation, 
a distinctive set of genes differentially expressed in IL-6 pre-exposed cells were associated with 
to cell proliferation and survival. This is consistent with altered effector phenotype of IL-6 pre-
exposed cells characterised by dose-dependent enhancement in activation and proliferative 
capacity. CD4+ T-cells from early RA patients showed no difference in proliferation compared 
to healthy controls, although our group has observed that a higher proportion are committed to 
the cell cycle as measured by ki67 expression. 
Conclusion 
These findings highlight that cytokine “pre-priming” during the early disease state may have 
consequences for naïve CD4+ T-cell effector function, impacting the transition to disease 
chronicity in early RA.  
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Chapter 1. Introduction 
 
1.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease in which painful and persistent 
synovial inflammation in symmetrically distributed small joints typically results in tissue 
damage and disability. Although sometimes termed an autoimmune disease, no disease specific 
auto-antigen explains the observed immune dysregulation and the cause of peripheral tolerance 
breakdown is not yet understood (1).  
1.1.1 Epidemiology and Heterogeneity 
RA is the most common inflammatory joint disease in humans with a population prevalence of 
0.5-1.1% and a mean annual occurrence of 0.02-0.05% (2). In several populations, including 
the UK, there is an apparent decline in RA prevalence and incidence (3). The peak incidence 
occurs between the ages of 40 and 50 and occurs more frequently in women compared to men 
with a sex ratio of between 2:1 and 3:1 (3).  
Patients with RA have an increased risk of co-morbidities with cardiovascular disease, 
myocardial infarctions and bacterial, fungal and viral infection rates disproportionately 
increased in RA (4). This ultimately influences quality of life and increases mortality. Timely 
treatment may reduce disease activity as well as incidence of comorbidities. Furthermore, 
delays in the diagnosis and treatment of RA results in adverse outcomes with studies showing 
that a high level of joint damage occurs within the first year of disease onset (5). This period is 
often described as a window of opportunity in which early treatment results in better response 
(6-8). For this reason, there is continued investigation into the discovery of biomarkers that can 
be used to predict disease – particularly in the substantial proportion of patients attending an 
early arthritis clinic with unclassifiable “undifferentiated” inflammatory arthritis. 
The clinical presentation of RA is very heterogeneous, posing challenge to clinicians seeking 
early diagnosis and effective treatment (9).  For example, it is becoming increasingly clear that 
the disease can be categorised into at least 2 subgroups, seropositive or seronegative, depending 
on the presence or absence of circulating autoantibodies respectively, but even within these sub-
populations, a high degree of variability remains (10).  
The natural history of seronegative RA progression differs from that of seropositive disease 
with late and explosive onset being well documented (10). The proportion of RA patients who 
are seronegative is now estimated to be around 0.22 (11).  
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It is increasingly being understood that heterogeneity of the disease extends beyond serotype 
and clinical presentation to include synovial pathology and treatment responsiveness. A lower 
rate of joint destruction has been documented in seronegative disease with lower levels of 
lymphocyte infiltration and lower levels of T-cell derived pro-inflammatory cytokines in 
synovial fluid (SF) (12, 13). Some treatments have demonstrated increased efficacy in 
seropositive individuals, which may reflect the differences in pathology (14, 15). This suggests 
a wide range of molecular and cellular mechanisms contribute to pathology, and these are likely 
to be distinct but slightly overlapping in the RA serotypes underlying the differences seen 
between the two subgroups.  
1.1.2 Genetic Factors Influencing RA 
Genetics has long been known to play an important role in the development of RA. Twin studies 
highlight the role of genetics with concordance among monozygotic twins around 15-30% 
compared to 3.6% for dizygotic twins (16, 17). The heritability of RA has been estimated to be 
60% for seropositive disease but the heritability of seronegative disease is thought to be much 
less (18, 19).  
The region of the genome on chromosome 6 encoding the major histocompatibility complex 
(MHC), involved in the process of antigen presentation, has been shown to have strong 
associations with RA (20). This region encodes MHC class I molecules such as human 
leukocyte antigen (HLA)-A, HLA-B and HLA-C recognised by cluster of differentiation 8 
(CD8+) T-cells and MHC class II molecules encoding HLA-DR, HLA-DQ, HLA-DP 
recognised by CD4+ T-cells. A strong genetic association can be seen with the HLA-DR alleles 
with over 80% of RA patients carrying variants of the HLA-DRB1*04 alleles (21). HLA risk 
alleles across 3 loci encode a common 5-amino acid sequence within the hypervariable region 
of MHC II, which is the site of the peptide binding groove important for antigen binding and 
presentation to CD4+ T-cells, these explain the majority of the HLA association to RA (22). 
These sets of alleles are known as the “shared epitope” (SE) and confer susceptibility to RA 
and increase disease severity with odds ratios (OR) of 4.37 for heterozygotes and 11.79 for 
homozygotes (23-25). Although many variants of the DRB1 allele confer susceptibility others 
have also been shown to confer protection against RA, namely HLA-DRB1*13 (26). The SE is 
particularly associated with seropositive disease, which may be due to an increased ability of 
citrullinated peptides to bind HLA (27, 28). It is now suggested HLA-DRB1 alleles provide the 
basis for the development of self-recognising auto-reactive T-cells that respond to anti-cyclic 
citrullinated peptide (CCP) formation (29). Conversely, in seronegative disease the HLA region 
confers relatively little risk, although the DRB1*13 allele conferring protection from 
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seropositive disease has been shown to work in combination with DRB*03 to increase the 
susceptibility of seronegative disease (30).  
The HLA region accounts for only around a third of the genetic contribution to RA meaning 
there are many more associations in other parts of the genome (31). Genome wide association 
studies (GWAS) confirm the association of HLA-DRB1 and protein tyrosine phoshphatase-22 
(PTPN22), which together explain 50% of familial aggregation (32). The association of 
PTPN22 involves a missense substitution of arginine to tryptophan at residue 620, R620W, 
which results in enhanced regulation of CD4+ lymphocyte T-cell receptor (TCR) signalling 
resulting in the presence of auto-reactive T-cells in the periphery (33, 34).  
Further associations with non-HLA regions of the genome have been discovered including 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and signal transducer and activation of 
transcription-4 (STAT-4) (35, 36). CTLA-4 is a CD28 homologue found on the surface of T-
cells involved in down-regulating T-cell co-stimulation and activation. One of the most studied 
polymorphisms involves the substitution of threonine to alanine at position 49, T49A, which 
results in incomplete glycosylation and lower surface levels (37). STAT-4 is a transcription 
factor activated by interleukin-12 (IL-12) and IL-23 signalling, and a haplotype of this gene has 
been associated with susceptibility to RA. This molecule can activate interferon-γ (IFN-γ) genes 
which play a key role in T-cell differentiation (36, 38, 39).  
Many of the non-MHC risk alleles identified are associated with seropositive disease, in 
contrast, for seronegative disease only 15 non-MHC risk alleles have been identified including 
ankyrin repeat domain 55 (ANKRD55) and B lymphocyte kinase (BLK) with OR of 0.8 and 
0.13, resulting in protective effects or increased risk, respectively. This highlights the 
genetically distinct nature of these diseases (10). 
The total number of disease associated SNPs now stands at 101 and a disproportionate number 
of these are found at loci containing genes whose products are involved in T-cell function (40). 
Many of these SNPs overlap with CD4+ T-cell specific chromatin marks providing evidence of 
the importance of CD4+ T-cells in RA pathogenesis (41). Although risk conferred by these 
disease associated SNPs alone is small, presence of a number of these loci may confer higher 
risk. Most likely, the development of RA will come from a combination of both genes and 
environmental factors.  
1.1.3 Environmental Influences 
The most prominent environmental influence on the development of RA is smoking (42). The 
increased amount and duration of smoking has been shown to cause dose-dependent increased 
4 
 
risk of RA (43, 44). The influence of smoking is restricted to seropositive RA and is much 
greater in males compared to females with smoking increasing male OR from 1.89 to 3.02 (45-
47). Smoking causes multiplicative risk in individuals with HLA-DRB1 alleles with a dose 
effect with the number of risk alleles. In contrast, the consumption of alcohol has been described 
to have a protective influence on the development of seropositive RA with one study showing 
the highest level of alcohol consumption resulted in half the risk of disease (48).  
An environmental factor heavily linked to the development of seronegative RA is obesity. A 
body mass index (BMI) of over 30 for the decade prior to RA onset causes triple the risk of 
developing disease with an OR of 3.45 (49). Many other environmental influences have been 
described as contributing to the risk of developing RA; however, these have much less 
supporting evidence. For example, oral contraceptive use, high levels of vitamin D intake and 
previous blood transfusions have all been shown to both increase and decrease risk of RA (50).  
It is now generally believed that genetics pre-dispose towards RA but an environmental factor 
may play an important role in triggering disease, although the relative importance of these 
factors is likely to differ between seropositive and seronegative disease. For example, in 
seropositive disease it is likely that environmental factors influence citrullination and the HLA 
association confers the risk of mature autoantibody response.  
1.1.4 Role of the Immune System in RA 
The synovium is the layer of connective tissue that lines the inner surface of diarthrodial joints. 
The synovium consists of two layers: the underlying tissue, the subintima, and the continuous 
layer of surface cells, the intima. These synovial lining cells consist of fibroblast-like and 
macrophage-like synoviocytes, which maintain the composition of the SF filling the joint 
cavity. This SF provides an important source of nutrition for cartilage by transporting 
substances such as oxygen, glucose, proteinases and collagenases and provides lubrication to 
reduce friction between cartilage during movement.  
RA is characterised by inflammation of the synovium beginning with hypertrophy of the 
synovial lining with proliferation of fibroblast-like and macrophage-like synoviocytes (1). 
Concurrently, angiogenesis and infiltration by inflammatory cells occur. The result of this 
infiltration is the formation of the pannus, a leading edge of invasive tissue comprising 
proliferating synovial fibroblasts and inflammatory cells. As a result of pro-inflammatory 
cytokine release by this tissue, including IL-1, tumour necrosis factor (TNF) and matrix 
metalloproteinases (MMPs), other proteolytic enzymes are released by chondrocytes causing 
matrix destruction and osteoclast activation leads to bone degradation, Figure 1 (51). The 
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pathogenesis of RA is still not fully understood but cannot solely be attributed to one cell type 
or pathway. It is likely that the contribution of different immune cell subsets to pathogenesis 
varies between individuals.  
1.1.4.1 Antigen presenting cells 
Dendritic cells (DC) are professional antigen presenting cells (APCs) that present antigen via 
the MHC class II, hence are implicated in RA pathogenesis by the shared epitope association. 
DC infiltration occurs early in RA pathology with high numbers found in SF and synovial tissue 
(ST) (52). DCs are also highly abundant in T-cell clusters and their high levels of MHC class 
II and costimulatory molecules stimulate T-cell responses and perpetuate inflammation (52). 
Current therapy in RA methotrexate (MTX) has also been shown to alter the number and 
function of mature DCs (53). 
1.1.4.2 B-cells and Autoantibodies  
Due to the presence of autoantibodies, B-cells have long been thought to play a role in RA 
pathogenesis as antibodies against citrullinated proteins have been shown to amplify tissue 
injury (54). Further evidence for a role for B-cells in RA is the presence of germinal centre 
Figure 1. Healthy joint versus RA joint. In rheumatoid arthritis there is hypertrophy of 
synovial lining, influx of inflammatory cells into the synovial membrane and 
proinflammatory cytokine release. These factors then lead to the destruction cartilage and 
bone.  
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(GC) like structures in the inflamed synovium in around 30-50% of patients (55). B-cells in 
these GCs act as APCs to CD4+ T-cells perpetuating immune responses (56-58). Moreover, the 
depletion of B-cells has been successful in the treatment of RA, with reduced radiographic 
progression and improvements in disease activity score 28 (DAS28) scores, with a higher 
efficacy in seropositive RA (59, 60). 
Evidence that activation of the adaptive immune system by “self” antigens drives arthritis in 
RA is well-established; for example autologous SF induces proliferation of T-cell clones 
isolated from joints of affected patients (61). Although RA has been termed an autoimmune 
disease, many studies have failed to link tissue specific antigens, such as type 2 collagen, 
cartilage protein glycoprotein 39 (gp39) and proteoglycans, to the disease (62-64). 
Autoantibodies however, have been associated with RA such as anti-citrullinated peptide 
antibody (ACPA) and rheumatoid factor (RF) (65).  
Presence of ACPA are over 95% specific for RA and are found in less than 2% of healthy 
individuals (66). ACPA recognise post-translationally modified (citrullinated) epitopes such as 
on fibrogen, fibrinogen, vimentin, histones and collagen. Citrullination occurs naturally in the 
body as a result of peptidyl arginine deaminase dependent conversion of arginine to citrulline 
(67). The presence of ACPAs towards these citrulline residues has been shown to predict a 
worse clinical outcome with promotion of bone erosion by activation of osteoclasts, and in 
mouse models, these molecules have been shown to induce pain and enhance synovitis (54, 68, 
69).  
The presence of RF is closely linked to RA with 74% specificity, however, can be found in 
other autoimmune diseases such as Sjögren’s syndrome (SS), osteoarthritis (OA) and chronic 
infections, limiting the specificity of this autoantibody, although it is still used to aid diagnosis 
(70). This autoantibody recognises fragment crystallisation (Fc) segments of immunoglobulin 
G (IgG) molecules creating crosslinks resulting in the formation of immune complexes which 
can trigger complement activation (71). This innate response activates inflammation, lysis and 
immune clearance enhancing antigen presentation so is thought to play a role in disease 
pathogenesis (72, 73). 
The presence of ACPA and RF autoantibodies frequently predates clinical onset of disease, and 
predicts a more severe form of disease with higher rate of joint destruction (65, 74, 75). Despite 
the use of ACPA autoantibodies in RA diagnosis the absence of both autoantibody classes, 
termed seronegative or RF/ACPA-negative RA, accounts for about 20% of the overall disease 
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spectrum. The absence of autoantibodies contributes to diagnostic delays in this group, which 
may also be subject to sub-optimal treatment responses (76).  
1.1.4.3 T-cells 
T-lymphocytes are key mediators of cellular responses and recognise antigen presented on the 
surface of antigen presenting cells such as DCs by the MHC, via their TCR.  
These cells are derived from hematopoietic stem cells in the bone marrow and migrate to the 
thymus where they are able to mature from double negative cells, which do not express the CD3 
T-cell receptor (TCR) or CD4/CD8, into T-cells expressing combinations of CD3, CD4 and 
CD8. The interactions with MHC molecules helps to shape the TCR repertoire and surface 
molecule expression by determining whether these cells are single positive cells expressing 
CD3+ and either CD4+ or CD8+, with CD8+ T-cells recognising MHC class I and CD4+ T-cells 
recognising MHC class II (77). The TCR consists of αβ or γδ chains bonded with five subunits 
of CD3. Gene rearrangements between variable, diversity and joining (V-D-J) genes generates 
a diverse repertoire of TCR unique to individual cells (78).  
The microenvironment of the thymus is crucial for the generation of functional T-cells. The 
expression of self-antigens by medullary thymic epithelial cells (mTEC), regulated by the 
expression of autoimmune regulator (Aire) and FEZ family zinc finger 2 (FEZF2), promote 
tissue specific antigen expression to educate T-cells for the elimination of auto-reactive T-cells 
(79). During maturation in the thymus, T-cells undergo positive and negative selection, in the 
cortex and medulla respectively. During positive selection, T-cells that fail to recognise self-
MHC molecules are deleted. Those cells recognising self-MHC next undergo negative 
selection, where cells with strong responses to self-antigens are deleted, and those with 
intermediate TCR affinity are selected (78).  
T-cells are strongly implicated in RA pathogenesis with the high abundance of CD4+ and CD8+ 
lymphocytes in the synovium of RA patients (12, 80, 81). Due to the focus of this thesis, CD4+ 
T-cells will be dealt with in more detail in Chapter 1.2.  
CD8+ T-cells are also known as cytotoxic T-cells as these cells are responsible for the killing 
of pathogenic cells via the release of cytotoxins such as perforin and granzymes. CD8+ T-cells 
make up 40% of all T-cells in the SF and play a crucial role in the formation of germinal centres 
in the synovium (82). The role of CD8+ T-cells in the pathogenesis of RA is poorly understood, 
however, it has been documented that peripheral blood CD8+ T-cells from RA patients appear 
to have an increased proportion of central memory cells and increased numbers of regulatory 
T-cells which appear to correlate with DAS28 (83, 84).  
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1.2 CD4+ T-cells 
Following thymic development, naïve CD4+ T-cells enter the circulation and are maintained by 
low affinity interaction of TCR with self-antigen. These cells can be identified by the expression 
of CD45RA, a molecule involved in cell signalling, which is alternatively spliced to CD45RO 
following T-cell activation. Naïve cells migrate towards secondary lymphoid organs (SLOs) 
such as lymph nodes, spleen and tonsils, due to expression of lymph node homing receptors 
such as CD62L and C-C chemokine receptor type 7 (CCR7), where APCs can display antigen 
via the MHC class II to induce an adaptive response. In addition to the TCR-MHC interaction, 
additional signals are required for T-cell activation including co-stimulation, where CD28 on 
CD4+ T-cells interact with CD80/CD86 on APCs and signals from cytokines in the surrounding 
environment (85, 86).  
Activated cells will then proliferate, differentiate and leave the SLOs as effector cells. T-cells 
will divide to produce identical progeny, termed clonal expansion (87). The type of effector cell 
generated depends on the concentration of antigen, number of costimulatory molecules 
involved, cytokines present during stimulation and the DC subset (88-90).  
Different subsets of T-helper cells can be differentiated which provide signals to B-cells for 
maturation, maintain CD8 responses and regulate innate effector cells. These T-helper subsets, 
which include but are not limited to Th1, Th2, Th17 and Treg, can be generated following 
activation by the TCR, and are determined by the activation of certain transcription factors 
including T-box expressed in T-cells (T-bet), GATA binding protein-3 (GATA-3), RAR-
related orphan receptor gamma (ROR-γt) and forkhead box P3 (Foxp3), respectively (78). The 
strength of the TCR signal is also an important regulator of cell differentiation (91, 92). Post-
translational modifications are able to influence the TCR signal strength, for example, 
citrullination enhances the production of a pathogenic form of helper cell, Th17 cells, through 
a low TCR signal (93). However, if the TCR is activated without the presence of co-stimulatory 
signals this will lead to the induction of tolerance via clonal anergy (94). After carrying out 
effector functions these cells will then undergo apoptosis to bring around homeostasis (95). 
Some of the activated T-cells will go on to be memory T-cells which can last up to 20 years. 
These quiescent cells circulate the body but have the ability to rapidly respond to previously 
encountered antigen. These cells are heterogeneous and there are two key populations with 
different migratory and effector capacity, central memory (TCM) and effector memory (TEM). It 
is now thought the amount and type of cytokine present and length of stimulation determines 
the outcome of effector or central memory T-cells. TEM have rapid effector function and reside 
in tissues whereas TCM reside in lymph nodes with little effector function but can rapidly 
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differentiate into effector cells (Teff) (96). Memory cells are characterised by the 
downregulation of CD45RA with the simultaneous upregulation of CD45RO. TCM and TEM can 
be further identified by the differential expression of CD62L, which is expressed only on TCM 
as it is required to aid migration.  
1.2.1 Evidence of CD4+ T-cell Involvement in RA Pathogenesis 
There is strong evidence suggesting that CD4+ T-cells play a crucial role in RA pathogenesis. 
The RA synovium has a high abundance of both CD4+ and CD8+ T-cells with a predominantly 
activated phenotype (80, 81, 97, 98). CD4+ T-cells can be found in high numbers in GCs and 
their presence depends on B-cell help (99). The level of infiltrating lymphocytes has been found 
to be higher in seropositive compared to seronegative disease though examination of the 
number of CD4+ T-cells in peripheral blood revealed no difference between the two disease 
groups (100, 101). The GCs in these patients were also shown to be less fibrotic and with a 
thinner synovial lining in seropositive disease. 
The ability of T-cells to recognise autoantigens has long cemented their role in disease 
pathogenesis. Although no disease specific autoantigen has been discovered T-cells have been 
shown to activate in an antigen-specific manner to CII, gp39 and heat shock proteins (63, 102). 
The clonal expansion of identical TCRs found in distinct joints suggests a role for these in 
disease mediation (103).  
Circulating CD4+ T-cells present in RA patients have been shown to have a highly altered 
phenotype compared to healthy controls. They have a high number of memory cells present in 
the joint but have also been shown to have a population of terminally differentiated cells 
(TEMRA) which are both CD45RA+ and CD45RO+ (104). CD4+ T-cells have also been shown to 
have increased expression of cell surface makers programme cell death protein 1 (PD-1), CD25, 
CTLA4 and decreased CD69, OX40 and IL-2 (105). These cells have a markedly contracted 
TCR repertoire with high abundance of or absence of certain TCR-β chains and this has been 
shown to occur even at the earliest stages of disease (106). This occurs in both the naïve and 
memory cell repertoire suggesting defects in the generation of these cells. The analysis of T-
cell receptor excision circles (TRECs) in RA reveals a decreased number compared to healthy 
controls. (107, 108). TRECs are small circles of deoxyribonucleic acid (DNA) which occur 
during TCR gene rearrangement in the thymus. TRECs are only present in T-cells which have 
come from the thymus and hence are diluted as a consequence of T-cell proliferation during 
memory formation or naïve homeostatic proliferation (109). This provides further evidence of 
diminished thymic production or increased cell turnover in RA.  
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The homeostatic expansion of circulating naïve CD4+ T-cells, evidenced by diminished TREC, 
in the wake of thymic dysfunction may be responsible for premature aging of T-cells in RA, 
demonstrated by the decreased length of telomeres in these cells, most prominent in naïve CD4+ 
T-cells (106, 110). This suggests an increase in replication of these cells occurring very early 
in disease, even potentially pre-dating disease onset (107). Despite the suggested increased 
replication of these cells in RA, telomere length does not correlate with disease duration.  
Despite the activated phenotype and their ability to respond to previous stimulation, many 
studies have shown that CD4+ T-cells isolated from RA patients have reduced proliferation in 
response to stimulation. Hypo-responsiveness can also be seen in response to 
phytohaemagglutinin (PHA) and anti-CD3 and anti-CD28 stimulation with both a decrease in 
the number of responsive cells and a decrease in the magnitude of response (111). Proliferation 
of RA CD4+ T-cells is also impaired in response to autologous APCs, which could be partially 
restored by IL-2 (112, 113). Many of the observations of diminished responses to stimulus 
amongst RA CD4+ T-cells have been made in the context of established disease. One study has 
reported that undifferentiated arthritis (UA) patients who progress to RA display decreased 
numbers of cells dividing and a decreased number of cell divisions compared to UA patients 
who progress to non-RA diseases (114). Furthermore, synovial memory cells have impaired 
response to mitogen stimulation compared to peripheral blood cells (115). Expression of the 
TCR was found to be unaltered in RA, however, it was seen that cells had impaired Ca2+ 
responses indicating defects in downstream signalling which was attributed to decreased 
tyrosine phosphorylation of TCR-ζ chain (116-118). Furthermore, RA CD4+ T-cells have been 
shown to be resistant to apoptosis resulting in the perpetuation of these cells in the joints (119, 
120).  
Despite the hypo-proliferative phenotype of CD4+ T-cells documented in RA, many other 
studies have in fact shown that these cells appear to be hyper-proliferative and committed to 
pro-inflammatory effector lineages. In particular, naïve CD4+ T-cells have been shown to be 
dysregulated in RA, with a shift in glucose metabolism from glycolysis to the pentose phosphate 
pathway leading to lower levels of ATP, lactate and intracellular ROS in addition to insufficient 
activation of cell cycle kinase ATM (121). These features also result in a bias towards 
inflammatory Th1 and Th17 lineages and promotion of pro-inflammatory properties of T-cells 
(122). On the other hand, memory CD4+ T-cell hyper-activation has been documented to be 
due to CD147 expression and other features of CD4+ T-cells in RA include increased 
susceptibility to apoptosis and autophagy-deficiency (123, 124).  
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1.2.2 Roles of CD4+ T-helper cells in RA 
CD4+ T-cells are important cells of the immune system that provide a “bridge” between innate 
and adaptive immunity. Differentiation of naïve CD4+ T-cells occurs following stimulation via 
the TCR, by cognate antigen presentation via the MHC and co-stimulation by APCs, and is 
greatly influenced by the presence of APC-derived cytokines. This results in activation of STAT 
signalling pathways, leading to changes in the chromatin of subset specific transcription factors 
including T-bet, GATA-3, ROR-γt and Foxp3 resulting in the differentiation of Th1, Th2, Th17 
and regulatory T-cells (Tregs) respectively, summarised in Figure 2 (78). These master 
transcription factors can then exert control over transcriptional programs by modifying 
chromatin structure. The duration of antigenic stimulation and strength of TCR signal 
determines the outcome of effector T-cells (89, 125).  
 
1.2.2.1 RA as a Th1-mediated disease 
RA was originally thought to be a Th1 mediated disease due to the high levels of IFN-γ detected 
in the synovial joints of established RA (126, 127). IFN-γ is the predominant cytokine produced 
by Th1 cells whose major role is in the cytotoxic response to extracellular bacteria. The majority 
of T-cell clones from the RA synovial membrane have been shown to represent Th1 cells and 
Figure 2. Overview of CD4+ T-helper subsets. Naïve CD4+ T-cells are able to differentiate 
into a number of T-helper subsets in the presence of particular cytokines and can be identified 
by their expression of master transcription factors and their production of cytokines.  
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are very stable with high levels of IFN-γ production (128). In contrast, the Th2 clones found 
were unstable and readily returned to the Th0 phenotype (129). Despite increased IFN-γ in the 
joints the production of this cytokine from peripheral T-cells of RA patients was shown to be 
reduced compared to healthy controls indicating that in contributing to synovial inflammation 
Th1 cells may become depleted from peripheral blood (130).  
Other studies also point to blunted Th2 responses in established RA (131). Th2 cells are the key 
cell type directed against extracellular parasites by the production of IL-4, IL-5 and IL-13. T-
cell clones from RA patients do not produce IL-4 on antigen challenge and RA CD4+ T-cells 
seem to have impaired Th2 differentiation under polarising conditions (132). The apparent 
imbalance in the Th1:Th2 ratio has been shown to correlate with disease activity, which is most 
prominent in early disease (127).  
The fact that pregnancy, itself associated with muted Th1 immunity, leads to improved 
symptoms of RA in around 75% of patients (with up to 90% relapsing within 6 months post-
partum (133)), has been invoked as further support for the concept of RA as a Th1 mediated 
disease. Those with allergic diseases also have reduced incidence of RA, which may be 
associated with the increased Th2 responses in these diseases, suggesting a possible beneficial 
role of Th2 cells (134). Further support for the protective role of Th2 responses in RA comes 
from the study of helminth infections, which have been shown to lead to the inhibition of 
autoimmune arthritis in two independent mouse models. This protective effect was shown to be 
dependent upon the presence of Th2 cells and specifically the IL-4 and IL-13 mediated STAT-
6 pathway (135). 
Some studies of RA have shown there is a predominance of Th2 related cytokines, including 
IL-2, IL-4, IL-13, IL-17 and IL-15, expressed by synovial T-cells in the earliest stages of 
disease whereas established disease is characterised by the presence of IFN-γ, TNF-α and IL-
10 but low levels or absence of IL-2, IL-4, IL-5 and IL-13 (136). This may reflect the promotion 
of autoantibody production early in the disease. It is not clear whether this transient Th2 
response in early disease represents a failed attempt at regulation or is merely a reflection of 
humoral immunity driving epitope spreading of autoantibodies. Despite the high levels of IFN-
γ reported in the SF of new-onset RA patients the levels of IFN-γ in peripheral blood 
mononuclear cells (PBMC) from active RA patients have been shown by others to only reach 
significance with high DAS28, suggesting Th1 cells play a role late in the progression of RA 
(137). This indicates the transition to chronicity may occur during the switch from Th2 to Th1 
predominance.  
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1.2.2.2 RA as a Th17-driven disease 
Following the discovery of the Th1 and Th2 subsets a further subset of pro-inflammatory CD4+ 
T-cells were identified, Th17 cells. These cells defend the body from extracellular bacteria and 
are characterised by the production of IL-17, which has been shown to be elevated in a number 
of autoimmune diseases including RA. IL-17 can be detected in high levels in SF and ST along 
with high expression of its receptors (138-140). The overexpression of IL-17 has been shown 
to exacerbate joint destruction through its ability to promote the production of IL-1 and TNF-α 
from monocytes and production of IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF) 
and MMPs from fibroblasts (141, 142). This cytokine also induces the production of receptor 
activator of nuclear factor kappa B ligand (RANKL) promoting local inflammation and 
exacerbating joint destruction (139).  Despite the high frequency of IL-17, the frequency of 
Th17 cells have been reported to be unaltered in RA (143). However, others have shown 
increased Th17 cells in peripheral blood of RA across all stages of disease suggesting its 
importance in RA progression (137). These controversies, along with disappointing results of 
clinical trials of drugs such as ustekinumab and secukinumab (targeting the IL-23/IL-17 “axis”) 
have tempered early enthusiasm for the notion of RA as a Th17-mediated disease (144, 145). It 
is now thought that the IL-23/IL-17 axis is particularly important prior to RA onset, in the pre-
articular phase of disease, with mouse models showing that the IL-23 dependent activation of 
Th17 cells resulted in the regulation of the glycosylation profiles of plasma cells, mirrored in 
individuals with circulating autoantibodies prior to arthritis development (146). This suggests 
a more prominent role for this axis in pre-RA, in particular in the development of seropositive 
disease.  
1.2.2.3 A role for regulatory T-cell dysregulation in RA pathogenesis 
Recently CD4+ T-cells with the capacity to inhibit and downregulate immune responses have 
been identified. These regulatory T-cells, termed Treg cells, have been heavily studied in the 
context of autoimmune disease as loss of immunological tolerance may result from the failure 
of these cells to control autoreactive T-cell responses. These cells are CD25+ Foxp3+ and make 
up somewhere between 5-15% of all CD4+ T-cells in healthy peripheral blood (147), and have 
suppressive effects on the proliferation and cytokine production of effector T-cells (Teff). 
Despite a low proliferative capacity in vitro (148, 149) these cells have been shown to be highly 
proliferative in vivo (150).  
On first inspection of these cells it was seen that frequency is related to disease activity, 
however, further investigation into the abundance of these cells in the circulation reveals 
inconsistent findings with some showing increased frequency and others showing decreased or 
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similar frequencies (151-153). Despite these inconsistencies, it appears Treg cells are elevated 
in inflamed ST and SF compared to peripheral blood in RA, suggesting recruitment to the joint 
(152, 154). As these cells are not consistently decreased in RA, it was suggested instead that 
these cells had impaired function in RA (155). This was shown not to be the case and in fact, 
synovial Tregs have been noted to have increased suppressive abilities compared to peripheral 
blood (156). As no defects in Treg frequency and function have been confirmed early hints 
indicate that there may be a role instead for Teff resistance to Treg suppression, with studies 
showing that certain cytokines, such as IL-2, IL-7 and TNF, are able to abrogate Treg 
suppression in established chronic RA (157, 158). The abrogation of Treg suppression induced 
by TNF occurs despite the ability of monocyte bound TNF to expand functional Treg cells 
enhancing the regulatory properties of this cytokine (159).  
1.2.2.4 Additional T-helper subsets in RA 
Further subsets of CD4+ T-helper cells have now been identified including T-follicular helper 
(Tfh), Th9 and Th22 cells.  
Tfh cells develop from naïve CD4+ T-cells and high affinity TCR interaction and have the 
capacity to regulate survival, proliferation, affinity maturation and differentiation of B-cells 
(160). Due to their crucial role in B-cell responses, these cells are present in high numbers in 
lymphoid tissue and aid in the formation and maintenance of GCs. These cells are characterised 
by the expression of C-X-C Motif Chemokine Receptor 5 (CXCR5), Inducible T-cell co-
stimulator (ICOS), CD40L and PD-1 and by the production of IL-21, which have all been 
described to play roles in B-cell function and GC formation (161). Differentiation of these cells 
is promoted by IL-6 and IL-21 signalling in a STAT-3 dependent manner and these cytokines 
have been shown to induce the master transcription factor BCL-6 (162, 163). More recently it 
has also been shown that BCL-3, a gene highly expressed in RA patients and shown to be 
upregulated by IL-6 signalling, plays a role in development of Tfh cells by the upregulation of 
BCL-6 (164). 
The presence of Tfh cells has been suggested as a biomarker for many diseases including RA, 
multiple sclerosis (MS), systemic lupus erythematosus (SLE), inflammatory bowel disease 
(IBD) and type 1 diabetes (T1D) (165). Increased frequency of circulating Tfh in the peripheral 
blood of RA has been documented and this level positively correlated with presence of anti-
CCP antibody (166). Further evidence of their role in disease comes as IL-21-/- deficient mice 
develop less severe spontaneous arthritis in the K/BxN model, with a reduced number of Tfh 
cells (167).  
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Th9 cells appear to play a role supplementary to Th2 against extracellular infections. A role for 
Th9 cells in inflammatory diseases such as experimental autoimmune encephalomyelitis (EAE) 
and IBD has been suggested, however, their role in rheumatic disease is unknown, with a 
possible role in T-cell dependent B-cell differentiation and antibody production (168). IL-9, the 
key cytokine of these cells, is increased in RA sera, SF and ST and levels correlate with the 
degree of inflammatory infiltrate (169, 170). IL-9 production by type 2 innate lymphoid cells 
(ILC-2s) has been shown in mouse models of arthritis to be crucial in cartilage destruction and 
bone loss. However, others have shown that the treatment of mice with this cytokine in chronic 
arthritis resulted in the resolution of inflammation, providing evidence that IL-9 may have a 
dichotomous role in different phases of disease. This suggests a novel therapeutic approach in 
the treatment of RA, where patients with active RA exhibit high levels of IL-9 producing ILC2s 
(171).  Th22 cells produce IL-22 whose receptor is restricted to stromal cells, implicating Th22 
cells in the interaction between the immune system and non-hematopoietic cells (172). Th22 
responses show many similarities with the Th17 response and their increased presence in RA 
has been positively correlated with the levels of Th17 cells, however, so far no pathologic 
associations of Th22 cells with RA have been reported (173).  
1.2.2.5 Plasticity of T-helper cell effector function 
The T-helper cell subsets have been shown to have a considerable degree of plasticity. 
Following stimulation with IFN-γ and to a lesser extent IFN-α upon viral infection Th2 cells 
can be induced to express Th1 transcription factor T-bet, with considerable overlap in their 
cytokine production (174). Th17 cells have a highly transient nature and T-cells with a mixed 
Th1/Th17 phenotype have been detected in the gut of patients with Crohn’s disease (CD), 
reported to arise from modulation by the presence of IL-12 (175). Cells with a Th17/Th2 profile 
have been found in patients with chronic asthma which can be derived by the culture of Th17 
cells with IL-4 (176).  
Treg cells have also been shown to have a degree of plasticity. The Treg transcription factor 
Foxp3 can bind RORα, a transcription factor with complementary roles to ROR-γt in the 
differentiation of Th17 cells, suggesting a common precursor for both subsets and the balance 
of cytokine influences their subsequent differentiation (177). Numerous cytokines have been 
implicated in driving the conversion of Tregs to Th17 cells, including IL-6, transforming 
growth factor-β (TGF-β), IL-21, IL-23, IL-1β, IL-2 (178-180). Tregs which have been induced 
to convert to Th17 cells produce high levels of IL-17 with high expression of ROR-γt, however, 
these cells still have the ability to suppress proliferation (181, 182).  
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Therefore, a simplistic view of differentiated T-helper subsets as rigidly discrete entities is now 
recognised to be unlikely. A more nuanced reality, in which dynamic effector functions of these 
cells are evident over time according to shifting immune contexts, presents challenges in 
investigating the pathogenesis of various autoimmune disorders.  
1.2.3 Mouse Models Implicating CD4+ T-cells in RA 
Mouse models provide a significant contribution to the understanding of the molecular 
mechanisms behind disease pathogenesis. There are numerous models used in the investigation 
of RA including; CIA, antigen induced arthritis (AIA), the SKG mouse and the K/BxN mouse 
(183). Many of these models are notable for their dependence upon T-cells during disease 
initiation and maintenance.  
1.2.3.1 Collagen Induced Arthritis 
The CIA model is the most extensively studied model of autoimmune inflammatory arthritis. 
This uses the immunisation of mice with CII, a protein found in cartilage, in the context of 
adjuvant to induce polyarticular arthritis akin to RA (184). Similarly, as with human RA, 
susceptibility to CIA is also associated with MHC class II, providing strong support for this 
model’s relevance to human disease for the purpose of mechanistic investigation. Humanised 
mice with the alleles DR4 and DQ8 have increased susceptibility to disease (185, 186). The 
elimination of CD4+ T-cells prevents disease and the transfer of these cells to severe combined 
immunodeficient (SCID) mice results in the transfer of disease (187, 188). In contrast to human 
RA, there is no presence of RF and in this model male mice are more susceptible to disease due 
to a protective role of hormones binding estrogen receptors (189).  
The CIA model is predominantly Th1 driven in the pre-arthritic stage of disease, indicated by 
the high levels of IFN-γ production (190). Neutralisation of IFN-γ prior to disease onset has a 
protective role, however, neutralisation late in the disease course exacerbates disease suggesting 
a change in helper cell contribution to pathogenesis as in human RA (191). Th17 cells have also 
been shown to be important in this model with increasing synovial IL-17 mRNA levels as 
disease progresses (192). Knock out (KO) of the IL-17A gene results in a decrease in disease 
incidence and severity while blockade following onset reduced progression and joint damage 
(193). Furthermore, the elimination of Tregs increases disease onset and severity (194). The 
increased number and function of Tregs is associated with disease improvement and resistance 
to disease (195, 196). 
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1.2.3.2 Antigen Induced Arthritis  
Intra-articular injection of mice with methylated bovine serum albumin (BSA) results in the 
induction of inflammatory arthritis in the AIA model. The role of CD4+ T-cells is highlighted 
in this disease as anti-CD4 can ablate disease, with more effect late in the disease (197). 
Blockade of the IL-17 receptor has also been shown to reduce disease severity implicating Th17 
cells in the pathogenesis (198).  
1.2.3.3 Models of Spontaneous Arthritis 
Spontaneous models of RA result from mutations in key genes of the immune system. For 
example, spontaneous arthritis arises in the SKG model as a result of a point mutation in zeta 
chain associated protein kinase 70 (ZAP-70), a key molecule in TCR signal transduction, 
resulting in replacement of tryptophan with cysteine at position 489. This lowers TCR 
signalling and affects the process of selection in the thymus, resulting in the escape of 
autoreactive T-cells (199). This model is characterised by high levels of pro-inflammatory 
cytokines IL-6, IL-1β and TNF-α which can drive Th17 responses (200). The ablation of IL-17 
meant that disease could not be transferred to recombination activating gene 2 (Rag2)-/- mice 
highlighting the dependence of this model on Th17 (201). Treatment with anti-CD4 protects 
against disease induction and progression by decreasing the numbers of Th17 cells and 
increasing the amount of Tregs (202).  
The K/BxN model involves crossing of non-obese diabetic (NOD) mice, which are susceptible 
to autoimmune disease with TCR transgenic mice recognising the autoantigen glucose-6-
phosphate isomerase (GPI) results in spontaneous joint disorder driven by CD4+ T-cells. The 
deletion of IFN-γR and the IL-12p35/IL-12RB2 genes results in reduced levels of arthritis 
indicating a role for Th1 cells in the disease (183). The deletion of Tregs results in faster 
progression of disease with more severe joint destruction highlighting their importance in 
disease models (183, 203). 
Such a large number of arthritis models with wide ranging mechanisms of disease highlights 
the importance of T-cells in the pathogenesis of various models that share the inflammatory 
arthritis phenotype and hence make a compelling case for their contribution to human 
inflammatory arthritis. 
1.2.4 RA Therapies Implicating CD4+ T-cells  
Many therapies used in the treatment of RA have been shown to have significant effects on 
CD4+ T-cell number and function, supporting a role for these cells in disease pathogenesis.  
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Disease modifying anti-rheumatic drugs (DMARDs) are the current first line therapeutics in 
the treatment of RA used to slow disease progression. These act by altering underlying disease 
processes, for example methotrexate (MTX) is an immune suppressant which works by 
inhibiting purine and pyrimidine synthesis ultimately blocking cell proliferation (204). This 
drug has been shown to decrease the production of IFN-γ and IL-2 by PBMC in vitro while 
promoting IL-4 and IL-10 production, modulating the balance between Th1 and Th2 (205). 
Those patients who achieve remission following MTX treatment have been shown to have 
increased frequency of naïve CD4+ T-cells at baseline, a potential biomarker of response (206). 
Other DMARDs have also been shown to affect the Th1-Th2 balance such as Leflunomide and 
Sulfasalazine (SSZ). These drugs inhibit Th1 while promoting Th2 responses with SSZ 
specifically inhibiting the production of IL-12 and IFN-γ while increasing production of IL-4 
(207, 208).  
Despite the efficacy of conventional DMARDs the introduction of biologics, which target 
specific inflammatory mechanisms, has greatly advanced the treatment of RA. The first biologic 
developed was anti-TNF. Primarily directed towards macrophages and monocytes this therapy 
has indirect effects on CD4+ T-cells by modulating IFN-γ and IL-17 production to alter the 
frequency of Th1 and Th17 cells (209, 210).  
Abatacept is a soluble Ig fusion protein of the CTLA-4 extracellular domain, able to bind co-
stimulatory molecules CD80/CD86 with higher affinity than CD28, resulting in the blockade 
of CD4+ T-cell co-stimulation. Production of pro-inflammatory cytokines such as IFN-γ, IL-6, 
TNF-α and TGF-β has been shown to be reduced following treatment (211, 212). Increased 
response to treatment, reduced disease progression and improved mobility have all been 
documented following treatment with CTLA-4 (213). More recent studies have also shown that 
treatment with this modulator of co-stimulation may restore tolerance towards citrullinated 
antigens (214).  
Despite many successful therapies whose mechanism of action involve modulating CD4+ T-
cells number and function, antibodies directed against anti-CD4 have not been successful in the 
treatment of RA with such antibodies having moderate efficacy but high levels of toxicity (215, 
216). This suggests the overall depletion of T-cells is not beneficial which may be due to the 
depletion of certain subsets such as Tregs, which may be beneficial in disease, therefore more 
complex modulation of T-cell subsets may be necessary in treatment of RA. Timing of 
treatments may also be important in the success of such therapies due to the differences in 
cytokine profiles throughout the progression of RA. 
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1.3 Cytokines in Early RA 
Cytokines are the key regulators of inflammatory responses, a crucial component in the 
pathogenesis of autoimmune diseases. The presence of circulating cytokines is dysregulated in 
RA, occurring even before the clinical onset of RA, and the contribution of these cytokines in 
immune dysregulation in the pathogenesis of RA is now being elucidated, Figure 3.  
Cytokines elevated prior to symptom onset include IL-6, TNF, IL-1β, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), IL-4, IL-5 and IL-17. Their presence prior to disease 
onset highlights the importance of certain cytokines in disease initiation. For example, Th2 
specific cytokines IL-4 and IL-5 show transient expression during the earliest stages of disease 
suggesting a discriminatory role for these cytokines in disease progression (136, 217). The IL-
17/IL-23 axis also appears particularly important in the pre-clinical phases of disease, 
particularly seropositive disease, as changes in antibody glycosylation mediated by these 
cytokines has been shown to trigger arthritis in mouse models (146). Furthermore, identification 
of the interferon gene signature has been shown to predict development of RA in at risk 
individuals (218). Unfortunately, the blockade of IL-1, IL-17 and IL-23 have been unsuccessful 
in established disease, this may be due to their particular dominance in early stages of disease 
whereas trials of these drugs largely occurs in established disease (144).  
In contrast, there is a dominance of pro-inflammatory cytokines TNF, IL-6 and GM-CSF during 
the inflammatory disease phase. TNF is responsible for the activation of osteoclasts and 
chondrocytes to drive joint destruction and induces the production of other pro-inflammatory 
cytokines including MMPs, IL-1 and IL-6 (219). Both TNF and IL-6 have been shown to 
abrogate PD-1 mediated suppression of CD4+ T-cells in inflammatory arthritis, highlighting 
these cytokines may be key mediators in the maintenance of synovitis (220). The blockade of 
these cytokines is highly successful in established disease, which may reflect their dominance 
in the later stages of disease pathogenesis.  
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These studies suggest that the hierarchical dominance of individual cytokines alters during 
disease phase, and likely between individuals, with cytokine dominance in early stages of 
seronegative disease remaining elusive (221). This has consequences on the optimal timing of 
therapeutics and controlling the balance of these cytokines during different disease stages may 
be a key strategy in therapeutic targeting of RA.  
1.3.1 IL-6 
IL-6 is of fundamental importance as a pro-inflammatory cytokine in RA (222). IL-6 was first 
discovered in 1986 as a T-cell derived cytokine thought to play a key role in the differentiation 
of B-cells into antibody producing cells (223). It is now known that IL-6 is a pleiotropic 
cytokine with a wide range of functions on a number of cells and tissues. Human IL-6 is a 
molecule 184 amino acids in length, with 65% and 42% homology with murine cDNA and 
protein respectively (224). The protein is 21-28kDa and has a structure made up of four long α 
helices (225).  
This cytokine belongs to the IL-6-type family along with IL-11, IL-27, IL-32, leukaemia 
inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotropic factor (CNTF), cardiotrophin-
1 (CT-1), cardiotrophin-like cytokine (CLC), neurotrophin-1 (NNT-1) and neuropoietin (NPN). 
These cytokines are produced by APCs, T-cells, B-cells, monocytes and non-hematopoietic 
cells such as fibroblasts, keratinocytes, endothelial cells, mesangial cells, adipocytes and 
tumour cells (226). They are produced in response to stimuli such as IL-1, TNF-α, 
Figure 3. Cytokine dominance throughout the progression of RA. Individual cytokines
show differing patterns of relative importance throughout the progression of seropositive RA.
The dominance of cytokines throughout seronegative RA is yet to be fully elucidated. Figure
adapted from Ridgley et al.Current Opinion in Rheumatology, 2017. 
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lipopolysaccharide (LPS) and platelet derived growth factor (PDGF) to activate differentiation, 
survival, apoptosis and proliferation. 
1.3.2 IL-6 Receptors 
Members of the IL-6 type cytokine family signal via the common signal transducing receptor 
chain gp130 (CD130), sometimes called gp130 family cytokines, providing functional 
redundancy within the system. Gp130 is a signal transducing receptor of 130kDa, which is 
ubiquitously expressed on cells including heart, kidney, spleen, liver, lung, placenta, brain and 
hematopoietic cells (227). Deletion of gp130 is embryonically lethal due to hypoplastic 
ventricular myocardium and reduced hematopoietic progenitors (228). The conditional deletion 
of gp130 results in defects in hematopoietic, cardiac, neurological, hepatic, pulmonary and 
immunological systems (229). On the other hand, continuous activation of this receptor causes 
hypergammaglobulinemia, splenomegaly, mesangial proliferative glomerulonephritis, 
lymphoid infiltration in the lung and myocardium hypertrophy (230).  
Despite studies documenting the ubiquitous expression of gp130 this receptor has been shown 
to be regulated on some cells. Vascular smooth muscle cells express modest levels of gp130 
which is upregulated in response to IL-6 driving an inflammatory state (231). Downregulation 
of gp130 expression also occurs in response to extracellular signal-regulated kinases 2 (ERK2) 
binding to the promoter region to inhibit expression. The p38 mitogen-activated protein kinase 
(MAPK) pathway also inhibits gp130 expression in juvenile idiopathic arthritis (JIA) patients 
to prevent excessive signalling of IL-6 (232, 233).  
In addition to the β receptor common to all IL-6 family members these cytokines also have their 
own specific α receptor subunit. IL-6 cannot signal directly via gp130 and requires the presence 
of an additional signalling molecule, the IL-6R (also known as CD126). This is a type 1 
transmembrane glycoprotein of 80kDa which contains an extracellular Ig-like domain, a 
cytokine receptor homology domain, a transmembrane domain and an intracellular domain 
which has no kinase activity (225).  
Unlike the β subunit the expression of IL-6R is restricted to hepatocytes, neutrophils, 
monocytes, macrophages and lymphocytes allowing tight control of signalling (234). The 
deletion of the IL-6R results in many of the same inflammatory defects see in IL-6 deficient 
mice namely defects in the generation of acute phase responses, impaired neutrophil resolution 
and delayed macrophage infiltration. However, differences do exist between the two KO 
systems with defects in wound healing less severe in IL-6R-/- (235). The deletion of IL-6R 
specifically in hepatocytes also reveals lower insulin sensitivity and lower glucose tolerance 
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(236). Conditional deletion in hepatocytes also suggests these cell types are crucial for the 
production of IL-6R in the acute phase response (235). 
In the absence of the membrane bound IL-6R IL-6 is able to signal via gp130 by enlisting a 
soluble form of the α receptor (sIL-6R). This soluble form of the receptor lacks both 
transmembrane and cytoplasmic regions and is generated by the proteolytic cleavage of 
membrane bound IL-6R or by the translation of an alternatively spliced IL-6R messenger 
ribonucleic acid (mRNA) (237, 238). Differential splicing of the IL-6R results in a 50-55kDa 
transcript lacking the 94 base-pairs which encode the transmembrane domain of the receptor. 
This has been shown to be the predominant form of the sIL-6R with levels decreasing with age 
suggesting a switch to generation by proteolytic cleavage (239). The cleavage site of the IL-6R 
is found immediately prior to the transmembrane domain and shedding occurs via cleavage 
carried out by the a disintegrin and metalloprotease domain 10/17 (ADAM-10/17), also known 
as tumour necrosis factor α converting enzyme (TACE) (240). It has been shown that ADAM10 
causes slow and constitutive shedding compared to ADAM17, which causes rapid proteolysis 
upon activation (241). IL-6R shedding has been shown to be induced upon phorbol 12-myristate 
13-acetate (PMA) stimulation, by pro-inflammatory cytokines, bacterial toxins, Ca2+, C-
reactive protein (CRP) and by apoptosis (242-247). The shedding of the IL-6R is a rapid process 
unlike alternative splicing which is a slower process hence subject to less control.  
The main producers of sIL-6R have been identified as hepatocytes and hematopoietic cells as 
the deletion of IL-6R in each cell type led to a decrease in the serum level of sIL-6R by 32% 
and 60% respectively (235).  
1.3.3 Classical versus Trans Signalling 
Signalling via gp130 and the membrane bound IL-6R complex is called classical signalling. 
During this signalling mechanism IL-6 binds directly to the membrane bound IL-6R which is 
then able to recruit gp130 subunits to coordinate signalling. Despite being the receptor specific 
for IL-6, CNTF and IL-27 have also been demonstrated to bind the IL-6R in vitro, although 
with a much lower affinity than IL-6 (248, 249).  
The sIL-6R is able to bind IL-6 with a similar affinity to the membrane bound IL-6R of 0.5-
2nM and signalling via this mechanism is termed trans signalling (239). During this mechanism, 
IL-6 first binds sIL-6R in the extracellular matrix to create the IL-6/sIL-6R complex, which is 
then able to bind to gp130 to initiate signalling. This method of signalling is agonistic therefore 
is able to sensitise cells not expressing the IL-6R to IL-6, broadening cellular responsiveness 
and prolonging the effective half-life of the cytokine.  
23 
 
Recently a further method of IL-6 signalling has been reported termed “IL-6 cluster signalling”.  
This method of signalling involves the trans presentation of IL-6 bound to IL-6R on DCs to T-
cells during cognate interactions (250). This method of signalling was shown to be crucial in 
the generation of pathogenic Th17 cells in vivo. The various mechanisms of IL-6 signalling are 
summarised in Figure 4.  
The signalling of IL-6 is made more complex by the presence of soluble forms of the gp130 
receptor, sgp130 (251). These soluble receptors are generated by alternative splicing and can 
be detected at high levels in circulation, around 100-400ng/ml (252, 253). Several forms have 
been detected at 50, 90 and 110kDa, which likely arise from differential processing. One of 
these forms is sgp130 rheumatoid arthritis associated peptide (sgp130-RAPS) (254). This 
soluble form of gp130 binds the IL-6/IL-6R complex in circulation to specifically inhibit trans-
signalling (255). Levels of sIL-6R and sgp130 in the steady state are 1000 times higher than 
IL-6 levels suggesting in healthy setting IL-6 is released which binds to sIL-6R and 
subsequently to sgp130 to provide a method of neutralisation.  
The contribution of both the classical and trans signalling pathways in various diseases has been 
assessed indicating the preferential involvement of the trans signalling pathway in numerous 
diseases. Classical signalling is crucial in the generation of the acute phase response (APR) 
hence, this pathway has been suggested to be responsible largely for the regenerative properties 
of IL-6. Confirming this, the classical signalling pathway has been shown to be an important 
factor in the elimination of pathogens, including Listeria monocytogenes and Mycobacterium 
tuberculosis (256, 257). 
Figure 4. Signalling mechanisms of IL-6. IL-6 can signal via three distinct mechanisms; 
classical signalling that requires membrane bound IL-6R, trans signalling which requires 
soluble IL-6R and newly described cluster signalling where IL-6 bound to IL-6R on DCs is 
presented to T-cells. 
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In contrast, despite the beneficial role of trans signalling in the rapid development of cytotoxic 
CD8+ T-cells against viruses and intracellular bacteria, numerous studies highlight the pro-
inflammatory role of this signalling mechanism in disease (258). The trans signalling pathway 
has been shown to be required for the progression of pancreatic adenocarcinoma and promotes 
pancreatitis associated lung injury (259, 260). The specific blockade of trans signalling with 
sgp130Fc, a dimer of two gp130 molecules fused to an Fc domain of an IgG protein, has been 
shown to be beneficial in animal models of disease including IBD, coronary artery disease and 
malaria (261-263). Evidence also suggests the involvement of this signalling mechanism in 
inflammatory arthritis as Hyper-IL-6, a fusion protein of the IL-6/sIL-6R complex, restores 
disease activity in AIA whereas sgp130Fc was able to ameliorate disease in this model and in 
a model of CIA (264, 265). These data highlights the importance of the trans signalling pathway 
in the pro-inflammatory effects of IL-6.  
1.3.4 Intracellular IL-6 Signalling 
In the initiation of signalling IL-6 first binds the membrane bound or soluble IL-6R and this 
complex of IL-6-IL-6R can then associate with gp130 inducing dimerization to form a 
hexameric structure (225). The binding of IL-6 to its receptor leads to rapid internalisation 
mediated by gp130. This process forms a high affinity functional receptor complex which is 
able to initiate signal transduction. The Janus kinase family are tyrosine kinases which 
transduce signals mediated by the IL-6 family cytokines, including JAK1, JAK2 and TYK2 
(266). These molecules are constitutively associated with the cytoplasmic tail of gp130 by 
multiple docking sites and are moved into close proximity upon dimerization. Upon JAK 
activation 4 specific tyrosine residues in the cytoplasmic domain of gp130 are phosphorylated 
and these become docking sites for transcription factors such as STAT-3 and to a lesser extent 
STAT-1 (267). 
1.3.4.1 STAT-3 
Following the recruitment of STATs these molecules are then phosphorylated by JAKs at a 
single tyrosine residue, Tyr701 for STAT-1 and Tyr705 for STAT-3, to induce dimerization 
(268). This can produce heterodimers, but more commonly homodimers which are able to 
translocate to the nucleus and initiate the transcription of certain genes containing STAT 
responsive elements. Although the mechanism of entry into the nucleus is largely unknown 
STAT-3 has been shown to bind the glucocorticoid receptor (GR) which contains nuclear 
localisation sequences (NLS) providing a possible mechanism of entry (269, 270).  
STATs are a family of transcription factors with Src homology 2 (SH2) domains that are 
induced as a result of cytokine signalling. Their translocation to the nucleus allows the binding 
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to responsive elements to promote transcription. STAT-3 can be activated by phosphorylation 
at either tyrosine or serine sites Y705 or S727, respectively (271). Tyrosine phosphorylation is 
mediated by JAK1 and is required for dimerisation and subsequent translocation to the nucleus. 
Serine phosphorylation is mediated by several kinases including ERK1/2, p38 and c-Jun N-
terminal kinases (JNK) depending on the signal and occurs in MAPK consensus site to both 
positively and negatively control gene transcription (272).  
1.3.4.2 Other signalling pathways 
IL-6 can also to a lesser extent initiate the MAPK and phosphoinositide-3 kinase (PI3K) 
pathways (273, 274). These pathways are important in mediating cell growth and cell cycle and 
have been shown to be important mediators of the anti-apoptotic effects of IL-6. In the case of 
MAPK, tyrosine phosphatase SHP2 is recruited to the Y759 phospho-tyrosine residue on gp130 
leading to phosphorylation which promotes the interaction with growth factor bound protein 2 
(Grb2) which is associated with Son-of-Sevenless (SOS) or Grb2-associated binder 1 (GAB1). 
Signals are then transmitted to activate ERK-MAPK resulting in the activation of transcription 
factors such as NF-IL-6 (C/EBPβ) and serum and glucocorticoid-stimulated kinase (SGK) (275, 
276). In the PI3K pathway, protein kinase B (Akt) is phosphorylated at serine/threonine sites 
which enables it to phosphorylate downstream molecules such as B-cell lymphoma 2 (BCL2) 
family member BCL2-associated death promoter (BAD). This molecule then associates with 
14-3-3 sequestering form B-cell lymphoma-extra-large (BCL-xL) to promote cell survival 
(225). Despite the documented roles of MAPK and PI3K in IL-6 signalling the predominant 
pathway activated by IL-6 is the STAT-3 pathway which has been shown to be crucial for cell 
survival and cell cycle transition, Figure 5.  
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1.3.5 Signal Termination  
Termination of signalling via the IL-6-STAT-3 signalling pathway can be achieved by multiple 
mechanisms. One of these mechanisms involves the protein tyrosine phosphatases (PTP) which 
are able to dephosphorylate components of signal transduction to prevent the recruitment or 
activation of STAT molecules. SHP2 is a key PTP which is recruited to Tyr759 on the SH2 
domain of activated gp130. This leads to protein unfolding and reduced enzymatic activity 
(277). SHP2 can also bind JAK and STAT molecules providing several means of signal 
termination. SHP2 regulates both the amount of activity and the amplitude of activity of STAT3 
but also has a positive role in MAPK signalling (278). Other PTPs involved in the termination 
of IL-6 signalling include PTP1B, CD45, SHP1 and PTPεC, which alters the onset of STAT-3 
activation (279-281).  
Figure 5. Downstream signalling mechanisms of IL-6. Following the binding of IL-6 to its 
receptors JAK molecules are activated which leads to the phosphorylation of gp130 and 
subsequently initiation of downstream signalling pathways such as MAPK, PI3K and STAT.
The predominant signalling pathway of IL-6 is the STAT-3 pathway, where STAT-3 
molecules are phosphorylated, form homo-dimers and translocate to the nucleus to induce gene
expression.  
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The JAK/STAT signalling pathway is also regulated by protein inhibitors of activated STAT 
(PIAS). This family of molecules contains 5 molecules which interfere with DNA binding of 
STATs in order to prevent gene expression (282). PIAS1 specifically inhibits STAT-1 
signalling whereas PIAS3 is specific for inhibition of STAT-3 (283, 284). Interaction requires 
STAT tyrosine phosphorylation, although the mechanism of inhibition remains unclear.  
The final mechanism of inhibition of signalling involves the cytokine inducible SH2 proteins 
(CIS) or the stat inducible stat inhibitors (SSI). These consist of janus kinase binding protein 
(JAB) and suppressor of cytokine signalling 1-7 (SOCS1-7) which all contain SH2 domains 
and in the case of SOCS include a SOCS box. These SOCS are classical feedback inhibitors as 
they are induced by JAK/STAT signalling. SOCS1 and SOCS3 are inhibitors of IL-6 signalling 
and are able to inhibit phosphorylation of gp130, JAK and STAT. SOCS3 associates with 
Tyr759 in activated gp130 which is also the binding site for SHP2, although SOCS3 can bind 
with higher affinity (285).  
A further mechanism of regulation involves the regulation of IL-6 and its receptors. The 
availability of IL-6 can be regulated at the level of mRNA or protein. The p38 MAPK signalling 
pathway has been shown to play an important role in stabilisation of IL-6 mRNA by the 
activation of mitogen activated protein kinase activated protein kinase 2 (MK2) (286). 
Alternatively, IL-6 protein can be regulated by protein proteolysis. For example, at sites of 
inflammation IL-6 induces serine protease elastase, proteinase 3 and cathepsin G from 
neutrophils which in turn degrade IL-6 (287). A widespread mechanism for signal termination 
is receptor internalisation. It has been shown that the regulation of IL-6 in hepatocytes involves 
down-regulation and degradation of gp130, suggesting gp130 plays an important role in 
preventing over activation (288). This was further validated and suggested to be due to gp130 
di leucine motif (289). It has since been suggested that gp130 internalisation is independent of 
signalling as cells not capable of activating the JAK/STAT molecules are still efficiently 
endocytosed (290). 
1.3.6 IL-6 Functions in Health and Disease 
IL-6 is induced rapidly by infection or tissue injury in the host defence mechanism. IL-6 is 
primarily regarded as pro-inflammatory although it also has anti-inflammatory properties, 
largely carried out by the classical signalling pathway (253). The classical signalling pathway 
is involved in homeostatic processes such as the acute phase response, glucose metabolism and 
haematopoiesis whereas the trans signalling pathway is involved in activation of stromal tissue, 
maintenance of effector T-cell functions and recruitment and apoptosis of leukocytes (291). 
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The functions of IL-6 are context dependent and affect cells of the immune system in addition 
to non-immune cells.  
1.3.6.1 Transition from Acute to Chronic Inflammation 
During the acute inflammatory response, IL-6 has an anti-inflammatory role by controlling the 
magnitude of acute inflammation by suppression of pro-inflammatory cytokines and 
stimulating the production of anti-inflammatory mediator IL-1R antagonist (292, 293).  
IL-6 and sIL-6R signalling has been shown to be a key regulator in the transition from acute to 
chronic inflammation by aiding the switch from neutrophil to monocyte recruitment, thereby 
assisting the resolution of inflammation (294). The proteolytic cleavage of IL-6R on infiltrating 
neutrophils drives the process of trans signalling in resident tissue cells causing suppression of 
neutrophil attracting chemokines, such as CXCL1 and CXCL8 enhancing trans migration of 
neutrophils away from inflammatory sites and contributing to apoptosis via caspase-3 (295, 
296). IL-6 enhances monocyte chemotactic protein 1 (MCP-1) and cell adhesion molecules 
such as intracellular adhesion molecule 1 (ICAM-1) on endothelial cells and CD62L on 
lymphocytes to aid recruitment of monocytes and leukocytes (294, 297).  
During the chronic inflammatory response IL-6 is responsible for inducing cellular responses 
such as plasma B-cell differentiation, antibody production and T-cell activation (298). IL-6 has 
the ability to skew monocyte differentiation to macrophages by the upregulation of MCSF 
expression and in DCs IL-6 can inhibit NF-κB, impairing their migration  and T-cell stimulatory 
ability (299, 300).  
These data highlight the role of IL-6 signalling in chronic inflammation. In contrast to acute 
inflammation in the chronic inflammatory response IL-6 has a pro-inflammatory role favouring 
the accumulation of cells and promoting their survival, ultimately leading to tissue damage. 
1.3.6.2 Acute Phase Response  
The APR is induced by inflammation to minimise tissue damage and consists of fever and 
increased vascular permeability. Acute phase proteins (APPs) are produced mainly by 
hepatocytes and the presence of IL-6 has been shown to regulate the production of these APPs. 
IL-6 has been shown to increase the production of positive APPs such as serum amyloid A 
(SAA), haptoglobin, alpha 1 acid glycoprotein (α1AGP), CRP, antitrypsin and fibrinogen and 
decrease the production of negative APPs, including transferrin and albumin (301, 302). The 
APR and hence IL-6 is necessary for the recovery from inflammation.  A further role of IL-6 
in the mediation of inflammation is the induction of excessive production of vascular 
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endothelial growth factor (VEGF) by synovial and mesothelial cells contributing to enhanced 
angiogenesis and vascular permeability (303, 304).  
1.3.6.3 Iron Metabolism 
IL-6 is also involved in the regulation of iron by the induction of iron regulatory hormone 
hepicidin (305). This blocks the action of iron transporter ferroportin-1 preventing the 
absorption of iron. The consequence of this inhibition is the development of hypoferremia and 
anaemia, which is often observed in chronic inflammatory diseases, including RA. The severity 
of this anaemia has been shown to correlate with serum IL-6 levels (306).  
1.3.6.4 Lipid Metabolism 
A role for IL-6 in controlling metabolism has also been suggested. IL-6 is produced by 
adipocytes and levels are found to be elevated in obesity, correlating with the subsequent 
development of type 2 diabetes mellitus (T2DM) (307, 308). Further studies have shown IL-6 
correlates with increased fat mass and can increase insulin stimulated glucose disposal in 
healthy individuals (309). IL-6 KO mice develop late onset obesity with glucose intolerance, 
insulin resistance and hepatic inflammation, however; exposure to a high fat diet corrects obese 
phenotype although hepatic inflammation and glucose intolerance persists (310, 311). In 
contrast, IL-6 is also produced by skeletal muscle cells upon exercise. This promotes 
glycogenolysis and lipolysis in skeletal muscle to enhance muscle efficiency and muscle growth 
highlighting the complex role of this cytokine in metabolism (312).  
1.3.6.5 Cartilage and Bone Metabolism 
The metabolism of cartilage and bone is also influenced by IL-6 trans signalling. Signalling via 
the sIL-6R stimulates the production of RANKL, a molecule responsible for osteoclast 
formation leading to bone resorption (313). Classical signalling of IL-6 inhibits the insulin-
induced differentiation of chondrogenic progenitor cells and increases MMP production of 
chondrocytes (314, 315). On the other hand, trans signalling induces the production of tissue 
inhibitors of MMPs (TIMPs) from chondrocytes suggesting a role for both signalling 
mechanisms in the contribution of matrix turnover (316).  
A number of processes are also mediated by trans signalling. IL-6 has been shown to be an 
important mediator of liver regeneration as IL-6 deficient mice have impaired regeneration 
(317). This process is dependent on the presence of sIL-6R, which is necessary for 
hepatocellular proliferation (318). Finally, trans signalling has been shown to be important in 
the sensation of pain. The sIL-6R signalling pathway plays a role in sensitising nociceptors to 
heat, mediated by protein kinase C (PKC) δ and the PI3K pathway (319, 320). 
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1.3.7 STAT-3 Functions in Health and Disease 
STAT-3 is the major signalling molecule downstream of IL-6 family cytokines and gp130 
signalling. The ablation of STAT-3 leads to early embryonic lethality suggesting a crucial role 
of this transcription factor in development (321). The conditional deletion of STAT-3 has led 
to the discovery of a wide range of diverse roles of STAT-3 in specific cells types. Deletion of 
STAT-3 has been shown to impair keratinocyte and endothelial cell migration and depletion in 
thymic epithelial cells results in a loss of thymocytes and thymic architecture (322, 323). STAT-
3 has been implicated in the differentiation, and subsequent proliferation of myeloid cells into 
macrophages (324). This is confirmed as defective STAT-3 in myeloid cells leads to aberrant 
expression of MHC II molecules and increased production of anti-inflammatory cytokines 
(325). STAT-3 has been shown to induce the expression of many genes in the cell cycle 
including Fos, Cyclin-D, c-Myc, proto-oncogene serine/threonine- protein kinase (PIM-1) as 
well as genes involved in protection from apoptosis such as BCL2, BCLXL, β2-macroglobulin 
indicating roles in cell cycle and survival (326). This is confirmed as deletion of STAT-3 in T-
cells leads to both impaired survival and impaired proliferation (327, 328).  
STAT-3 has been heavily implicated in numerous cancers due to its persistent activation found 
to be present in numerous malignancies (329-331). This activation results in the proliferation, 
survival and immune evasion of tumours. In colorectal cancer the level of STAT-3 activation 
has been shown to correlate with tumour grade, lymph node metastasis and extent of tumour 
invasion (332). The over-activation of this transcription factor is associated with poorer 
prognosis of many cancers (333, 334). The ablation of STAT-3 gene expression in human and 
mouse tumour models results in the inhibition of tumour growth, highlighting the potential 
targeting of this molecule as an approach for effective cancer treatment (335-337). Numerous 
approaches have been studied in order to prevent STAT-3 activation including strategies to 
prevent the homo-dimerisation, nuclear translocation or DNA binding of STAT-3 (338-340).  
The inhibition of the tyrosine kinase pathway also represents an attractive therapeutic target by 
the indirect inhibition of STAT-3 and such molecules have been shown to cause tumour growth 
arrest and apoptosis (341). Challenges remain in the targeting of STAT-3 for cancer therapy; 
however, this does represent a promising therapeutic target in anti-tumour immunity.  
The diverse functions of this transcription factor and its effect on many cell types highlights its 
pleiotropic nature emphasising the complex role of this transcription factor in immune 
responses.  
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1.3.8 IL-6 mediated STAT-3 Signalling 
The activity of an IL-6 mediated STAT-3 signalling pathway in numerous autoimmune diseases 
marks it out as a potentially important common pathogenic component, and feature of disease 
pathogenesis, highlighted as the CD4+ T-cell specific deletion of STAT-3 results in resistance 
to experimental autoimmune uveoretinitis (EAU), experimental autoimmune encephalomyelitis 
(EAE) and autoimmune pneumonitis (342, 343).  
The failure of autoimmune disease development with the deletion of STAT-3 in CD4+ T cells 
has been documented to be due to the role of the IL-6-STAT-3 signalling pathway, which has 
been shown to be an important regulator of the TGF-β driven differentiation of murine Th17 
cells (342, 344-346). This pathway has also been shown to promote the differentiation of T-
cells to Tfh cells with B-cell helper capacity (298, 347, 348). Despite the documented role of 
IL-6 in the inhibition of Treg development the presence of STAT-3 in these cells is crucial for 
their suppressive abilities and has been shown to protect against development of colitis (349).  
In the oncology field, markers of STAT-3 mediated IL-6 signalling have been shown to be 
potential prognostic markers of breast cancer. Naïve CD4+ T-cells from peripheral blood of 
patients with breast cancer have significantly lower levels of phosphorylated STAT-1 (pSTAT-
1) and pSTAT-3 showing reduced responsiveness to IL-6 (350). These responses were 
associated with defective Th17 differentiation and correlated with worse relapse free survival. 
In IBD, there is a high level of STAT-3 phosphorylation in both CD and ulcerative colitis (UC) 
patients (351). The level of pSTAT-3 has been shown to correlate with gut inflammation. It is 
thought that due to its role in mediating the proliferation and survival of CD4+ T-cells and Th17 
differentiation this STAT-3 activation exacerbates colitis. Its role in the disease is confirmed as 
IL-6 deficient mice have reduced development of colitis (352). In the dextran sodium sulphate 
(DSS) induced colitis model STAT-3 phosphorylation is enhanced causing more severe colitis 
in F59J-JAB transgenic mice with a defect in SOCS-3, the negative regulator of STAT-3.  
The importance of IL-6 mediated STAT-3 signalling in resistance to Treg suppression has been 
highlighted in MS and psoriasis where IL-6 is also found in high levels. The deletion of both 
IL-6 and STAT-3 lead to resistance against EAE (343). In patients with relapsing/remitting MS 
there is an elevated level of pSTAT-1:pSTAT-3 (353). This increased pSTAT-3 correlates with 
increased responsiveness to IL-6 and the resistance of cells to Tregs. Similarly, in psoriasis 
levels of IL-6 are elevated in both lesional skin and serum (354). This leads to the strong 
induction of pSTAT-3 which is prolonged in effector T-cells and promotes resistance of cells 
to Treg suppression. In both cases, this is thought to be a result of higher levels of IL-6R and/or 
gp130 on patient CD4+ T-cells.  
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1.3.9 Effect of IL-6 on CD4+ T-cells 
In addition to its effects on B-cells and myeloid cells, IL-6 is increasingly understood to have 
profound effects on T-cell responses. As well as being responsible for the cytokine-mediated 
recruitment of CD4+ T-cells inflammatory site (355, 356), IL-6 regulates the activation, 
proliferation, apoptosis and differentiation of CD4+ T-cells, influencing the nature and duration 
of chronic inflammation. Its enhancement of PHA-induced T-cell proliferation occurs 
independently of IL-2 (357), whilst blockade of IL-6 with anti-IL-6R has been shown to 
suppress anti-CD3 anti-CD28 induced proliferation by the partial inhibition of IL-2 production 
(358). Similarly, IL-6 protects CD4+ T-cells from activation induced cell death (AICD) and 
rescues from apoptosis independently of IL-2 through the downregulation of FASL surface 
expression and the STAT-3 dependent upregulation of anti-apoptotic molecules such as BCL-
2 (261, 359). IL-6 has been shown to play a role in the persistence of memory CD4+ T-cells: 
antigen-specific T-cells expanded more vigorously following immunisation with the addition 
of exogenous IL-6 as a result of decreased apoptosis (360).  
Presence of IL-6 during CD4+ T-cell activation plays a crucial role in the differentiation of T-
helper cell subsets with promotion of Th2, Th17 and Tfh cells and inhibition of Th1 and Treg 
cells being well documented. During the early stages of T-cell activation IL-6 has been shown 
to induce the expression of c-maf in naïve CD4+ T-cells. STAT-3 binds the c-maf promoter and 
subsequently regulates IL-4 transcription and commitment to the Th2 lineage (361). 
Furthermore, promotion of Th2 differentiation can be achieved by the presence of IL-6 during 
TCR stimulation, which has been linked to the production of IL-4 by CD4+ T-cells via the 
promotion of Nuclear factors of activated T-cells 2 (NFATc2) (362). The induction of c-maf 
alone is not sufficient for the development of Th2 cells suggesting induction of both pathways 
is necessary for Th2 differentiation. Alternatively, CD4+ T-cells activated in the presence of 
IL-6 have decreased Th1 differentiation due to the increased induction of SOCS1 resulting in 
inhibition of IFN-γ production (363). Together these data suggest IL-6 and TCR stimulation 
alters the balance of T-helper T-cells towards a Th2 response, indicating a possible role in 
allergy related diseases.  
A number of studies have shown that culture of CD4+ T-cells with a combination of IL-6, TGF-
β, IL-1β and IL-23 results in the differentiation of pathogenic Th17 cells. The contributions of 
these various cytokines is controversial but it is important to note that many of these studies 
were carried out in mice and the contribution of IL-6 towards the skewing of human CD4+ T-
cells towards Th17 is still debateable. In mice, IL-6 and TGF-β generate Th17 cells from a 
precursor also common to Foxp3 Tregs (364-366). These studies show variable roles for IL-23 
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and possible amplification by IL-1β and TNF. In these mouse models, as IL-6R is 
proteolytically cleaved from the surface of activated CD4+ T-cells, development of Th17 cells 
is mediated by classical signalling whereas the maintenance of these cells is mediated by trans 
signalling (367, 368). In contrast, human Th17 cells have been shown to require IL-1β and IL-
23 or IL-1β and IL-6 in their generation with no role for TGF-β (369, 370). IL-6 may play a 
role in human Th17 differentiation although further work is required to clarify the exact 
conditions required.  
The trans signalling mechanism of IL-6 is well known to abrogate the induction of Foxp3 in 
naïve CD4+ T-cells through the induction of mothers against decapentaplegic homolog 7 
(SMAD7), an inhibitor of the TGF-β signalling pathway (371). Despite the debate over the 
contribution of IL-6 to the development of Th17 the inhibition of STAT-3 in CD4+ T-cells 
prevented the differentiation of Th17 cells and increased the proportion of Tregs (372). This 
overall effect of IL-6 shifts the balance of T-helper cells away from Treg and immune tolerance.  
Loss of immunological tolerance in autoimmune diseases may result from the failure of Tregs 
to control autoreactive effector responses (373). Numerous studies have suggested an apparent 
role for IL-6 in inhibiting Treg function, explained by its ability to render Teff cells resistant to 
Treg-mediated suppression via STAT-3 signalling (374, 375). A high pSTAT-3:pSTAT-1 ratio 
has recently been associated with the loss of Treg suppression (375). It has been shown that 
inhibition of pSTAT-3 restores Treg suppression, however, the presence of pSTAT-3 early in 
responses are required in both effector cells and Tregs in order for IL-6 to mediate the reversal 
of suppression. This mechanism of effector T-cell resistance to suppression has been 
demonstrated in mouse models of SLE, EAE and T1D (376-378). This pathway has also been 
highlighted as playing an important role in a number of human diseases, including SLE, T1D, 
JIA, MS and psoriasis (354, 379-383).  
IL-6 has been shown to regulate the expression of BCL-6, the major transcription factor of Tfh 
cells, with a specific requirement of STAT-1 signalling (162, 384). One proposed mechanism 
identifies IL-6 mediated upregulation of BCL-3, a feature present in early RA, as a key driver 
of BCL-6 expression (164). IL-6 induces both the gene expression and protein induction of IL-
21 in both naïve and memory CD4+ T-cells stimulated in the presence of IL-6 in a STAT-3 
dependant manner (298, 385). Furthermore, deficiency of STAT-3 resulted in compromised 
expression of IL-21 and diminished B-cell helping capacity (348). IL-6 is not the only cytokine 
required for commitment to the Tfh cell lineage with many studies showing a role for IL-21 and 
more recently studies suggests roles for TGF-β and IL-12 or IL-23 (386, 387).  
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It has recently been shown that IL-6 can regulate effector function by its influence on 
mitochondrial membrane potential (388). This study shows that IL-6 in a STAT-3 dependent 
manner facilitates the formation of mitochondrial respiratory chain complexes enabling cells to 
sustain high mitochondrial membrane potential. This increased potential results in increased 
levels of mitochondrial Ca2+, shown to prolong the expression of IL-4 and IL-21 late during T-
cell activation. This reveals a novel mechanism by which IL-6 regulates effector cell functions.  
This critical role for IL-6 in T-cell differentiation highlights its importance in the maintenance 
of effector responses and hence chronic inflammation and is summarised in Figure 6. The 
induction of pro-inflammatory Th17/Th2 and inhibition of Tregs indicates its importance in 
shifting the immune response towards chronic inflammation and disruption of immune 
tolerance. 
 
1.3.10 Role of IL-6 in Inflammatory Arthritis 
In RA there is a positive correlation between serum and SF IL-6 levels and markers of 
inflammation, such as acute phase proteins, disease activity and chronic synovitis (222, 389-
392), with pre-treatment levels of IL-6 shown to predict bone erosion (393). In healthy 
individuals IL-6 levels are barely detectable within the range of 2-6pg/ml whereas in 
inflammatory diseases such as RA levels of up to 150ng/ml have been reported with only 2-5 
fold increases in sIL-6R and sgp130 levels (291). This suggests that in disease states IL-6 levels 
exceed sIL-6R and sgp130 to act systemically.  
Figure 6. Effects of IL-6 on CD4+ T-cells. IL-6 has numerous effects on CD4+ T-cell function 
including the induction of cytokine mediated migration and increasing cell survival and 
proliferation. IL-6 also plays a role in CD4+ T-helper cell differentiation by promoting Th2, 
Tfh and Th17 cells and inhibiting development of Th1 cells and Tregs through the induction 
of certain transcription factors and cytokines.    
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Levels of sIL-6R are also elevated in RA, particularly in SF, which correlate with leukocyte 
infiltration (389, 390, 394, 395). Trans signalling promotes VEGF production by mesothelial 
cells which contributes to angiogenesis, inhibits proteoglycan synthesis in RA chondrocytes 
and promotes osteoclast-like cell formation all suggesting a role in cartilage and bone 
destruction (390, 396).  
The role of IL-6 in RA has been further suggested by many mouse models. Mice deficient for 
IL-6 have been shown to be resistant to the induction of AIA or exhibit reduced disease severity, 
fewer osteoclasts and lower levels of IL-17 (397-399). One study has reported that IL-6 is 
essential for CIA development, however, other studies of IL-6 deficient mice have shown 
delayed onset and reduced severity of CIA with lower humoral and cellular responses (400, 
401). Furthermore, in CIA the administration of anti-IL-6 blocking antibody reduces both the 
incidence and severity of disease, with reduced T-cell and B-cell proliferative response to 
mitogens (402).  Finally, specific targeting of the trans signalling pathway with sgp130Fc has 
been shown to ameliorate experimental inflammatory arthritis highlighting the trans signalling 
pathway in disease pathogenesis (265).  
Mouse models of arthritis have also been developed by altering the IL-6 signalling pathway. 
For example, mutations of the tyrosine residues which make up the phosphatase binding site of 
gp130 have been shown to induce inflammatory arthritis. These mutations cause enhanced 
STAT-3 activation resulting in CD4+ T-cell accumulation, autoantibody production and 
increased IL-17 which increases proliferation and decreases apoptosis (403). A further mouse 
model with a knock in mutation in gp130Y757F/Y757F resulting in hyper-activation of STAT-3 
although not directly resulting in arthritis causes increased severity of autoimmune arthritis 
which can be abolished by IL-6 targeted therapy (264).  
In humans, an SNP in the gene ANKRD55, 150kb proximal to the IL-6 signal transducer gene 
(IL6ST), has been shown to have significant association with RA (404). The function of the 
ANKRD55 gene is unknown; however, IL6ST is a more compelling candidate as this plays a 
role in the IL-6 receptor complex, hence could alter IL-6 signalling. A polymorphism within 
the IL-6R gene has been shown to be associated with RA with the presence of alanine strongly 
correlates with circulating levels of the IL-6 and sIL-6R. This may impair classical IL-6R 
signalling by reducing IL-6R levels, which could be due to increased proteolytic cleavage of 
the membrane bound IL-6R (405, 406). Other risk variants within genes in the IL-6 signalling 
pathway have also been identified as being associated with RA, including those in TYK2 and 
STAT-3 genes (405, 407).  
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1.3.11 Therapeutic Targeting of IL-6 in RA 
Due to its numerous roles in inflammation and its suggested role in RA pathogenesis, 
therapies that target the IL-6 signalling pathway have been extensively studied for use in the 
treatment of RA, Table 1.  
It was first seen that treatment of RA with MTX decreases levels of IL-6 relating to better 
clinical outcome (408). Since the development of biologics a number of therapies targeting 
different aspects of the IL-6 signalling pathway have been investigated and now such a therapy 
has been approved for use in over 100 countries (409). 
Tocilizumab (TCZ) is a humanised monoclonal antibody (mAb) which blocks the IL-6 binding 
site of the IL-6R. This antibody is effective at blocking both the classical and trans signalling 
pathways of IL-6. TCZ therapy has proved to be efficacious both alone and in combination with 
DMARDs with an efficacy similar to other approved biologics (410, 411). Importantly, this 
therapy has also been shown to be effective in early RA in patients not previously treated with 
DMARDs and in those refractory to treatment with anti-TNF and/or MTX (411, 412). Further 
investigations reveal the therapy is effective in reducing disease severity, delaying joint 
destruction and improving physical function. It has been suggested that the level of IL-6 in the 
SF of RA patients correlates with subsequent positive response to IL-6R inhibition (413).  
Due to the relative success of anti-IL-6R in the treatment of RA the mechanism by which 
treatment results in disease improvement have also been studied. There have been documented 
improvements in bone resorption, cartilage turnover and decreases in chemokine levels with 
TCZ treatment (414, 415). Therapy has also been shown to reduce the expression of T-cell 
activation markers and chemokines and induce the expression of pro-repair genes (416). There 
has been controversy as to the effects of TCZ and its influence on CD4+ T-helper cell subsets. 
Some studies have suggested a decrease in Th17 cells with increased numbers of Tregs three 
month’s post-TCZ treatment. Others suggest increased Tregs with no changes in Th17 numbers, 
or decreases in Th1, Th17 and Tregs with an increase in Th2 cells (417-420). This suggests the 
effects of the blockage of IL-6 signalling is highly complex and warrants further investigation.  
Sarilumab, another mAb against IL-6R, has a similar efficacy as TCZ both in combination with 
MTX or as a monotherapy (421, 422). Further therapies are also being developed against the 
IL-6 ligand including Sirukumab and Olokizumab. A consequence of these drugs is that the 
level of circulating IL-6 does not increase following treatment, as seen with TCZ, the 
consequences of this remain unclear, however, phase II clinical trials of these molecules so far 
suggests reduced symptoms of RA in those unresponsive to anti-TFN or MTX (423-425). 
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Clinical trials are now underway to specifically block the trans signalling pathway of IL-6 using 
the sgp130Fc, Olamkicept. Phase I trials have proved the safety of this drug which will progress 
to Phase II trials (426). Treatments which specifically target the trans signalling pathway of IL-
6 hold much promise in the treatment of numerous inflammatory diseases due to the various 
pathogenic consequences of this signalling pathway described in Chapter 1.2.  
Although it is not clear how the blockade of IL-6 results in improvement of RA, the clinical 
efficacy of these treatments highlights the importance of IL-6 in RA pathogenesis.  
Mode of action Therapy Stage of development 
Binds IL-6R Tocilizumab Approved for use 
 Sarilumab Approved for use 
Binds IL-6 Sirukumab Phase III trials 
 Olokizumab Phase II trials 
Binds IL-6/sIL-6R Olamkicept Phase I/II trials 
Binds JAK molecules Tofacitinib Phase III trials 
1.3.12 IL-6 mediated STAT-3 Signalling in RA 
Work carried out on the STAT-3:STAT-1 balance in CD4+ T-cells as a predictive biomarker 
for early RA development suggests that IL-6 mediated STAT-3 signalling in resistance to Treg 
suppression may also act in this disease setting (427). Teff resistance may be relevant in the 
pathogenesis of RA with studies showing that cytokines such as TNF-α, IL-2 and IL-7 are able 
to abrogate Treg suppression in established chronic RA (157, 158). Treatment of RA with TCZ 
is associated with an increase in Treg numbers and decreases in Th17 cells and a further study 
has shown TCZ treatment results in improved levels of suppression further confirming the 
possibility of this mechanism in disease pathogenesis (428-430).  
As previously mentioned in Chapter 1.3.10, numerous experimental arthritis mouse models 
implicate IL-6 signalling in their pathogenesis. Mechanisms have been further elucidated 
showing the effects of IL-6 are mediated by STAT-3 signalling thus highlighting the role of 
this pathway in the pathogenesis of RA. For example, the deletion of STAT3 in gp130Y757F 
mice resulted in reduced arthritis severity and reduced synovial infiltration suggesting a key 
role of this pathway in regulating the inflammatory infiltrate (264).  
Table 1. IL-6 directed therapies for the treatment of RA. Numerous molecules, which target 
the IL-6 signalling pathway, have been approved for use or are in clinical development for use 
in the treatment of RA. These drugs target different parts of the IL-6 pathway such as binding 
of IL-6R, sIL-6R, IL-6 or JAK molecules. Sirukumab is no longer in development.  
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The global gene expression of circulating CD4+ T-cells of early RA patients have been profiled 
by Pratt et al. with the aim of obtaining biomarkers that predict the development of RA whist 
shedding light on pathogenesis (431). This study identified the robust differential expression of 
12 genes between untreated early RA and non-RA patients. This “12-gene signature” provided 
added value to existing tools for predicting the progression to RA amongst patients with 
undifferentiated arthritis. It did this most reliably in the most diagnostically challenging 
subgroup of patients, the seronegative RA subgroup. 
Pathway analysis revealed that the 12-gene signature comprised a statistically significant over 
representation of genes regulated by STAT-3. These genes were found to be maximally 
upregulated in seronegative disease and include B-cell lymphoma-3 (BCL3), PIM1, SOCS3, 
strawberry notch homolog 2 (SBNO2) and mucin 1 (MUC1). The expression of these genes 
was found to correlate with paired serum IL-6 levels but not with any of the other relevant 
serum mediators investigated including TNF, IL-1α, IL-10, leptin, IL-17 and IL-23. More 
recently, findings in relation to BCL3, PIM1 and SOCS3 have been validated in an 
independently recruited early arthritis cohort of 161 patients. Meta-analysis of the data from 
the two cohorts has confirmed the atypical IKB-encoding BCL3 as the single most differentially 
expressed gene, independent of baseline clinical parameters including measures of systemic 
inflammation (Figure 7, Table 2; Pratt et al, manuscript under review).  
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Additional studies have highlighted a strong correlation between constitutive intracellular 
pSTAT-3 and serum IL-6 that is unique to CD4+ T-cells and not seen in other circulating 
leukocyte subsets of early arthritis patients (427). This relationship appears to be the strongest 
in the true naïve CD4+ T-cell subset (CD45RA+CD62L+; Figure 8A, unpublished data). This 
suggests that, compared with central memory and effector memory CD4+ T-cells, the naïve 
CD4+ T-cell population is maximally sensitive to circulating IL-6. To examine whether this 
observation related to a higher propensity for IL-6 classical signalling in naïve cells due to 
higher availability of membrane bound IL-6R, its expression was examined on different subsets 
Figure 7. Volcano plot representing global CD4+ T-cell gene expression amongst early 
arthritis patients. Bcl-3 has the highest fold difference between 334 RA patients and non-RA 
(3.4 fold), which is highly significant following Benjamini-Hochberg multiple test correction. 
Figure from Pratt et al, manuscript in preparation.  
Table 2. Logistic regression in respect of RA versus non-RA diagnoses, with BCL-3 an 
independent variable alongside age, CRP, ESR and swollen joint count (SJC). Figure from 
Pratt et al, manuscript in preparation. 
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of CD4+ T-cells. IL-6R expression was in fact expressed maximally on central memory CD4+ 
T-cells opposed to naïve CD4+ T-cells, which have maximal pSTAT-3 (Figures 8B and C, 
unpublished data). This data suggests naïve CD4+ T-cells are most sensitive to IL-6 through a 
mechanism not fully explained by levels of IL-6R expression.  
The importance of the IL-6-STAT-3 pathway in early RA is corroborated by further studies 
showing baseline pSTAT-3 is found in 56% of RA patient CD4+ T-cells and levels correlated 
with DAS28 and treatment response (432). Levels of pSTAT-3 have also been shown to be 
higher in early RA than healthy controls, which correlated with elevated levels of IL-6 (433).  
Figure 8. Naïve CD4+ T-cells are maximally sensitive to paired serum IL-6 by a 
mechanism other than IL-6R expression. (A) There is a strong correlation between 
constitutive STAT-3 phosphorylation and paired serum IL-6 in CD4+ T-cells; with the 
relationship strongest in true naïve CD4+ T-cells. Significant differences occur between best fit 
line slopes (analyses of covariance p<0.001) (B) IL-6R expression is highest on central memory 
CD4+ T-cells and lower on effector memory and true naïve CD4+ T-cells. (C) STAT-3 
phosphorylation is highest in true naïve CD4+ T-cells compared to central memory and effector 
memory, significance determined by non-parametric analysis of variance (Friedman) with 
Dunn’s posthoc pairwise analyses, ***p<0.001. 
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1.4 Hypothesis 
The observational data generated in early RA showing high level of circulating IL-6 which 
correlate with significantly enhanced STAT-3 gene expression highlights IL-6 mediated STAT-
3 signalling as an early event in RA pathogenesis. This raises important questions as to the 
mechanisms via which IL-6 induced gene induction in CD4+ T-cells of early RA patients may 
play a role in the induction of immune dysregulation. I hypothesise that in early RA circulating 
naïve CD4+ T-cells are chronically pre-exposed to IL-6, which mediates STAT-3 activation and 
subsequent aberrant effector function following TCR stimulation providing a mechanism of 
antigen non-specific immune dysfunction in early RA. 
Therefore, the aims of this thesis are:  
1. To establish a robust in vitro model to mimic chronic IL-6 pre-exposure of naïve and 
memory CD4+ T-cells and subsequent TCR-mediated activation. 
2. To determine the phenotypic consequences of chronic IL-6 pre-exposure on naïve and 
memory CD4+ T-cell effector function following TCR-mediated stimulation.   
3. To investigate the molecular consequences of IL-6 pre-exposure by identifying 
transcripts differentially induced in naïve and memory CD4+ T-cells as a result of IL-6 
pre-exposure. 
4. To correlate findings from the effects of IL-6 pre-exposure to the situation in primary 
CD4+ T-cells from early RA patients. 
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Chapter 2. Materials and Methods 
 
2. 1. Reagents 
RF10 – Roswell Park Memorial Institute media 1640 (RPMI 1640; Sigma Aldrich, UK) 
supplemented with 5% fetal calf serum (FCS; Thermo Fisher Scientific; Massachusetts, USA), 
penicillin (50U/ml; Sigma Aldrich), streptomycin (50mg/ml; Sigma Aldrich) and glutamine 
(2mM; Sigma Aldrich) 
TexMACS – (Miltenyi Biotech; Cologne, Germany) supplemented with 100U/ml penicillin and 
100µg/ml streptomycin 
IMDM + 10% FCS – Iscove’s Modified Dulbecco’s Medium (IMDM; Thermo Fisher 
Scientific) supplemented with 10% FCS, 2mM glutamine, 100U/ml penicillin and 100µg/ml 
streptomycin  
IMDM + 10% SR – IMDM supplemented with 10% serum replacement (SR; Invitrogen; 
California, USA), 2mM glutamine, 100U/ml penicillin and 100µg/ml streptomycin  
Xvivo – Xvivo-15 (Lonza) supplemented with 100U/ml penicillin and 100µg/ml streptomycin 
HBSS + EDTA - Hanks Balanced Salt Solution; Ca2+ and Mg2+ free (HBSS; Lonza; Basel, 
Switzerland) supplemented with 2mM ethylene diamine tetra-acetic acid (EDTA; Thermo 
Fisher Scientific) 
HBSS + 1% FCS – HBSS; Ca2+ and Mg2+ free (Lonza) supplemented with 5ml FCS (Labtech; 
Sussex, UK) 
PBS + 2% FCS – Phosphate buffered saline; Ca2+ and Mg2+ free (PBS; Lonza) supplemented 
with 10ml FCS (Labtech) 
Lymphoprep – (Axis-Shield Diagnostics; Dundee, UK) 
FACS buffer – PBS (Lonza) containing 0.5% bovine serum albumin (BSA; Sigma Aldrich), 
1mM endotoxin free EDTA and 0.01% sodium azide (Sigma Aldrich) 
MACS buffer – PBS (Lonza) containing 0.5% FCS and 0.5M EDTA  
Binding buffer – 0.1M Hepes (pH 7.4; Sigma Aldrich) with 1.4M NaCl (Sigma Aldrich) and 
2.5mM CaCl2 (Sigma Aldrich) 
ELISA wash buffer – PBS (0.14M NaCl, 8.52mM Na2HPO4, 1.59mM NaH2PO4.H2O (BDH 
Chemicals)) with 0.1% Tween 20 (Sigma Aldrich) 
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ELISA block – PBS (0.14M NaCl, 8.52mM Na2HPO4, 1.59mM NaH2PO4.H2O) containing 1% 
BSA  
ELISA diluent – PBS (0.14M NaCl, 8.52mM Na2HPO4, 1.59mM NaH2PO4.H2O) containing 
1% BSA and 0.1% Tween 20   
Citrate Phosphate Buffer – 0.03M citric acid (Sigma Aldrich), 0.05M Na2HPO4, 0.03M 
Na2HPO4.2H2O and H2O (6μl, 30% stock) 
3M Sulphuric acid – 3M H2SO4 (Sigma Aldrich) diluted in 250ml dH2O 
4% formaldehyde – 100ml PBS (Lonza) containing 4g paraformaldehyde (Sigma Aldrich)  
2.2. Subjects 
The subjects used for the study mainly comprised of healthy volunteers and patients recruited 
from the Northeast Early Arthritis Cohort (NEAC). All donors gave written informed consent 
for inclusion in the study prior to giving blood. Ethical approval for patient samples was 
obtained from Newcastle and North Tyneside 2 Research Ethics Committee (reference 
12/NE/0251). Ethical approval for healthy control blood was obtained from Newcastle 
Academic Health Partners Bioresource and Newcastle and North Tyneside 1 Research ethics 
Committee (reference 12/NE/0395, R&D 6579).  
2.2.1. National Blood Service 
Leukocyte reduction system (LRS) cones from healthy donors were provided by the National 
Blood Service. This is a way of eliminating leukocytes from blood products such as platelets. 
Cones provide a viable source of white blood cells which can be used for further cell isolations. 
2.2.2 Healthy Laboratory Donors 
Peripheral blood was obtained from healthy laboratory donors from the Musculoskeletal 
Research Group. According to an established standard operating procedure, healthy donors 
volunteered in response to an e-mail sent to people on the blood donation list and provided fully 
informed consent prior to blood donation. Ethical approval was obtained from Newcastle and 
North Tyneside 1 research ethics Committee (reference 12/NE/0395, R&D 6579).  
2.2.3 Early Arthritis Patients 
Patients were recruited from the Musculoskeletal Unit at the Freeman Hospital, Newcastle upon 
Tyne. Having provided fully informed consent for enrolment into the Northeast Early Arthritis 
Cohort (NEAC; REC 12/NE/0251), volunteers donated blood prior to commencement of 
immune-modulatory treatments (including steroids and DMARDs). Diagnoses and 
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clinical/laboratory parameters were recorded on a secure database at the time of blood draw, 
using codes to identify patients, and diagnoses could be confirmed at follow-up.  
2.3 Obtaining Peripheral Blood 
A volume of blood (between 70-140ml) was drawn into ethylene diamine tetra acetic acid 
(EDTA) or citrate vacuette tubes (Greiner Bio-One; Kremsmünster, Austria).  
Numerous studies have shown differences in cell properties as a result of anti-coagulant use, 
possibly due to the metal cation chelation property of these substances altering the availability 
of Ca2+ involved in metabolic processes. For example, studies describe higher cell yield with 
blood drawn into EDTA although other studies show lower levels of cytokine secretion and 
protein secretion of monocytes and impaired CD4+ T-cell proliferation with this anti-coagulant 
(434-439). In contrast, citrate was reported to result in high quality RNA/DNA and smaller 
variation in gene expression which may be due to the lower binding affinity of this anti-
coagulant (440, 441).  
Due to this the effects of EDTA and citrate on naïve CD4+ T-cell  proliferation was compared. 
This revealed that naïve CD4+ T-cells from blood stored in citrate were more sensitive to 
changes in proliferation, data not shown. For this reason, citrate was chosen as the preferred 
anti-coagulant. 
In some cases sera was also collected into serum/gel vacuette tubes (Greiner Bio-One).  
2.4 Cell Isolation 
A variety of cell isolation methods were used in this study to obtain both total CD4+ T-cells and 
naïve CD4+ T-cells. A number of different naïve CD4+ T-cell isolation methods were compared 
in order to choose the method of isolation which gave both a high yield and high purity. Purity 
of all isolated cells was assessed by subjecting aliquots of cells to flow cytometry.  
2.4.1 Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) can be isolated from fresh whole blood using 
density centrifugation on density medium. On centrifugation cells separate according to density 
with heavier cells including red blood cells (RBCs) and granulocytes forming a pellet at the 
bottom of the tube. PBMCs (including lymphocytes and monocytes) form a layer at the 
interface which can be recovered for further use. 
Fresh whole blood or LRS cones was diluted 1:2 or 1:3 respectively with HBSS + EDTA 
(Chapter 2.1). 15-20ml of diluted blood was then slowly layered over 15ml Lymphoprep 
(Chapter 2.1) and centrifuged at 895g for 30 minutes at room temperature. PBMCs were 
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recovered from the plasma interface with a sterile Pasteur pipette and transferred to a new 50ml 
Falcon tube. Cells were resuspended in 50ml HBSS + 1% FCS (Chapter 2.1) and centrifuged 
at 600g at 4°C for 7 minutes to remove any contaminating Lymphoprep. Supernatant was 
discarded and cells washed again by resuspending in HBSS + 1% FCS and centrifuging at 250g 
at 4°C for 7 minutes. The supernatant was then aspirated which will remove any remaining 
platelets. At this stage, PBMCs were re-suspended in an appropriate amount of RF10 (Chapter 
2.1), counted using a Burker chamber, and then used for further downstream applications. 
2.4.2 Isolation of total CD4+ T-cells by positive selection 
Monocytes express low levels of CD4 so must be depleted from blood using CD36 RosetteSep 
before positive CD4+ T-cell isolation. This crosslinks CD36 on the surface of monocytes with 
RBCs to form heavy density immunorosettes. On addition of an erythrocyte aggregation agent, 
these rosettes then pellet and leukocytes can be recovered for further use. CD4+ T-cells can then 
be isolated through the binding of tetrameric antibody complexes to CD4 which are then bound 
by dextran coated magnetic particles. These cells can then be separated using magnetic field.  
Fresh whole blood was incubated with monocyte depleting CD36 RosetteSep (25µl/ml; 
Stemcell Technologies; Vancouver, Canada) at room temperature for 20 minutes. Hetasep 
(Stemcell Technologies) was added, at 1/5 of the starting volume of blood, and centrifuged at 
50g room temperature for 5 minutes. Cells were left to stand for 10 minutes and supernatant 
containing desired leukocytes transferred to a new universal. Cells were then centrifuged at 
400g for 7 minutes at room temperature. Cells were resuspended in a volume of HBSS + 1% 
FCS equivalent to 1/5 the starting volume of blood and loaded along with other reagents onto 
the Robosep automated cell separator (Stemcell Technologies) which was programmed for 
human CD4 whole blood positive selection and run according to manufacturer’s protocol. 
Briefly, this involves incubation of sample with CD4 antibody complexes for 15 minutes 
followed by incubation with magnetic particles for further 10 minutes which cross link with the 
CD4 antibody. Cells were incubated in the magnetic field of an EasySep magnet for 5 minutes 
following which cells unbound to magnetic particles are removed by pipetting off supernatant. 
Positively selected CD4+ T-cells were manually removed from the robosep magnet and 
resuspended in culture media for cell counting.  
2.4.3 Isolation of total CD4+ T-cells by enrichment 
CD4+ T-cells were enriched from the blood by density centrifugation. The human RosetteSep 
CD4+ T-cell enrichment cocktail (Stemcell Technologies) forms immunorosettes by cross-
linking antibodies on all CD4 negative cells to RBCs. On centrifugation over density medium, 
these form a pellet and unlabelled CD4+ T-cells can be recovered from the interface.  
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Total CD4+ T-cells were isolated from fresh whole blood or LRS cones by incubating with 
Human CD4+ T-cell Enrichment Cocktail as per manufacturers instructions (50µl/ml for blood 
or 75µl/ml for cone, Stemcell Technologies) for 20 minutes at room temperature. Samples were 
then diluted 1:2 or 1:3 respectively with PBS+ 2% FCS (Chapter 2.1) and 15-20ml was layered 
over 15ml Lymphoprep. Cells were then separated by centrifugation at 895g, room temperature 
for 30 minutes. CD4+ T-cells were recovered from the interface using a sterile pasteur pipette 
and were centrifuged at 600g at room temperature for 7 minutes to remove contaminating 
Lymphoprep. Another 400g for 7 minutes room temperature centrifuge was carried out and 
cells were then resuspended in culture media for counting.  
2.4.4 Isolation of naïve CD4+ T-cells by EasySep enrichment 
Naïve CD4+ T-cells can be enriched from blood by the use of tetrameric antibody complexes 
recognising surface antigens of all CD45RA negative cells. These antibodies bind to their target 
cells and are subsequently labelled with dextran coated magnetic nanoparticles. These cells are 
then separated from unlabelled naïve CD4+ T-cells using the magnetic field of an EasySep 
magnet (Stemcell Technologies).  
PBMCs were isolated from fresh whole blood or LRS cones by gradient density centrifugation 
as previously described (Chapter 2.4.1). Naïve CD4+ T-cells were purified from PBMCs at a 
concentration of 5x107 cells/ml by incubating with biotinylated anti-CD45RO antibody 
(50µl/ml; Stemcell Technologies) for 15 minutes at room temperature. Cells were incubated 
with EasySep Human Naïve CD4+ T-cell Enrichment Cocktail (50µl/ml; Stemcell 
Technologies) for 10 minutes at room temperature. Nanoparticles were then added (100µl/ml; 
Stemcell Technologies) and incubated at room temperature for 10 minutes. The cell suspension 
was then made up to a total of 2.5ml and passed through a magnet for 10 minutes. The desired 
fraction was poured off into a new tube. This process was repeated for two separations with the 
magnet in order to improve purity. This left the negatively selected naïve CD45RA+ T-cells 
which were re-suspended in culture media for counting. 
2.4.5 Isolation of naïve CD4+ T-cells using PluriBeads 
Naïve CD4+ T-cells can be positively selected by non-magnetic mono-dispersed micro-particles 
with mAbs on the surface which recognise CD45RA on naïve CD4+ T-cells. Cells are isolated 
by filtration with the naïve CD4+ T-cells bound to the pluriBeads (PluriSelect Life Science; 
Leipzig, Germany) being unable to pass through the cell strainer. Target cells are then detached 
from the beads by addition of detachment buffer and naïve cells collected.  
48 
 
Naïve CD4+ T-cells were isolated from fresh whole blood by adding stabilisation buffer 
(50µl/ml; PluriSelect Life Science) followed by pluriBeads (80µl/ml; PluriSelect Life Science) 
and incubating for 30 minutes. Cells were then strained through S-pluriStrainer (PluriSelect 
Life Science) into 50ml centrifuge tube. Unlabelled cells run through the strainer whereas 
desired naïve CD4+ T-cells with rosette beads remain on the strainer. The strainer was washed 
with 5x 2ml wash buffer (PluriSelect Life Science) and attached to a new 50 ml centrifuge tube. 
It was then washed with 1ml wash buffer followed by 1ml detachment buffer and incubated for 
10 minutes at room temperature. The strainer was washed with a further 1ml wash buffer 
(PluriSelect Life Science). The Luer lock was then opened allowing the isolated cells to pass 
through. The strainer was washed with 10x 1ml wash buffer (PluriSelect Life Science). Cells 
were then centrifuged at 400g for 7 minutes and supernatant aspirated. Cells were then re-
suspended in an appropriate amount of media for counting.  
2.4.6 Isolation of naïve CD4+ T-cells by MACS enrichment  
In this method naïve CD4+ T-cells are isolated form a starting population of PBMCs by 
magnetic-activated cell sorting (MACS). Undesired cells are labelled with biotin-conjugated 
mAbs recognising cell surface antigens of CD45RA negative cells. These are then magnetically 
labelled with microbeads conjugated to monoclonal anti-CD61 and anti-biotin antibodies. 
Labelled cells are depleted when they are retained on a MACS separation column in the 
magnetic field of a MACS separator (Miltenyi Biotec). Unlabelled naïve CD4+ T-cells are 
collected as they pass though the column.  
PBMCs were isolated from fresh blood as previously described (Chapter 2.4.1). PBMCs were 
re-suspended in MACS buffer (40µl per 107 total cells; Chapter 2.1) and incubated with 
biotinylated antibody cocktail (10µl per 107 cells) for 5 minutes, 4°C. MACS buffer (30µl per 
107 total cells) and Naïve CD4+ T-cell MicroBead Cocktail II (20µl per 107 total cells; Miltenyi 
Biotec) were added before incubation for 10 minutes, 4°C. MACS buffer was added to a total 
volume of 500µl. Cells were then applied to LS column (Miltenyi Biotec) in the magnetic field 
of a MACS separator. The column was washed with 3x 3ml MACS buffer. The negative 
fraction, the naïve CD4+ T-cells, flow through the column and were collected. Cells were re-
suspended in culture media for counting. 
2.4.7 Isolation of naïve CD4+ T-cells by CD45RA/RO microbeads 
Naïve CD4+ T-cells are isolated from a starting population of enriched CD4+ T-cells, as 
previously described in Chapter 2.4.3, by addition of magnetically labelled CD45RA or 
CD45RO MicroBeads (Miltenyi Biotec). The cell suspension is passed through a MACS 
separation column in the magnetic field of a MACS separator. In the case of CD45RA 
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microbeads naïve  CD4+ T-cells are magnetically labelled and retained in the column, these can 
be removed from the magnetic field and eluted. In the case of CD45RO microbeads unlabelled 
naïve CD4+ T-cells are collected as they pass through the column.  
Naïve CD4+ T-cells were isolated from purified CD4+ T-cells by re-suspending cells in MACS 
buffer (80µl/10x106 cells) and incubating with CD45RA/RO MicroBeads (Miltenyi Biotec) for 
15 minutes at 4°C. Cells were then washed in 2ml MACS buffer and centrifuged at 700g for 7 
minutes. Cells were resuspended in 50µl MACS buffer and applied to an LS column in the 
magnetic field of a MACS separator. The MACS column was washed with 3x 3ml MACS 
buffer. The negative fraction of naïve CD4+ T-cells flow through the column and were 
collected. Cells were then re-suspended in culture media for counting. 
2.5 Cell Counting 
Cell counting was carried out by diluting cells 1:1 with media and/or 0.4% trypan blue (Sigma 
Aldrich). Trypan blue is able to identify dead cells by passing through the membrane and 
making cells appear blue. Cells were then loaded onto the cover slip of a Burker chamber, 
Haemocytometer (Marienfeld Superior; Germany) and the number of cells in 25 squares was 
counted, including those touching upper and right borders, using a  M20 phase contrast 
microscope (Wild; Switzerland) at 40X objective. The number counted was multiplied by the 
dilution factor to give cells x104/ml. All subsequent cell counts were carried out in this way. 
2.6 Cryopreservation of CD4+ T-cells 
In some cases, cells were frozen following isolation before use in culture. Cryopreservation 
allows the cells to be stored for a long length of time before use. Cells can be preserved in 
dimethyl sulfoxide (DMSO) which protects biological material from freezing damage due to 
ice formation.  
To do this, cells were centrifuged 400g for 7 minutes and re-suspended in 1ml of FCS + 10% 
DMSO (Sigma Aldrich) per 10x106 cells. Cells were transferred to cryovials (Corning; New 
York, USA) and gradually cooled to -80°C in polystyrene box.  
Upon thawing cells were placed in water bath until defrosted. Cells were then washed twice at 
400g for 7 minutes re-suspended in culture media and counted for further use.  
2.7 In Vitro Cell Culture  
Following isolation total CD4+ T-cells, naïve CD4+ T-cells or memory CD4+ T-cells were 
cultured at 37°C with 5% CO2 in 24 well or 96 well flat bottom culture plates (Costar, Corning) 
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unless stated otherwise. Cells were examined under a CKX41 inverted microscope (Olympus 
Corporation; Tokyo, Japan) at appropriate times throughout culture.  
Cells were then used in subsequent flow cytometry phenotype or proliferation assays, Chapter 
2.9. Supernatants from these cultures was stored at -20°C for subsequent cytokine measurement 
by ELISA or MSD, Chapter 2.10. 
2.7.1 IL-6 pre-exposure 
Purified naïve CD4+ T-cell and memory CD4+ T-cells were cultured at 1x106 in 500µl 
TexMACs (Miltenyi Biotec) or Xvivo-15 (Lonza) in 24 well culture plates (Costar, Corning). 
A concentration titration was carried out using recombinant human IL-6 (20.9kDa; Peprotech; 
London, UK) at final concentrations of 50ng/ml, 5ng/ml, 0.5ng/ml and 0.1ng/ml with respective 
equimolar final concentrations of sIL-6R (37.6kDa; Peprotech). Stocks of IL-6 and equimolar 
sIL-6R were made by diluting with TexMACs or Xvivo-15 media then mixing with cells at a 
1:1 ratio. Cells were cultured for 3 days unless stated otherwise, then harvested and centrifuged 
twice at 400g for 7 minutes to wash away IL-6. Cells were then stimulated by anti-CD3 and 
anti-CD28 (Chapter 2.7.3), in a mixed lymphocyte reaction (Chapter 2.7.4) or differentiated 
into T-helper subsets (Chapter 2.7.5). 
2.7.2 Cytokine stimulation 
Total CD4+ T-cells were isolated by positive selection using the robosep, Chapter 2.4.2. Cells 
were cultured in 24 well plates at 1x106  cells in 500µl TexMACs alone or in 500µl TexMACs 
with final concentrations of 50ng/ml IL-6, TNF-α (17.4kDa; Peprotech), IL-21 (15.5kDa; 
Miltenyi Biotech), IL-23 (53.5kDa; Peprotech), IL-27 (47.8kDa; Peprotech) or IFN-α (gift from 
Catharien Hilkens, Newcastle University) for 1, 6 and 24 hours at 37°C with 5% CO2. 
2.7.3 Anti-CD3 and anti-CD28 stimulation 
T-cells can be stimulated by anti-CD3 and anti-CD28, which mimic the stimulus from an 
antigen-presenting cell. Anti-CD3 provides the initial activation signal and a co-stimulatory 
signal is provided by anti-CD28 resulting in proliferation. This method of CD4+ T-cell 
activation provides the ability to accurately control strength of stimulus which is advantageous 
when measuring outcome following stimulation.  
Anti-CD3 (OKT3; eBioscience; San Diego, USA) was immobilised on to 96 well flat bottom 
culture plate (Costar, Corning) at a final concentration of 1µg/ml (high), 0.5µg/ml (medium) or 
0.2µg/ml (low). 2x105 naïve CD4+ T-cells were added to each well in 150µl TexMACs or X-
vivo-15 medium and soluble anti-CD28 (CD28.2; Biolegend; San Diego, USA) was added at 
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final concentration of 5µg/ml (high) or 1µg/ml (medium and low) in a final volume of 200µl, 
unless otherwise stated.  
All culture incubations following anti-CD3 anti-CD28 stimulation were carried out for 6 days 
at 37°C with 5% CO2 unless stated otherwise. 
For intracellular staining cells were harvested at day 6, centrifuged 400g 7 minutes and 
resuspended in TexMACs or Xvivo-15 at a concentration of 1x106 cells/ml. Cells plated out to 
24 well plates and rested overnight at 37°C with 5% CO2. 
2.7.4 Mixed lymphocyte reactions 
A mixed lymphocyte reaction (MLR) occurs when T-cells from one donor are co-cultured with 
allogeneic DCs from a second donor. T-cells will recognise the DCs as foreign due to the 
different MHC molecules resulting in T-cell activation and proliferation. This method of CD4+ 
T-cell activation is less accurately controlled, compared to anti-CD3 anti-CD28 stimulation, 
although is more physiologically relevant.  
1x105 naïve CD4+ T-cells were co-cultured with 1x104 mature DCs. Mature DCs were isolated 
using CD14 MicroBeads (Miltenyi Biotech) and cultured in the presence of IL-4 and GM-GSF 
both at 50ng/ml for 6 days followed by culture with 0.1μg/ml lipopolysaccharide (LPS) for 24 
hours to generate mature DC (from Katie Crossland, Newcastle University). Cells were cultured 
at a 1:10 ratio in a total volume of 200µl TexMACs (Miltenyi) or RF10 medium in triplicate in 
a flat bottom 96 well plate (Costar, Corning) for 6 days at 37°C with 5% CO2. After 6 days, 
cells were used for tritiated thymidine incorporation assays (Chapter 2.8.2). 
2.7.5 T-helper cell differentiation 
Naïve, memory or total CD4+ T-cells were cultured at 1x106 cells per well of a 24 well plate 
(Costar, Corning). For Th1 and Th2 skewing, naïve CD4+ T-cells were cultured in IMDM + 
10% FCS (Chapter 2.1); however, for differentiation into Th17 cells, memory CD4+ T-cells 
were cultured in IMDM + 10% SR (Chapter 2.1). For Tfh cell differentiation, total CD4+ T-
cells were cultured in TexMACs or IMDM + 10% FCS (Chapter 2.1).  
The conditions for the generation of T-helper cell subtypes can be seen in Table 3. For the 
generation of Th1 cells 10 IU/ml IL-2 (15kDa; Roche; West Sussex, UK), 1ng/ml IL-12 
(75.0kDa; Peprotech), 10µg/ml anti-IL-4 (Biolegend) were added and anti-CD3/anti-CD28 T-
cell expander Dynabeads (Invitrogen) were added at a ratio of 1 bead per 10 cells.  
For the generation of Th2 cells 10 IU/ml IL-2 (Roche), 20ng/ml IL-4 (15.1kDa; Miltenyi 
Biotech), 10µg/ml anti-IL-12 (Biolegend) and 10µg/ml anti-IFN-γ (eBiosciences) were added 
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and anti-CD3/anti-CD28 T-cell expander Dynabeads (Invitrogen) were added at a ratio of 1 
bead per 10 cells.  
For the generation of Th17 cells 10ng/ml IL-1β (17.3kDa; Peprotech), IL-23 (Peprotech) and 
TGF-β (25.0kDa; Peprotech) was added and anti-CD3/anti-CD28 T-cell expander Dynabeads 
(Invitrogen) were used at a ratio of 1 bead per 50 cells.  
For the generation of Tfh cells 10ng/ml IL-12 (Peprotech), 10ng/ml IL-6 (Peprotech), 10ng/ml 
IL-1β (Peprotech) and 10ng/ml TGF-β (Peprotech) was added to each well. Anti-CD3/anti-
CD28 T-cell expander Dynabeads (Invitrogen) were added at a ratio of 1 bead per 10 cells. 
Cells were cultured for 6 days at 37°C with 5% CO2 and either split or refreshed as necessary, 
which was indicated by media colour and/or cell clumping.  
On day 6 of culture cells were harvested into EasySep tubes (Stemcell Technologies) and placed 
in EasySep magnet (Stemcell Technologies) for 5 minutes to remove anti-CD3/anti-CD28 T-
cell expander Dynabeads (Invitrogen). The magnetic beads are attracted to the magnet and the 
CD4+ T-cells were poured off into new universal topped with HBSS + 1% FCS and centrifuged 
T-helper 
skewing 
Cell type CD3/CD28 
bead:cell ratio 
Cytokines Refresh/Split 
Th1 Naïve CD4+ 
T-cells 
1:10 IL-2 10 IU/ml 
IL-12 1ng/ml 
anti-IL-4 10µg/ml 
IL-2 10 IU/ml 
IL-12 1ng/ml 
Th2 Naïve CD4+ 
T-cells 
1:10 IL-2 10 IU/ml 
IL-4 20ng/ml 
anti-IL-12 10µg/ml 
anti-IFN-γ 10µg/ml 
IL-2 10 IU/ml 
IL-4 20ng/ml 
Th17 Memory 
CD4+ T-cells 
1:50 IL-1-β 10ng/ml 
IL-23 10ng/ml 
TGF-β 10ng/ml 
IL-2 10U/ml 
IL-23 10ng/ml 
 
Tfh Total CD4+ 
T-cells 
1:10 IL-12 10 ng/ml 
IL-6 10 ng/ml 
IL-1β 10 ng/ml 
TGF-β 10 ng/ml 
IL-12 10 ng/ml 
IL-6 10 ng/ml 
IL-1β 10 ng/ml 
TGFβ 10 ng/ml 
Table 3. Conditions for the differentiation of T-helper cell subsets. Table showing the 
conditions for T-helper differentiation including cell type used, bead: cell ratio and cytokines 
used. 
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400g for 7 minutes. Cells were counted and plated out at a concentration of 1x106 cells/ml. Tfh 
cells were rested for 24 hours in the absence of IL-2, which has been shown to inhibit Tfh 
differentiation (442, 443). Th1, Th2 and Th17 cells were rested for 4 days with addition of 10 
U/ml IL-2 (Roche) per well. Cells incubated at 37°C, 5% CO2. After 1 or 4 days rest cells were 
further stimulated with PMA/ionomycin to assess intracellular cytokines (as described in 
Chapter 2.9.3).  
2.8 Measurement of Proliferation 
Proliferation of total CD4+ T-cells, naïve and memory CD4+ T-cells was measured in one of 
two ways: by CFSE labelling followed by flow cytometry or by tritiated thymidine 
incorporation assay. 
2.8.1 CFSE labelling  
Proliferation of cells can be tracked by use of 5, 6-carboxyfluoroscein diacetate succinimidyl 
ester (CFSE). This dye is able to cross intact cell membranes where its acetate groups are 
cleaved by intracellular esterase to give fluorescent carboxyfluoroscein. The dye is able to form 
crosslinks with intracellular proteins by interaction between succinimidyl ester and primary 
amines. Cell divisions can be tracked by the halving in fluorescence intensity, which can be 
monitored using flow cytometry. 
Freshly isolated total CD4+ T-cells, naïve and memory CD4+ T-cells were centrifuged at 400g 
for 7 minutes and resuspended in 14ml PBS. Cells were centrifuged at 600g for 7 minutes, 
washed with PBS and then centrifuged at 600g for 10 minutes. Cells were then incubated for 5 
minutes at 37°C with 1µM CFSE (eBioscience) at a ratio of 1:1, giving a final concentration of 
0.5 µM. Staining was terminated by adding 15ml RF10 + 10% FCS, which will bind to any 
remaining CFSE, and incubating on ice for 5 minutes. Cells were then centrifuged twice at 600g 
for 7 minutes and resuspended in culture media before being counted and cultured.  
2.8.2 Tritiated thymidine incorporation assay 
Tritiated thymidine (3H-TdR) is a radioactive nucleotide that is added to the cell culture. This 
molecule will then be incorporated into newly synthesised strands of DNA by binding to 
adenosine, allowing the cell divisions to be quantified.  
Following stimulation in an MLR or with anti-CD3 and anti-CD28 as described in Chapter 
2.7.3-4, cells were incubated with 20µl 3H-TdR (Perkin Elmer; Massachusetts, USA) for 8 
hours at 37°C with 5% CO2. Cells were then harvested onto filters and counted with a 1450 
micro-B trilux, microplate scintillation and luminescence counter (Perkin Elmer). Results are 
given as counts per minute (CPM).  
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2.9 Flow Cytometry 
Flow cytometry is the measurement of cell characteristics using light. Cells are passed singly 
through a laser, which causes light to scatter, and fluorescence of differing wavelengths can be 
produced, which is detected by the optics system and recorded. Light is turned into numerical 
values by the electronics system and results are displayed visually as dot plots. The amount and 
the direction of light scatter indicate the cells size (forward scatter; FSC-A) and granularity 
(side scatter; SSC-A). Multiple parameters can also be measured including cell surface markers, 
intracellular cytokines, proliferation and viability by the use of fluorescently labelled antibodies 
or dyes which have specific wavelengths of absorption.  
2.9.1 Cell surface markers 
To measure parameters such as cell surface markers mAbs to specific antigens can be 
conjugated to fluorescent dyes (fluorochromes) which emit fluorescent light when excited by 
lasers. These antibodies can be used to give knowledge of cell phenotype. 
Freshly isolated or cultured cells, 0.2x106-1x106, were resuspended in 200µl fluorescence 
active cell sorting (FACS) buffer (Chapter 2.1), transferred to 96 well v-bottom plate, and 
further centrifuged at 400g for 3 minutes. Cells were subsequently incubated for 30 minutes in 
the dark at 4°C with FACS buffer, hIgG (gift from Dr. Sophie Hambleton, Newcastle 
University) at 4µg/ml to block non-specific binding of antibodies to Fc receptors. Antibodies 
were added with the dilution determined by titration of the antibody on 1x106 PBMC by 
members of the Musculoskeletal Research Group (Table 4). Cells were then washed twice with 
FACS buffer and centrifuged at 400g for 3 minutes, prior to acquisition. 
Cells were either acquired immediately or resuspended in FACS buffer with 1% formaldehyde 
and acquired within one week of staining. Formaldehyde is able to fix cells by forming 
crosslinks between proteins in the cell.  
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Surface stain Antibody Fluorophore Clone Species Isotype Dilution Company 
CD4 Purity CD3 PB UCHT1 Mouse IgG1 1:50 BD Biosciences 
 CD4v4 FITC L120 Mouse IgG1 1:10 BD Biosciences 
 CD14 PE M5E2 Mouse IgG2a, κ 1:20 BD Biosciences 
 CD19 APC HIB19 Mouse IgG1, κ 1:10 BD Biosciences 
Naïve Purity CD3 PB UCHT1 Mouse IgG1 1:50 BD Biosciences 
 CD4 FITC RPA-T4 Mouse IgG1, κ 1:50 Biolegend 
 CD14 PE M5E2 Mouse IgG2a, κ 1:20 BD Biosciences 
 CD19 APC HIB19 Mouse IgG1, κ 1:10 BD Biosciences 
 CD45RA PerCpCy5.5 HI100 Mouse IgG2b, κ 1:50 Biolegend 
Phenotype CD3 BV510 UCHT1 Mouse IgG1, κ 1:50 Biolegend 
 CD4 APCeFluor780 SK3 Mouse IgG1, κ 1:50 eBioscience 
 CD25 PECy7 BC96 Mouse IgG1, κ 1:50 Biolegend 
 CD27 V450 M-T271 Mouse IgG1, κ 1:50 BD Biosciences 
 CD28 APC CD28.2 Mouse IgG1, κ 1:10 BD Biosciences 
 CD45RA PerCpCy5.5 HI 100 Mouse IgG2b, κ 1:50 Biolegend 
 CD126 (IL-6R) CFS 17506 Mouse IgG1 1:10 R & D Systems 
 CD130 (gp130) PE 2E1B02 Mouse IgG2a, κ 1:10 Biolegend 
Activation CD3 BV510 UCHT1 Mouse IgG1, κ 1:50 Biolegend 
 CD4 APCeFluor780 SK3 Mouse IgG1, κ 1:50 eBioscience 
 CD25 PECy7 BC96 Mouse IgG1, κ 1:50 Biolegend 
 CD154 PE 24-31 Mouse IgG1, κ 1:10 Biolegend 
 CD185 AF647 J252D4 Mouse IgG1, κ 1:10 Biolegend 
 
Table 4. Flow cytometry antibodies used for purity, phenotype and activation analysis. Table shows fluorophore, 
clone, dilution and source of each antibody. CD4v4 is a different clone recognising amino acids 306-370 of the CD4 
antigen which are not masked by the binding of CD4 antibody complexes in the positive selection of CD4+ T-cells.  
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2.9.2 Viability staining 
Annexin V and 4’, 6-diamidino-2-phenylidone (DAPI) staining is a common method of 
assessing viability and gives information regarding the stages of apoptosis. DAPI is a dye that 
can cross the membrane of only dead cells. Annexin V is a protein, conjugated to a 
fluorochrome, which is able to bind phospholipid phosphatidylserine (PS) residues typically 
found on the inner cytoplasmic membrane. These residues are translocated to the outer 
cytoplasmic membrane in the early process of apoptosis to signal that the cell can be 
phagocytosed. The combination of these two viability markers aids analysis by allowing the 
identification of viable, early/late stages of apoptosis and dead cells. Zombie aqua is a similar 
viability dye that crosses the cell membrane, showing viable and dead cells. 
As a measure of viability freshly isolated and cultured naïve CD4+ were harvested and washed 
with FACS buffer as previously described. Cells were resuspended in binding buffer (Chapter 
2.1) prior to addition of Annexin V APC (Biolegend; 1:10) and 3µM DAPI (Life Technologies; 
California, USA). Cells were incubated in the dark for 15 minutes at room temperature prior to 
acquisition.  
Alternatively, cultured cells were harvested and washed in PBS (Lonza) as previously 
described. Cells were resuspended in 50µl PBS and 0.5µl zombie aqua (Biolegend) and 
incubated in the dark for 15 minutes at room temperature. Cells were washed and resuspended 
in FACS buffer for acquisition or subsequent cell surface staining. 
2.9.3 Intracellular cytokines 
In order to detect intracellular cytokines naïve or memory CD4+ T-cells were stimulated in a 
non-specific manner with PMA and ionomycin. PMA diffuses across cell membranes to 
activate protein kinase C and ionomycin triggers intracellular calcium release, which together 
activates cells and triggers cytokine production as resting cells only produce a minimal level of 
cytokine. Brefeldin A (BFA) is then used to retain the cytokines in the cell by preventing 
formation of transport vesicles and stopping protein transport from the endoplasmic reticulum 
(ER) to the Golgi apparatus. Cells must then be permeabilised to allow staining with anti-
cytokine antibodies.  
To cells cultured for intracellular cytokine staining 10ng/ml PMA (Sigma Aldrich) and 1µg/ml 
ionomycin (Sigma Aldrich) were added to cells and incubated at 37°C for 1 hour. After 1 hour 
BFA (Sigma Aldrich) was added at 1mg/ml and cultured for a further 4 hours at 37°C (unless 
otherwise stated). Control wells with BFA only were also added in order to carry out gating.  
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Cells for staining were harvested, resuspended in 200µl FACS buffer transferred to 96 well v-
bottom plate and centrifuged at 400g for 3 minutes. Cells were subsequently incubated for 30 
minutes in the dark at 4°C with FACS buffer, hIgG and antibodies for surface stain (Table 6). 
Cells were washed twice with FACS buffer as previously described. Cells were then incubated 
in Foxp3 fixation/permeabilisation buffer (eBioscience) for 30 minutes in the dark at 4°C. This 
buffer fixes the cells via formaldehyde but also permeabilises cells using saponin, allowing 
antibodies to bind intracellular proteins. Cells were then washed twice with FACS buffer before 
resuspending in FACS buffer to be stored overnight at 4°C in the dark. 
Within a week of surface staining cells were centrifuged at 400g for 3 minutes and incubated 
in 150µl Foxp3 permeabilisation buffer (eBioscience) for 15 minutes in the dark at 4°C. Cells 
were centrifuged 400g for 3 minutes and incubated for in the dark at 4°C for 15 minutes with 
50µl permeabilisation buffer and 2% mouse serum (Sigma Aldrich) to block non-specific 
binding. Subsequently, antibodies for intracellular cytokine staining or transcription factor 
staining were added (Table 5) and incubated for 30 minutes, as before. Cells were then washed 
twice with permeabilisation buffer and resuspended in FACS buffer for subsequent acquisition.  
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Intracellular 
staining 
Antibody Fluorophore Clone Species Isotype Dilution Company 
Cytokines CD3 (surface) PB UCHT1 Mouse IgG1 1:50 BD Biosciences 
 CD4 (surface) PerCP SK3 Mouse IgG1, κ 1:20 BD Biosciences 
 IFN-g FITC 4S.B3 Mouse IgG1, κ 1:100 EBiosciences 
 IL-4 PeCy7 8D4-8 Mouse IgG1, κ 1:200 EBiosciences 
 IL-17 APCeF660/ 
APCCy7 
64DEC17/BL
168 
Mouse IgG1, κ 1:10 EBiosciences/ Biolegend 
 IL-21 PE EBIO3A3-N2 Mouse IgG1, κ 1:10 EBiosciences 
Transcription factors CD3 PerCP SK7 Mouse IgG1, κ 1:20 BD Biosciences 
 CD4 APCeF780 SK3 Mouse IgG1, κ 1:50 EBiosciences 
 T-bet BV421 O4-46 Mouse IgG1, κ 1:20 BD Biosciences 
 GATA-3 eF660 TWAJ Mouse IgG2b, κ 1:20 EBiosciences 
 ROR-γt AF488 Q21-559 Mouse IgG2b, κ 1:20 BD Biosciences 
 Foxp3 PE 236A/E7 Mouse IgG1, κ 1:20 BD Biosciences 
Table 5. Flow cytometry antibodies used for intracellular cytokine staining. Table includes fluorophore, clone, dilution and source of 
each antibody. 
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2.9.4 Whole blood phenotype 
Whole blood staining for flow cytometry is the process of staining blood with fluorophore-
conjugated mAbs to specific antigens on cells in the blood. This process involves the addition 
of lysing solution to remove red blood cells and fix white blood cells. As cell processing can 
introduce variability whole blood was used to analyse the expression of IL-6 signalling 
receptors gp130 and IL-6R on CD4+ T-cell subsets (true naïve, central memory and effector 
memory, Figure 9) from early arthritis patients.  
 
200µl EDTA fresh whole blood of patients from the Early Arthritis Clinic was incubated with 
antibodies for whole blood staining (Table 6) for 30 minutes at 37°C. Samples were then 
incubated with 10x volume of FACS lysing solution (BD Biosciences; Oxford, UK) for 12 
minutes at 37°C. Cells were then washed once in FACS buffer, prior to acquisition.  
Figure 9. Identification of true naïve, central memory and effector memory CD4+ T-cells. 
CD4+ T-cells are gated as CD3+CD4+ and from this T-cell subsets are identified by their 
differential expression of CD45RA and CD62L. True naïve CD4+ T-cells are 
CD45RA+CD62L+, central memory CD4+ T-cells are CD45RA-CD62L+ and effector memory 
CD4+ T-cells are CD45RA-CD62L-.  
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Whole blood 
stain 
Antibody Fluorophore Clone Species Isotype Dilution Company 
Phenotype CD3 BV510 UCHT1 Mouse IgG1, κ 1:20 Biolegend 
 CD4 APCeFluor780 SK3 Mouse IgG1, κ 1:200 eBioscience 
 CD27 V450 M-T271 Mouse IgG1, κ 1:200 BD 
Biosciences 
 CD28 APC CD28.2 Mouse IgG1, κ 1:50 BD 
Biosciences 
 CD45RA FITC HI 100 Mouse IgG2b, κ 1:200 BD 
Biosciences 
 CD62L PECy7 DREG-56 Mouse IgG1, κ 1:100 Biolegend 
 CD126 PerCPeFluor710/ 
CFS 
47.797.1F2/ 
17506 
Mouse IgG1 1:50 eBioscience 
 CD130 PE 2E1B02 Mouse IgG2a, κ 1:50 Biolegend 
Table 6. Flow cytometry antibodies used in whole blood phenotype staining. Table includes fluorophore, clone, 
dilution and source of each antibody. 
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2.9.5 Data acquisition and analysis 
Cells were analysed using FACS Canto II (BD Biosciences) and compensated using 
compensation beads (BD Biosciences) bound to the antibody of interest.  
Subsequent data was analysed using FlowJo version 10 (Treestar Inc.; Oregon, USA). To ensure 
the correct placement of gates internal negative controls were used in whole blood assays, with 
gates set based on other populations in the sample which do not express the marker of interest. 
In experiments where the starting population of CD4+ T-cells were available, as in purity and 
phenotype analyses, gates were set on this population and transferred to the population of 
interest, namely naïve or memory CD4+ T-cells. The disadvantage to this method is that with 
purified population the antibody to antigen ratio can decrease if not enough antibody is added 
compared to the starting population resulting in a left shift. Further optimisation of the antibody 
would be required for use on purified populations. For intracellular staining gates were set on 
BFA only controls (i.e. unstimulated) and then applied to the population of interest.  
In some cases, there was clear bimodal expression of a particular antigen resulting in clear 
positives and negatives meaning gates could be easily determined. In other cases, gates were 
set based in an unstained population of cells and in the case of CD40L; gates were set on 
fluorescence minus one (FMO) controls. The use of unstained cells takes into account the 
background fluorescence and autofluorescence of the sample and gates can be set to determine 
the negative populations. An FMO control includes all of the antibody conjugates present in the 
test sample except one. The advantage of an FMO control is that it can help identification of a 
positive population when the expression of that marker is low. This method allows the 
assessment of the spread of fluorescence as a fluorophore from another may leak into the 
channel of interest causing false positive staining. This approach however does not provide 
information on background non-specific staining which can be tested for by the use of isotype 
controls. Isotype controls ensure that observed staining is due to the specific binding of antibody 
to its target and not due to non-specific binding to Fc receptors or cellular components. 
However, the ratio of fluorophore to antibody must be the same as the antibody of interest, 
which can very greatly between reagents, creating variable levels of background staining. These 
controls also do not account for fluorescence spill over from other channels (444). For this 
reason isotype controls were not used in this thesis. 
Proliferation was calculated using the proliferation tool on FlowJo. This tool calculates division 
index (DI), proliferation index (PI) and the percent divided (% divided) for each sample. These 
provide information on cell divisions and numbers of cells entering division:  
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 DI – The average number of cell divisions a cell in the original population has 
undergone (includes undivided cells). 
 PI – Total number of divisions divided by the number of cells that went into division 
(includes only divided cells). 
 Percentage divided – Precursor frequency of dividing cells (the probability of a cell 
dividing).  
An example of the gating strategy for proliferation analysis can be seen in Figure 10, all other 
gating strategies can be found in Figures 1-8 in the Appendix.  
2.10 Cytokine Detection 
A sandwich enzyme linked immunosorbent assay (ELISA) or MesoScale Discovery (MSD) 
allows quantitative measurement of substances such as peptides within a known range.  
In the case of an ELISA, the capture antibody, toward the antigen of interest, must be 
immobilised onto 96-well high affinity EIA/RIA flat bottom plates. Non-specific binding sites 
are blocked so the antibody captures the antigen within the sample. A biotinylated detection 
antibody binds to the antigen of interest, followed by a streptavidin conjugated enzyme label 
which binds the biotin of the detection antibody. A substrate is added which once bound to the 
enzyme can be converted to absorbance signal to indicate antigen quantity. This can be 
compared to a standard curve of known concentrations.  
The MSD is a similar technique using the “sandwich principle”, however, plates are bought 
pre-coated with up to 16 antibodies of interest and detection occurs using electro-
chemoluminescence. This works as high binding carbon electrodes in the microplates attach 
biologic reagents. Electrochemiluminescent labels are conjugated to detection antibodies, when 
voltage is applied to the plate electrodes light is emitted from these labels, and light intensity 
can be quantified.  
Figure 10. Gating strategy for proliferation analysis. CFSE labelled naïve and memory 
CD4+ T-cells were stained with DAPI before acquisition on the flow cytometer. Cells were 
gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-A to gate lymphocytes. 
Proliferating cells were then gated as DAPI negative and proliferation analysed using FlowJo 
proliferation tool.  
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Supernatants from cell cultures were frozen at -20°C at the time of harvest for detection of IL-
10, IFN-γ, IL-4 and IL-5. Serum from healthy donors and EAC attendees were taken at baseline. 
Serum was separated by centrifuging 1200g for 12 minutes at room temperature and then frozen 
at -20°C. Samples were defrosted for use in ELISA or MSD.  
2.10.1 Sandwich Enzyme Linked Immunosorbent Assay  
96 well EIA/RIA flat bottom plates (Costar, Corning) were coated with IL-10, IFN-γ, IL-4, IL-
5 (BD biosciences) or IL-17 (eBiosciences) capture antibody diluted in phosphate buffer 
(Chapter 2.1) as per manufacturers instructions, overnight at 4°C, Table 7. Plates were then 
washed 3 times with ELISA wash buffer (Chapter 2.1) then blocked with 100µl ELISA 
blocking buffer for 2 hours at room temperature. Plates were then washed 5 times in wash 
buffer. Cell supernatants (diluted to 1:2 and 1:10 with diluent (Chapter 2.1)) and standards (top 
standard with 2-fold serial dilution) were added to the plate and incubated overnight at 4°C. 
After washing plates as before biotinylated detection antibody was added diluted in diluent 
(final concentrations in Table 7) and incubated at room temperature for 1 hour. Plates were 
washed again and 50µl of streptavidin-horseradish peroxidase (HRP; Extr Avidin; Sigma 
Aldrich) diluted 1/1000 in diluent was added and incubated at room temperature in the dark for 
30 minutes. Plates were washed before addition of ortho-phenylenediamine dihydrochloride 
substrate (OPD; Sigma Aldrich; Missouri, USA), diluted in 13ml citrate phosphate buffer with 
H2O2 (6μl 30% stock, added immediately prior to use) and plates incubated for 30 minutes in 
the dark, or until colour developed. Reaction was stopped by adding 3M H2SO4 and optical 
density was read at 450nm or 490nm (Table 7) on a Sunrise micro-plate reader (Tecan Group 
Ltd; Mannedorf, Switzerland). A standard curve of absorbance can be plotted using known 
concentrations for the cytokine of interest as in Figure 11. Samples were analysed in duplicate 
and a line of best fit is then applied using Microsoft Excel. The concentration of the cytokine 
of interest can then be calculated for samples using the equation y=mx+c and R2.  
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Cytokine Capture 
Antibody 
(µg/ml) 
Detection 
Antibody 
(µg/ml) 
Top 
Standard 
(pg/ml) 
Developing 
Time 
(mins) 
Absorbance 
(nM) 
IFN-γ 1 1 2000 20-30 490 
IL-5 0.5 0.5 3000 30 490 
IL-10 2 1 2000 30-40 490 
IL-17 1/250 1/250 500 15 450 
Table 7. The concentration of antibodies used for ELISA. Table includes concentrations of 
capture and detection antibodies, concentration of the top standard, developing time of the assay 
and the absorbance of each assay.  
Figure 11. Example of IFN-γ standard curve in ELISA analysis. Standard curve plotted 
using known concentrations of the cytokine of interest and line of best fit is applied. 
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2.10.2 MSD 
MSD analysis of supernatants was carried out according to manufacturer’s instructions. Briefly, 
calibrators of known concentration for IL-17 and tenplex cytokines were made with 4-fold 
dilutions from 10000pg/ml to 0pg/ml. 25µl of samples were added to IL-17 plate or 50µl 1:1 
samples diluted with diluent (Meso Scale Discovery; Maryland, USA) were added to tenplex 
plates. Plates were sealed and incubated for 2 hours at 500rpm. Plates were washed 3 times in 
PBS + 0.05% tween 20 and 25µl diluted detection antibodies were added. Plates were sealed 
and incubated for 2 hours with shaking. Plates were washed 3 times as before and 150µl read 
buffer, diluted 1:1, was added. The plate was then analysed plate on SECTOR imager (Meso 
Scale Discovery). The dynamic range for each cytokine measured can be seen in Table 8. 
Cytokine Dynamic Range (pg/ml) 
IFN-γ 0.20-938 
IL-1β 0.04-375 
IL-2 0.09-938 
IL-4 0.02-158 
IL-6 0.06-488 
IL-8 0.04-375 
IL-10 0.03-233 
IL-12p70 0.11-315 
IL-13 0.24-353 
TNF-α 0.04-248 
IL-17 0.4-10000 
2.11 Quantification of Gene Expression 
For the quantification of gene expression RNA is extracted from cells under different 
experimental conditions. Samples are first lysed to disrupt cell walls and homogenised to sheer 
the DNA and other cell components. Samples are then applied to spin columns which binds 
RNA and contaminants are washed away. Additional DNase treatment removes any residual 
DNA. Total RNA can then be eluted, quantified and reverse transcribed into complementary 
DNA (cDNA). First RNA is denatured with the help of reducing agent dithiotheritol (DTT) 
which breaks disulphide bonds to generate single stranded RNA. The cDNA is then made, a 
process involving annealing and extension, random hexamers act as primers and 
Table 8. Dynamic range of cytokine detection of the MSD plate. Table showing cytokines 
used in MSD analysis and the dynamic range of detection for each cytokine. 
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deoxynucleoside triphosphates (dNTPs) provide the nucleotides for the synthesis of cDNA 
which is driven by superscript II reverse transcriptase enzyme.  
Following reverse transcription cDNA is amplified and quantified by TaqMan real time PCR. 
This technique works as an initial high temperature allows the denaturation of double stranded 
cDNA. The temperature is then lowered which allows the binding of primers, short sequences 
against the gene of interest. Temperature is then raised again to drive a thermostable polymerase 
enzyme which is able to synthesise the complementary sequence. This cycle creates twice the 
copy number and is carried out for a total of 40 cycles. In the TaqMan real time PCR reaction 
this process is monitored by the detection of fluorescence which is provided by probes. Probes 
are DNA oligonucleotides which have a fluorescent reporter molecule at the 5’ end and a 
quencher molecule at the 3’ end. The interaction of these molecules mean fluorescence is 
suppressed. Probes bind downstream of primers and are then cleaved by the polymerase enzyme 
to separate the reporter and the quencher allowing fluorescence at a certain wavelength. This 
level of fluorescence correlates with the level of DNA amplification to allow quantification.  
Housekeeping genes are genes which are constitutively expressed by a certain cell which do 
not change under differing experimental conditions such as RNA polymerase II subunit A 
(POLR2A, RPB1), a polymerase responsible for synthesising mRNA, and 18S, a ribosomal 
RNA . These genes are used as a reference point for analysis of expression levels of the gene 
of interest in order to normalise data. This allows a ratio for the expression of genes of interest 
divided by the expression of the normalised housekeeper gene to allow comparison between 
samples without the knowledge of absolute expression.  
2.11.1 RNA homogenisation 
CD4+ T-cells at 1x106 were harvested, washed with Hanks + 1% FCS and centrifuged at 400g 
for 7 minutes. Cells were then homogenised in RLT buffer (Qiagen; Hilden, Germany) 
supplemented with 10% β-metacaptoethanol (Sigma Aldrich). Cells were vortexed and 
transferred to QIA shredder columns (Qiagen) before being centrifuged at 13000rpm for 2 
minutes. Shredder columns were removed and homogenates stored at -80°C for maximum of 3 
months. 
2.11.2 RNA Extraction 
RNA was then isolated using Qiagen RNeasy mini kit according to manufacturer’s protocol. 
To the homogenised lysate 1 volume of 70% ethanol (Fisher Scientific) was added, transferred 
to an RNeasy spin column, centrifuged for 15 seconds at 8,000 g and flow-through was 
discarded. Cells were then washed once with 500µl of buffer RPE and centrifuged for 15 
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seconds at 8,000 g. Cells were washed again with 500µl of buffer RW1 and centrifuged for 15 
seconds at 8,000 g before being incubated with DNase I for 15 minutes. Cells were then washed 
as previously described with RW1 followed by RPE. Cells were then placed in a new RNeasy 
column and 30µl RNase-free water (Qiagen) was added and centrifuged for 1 minute at 10,000 
rpm. 
Using a Nanodrop 1000 UV Spectrophotometer (Thermo Fisher Scientific) RNA was 
quantified and quality assessed according to manufacturer’s instructions. Concentrations and 
260:280 ratios, which provide a measure of nucleic acid quality, are given in the Appendix. 
Typically, a concentration of 1x106 cells gave a median yield of 29.75ng/µl RNA with a median 
260:280 ratio of 1.905.  
2.11.3 Reverse Transcription 
cDNA was synthesised from RNA (in duplicate) using Superscript II Reverse Transcriptase 
(Invitrogen). A reverse transcriptase free sample and water sample were also used as negative 
controls. 
To all samples 1µg/µl random hexamers (Thermo Fisher Scientific) was added and incubated 
for 10 minutes at 70°C on thermal cycler, followed by a 10 minute incubation on ice. To each 
of the samples 4µl 5x RT buffer (Thermo Fisher Scientific), 2µl 0.1M DTT (Invitrogen), 0.5µl 
10mM dNTP (Invitrogen), 0.5µl Superscript II and 2µl H2O was added and incubated for 1 
hour at 42°C, Table 9.  
Stage of Reverse Transcription Thermocycler Setting 
Denaturation 70°C, 10 minutes 
cDNA synthesis 42°C, 1 hour 
2.11.4 TaqMan real time Polymerase Chain Reaction 
After reverse transcription, cDNA was transferred to 96 well PCR plates in duplicate (Starlab; 
Brussels, Belgium) and then amplified using TaqMan assay (Applied Biosystems; California, 
USA). For genes of interest and POLR2A, RPB1 housekeeping gene, cDNA was diluted 1 in 
2.5, with water (Sigma Aldrich). To cDNA universal FAM probes, forward and reverse primers 
(Table 10) were added at 10µM along with 10µl of TaqMan Gene Expression Master Mix (2x; 
Applied Biosystems). For the housekeeping gene, 18S, cDNA was diluted 1 in 100, in-house 
FAM-TAMRA probe was used at 15µM, forward and reverse primers were used at 30µM and 
Table 9. Thermocycler settings for reverse transcription. Table showing the stage of reverse 
transcription with the temperature and length of incubation on the thermocycler.  
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4.7µl of TaqMan Gene Expression Master Mix (2x) were added. PCR settings can be seen in 
Table 11 and included 1 cycle of denaturation at 90°C for 1 minute, 45 amplification cycles at 
95°C for 15 seconds, 55°C for 15 seconds and 72°C for 10 seconds. Raw gene expression data 
was normalized to the 18S or POLR2A housekeeping genes using the calculation 2-
ΔCT
 values, 
where ΔCT represents CT(target gene) – CT(housekeeping gene).  
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Gene Forward Primer Reverse Primer Probe 
18S 
(NR_003286) 
cgaatggctcattaaatcagttatgg tattagctctagaattaccacagttatcc tcctttggtcg
ctcgctcctc 
POLR2ARPB1 
(NM_000937.4) 
ttgtgcaggacacactcaca caggaggttcatcacttcacc UPL 1 
BCL-3 
(NM_005178) 
cgacatctacaacaacctacgg ccacagacggtaatgtggtg UPL 39 
SOCS-3 
(NM_003955) 
agacttcgattcgggacca aacttgctgtgggtgacca UPL 36 
PIM-1 
(NM_002648) 
gatttccgactggggagag agtccaggagcctaatgacg UPL 18 
BCL-6 
(NM_001706) 
ttccgctacaagggcaac 
 
tgcaacgatagggtttctca 
 
UPL 5 
REXO2 
(NM_015523) 
aaggagcatcacgggaagt 
 
tcgtacaaaggacagaaattcatact 
 
UPL 40 
SBNO2 
(NM_014963) 
gactacgtgccgtccaagtc 
 
cagggtgtaggtgatgtctgg 
 
UPL 54 
LRP8 
(NM_004631) 
actcccgaagaaccctcttt caaggcttaatgccactcg 
 
UPL 27 
C10orf10 
(NM_007021) 
gtccctgctcatccattctc 
 
cactctggcgagaggaggt 
 
UPL 1 
CST7 
(NM_003650) 
ctctcaggcctctgacgagt 
 
ttaggaggtgctaccatgctg 
 
UPL 59 
GPT2 
(NM_001142466) 
gatcctgcaggcttgtgg 
 
ttcacggatgcagttgacac 
 
UPL 64 
RRAD 
(NM_001128850) 
gacgagagcgtttacaaggtg 
 
ggagcgatcataggtgtgc 
 
UPL 3 
CBS 
(NM_001178008) 
atcatttcccctcccgtct 
 
cagagacacaaagtcgatcagc 
 
UPL 52 
GSTO1 
(NM_004832) 
gcacttttgagctaaggaggaa 
 
aggggattcaggaagtaggtg 
 
UPL 12 
Table 10. Nucleotide sequences of forward and reverse primers and probes for each gene 
used in TaqMan real time PCR assays. Probes from Universal Probe Library (Roche). 
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2.11.5 Real time PCR analysis 
RT-PCR was carried out using the Aria Mx Real-Time PCR system (Agilent Technologies, 
California, US). A graph was produced of fluorescence intensity versus cycle number on a log 
scale. Thresholds were set for each gene at the point where the fluorescence curve begins its 
exponential phase. CT values were then analysed in Excel (Microsoft Office). Delta CT can be 
calculated by subtracting gene of interest CT value from the selected housekeeping gene CT 
value. The housekeeping gene chosen for cytokine stimulation experiments, Chapter 4.3.1, was 
18S as this is a commonly used housekeeping gene, which had been previously established in 
the lab to be consistent across CD4+ T-cells in different experimental conditions (Dr Pratt, 
personal communication). For the analysis of gene expression of early arthritis patients 
compared to healthy controls, Chapter 6.3.3-4, housekeeping gene POL2RPB1 was tested 
against the 18S housekeeping gene. For these experiments, the CT values of both the 18S and 
the POL2RPB1 housekeeping genes were measured and the CT values of the POL2RPB1 gene 
were found to be most comparable to the CT values of the genes of interest and were more 
stably expressed so this was chosen in order to allow for fairer comparisons (data not shown). 
The relative quantity of mRNA is 2-
ΔCT
.
 
Fold induction could be analysed by comparing 
cytokine-stimulated conditions with untreated conditions at each time point. 
2.12 Microarray 
Microarray is a high throughput method of measuring gene expression levels of a large number 
of genes in RNA samples simultaneously. The Illumina microarray uses bead-based technology 
to provide gene expression profiling. This method involves 3-micron silica beads, which are 
attached to oligonucleotide probes and immobilised by random distribution in microwells.  
These oligonucleotide probes are 79 nucleotides in length and each bead has a 29 base 
identifiable “address” probe to identify the location of each bead. Multiple copies of each bead 
may be present in one well. This can be used as technical replicate for variance stabilising 
transformation. The remaining 50 nucleotides are specific for gene sequences and detect 
Stage of RT-PCR Thermocycler Setting Number of Cycles 
Glycosylase activation 50°C, 2 minutes 1 
Polymerase activation 95°C, 10 minutes 40 
Denaturation 95°C, 15 seconds 40 
Annealing and Extension 60°C, 1 minute 40 
Table 11. Thermocycler settings for TaqMan real time PCR. Table showing the stage of 
real time PCR with the temperature and length of each cycle. 
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labelled cRNA. This provides high sensitivity and highly reproducible gene expression 
quantification with reduced sample-to-sample variability.  
RNA was extracted as described in Chapter 2.11 from naïve and memory CD4+ T-cells of 4 
biological replicates. RNA was then shipped on dry ice to Tepnel Pharma Services, where 
samples were processed into double stranded cDNA, amplified to create cRNA and hybridised 
to Illumina Human HT-12 v4.0 microarray. The Human HT-12 v4.0 Expression BeadChip 
allows human genome wide expression profiling of well-characterised genes, gene candidates 
and spice variants. Each array contains probes for over 47,000 transcripts.  
Briefly, total RNA was reverse transcribed to synthesise single-strand cDNA. This was 
converted to double stranded DNA to provide the template for transcription. cDNA is then 
purified before being amplified and labelled generating a pool of biotin labelled cRNA. This 
cRNA is then purified and quantified for use on the assay. Equivalent amounts of labelled RNA 
is loaded into BeadChips, which are then placed in hybridisation chambers and incubated for 
14-20 hours at 58°C. cRNA is hybridised to each array on the BeadChip, which contains the 
complementary gene sequence. The BeadChip is then washed numerous times before being 
blocked. Finally, Cy3-Streptavadin is introduced to the array, which binds the analytical probes 
hybridised to the BeadChip, allowing differential detection of signals upon scanning. The 
Illumina HiScan or BeadArray Reader, a high-resolution imager, scans the BeadChip at a 
particular wavelength and light emissions are recorded as high-resolution images. The 
fluorescence intensity at each bead location can be determined and the intensity of the signal is 
proportional to the quantity of transcript in the original sample. Data files of this information 
are created and GenomeStudio software is then used to export probe summary profiles as files, 
which allows further analysis of the data. The raw data of intensities was securely transferred 
electronically in the form of IDAT files, which were used for analysis.  
Controls included housekeepers, genes known to be constitutively expressed to ensure the 
biological specimen remained intact, RNA Spike, the introduction of known concentration of 
RNA to ensure correct sample labelling, Cy3-labelled hybridisation controls, which test the 
hybridisation of assay products to the array beads, Biotin control, to monitor signal generation 
and negative controls to determine the background of the system and any signal resulting from 
non-specific binding or cross hybridisation.  
2.12.1 Microarray analysis 
Prior to receiving data background correction was carried out in GenomeStudio (Illumina Inc., 
San Diego). Probe profiles were read into R software version 3.3.0 and all data analysis was 
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carried out in the R software environment, a free open-source software for statistical computing. 
Data was analysed using the Bioconductor and limma packages, add-on modules that provide 
the tools for analysis of high-throughput genomic data. Code for data analysis on R was carried 
out in dialogue with a bioinformatician via collaboration with Newcastle University’s core 
Bioinformatics Support Unit and the author carried out further analysis.  
Microarray data was processed, including quality control, normalisation and gene annotation, 
using the lumi package in Bioconductor (445, 446). Data quality was assessed by visualising 
raw data as box-plots to assess background intensities, to highlight whether any arrays had 
unusually high background intensities. Within-assay normalisation was performed using 
variance stabilising transformation (VST) (447). This uses within-array technical replicates to 
reduce false positives. Following this between array normalisation was carried out using robust 
spline normalisation (RSN), which ensures intensity values across arrays have the same 
distribution using a combination of quantile normalisation and Loess normalisation (446). At 
this stage probes can be removed which fail to pass detection threshold and transformation and 
normalisation procedures repeated. Data was then subject to principle component analysis 
(PCA) and plots were generated which plot the 2 measures which account for the greatest 
variance in the data and arrays whose gene expression is similar will cluster together (448). As 
probes are specific to the technology used these need to be matched to external identifiers such 
as nuID’s to allow for cross platform data integration (449).  
The limma package is used for further differential gene expression analysis, which uses 
Empirical Bayesian methods to moderate variance of log fold changes across arrays (450). A 
design matrix was created and a linear model fitted to each gene. Comparisons can then be 
made by fitting to the linear model and applying empirical Bayes statistics to obtain differential 
expression values for all probes. The final stage of analysis involves filtering of differential 
expression lists by applying log fold change and p-value cut offs and applying multiple test 
correction to test statistics, which controls for error rate giving a lower number of false 
positives.  Data was analysed with an adjusted p-value cut off of p<0.05 and a log fold change 
of 1.5 and multiple test correction carried out using the Benjamini-Hochberg method (451). 
Differential gene induction was visualised using volcano plots and the ggplot2 package. Lists 
of differentially expressed genes, Gene Lists 1A-5D, can be found in CD-ROM in the Appendix. 
Further tests used in the analysis of gene expression data include hypergeometric testing which 
is a statistical test to determine the probability of genes differentially expressed between early 
RA and disease controls occurring in IL-6 exposed naïve CD4+ T-cells. Functional pathway 
analysis was carried out using Ingenuity Pathway Analysis (Qiagen). This is a web-based 
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software for analysis of microarrays. It can provide information on genes and proteins and build 
models to explore experimental systems. Information is provided in the form of p-values and 
z-scores. A z-score is the measurement of the number of standard deviations the raw score is 
from the population mean.  
2.13 Statistical Analysis 
For flow cytometric analyses percentage positive cells, proliferation index, division index or 
percentage of cells divided were visualised as graphs using GraphPad Prism 5.03 (GraphPad 
Software Inc.; California, USA). For cell surface markers percentage positive cells were used 
to create graphs using GraphPad Prism. Various statistical analyses were carried out on the data 
of three biological replicates or more, including the use of both parametric and non-parametric 
tests. Student t-tests were performed to analyse parametric data. For non-parametric data, either 
Wilcoxon matched paired t-test or Mann-Whitney U test were performed depending on whether 
dependent (paired) or independent samples were the subject of analysis. These statistical tests 
were performed using GraphPad Prism (GraphPad Software Inc.) and p-values < 0.05 were 
considered statistically significant.  
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Chapter 3. In vitro model of IL-6 pre-exposure 
 
3.1 Introduction  
Based on the hypothesis outlined in Chapter 1, the overarching aim addressed in this chapter is 
the development of an in vitro system in order to recapitulate the chronic exposure of naïve and 
memory human CD4+ T-cells to a robust, but approximately physiological, level of IL-6 
believed to be occurring in vivo in the early stages of RA. The downstream effects of this period 
of IL-6 pre-exposure on naïve and memory effector phenotypes and transcriptional profiles 
were then interrogated as outlined in Chapters 4 and 5 to provide further insight into cytokine 
mediated priming in immune dysregulation in early RA. 
Naïve CD4+ T-cells have been shown to be particularly sensitive to IL-6, indicated by the high 
levels of pSTAT-3, Chapter 1.3.12. This increased sensitivity appears to be independent of 
serum levels of sIL-6R and sgp130 and independent of IL-6R expression. For this reason, the 
work presented in this chapter aims to assess whether expression of the IL-6 signal transducing 
subunit gp130 can account for the high sensitivity of this naïve subset compared to the memory 
subset. 
In order to assess the consequences of IL-6 pre-exposure on downstream effector profile and 
transcriptional profiles, naïve and memory CD4+ T-cells will be isolated and subject to a period 
of pre-exposure to IL-6 before the cytokine is removed from the system and cells are stimulated 
via the TCR. To ascertain whether effects of IL-6 pre-exposure are more pronounced in naive 
CD4+ T-cells, as a result of their apparent increased sensitivity, these subpopulations will be 
isolated and cultured in parallel.  
One of the key elements of the in vitro IL-6 pre-exposure model is the isolation of naïve CD4+ 
T-cells and a comparator memory CD4+ T-cell population.  Naïve and memory CD4+ T-cells 
differ in expression of several T-cell maturity markers which allows their characterisation and 
isolation for functional applications. Naïve CD4+ T-cells express CD45RA whereas their 
memory counterparts express CD45RO. Memory CD4+ T-cells can then be further sub divided 
into central memory and effector memory by differential expression of CD62L, the lymphocyte 
homing marker absent on effector memory CD4+ T-cells, Figure 9 Chapter 2.9.4. A small 
population of effector T-cells are able to regain the expression of CD45RA and these are termed 
terminally differentiated cells, these cells are only present in a small proportion of individuals 
at relatively low levels. The cells that are isolated will impact the interpretation of the data so 
it is important that isolated populations have high levels of purity.  
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Another key element to the in vitro model is the IL-6 pre-exposure period. This has several 
variables which require optimisation including; concentration of IL-6, the presence of sIL-6R 
and the length of pre-exposure. It is important for the concentration of IL-6 used in the system 
to be physiologically relevant while still having robust effects on downstream phenotype. It has 
been described that levels of IL-6 reach up to 184pg/ml in RA sera and 9.46ng/ml in synovium, 
therefore to ensure physiological relevance a range of IL-6 concentrations will be tested (265, 
452, 453). As previously mentioned IL-6 can signal via membrane bound IL-6R or sIL-6R in 
classical and trans signalling respectively, Chapter 1.3.2. The presence of sIL-6R in the culture 
system enables the possibility of trans signalling, whereas the absence will restrict the in vitro 
model to predominantly classical signalling. The different signalling pathways of IL-6 may 
have potential implications on downstream effector phenotype. The inclusion of sIL-6R will 
encompass both signalling mechanisms, ensuring the system will be saturated and will result in 
high levels of signalling to ensure any effect of pre-exposure is observed. The length of culture 
of cells during the pre-exposure period also needs to be carefully determined in order to balance 
chronicity of exposure, as occurs in early RA, with the viability of cells in the absence of TCR 
stimulation. 
All aspects of the in vitro model need to be carefully optimised in order to balance 
approximation to the physiological state with experimental reductionism in order for the effect 
of IL-6 pre-exposure to be determined.  
3.2 Aims and Objectives  
The work outlined in this chapter aims to establish a robust system for isolating naïve and 
memory CD4+ T-cells from healthy controls and culturing in the presence or absence of IL-6 
before its removal from the system followed by stimulation via the TCR to examine the effects 
of IL-6 pre-exposure on CD4+ T-cell effector function. The role of this optimised in vitro model 
is to mimic the situation in early RA patients where cells are chronically exposed to circulating 
IL-6. Presence of IL-6 at time of stimulation of CD4+ T-cells has been widely studied and for 
this study, we are interested in the cytokine pre-priming effects of prior exposure to IL-6 on 
circulating CD4+ T-cells. This in vitro system can then be used to investigate the effect of 
chronic IL-6 stimulation and assess its ability to influence effector phenotype following TCR 
mediated activation in terms of proliferation, activation and cytokine production, Chapter 4.  
The specific objectives were to: 
 Assess the expression of IL-6 signalling components on CD4+ T-cell subsets 
 Determine the optimal method of naïve CD4+ T-cell isolation. 
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 Obtain a comparator memory cell fraction for each isolation. 
 Assess the optimal culture conditions of naïve CD4+ T-cells in terms of culture medium, 
length of culture and culture with cytokines. 
 Examine the phenotypic consequences of pre-exposure of naïve and memory CD4+ T-
cells to IL-6 prior to TCR mediated activation.  
 Determine the optimal method of TCR stimulation. 
 
3.3 Results 
3.3.1 Expression of IL-6 receptor components on CD4+ T-cell subsets  
It was observed in Chapter 1.3.12 that there is an apparent increase in sensitivity of 
CD45RA+CD62L+ naïve CD4+ T-cells to IL-6, documented by the strong correlation between 
serum IL-6 and activated STAT-3 (Figure 8, Chapter 1. 3.12). This was not related to IL-6R 
expression, which was maximal on central memory CD4+ T-cells suggesting a mechanism other 
than IL-6R expression is responsible for increased sensitivity of these cells to IL-6. For this 
reason, the initial focus was to examine whether this increased sensitivity was due to differences 
in expression of the gp130 signalling component.  
The expression levels of both gp130 and IL-6R on CD4+ T-cells of patients from the NEAC 
were assessed by whole blood staining, the gating strategy for this analyses, employing the 
setting of gates on internal negative controls, Methods 2.9.5, is depicted in Figure 8, Appendix. 
Clinical information of these patients can be seen in Table 12. Whole blood was stained with a 
panel of antibodies to identify CD3+CD4+ T-cells and expression of CD45RA and CD62L were 
used to determine true naïve and memory cell sub-populations. Staining of these populations 
for IL-6R using the IL-6R-PerCPeFluor710, clone 47.797.1F2, reflected expression previously 
seen in Figure 8, Chapter 1.3.12. Representative dot plots show fewer naïve CD4+ T-cells 
positive for IL-6R but a higher number of cells positive for gp130, Figure 12A and C. This was 
consistent amongst 27 donors with the median represented in Figure 12B and D. True naïve 
CD4+ T-cells had the lowest levels of IL-6R, with the highest expression on central memory 
CD4+ T-cells, with moderate levels on effector memory CD4+ T-cells, Figure 12A-B. This 
pattern could also been seen using a different antibody, IL-6R-CFS, clone 17506 recognising a 
different epitope of the IL-6R, Figure 9, Appendix. In contrast, staining of these populations 
revealed maximal expression of gp130 on true naïve CD4+ T-cells, with reduced levels on 
central memory and further reduced levels on effector memory cells, Figure 12C-D. This 
increased expression of the IL-6Rβ signalling subunit provides a possible explanation as to the 
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apparent increased sensitivity of naïve CD4+ T-cells to IL-6 and a potential mechanism for 
increased levels of trans signalling.  
 Rheumatoid 
Arthritis (n=8) 
Other 
Inflammatory 
(n=7) 
Non-Inflammatory 
(n=11) 
Age (years, mean, 
SD) 
61 (49-73) 48 (26-70) 47 (37-57) 
% Female 63 29 72 
CRP (g/l; median) 18.5 7 4 
ESR (s, median) 40.5 9 2 
ACPA+ 6 1 1 
RF+ 6 2 2 
Table 12. Clinical characteristics of EAC attendees that donated whole blood for gp130 
and IL-6R expression staining. Table showing the clinical characteristics of EAC attendees 
including age, sex, levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) 
and anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) status.  
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In summary, there are high levels of gp130 on naïve CD4+ T-cells compared to memory CD4+ 
T-cells and of the memory subsets, the effector memory cells have the lowest expression of 
gp130. Alternatively central memory CD4+ T-cell express the highest level of IL-6R with true 
naïve CD4+ T-cells having the lowest level of IL-6R. Due to the difference in expression of IL-
6 receptor subunits on naïve and memory CD4+ T-cells it was decided that future experiments 
should compare the responses of both naïve and memory CD4+ T-cells to IL-6.  
3.3.2 Isolation of naïve CD4+ T-cells  
The initial focus in the optimisation of the in vitro model was to determine a method of naïve 
CD4+ T-cell selection yielding an equivalent population of memory CD4+ T-cells. The method 
Figure 12. Expression of IL-6R and gp130 on CD4+ T-cell subsets of early arthritis 
patients. Whole blood of early RA patients was stained for flow cytometry with a panel of 
antibodies to detect cell surface expression of IL-6R (A-B) and gp130 (C-D). CD4+ T-cells 
were identified as CD3+CD4+ and from this population true naïve cells were identified as 
CD45RA+CD62L+, central memory cells identified by CD45RA-CD62L+ and effector memory 
cells identified as CD45RA-CD62L-. Proportions of IL-6R (A) and gp130 (C) positive cells 
were determined by gating on internal negative controls, with representative dot plots from one 
donor showing the percentage of cells positive for IL-6R and gp130 (A and C). Data from 27 
individual donors were plotted as graphs with horizontal bars representing the median value, 
significance was determined by non-parametric analysis of variance (Friedman) with Dunn’s 
posthoc pairwise analyses: ** p<0.001, ***p<0.0001, (B and D).  
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of isolation would need to provide sufficient numbers for use in subsequent experiments but 
also high purity with as little cell contamination as possible to ensure measured response was a 
result of naïve or memory CD4+ T-cells. 
Whereas in Chapter 3.3.1 identification of naïve cells was aided by the expression of CD62L 
this was not feasible during cell isolation thus further investigations involve the identification 
of naïve cells by only CD45RA expression. 
Isolation of naïve CD4+ T-cells can be achieved by positive selection or enrichment (also called 
negative selection). Several means of naïve CD4+ T-cell isolation were tested in this Chapter, 
including two positive selection and three enrichment techniques, as described in Chapter 2.4. 
The isolation methods are termed as follows:  
 PluriBead isolation (positive selection)  
 CD45RA MicroBead selection (positive selection)  
 EasySep naïve CD4+ T-cell isolation kit (enrichment)  
 MACS naïve CD4+ T-cell isolation kit (enrichment) 
 CD45RO MicroBead selection (enrichment)  
Each isolation method was carried out on fresh whole blood or LRS cones. Total numbers of 
naïve CD4+ T-cells were determined to give absolute yield and percentage yield was calculated, 
based on the number of naïve CD4+ T-cells in the starting population of PBMC or CD4+ T-
cells, Table 13. To determine the presence of naïve and memory cells in both the final purified 
naïve population and the remaining fraction immediately following isolation both populations 
and the starting populations were stained with a naïve purity panel of antibodies for flow 
cytometry, Table 4, Chapter 2.9.1. The gating strategy for purity analyses employs the approach 
of setting gates on starting population of CD4+ T-cells (Methods, Chapter 2.9.5), and can be 
seen in Figure 2, Appendix. Here, expression of CD45RA showed clear positive and negative 
populations which were easily distinguishable on the starting population, gates were set on this 
population and applied directly to the final populations and remaining populations. In some 
cases the gates on the final population of naïve CD4+ T-cells required adjusting, this is because 
on a purified population of cells the antibody to antigen ratio may be decreased if not enough 
antibody is added. In these cases the gates shift to the left as less antibody binds per cell, to 
correct for this the antibody needs to be optimised for use on purified naïve CD4+ T-cells. A 
representative of the starting populations of PBMCs or CD4+ T-cells, purified naïve CD4+ T-
cell populations and the remaining negative fraction for each isolation can be seen in Figure 
13.  
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Figure 13. Purity of naïve CD4+ T-cells for each isolation method. Naïve CD4+ T-cells were 
isolated from LRS cones or healthy blood using PluriSelect positive selection, Stemcell 
EasySep naïve CD4+ T-cell enrichment, Miltenyi naïve CD4+ T-cell MACS enrichment, 
CD45RO MicroBead isolation or CD45RA MicroBead positive selection. Cells were stained 
for flow cytometry with a panel of antibodies to detect cell purity (this population was not 
available for the PluriBead isolation method). Singlets were gated, followed by lymphocytes 
and CD4+ T-cells were identified as CD3+CD4+. Naïve CD4+ T-cells were identified as 
CD4+CD45RA+ and memory CD4+ T-cells identified as CD4+CD45RA- ,these gates were set 
on the starting population and then applied to the final and remaining populations with slight 
adjustments required for the final population. Purity of each population is shown in the flow 
cytometry plots and was calculated as the percentage of CD45RA+ of total alive lymphocytes 
for the naïve and memory CD4+ T-cells from the starting population of PBMC or CD4+ T-cells 
(A), the final population of purified naïve CD4+ T-cells (B) and the non-naïve fraction (C). 
Flow cytometry plots representative of one experiment.  
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Isolation of naive CD4+ T-cells using the PluriBead positive selection protocol (PluriSelect) 
produced a percentage yield of 118% (Table 13) meaning a higher number of cells were isolated 
than expected based on the number in the starting population of CD4+ T-cells. This method also 
had one of the lowest levels of purity with only 78.2% of lymphocytes being CD45RA+, Figure 
13B.  Isolation of naïve CD4+ T-cells using CD4+ RosetteSep (Stemcell Technologies) to obtain 
untouched CD4+ T-cells followed by CD45RA+ MicroBead positive selection (Miltenyi Biotec) 
gave a good yield of cells with the highest purity, with 58% and 92.8% respectively, and had 
almost no naïve CD4+ T-cells remaining in the negative fraction. Positive selection procedures 
involve antibody binding to CD45RA, which could have potential implications on downstream 
phenotype by the activation of signalling pathways in the naïve CD4+ T-cells. For this reason, 
negative enrichment for naïve CD4+ T-cells was favoured, as this will result minimal 
background signalling in the naïve CD4+ T-cells, which may have adverse consequences on 
subsequent experiments. 
Isolation of naïve CD4+ T-cells by EasySep naïve CD4+ T-cell enrichment (Stemcell 
Technologies) gave an extremely low yield of 12% from the starting PBMC population, Table 
13. Although this isolation method gave a high purity with 83.6% of cells in the final population 
being CD45RA+ (Figure 13), the yield of this method was too low for this isolation method to 
be a viable option for future experiments. Isolation using MACS naïve CD 4+ T-cell isolation 
kit (Miltenyi Biotech) resulted in a yield of 99%, Table 13, however the final population of 
naïve CD4+ T-cells had a high number of contaminating memory CD4+ T-cells remaining in 
the purified population meaning a purity of only 76.5%, Figure 13B. The naïve CD4+ T-cell 
Type of Isolation Selection 
Method 
Absolute 
Yield (x106) 
Percentage 
Yield 
Cell Purity 
(CD45RA+ % of 
alive lymphocytes) 
Positive selection PluriBead 1.84 118 78.2 
Enrichment EasySep 6.96 12 83.6 
Enrichment MACS 9.84 99 76.5 
Enrichment CD45RO 8.44 61 80.4 
Positive selection CD45RA 7.04 58 92.8 
Table 13. Yield and purity of naïve CD4+ T-cell isolations. Percentage yield of naïve CD4+ 
T-cells was calculated by dividing the number of pure CD45RA+ cells (absolute yield 
corrected for purity) by the number of CD45RA+ cells expected to isolate from the starting 
population of PBMC/CD4+ T-cells. Purity was calculated as a percentage of CD45RA+ of total 
alive lymphocytes.  
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isolation method selected for use in subsequent experiments involved enrichment of CD4+ T-
cells by RosetteSep (Stemcell Technologies) followed by CD45RO MicroBead selection 
(Miltenyi Biotech). This method, although not the most efficient, gave a high level of purity at 
80.4% (Figure 13B) and a good yield of 61% (Table 13). This method also provides untouched 
naïve CD4+ T-cells, which is beneficial as this will limit any signalling potentially caused by 
antibody binding in these cells. These data suggest that the purified population is largely of the 
naïve CD4+ T-cell phenotype using this method, with only low levels of memory cell 
contamination; and importantly, sufficient cell yields for use in subsequent experiments can 
reliably be obtained. 
To summarise, the method of isolation of naïve and memory CD4+ T-cells used for the 
remainder of experiments in this thesis involved enrichment of CD4+ T-cells by RosetteSep 
(Stemcell Technologies) followed by selection of memory CD4+ T-cells by CD45RO 
MicroBeads (Miltenyi Biotech).    
3.3.3 Characterising naïve and memory CD4+ T-cell phenotype pre-IL-6 exposure 
Prior to characterising the effects of IL-6 exposure on naïve and memory CD4+ T-cells, it was 
necessary to validate the phenotype of these isolated cells at baseline. The phenotype of both 
naïve and memory CD4+ T-cells was analysed by staining with a phenotype panel of antibodies 
for flow cytometry immediately following isolation from LRS cones. This panel of antibodies 
contained various cell surface markers to assess activation CD25, CD27, CD28, and IL-6 
signalling components IL-6R and gp130. Both CD27 and CD28 are known T-cell co-
stimulatory molecules required for T-cell immunity. Another activation marker is CD25, the 
IL-2Rα chain, which is found on activated T-cells but is also a marker of Treg cells. The gating 
strategy for this analysis, employing the approach of setting gates on starting population of 
CD4+ T-cells ( Chapter 2.9.5), is depicted in Figure 3, Appendix.  
Representative plots show that there are more cells negative for both CD27 and gp130 
expression and more cells positive for IL-6R expression in the memory CD4+ T-cells 
compared to naïve CD4+ T-cells, Figure 14A-B. Expression of CD28 and CD27 is high on 
both naïve and memory CD4+ T-cells, although in the case of CD27 expression is higher on 
naïve CD4+ T-cells than memory CD4+ T-cells, Figure 14C. In contrast, CD25 expression is 
much lower with similar levels between naïve and memory CD4+ T-cells. Levels of IL-6R are 
around 40% for memory cells but there is significantly lower expression on naïve CD4+ T-
cells, of around 20%, consistent with Figure 12 , Chapter 3.3.1, showing expression of IL-6R 
is higher on memory CD4+ T-cells, particularly the central memory subset of CD4+ T-cells. In 
contrast, the previously assumed ubiquitously expressed gp130 receptor was found to be 
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substantially higher on naïve CD4+ T-cells, with around 90% positive compared to around 
50% positive for memory CD4+ T-cells, Figure 14. This reflects Figure 12, Chapter 3.3.1, 
which shows increased expression of gp130 in naïve CD4+ T-cells compared to central and 
effector memory CD4+ T-cells. However, levels of expression are much higher in cells which 
were analysed following naïve and memory CD4+ T-cell isolation, Figure 14, compared to 
whole blood staining, Figure 12, which may be a consequence of the isolation procedure. 
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In summary, naïve CD4+ T-cells show significantly lower expression of IL-6R and higher 
expression of gp130, validating the phenotype of the cells seen in whole blood staining, as in 
Chapter 3.2.1. As expected there was no difference in expression of CD25 between naïve or 
Figure 14.  Naïve and memory CD4+ T-cell basal cell surface marker expression. 
Freshly isolated naïve and memory CD4+ T-cells were stained for phenotype cell surface 
markers for flow cytometry. Cells were gated as singlets, lymphocytes and CD4+ T-cells 
were identified as CD3+CD4+, naïve CD4+ T-cells were identified as CD4+CD45RA+ and 
memory CD4+ T-cells identified as CD4+CD45RA-. . Gates were set on starting populations 
of CD4+ T-cells and applied to naïve and memory CD4+ T-cells. Expression of CD25, CD27, 
CD28, IL-6R and gp130 were measured on naïve CD4+ T-cells (A) and memory CD4+ T-
cells (B), with representative plots for one donor shown for CD27, IL-6R and gp130. Values 
from 9 biological replicates were plotted on a graph with bars showing the median and error 
bars showing SEM (C). Significance was determined by 2 way ANOVA with Bonferroni 
post hoc pairwise analyses; **p<0.01, *** p<0.001.  
86 
 
memory CD4+ T-cells. Furthermore, lower expression of CD27 is seen on memory CD4+ T-
cells, in keeping with published literature (454). 
3.3.4 Culture of naïve and memory CD4+ T-cells 
Following naïve and memory CD4+ T-cell characterisation the next aim was to develop an in 
vitro culture system in which the effects of IL-6 pre-exposure could be assessed. There were a 
number of factors to consider when determining the optimal cell culture conditions, including 
the type of medium used, the length of culture and the addition of cytokines and whether these 
cytokines are refreshed during culture. These factors have the potential to influence cell 
viability and response to TCR stimulation. 
An important factor to consider in the culture of naïve and memory CD4+ T-cells was the type 
of culture media used. RF10 is a medium used for the culture of cells, which typically contains 
around 10% FCS, a widely used serum-supplement for in vitro cell culture as it contains growth 
factors and protein components to assist cell survival and growth. Although this can greatly 
increase cell survival there are a number of undefined proteins present which can lead to 
stimulation of cells and activation of signalling pathways. TexMACS (Miltenyi Biotec) is a 
serum free media designed specifically for T-cells, which contains only a small number of 
human serum proteins, thereby limiting the amount of signalling through the naïve or memory 
CD4+ T-cell. The effect of media selection upon viability and phenotype of cultured naïve CD4+ 
T-cells was assessed after 10 days culture. Naïve CD4+ T-cells, isolated from LRS cones, were 
cultured in duplicate in RF10 or TexMACS. After 10 days, phenotype and viability were 
assessed by flow cytometry, gates were set on the starting population of CD4+ T-cells (Chapter 
2.9.5) and for viability analysis clear populations allowed for placement of gates, gating can be 
seen in Figures 3 and 5, Appendix. There appeared to be a decrease in the level of expression 
of CD27 and gp130 but an increase in expression of IL-6R as a result of 10 days of culture 
compared to naïve CD4+ T-cells at baseline, Figure 15. Despite this, there was no large 
differences in cell surface markers after 10 days of culture in RF10 compared to TexMACS 
Figure 15A. No clear differences could be seen in terms of cell viability with  RF10 giving a 
viability of around 21% compared to a viability of 29% following culture in TexMACS for 10 
days, Figure 15B. The low level of viability seen may reflect the long culture period of 10 days, 
which appears to be too long for cells to remain viable, however this is only one donor so may 
be a reflection of donor variation.   
In light of these findings, future experiments using the optimised in vitro model would use 
TexMACS as the culture media, unless otherwise stated, to prevent the possibility of 
downstream signalling events, which may affect subsequent read out of future experiments. 
87 
 
 
3.3.5 Characterising naïve and memory CD4+ T-cell phenotype post-IL-6 exposure 
Next, the phenotype and viability of naïve CD4+ T-cells was assessed following exposure to 
IL-6 and or equimolar sIL-6R in order to determine the optimal conditions for culture with 
cytokine.  
The phenotype of naïve CD4+ T-cells, isolated from LRS cones, was assessed following 3 days 
of culture in the presence of 50ng/ml IL-6 with equimolar sIL-6R, included to maximise 
signalling via both the classical and trans mechanisms. Expression of CD25, CD27 and CD28 
on naïve CD4+ T-cells following 3 days of culture remain at similar levels as detected in 
Chapter 3.3.3 in the starting population of naïve CD4+ T-cells in both untreated and IL-6 
exposed cells, Figure 16A. There was also no change in these cell surface markers when 
Figure 15. Comparison of cell culture media on naïve CD4+ T-cell phenotype and viability. 
Freshly isolated naïve CD4+ T-cells were cultured for 10 days in RF10 or TexMACS. After 10 
days cells were stained for cell surface markers for phenotype analysis (A) or with Annexin V 
and DAPI for viability analysis (B). For phenotype analysis cells were gated as singlets, 
lymphocytes and CD4+ T-cells were identified as CD3+CD4+, naïve CD4+ T-cells were 
identified as CD4+CD45RA+ and memory CD4+ T-cells identified as CD4+CD45RA-. . Gates 
were set on starting populations of CD4+ T-cells and applied to naïve CD4+ T-cells. Expression 
of CD25, CD27, CD28, IL-6R and gp130 were measured (A). .For viability cells were gated as 
DAPI-Annexin V- (B). N=1.  
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cultured alone compared to culture with IL-6 and sIL-6R (Figure 16A) indicating the cells 
remain in their naïve, phenotypically inactivated state during culture with IL-6. 
By contrast, expression of both IL-6R and gp130 dramatically decreases following 3 days of 
culture in the presence of 50ng IL-6 and equimolar sIL-6R, Figure 16A, compared to when 
cultured in media alone where expression levels remain similar to that seen immediately 
following isolation, Figure 14, Chapter 3.3.3. There is no difference in the expression of these 
markers when cultured with IL-6 alone compared to when cultured with IL-6 and sIL-6R, 
Figure 10, Appendix. However, this observation is only representative of one experiment.  
Again, there was a low level of viability following 10 days culture with a small decrease in 
viability seen between cells cultured alone compared to cells cultured with IL-6 alone with 
percentage viable cells 29% and 17%, respectively. There is no difference in viability between 
cells cultured in IL-6 alone compared to cells cultured with IL-6 + sIL-6R with both conditions 
having around 16-17% viability after 10 days, Figure 16B.  
 
Next, the response of naïve CD4+ T-cells to refreshment of cytokines during culture was 
evaluated. Naïve CD4+ T-cells were cultured for 10 days in duplicate in RF10 alone or with 
final concentration of 50ng/ml IL-6 and equimolar sIL-6R. For one well of each condition 
culture medium was refreshed on days 3 and 6, with the same final concentrations of IL-6 and 
sIL-6R added as on Day 0. As seen in Figure 16 there was no change in CD25, CD27 or CD28 
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Figure 16. Surface marker expression of untreated and IL-6 treated naïve CD4+ T-cells 
following 3-day culture. Freshly isolated naïve CD4+ T-cells were cultured for 10 days in 
TexMACS alone or TexMACS with 50ng/ml IL-6 and equimolar sIL-6R. After 3 days cells 
were stained for cell surface markers for phenotype analysis (A) or with Annexin V and DAPI 
for viability analysis (B). Viable cells were gated as DAPI-Annexin V-. Cells were gated as 
singlets, followed by lymphocytes and CD4+ T-cells were identified as CD3+CD4+, naïve 
CD4+ T-cells were identified as CD4+CD45RA+ and memory CD4+ T-cells identified as 
CD4+CD45RA-. N=1. 
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expression with culture with IL-6 and no difference was seen with refreshing cytokines 
compared to unrefreshed cells, Figure 17A. In contrast to the previous experiments, the viability 
of cells was much higher for this donor, around 60-70%, Figure 17B. However, addition of IL-
6 and the refreshment of cytokines also had no impact on cell viability after 10 days culture, 
with a difference of only 3-8% in viability with cytokine refreshment, Figure 17B.  
  
Further to this, the effect of culture with varying concentrations of IL-6 and equimolar 
concentrations of sIL-6R on naïve CD4+ T-cell viability and phenotype was also measured over 
3 days, to further investigate the downregulation of IL-6R and gp130. Naïve CD4+ T-cells were 
cultured for 1-3 days either alone or exposed to IL-6 at final concentrations of 0.1ng/ml, 
0.5ng/ml, 5ng/ml and 50ng/ml all with equimolar concentrations of sIL-6R. Levels of cell 
surface markers were assessed by flow cytometry on each day throughout the culture. There 
was no effect of differing concentrations of IL-6 on any of the surface markers, CD25, CD27 
or CD28, (Figure 11, Appendix). However, levels of both IL-6R and gp130 show a dose 
dependent decrease with increasing concentrations of IL-6 and equimolar sIL-6R, Figure 18. 
This decrease in expression is most striking for gp130 as expression of this molecule remains 
at a high level of over 80% throughout the culture in untreated naïve CD4+ T-cells. The biggest 
observed difference occurred between 0.5ng/ml and 5ng/ml at each time point during the 
culture. Furthermore, the expression of these markers was decreased from baseline levels 
following only 24 hours exposure to IL-6 and equimolar sIL-6R and this reduced expression 
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Figure 17. Comparison of refreshing culture media with IL-6 and sIL-6R on naïve CD4+ 
T-cell phenotype and viability. Freshly isolated naïve CD4+ T-cells were cultured for 10 days 
in RF10 alone or RF10 with 50ng/ml IL-6 and equimolar sIL-6R. Conditions were carried out 
in duplicate and to one of each conditions 50ng/ml IL-6 or 50ng/ml IL-6 and equimolar sIL-6R 
were added to the culture on day 3 and day 6. After 10 days cells were stained for cell surface 
markers for phenotype analysis (A) or stained with Annexin V and DAPI for viability analysis 
(B). Viable cells were gated as DAPI-Annexin V-. Cells were gated as singlets, followed by 
lymphocytes and CD4+ T-cells were identified as CD3+CD4+. N=1. 
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remained throughout days 2-3 of culture, Figure 18. This confirms the observations that culture 
with IL-6 reduces expression of gp130, indicating that it is an early event following exposure. 
Figure 18. Effect of culture with different concentrations of IL-6 and sIL-6R on naïve 
CD4+ T-cell viability and phenotype. Freshly isolated naïve CD4+ T-cells were cultured for 3 
days in TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6, 5ng/ml IL-6 or 50ng/ml IL-6, all 
with equimolar sIL-6R. On days 1-3 cells were stained for stained for cell surface markers for 
flow cytometry, representative plots shown for IL-6R (A) and gp130 (B) at day 3. IL-6R (C) 
and gp130 (D) expression was similar over 3 days of culture. On day 3 cells were stained with 
Annexin V and DAPI for viability analysis (E). Viable cells were gated as DAPI-. Cells were 
gated as singlets, followed by lymphocytes and CD4+ T-cells were identified as CD3+CD4+. 
N=1. 
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Despite the changes in cell surface marker expression at 3 days of culture there was no 
production of cytokines, IFN-γ, IL-10, IL-4 or IL-5, either when cultured alone or when 
cultured with varying concentrations of IL-6 with equimolar sIL-6R with supernatants having 
below the level of detection for each cytokine (Figure 12, Appendix).  
As a result of these data subsequent experiments involved culture of naïve and memory CD4+ 
T-cells with varying concentrations of IL-6 and equimolar concentrations of sIL-6R without 
further refreshment of cytokines. 
3.3.6 Optimal length of naïve CD4+ T-cell culture  
After determining, the optimal conditions for the culture of naïve CD4+ T-cells in TexMACS 
with IL-6 and equimolar sIL-6R the next step was to determine the optimal length of culture. 
During in vitro cell culture viability decreases, especially in the absence of TCR stimulation, 
with the potential for decreased viability due to culture in serum free media. The maximal length 
of culture over which naïve CD4+ T-cell viability could be maintained in serum free media prior 
to TCR stimulation was determined by assessing viability of naïve CD4+ T-cells over a period 
of 6 days using Annexin V and DAPI staining. Naïve CD4+ T-cells, isolated from LRS cones, 
were cultured in TexMACS alone or TexMACS with final concentration of 50ng/ml IL-6 and 
equimolar concentration of sIL-6R, 90ng/ml.  Phenotype analysis showed that the level of 
expression of cell surface markers remained unchanged throughout the 6 days of culture, Figure 
19A, although gp130 appears to increase throughout the culture. There was no difference in 
viability between the untreated or IL-6 treated conditions at each time point Figure 13, 
Appendix. During the first three days of culture it can be seen that cells are over 90% viable, 
which rapidly decreases to less than 40% at day 4, Figure 19B. This experiment reflects Figures 
15 and 16 showing low viability, less than 10% after 6 days of culture, Figure 19B.  
Consequently, it was determined that subsequent experiments should involve pre-exposure to 
IL-6 for no longer than 3 days, balancing chronicity of IL-6 exposure with cell viability.  
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3.3.7 Stimulation of naïve CD4+ T-cells  
Following naïve and memory CD4+ T-cell isolation and culture with varying concentrations of 
IL-6 and equimolar sIL-6R cells were washed thoroughly prior to TCR stimulation in order to 
remove all cytokines from the culture media so that no IL-6 will be present at time of 
stimulation. The stimulation of naïve and memory CD4+ T-cells was optimised in terms of anti-
CD3 and anti-CD28 concentrations and length of stimulation. This approach carries the 
potential advantage of allowing the strength of stimulus to be controlled in a manner not 
possible in an MLR. The aim of the optimised concentration of anti-CD3 and anti-CD28 is to 
induce sub-optimal levels of proliferation so that any difference with IL-6 pre-exposure will be 
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Figure 19.  Effect of length of culture with IL-6 and sIL-6R on naïve CD4+ T-cell
phenotype and viability. Freshly isolated naïve CD4+ T-cells were cultured for 1 to 6 days in
TexMACS with 50ng/ml IL-6 and equimolar sIL-6R. (A) On days 1-6 cells were stained for
cell surface markers for phenotype analysis (A) or stained for Annexin V and DAPI for viability
analysis (B). Viable cells were gated as DAPI- Annexin V-. Cells were gated as singlets,
followed by lymphocytes and CD4+ T-cells were identified as CD3+CD4+. N= 1. 
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more likely to be observed. These optimised conditions will be applied in Chapter 4 to look in 
detail at the effect of IL-6 pre-exposure on effector function.  
Firstly, the proliferation of naïve and memory CD4+ T-cells following IL-6 pre-exposure and 
subsequent TCR stimulation by anti-CD3 and anti-CD28 followed by tritiated thymidine 
incorporation assay was assessed. Freshly isolated naïve CD4+ T-cells, isolated from LRS 
cones, were cultured in the absence or presence of IL-6 and sIL-6R, at 0.1ng/ml IL-6 or 50ng/ml 
IL-6 each in the presence of equimolar sIL-6R for 3 days. Cells were harvested and washed to 
remove any cytokines present in the media and cultured in the presence of varying 
concentrations of anti-CD3 and anti-CD28 stimulus, for 6 days. After 6 days tritiated thymidine 
incorporation assays were carried out, each condition was carried out in triplicate with the 
median represented in Figure 20, this shows that higher concentrations of anti-CD3 and anti-
CD28 produce higher levels of proliferation. When stimulated with 1μg/ml anti-CD3 and 0.1-
1μg/ml anti-CD28 there are only very low levels of proliferation whereas proliferation was 
much higher when using 10μg/ml anti-CD28, specifically with 1μg/ml anti-CD3 and 10μg/ml 
anti-CD28 stimulation concentrations pre-exposure to IL-6 causes an increase in proliferation, 
Figure 20B.  
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Figure 20. Proliferation of naïve CD4+ T-cells following IL-6 exposure and stimulation 
with anti-CD3 and anti-CD28 and tritiated thymidine incorporation assay. Freshly isolated 
naïve CD4+ T-cells were cultured for 3 days in TexMACS alone, TexMACS with 0.1ng/ml IL-
6 or TexMACS with 50ng/ml IL-6 both with equimolar sIL-6R. After 3 days cells were cultured 
with varying concentrations of anti-CD3 and 10μg/ml anti-CD28 (A) or varying concentrations 
of CD28 with 1μg/ml CD3 (B) for a further 6 days. Proliferation was then assessed by tritiated 
thymidine incorporation assay, each condition was carried out in triplicate with median for each 
condition represented. Graph shows one experiment with 3 technical replicates.   
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Next, tritiated thymidine incorporation was measured from naïve CD4+ T-cells stimulated for 
3, 6 or 9 days with 1ug/ml anti-CD3 and 10ug/ml anti-CD28 to assess the optimal length of 
stimulation time. Each condition was carried out in triplicate with median for each condition 
represented in Figure 21. This concentration of anti-CD3 and anti-CD28was chosen due to its 
ability to induce optimal induction of proliferation in the previous experiment, resulting in a 
dynamic range of response seen according to pre-exposure to IL-6 and sIL-6R. There is only a 
weak level of proliferative response of less than 1x105 cpm after only 3 days of stimulation, 
indicating the stimulation time is too short to induce good levels of proliferation, Figure 21. 
Proliferation increases to around 3x105 cpm after 6 days stimulation and further increased levels 
of proliferation can be seen after 9 days stimulation with a proliferative response of just over 
4x105 cpm.  
 
Finally, the effect of stimulation with anti-CD3 and anti-CD28 was assessed by CFSE 
proliferation assay, as a potentially more sensitive system than the tritiated thymidine 
incorporation assay. Cells were labelled with 0.5μM CFSE, prior to 3-day culture in media 
alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 50ng/ml IL-6 all with equimolar sIL-6R. Cells were 
harvested and washed to remove any cytokines present in the media and cells cultured for a 
further 3 or 6 days with 1μg/ml anti-CD3 and 5μg/ml anti-CD28 (high stimulus) or 0.5μg/ml 
anti-CD3 and 1μg/ml anti-CD28 (low stimulus). The two anti-CD3 and anti-CD28 
concentrations were chosen to probe whether changes could be seen even when given a strong 
stimulatory signal; it was possible that this stimulation may cause maximal levels of 
Figure 21. Length of naïve CD4+ T-cell stimulation following IL-6 exposure using anti-
CD3 and anti-CD28 and tritiated thymidine incorporation assay. Freshly isolated naïve 
CD4+ T-cells were cultured for 3 days in TexMACS 0.5ng/ml IL-6 and equimolar sIL-6R. 
After 3 days cells were washed and cultured with 1μg/ml anti-CD3 and 10μg/ml anti-CD28 
for 3, 6 or 9 days. Proliferation was then assessed by tritiated thymidine incorporation assay, 
each condition was carried out in triplicate with median for each condition represented. Graph 
shows one experiment with 3 technical replicates.   
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proliferation masking any differences caused by IL-6 pre-exposure. Similar to the tritiated 
thymidine incorporation assay, 3 days of stimulation with anti-CD3 and anti-CD28 results in 
only minimal levels of proliferation with little difference between increasing concentrations of 
IL-6, Figure 22. In contrast, stimulation of cells for 6 days produced higher levels of 
proliferation, although as this was carried out with a sub-optimal concentration this level was 
fairly low, however there is a clear increase with increasing concentrations of IL-6 pre-
exposure, with the exception of 0.5ng/ml IL-6 with the high stimulus, Figure 22B.  
There was no clear difference between proliferation with the high and low stimulus at day 3, 
however, at day 6 the high stimulus induced higher levels of proliferation though a better dose-
response was seen more clearly with the low stimulus. Thus, a stimulation time of 6 days 
appears to result in the best level of proliferation when using anti-CD3 and anti-CD28 at either 
Figure 22. Proliferation of CFSE labelled naïve CD4+ T-cells following IL-6 exposure and 
stimulation with anti-CD3 and anti-CD28. Freshly isolated naïve CD4+ T-cells were labelled 
with 0.5µM CFSE and cultured for 3 days in TexMACS alone, with 0.1ng/ml IL-6, with 
0.5ng/ml IL-6 or with 50ng/ml IL-6, all with equimolar sIL-6R. After 3 days cells were cultured 
with 1μg/ml anti-CD3 and 5μg/ml anti-CD28 (high) or 0.5μg/ml anti-CD3 and 1μg/ml anti-
CD28 (low) for a further 3 days or 6 days. Proliferation was then assessed by flow cytometry 
with representative CFSE histograms (A). Proliferation at day 3 (B) and day 6 (C) were plotted 
as graphs. Cells were gated as singlets, followed by lymphocytes and proliferating cells were 
identified as DAPI-. Proliferation was calculated using the FlowJo proliferation tool with 
percentage divided indicating the precursor frequency of dividing cells. N=1. 
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a high or a low concentration and the CFSE proliferation assay provides good indication of 
proliferative response of naïve CD4+ T-cells.  
3.4 Discussion  
In this chapter, I set out to establish an in vitro model in which to mimic the chronic pre-
exposure of naïve CD4+ T-cells to IL-6 prior to TCR mediated stimulation in order to assess 
the consequences on T-cell effector function. The initial focus was to optimise a method of 
naïve CD4+ T-cell isolation to provide both high yield and high purity. Optimisation 
experiments determined the length of culture of naïve and memory CD4+ T-cells in the absence 
or presence of varying concentrations of IL-6 and sIL-6R was 3 days. Stimulation of cells was 
optimised to provide a sensitive assay to reveal any differences in proliferation that may occur 
between conditions. This involves stimulation with anti-CD3 and anti-CD28 antibodies at 
varying concentrations for 6 days, using CFSE to measure levels of proliferation.  
3.4.1 Expression of IL-6 signalling receptors  
In Chapter 1.3.12 it was seen that naïve CD4+ T-cells have a strong correlation between serum 
IL-6 levels and constitutive intracellular pSTAT-3 indicating these cells are particularly 
sensitive to circulating IL-6. In this Chapter, it was assessed whether the increased sensitivity 
of these cells was due to differential expression of the IL-6R responsible for signal transduction.  
In this Chapter, the observation shown in previous work, Figure 8, Chapter 1.3.12 (Amy 
Anderson, Newcastle University, unpublished data), of higher expression of IL-6R on central 
memory CD4+ T-cells compared to naïve CD4+ T-cells, was confirmed. In contrast, naïve CD4+ 
T-cells from EAC patients have higher expression of gp130 compared to both central memory 
and effector memory CD4+ T-cells.  
The finding of low expression of IL-6R and high expression of gp130 was also confirmed in 
naïve CD4+ T-cells isolated from healthy donors in Figure 14, suggesting this is not a disease 
specific effect. However, expression of gp130 is much higher on both naïve and memory CD4+ 
T-cells following isolation compared to levels seen in whole blood staining with levels reaching 
around 95% on freshly isolated naïve CD4+ T-cells compared to 50% on naïve CD4+ T-cells 
from whole blood, Figure 12, Chapter 3.3.1. This may be due to the sensitivity of this molecule 
to the cell isolation procedure causing its upregulation, however, the trend still reflects the levels 
of expression seen with whole blood staining, confirming this observation in healthy controls.  
In the published literature gp130 is widely described as ubiquitously expressed across cell types 
and organs (227). However, it has been described that vascular smooth muscle cells do not 
constitutively express gp130 but both mRNA and protein can be upregulated upon stimulation 
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by IL-6 (231).  It has further been reported there is differential expression of gp130 according 
to cell type (455). For example, monocytes express high levels of both gp130 and IL-6R 
compared to NK cells, which lack both molecules. B-cells have low levels of gp130 but high 
IL-6R whereas CD4+ and CD8+ T-cells have variable expression of both markers. 
Several studies have now shown that expression of gp130 and IL-6R varies depending upon 
anatomical location (233, 456).  In the case of monocytes, expression of gp130 is reduced in 
SF in a MAPK dependent manner compared to peripheral blood (233). Similarly, expression of 
the IL-6R on CD4+ T-cells has been shown to be significantly lower in SF and ST compared to 
peripheral blood of RA patients (456), whereas expression of gp130 was only significantly 
lower on SF cells compared to peripheral blood. IL-6 has been shown to be present in high 
concentrations in the ST suggesting there is regulation of receptor expression in the inflamed 
microenvironment. Our data further suggests another level of regulation dependent upon the 
maturity phenotype of cells in the periphery.  
Expression levels of IL-6R and gp130 were decreased following exposure to IL-6 in a dose-
dependent manner, consistent with the literature which suggest IL-6 signalling downregulates 
IL-6R and gp130 expression and hence the cells’ ability to signal via this mechanism (288, 368, 
455). This is due to the internalisation of the receptor complex and the synthesis of new 
receptors is required before further signalling (288). Levels of gp130 and IL-6R remain low 
until 48 hours following exposure to IL-6 possibly due to the high availability of IL-6 and levels 
begin to gradually increase with further culture possibly because of decreased IL-6 availability.  
The biggest observed difference in both IL-6R and gp130 expression when cultured with IL-6 
and equimolar sIL-6R occurs between 0.5ng/ml and 5ng/ml, Figure 18. The concentration of 
0.5ng/ml IL-6 was chosen as optimal for future experiments, as this was deemed to be at the 
higher level of the physiological range, however, still result in consequences upon effector 
function, Chapter 4.3.8. There was a small reduction in IL-6R and gp130 expression at this 
concentration but levels were still comparable to ex vivo levels of expression whereas at 5ng/ml 
IL-6 levels receptor expression levels were almost completely lost. This is reassuring as it 
suggests the optimised in vitro model is not creating a completely irrelevant environment.  
To summarise, there is a high level of expression of gp130 on naïve CD4+ T-cells compared to 
memory CD4+ T-cells. The high expression of gp130 on naïve CD4+ T-cells compared to 
memory CD4+ T-cells suggests a potential mechanism of increased sensitivity of these cells to 
IL-6 signalling and suggests a role for this cell type in mediating the effects of IL-6 pre-
exposure.  
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3.4.2 Defining naïve and memory CD4+ T-cells for functional experiments  
Isolation of naïve and memory CD4+ T-cells involved the use of CD45RO for the positive 
selection of memory CD4+ T-cells. In contrast to the whole blood staining identifying IL-6 
receptor expression, this method did not involve the use of CD62L. For this reason, the memory 
CD4+ T-cell population will consist of a combination of the central memory and effector 
memory subpopulations. Furthermore, there is the potential for the naïve CD4+ T-cell sub-
population to contain CD45RA+CD62L-, terminally differentiated cells. These cells are only 
found in a small proportion of individuals, are found at extremely low numbers and have 
decreased proliferative capacity (457). These cells do however display potent cytotoxic activity 
following activation so this must be taken into account when interpreting the data form naïve 
CD4+ T-cells. 
Basal phenotype of naïve and memory CD4+ T-cells was also examined in terms of co-
stimulatory molecules, including CD27 and CD28. These have always been known as markers 
of antigen experience, however, the expression of these molecules is now realised to be more 
complex and may represent distinct populations of cells.  
In keeping with previous studies our data confirmed CD27 is expressed by all naïve CD4+ T-
cells whereas it is only found on around 80% of  memory CD4+ T-cells (454). It has been 
described that memory CD4+ T-cells lacking CD27 display high antigen recall responses and 
produce higher levels of effector cytokines compared to resting CD27+ cells which require co-
stimulation for TCR triggering (454). It is suggested that loss of CD27 expression represent a 
functionally differentiated population, which occur following chronic antigen stimulation 
(458).  
In this Chapter, it was seen that expression of CD28 is maximal on both naïve and memory 
CD4+ T-cells. Cells which express CCR7, including naïve and central memory CD4+ T-cells, 
have been reported to have high levels of expression of CD28 (459). In contrast, effector 
memory CD4+ T-cells lacking CCR7 can be divided by their differential expression of CD28. 
Effector memory cells lacking CD28 expression correlate with those cells lacking CD27 
expression and are associated with increased expression of cytolytic molecules and the 
predominant production of IFN-γ. It is now suggested that cells lacking CCR7 should not be 
considered to be a single population of cells and likely contains many subgroups based on both 
CD27 and CD28 expression. This population of memory CD28-CD4+ T-cells was not seen in 
cells isolated in the work outlined in this Chapter, however, this may be due to the process of 
isolation resulting in altered expression of this molecule.  
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3.4.3 Strengths of the in vitro model  
In this study, it was important to optimise a method of isolation, which would provide a high 
yield of pure CD45RA+ naïve CD4+ T-cells. One of the strengths of this model is the method 
of isolation chosen which involves enrichment of CD4+ T-cells followed by depletion of 
CD45RO memory CD4+ T-cells resulting in a population of untouched naïve CD4+ T-cells.  
Another strength of the in vitro model is the reductionist approach of the cell culture system. 
This approach aimed to establish a simplified in vitro model to limit the number of confounding 
factors in the system which may mask the effects of IL-6 pre-exposure. This meant that cells 
were cultured in serum free media TexMACS to avoid non-specific signalling in cells as a result 
of culture which have the potential to conceal the effects of IL-6 pre-exposure. Cells were also 
cultured in the absence or presence of IL-6 with equimolar concentrations of sIL-6R and 
without the refreshment of cytokines as this was revealed to have no effect on cell viability or 
surface marker expression. The addition of the sIL-6R allows both the classical and trans 
signalling mechanisms thereby encompassing both the anti- and pro- inflammatory properties 
of IL-6. The effect of sIL-6R in the system is further explored in Chapter 4.  
The reductionist approach of this in vitro system allows the consequences of IL-6 pre-exposure 
to be directly probed with fewer confounding factors. Although the approach of refreshing 
cytokines could be considered to be more physiological and may have impacted the magnitude 
of differential phenotype following downstream TCR activation, this is an example of where 
the balance between reductionism and the approximation to the physiological state results in 
compromise hence resulting in unavoidable deviation from physiology. 
As the work outline in thesis aims to investigate the effects of IL-6 pre-exposure on effector 
phenotype, it is important that IL-6 is no longer present at the time of TCR stimulation. To 
achieve this cells are thoroughly washed twice before stimulation. The stimulation of naïve and 
memory CD4+ T-cells with anti-CD3 and anti-CD28 and measurement of proliferation using 
CFSE allows for a more controlled level of stimulation which will determine a clear functional 
readout. Although stimulation with mature DCs is a more physiologically relevant stimulus as 
skewing cytokines will be provided by the DC this method resulted in high level of variability 
potentially due to biological variation (data not shown). The use of anti-CD3 and anti-CD28 
ensures a quantifiable stimulus and permits the assessment of stimulation strength as a covariate 
influencing response of naïve CD4+ T-cells to IL-6 pre-exposure. The use of CFSE to track cell 
proliferation also allows more detailed analysis as it allows the tracking of the number of cell 
divisions and the number of cells in the starting population that underwent division.  
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3.4.4 Weaknesses of the in Vitro Model  
Despite one of the strengths of the in vitro model being the isolation of large numbers of highly 
pure naïve CD4+ T-cells one of the weaknesses of this system is that this comes via the positive 
selection of memory CD4+ T-cells. The targeting of the CD45RO co-receptor may result in 
non-specific stimulation of the memory CD4+ T-cells and this has an unknown impact on 
downstream effector phenotype in terms of both gene expression and cell activation. Despite 
the binding of antibodies to co-receptors, it has been shown that isolation technique results in 
no significant differences in the gene expression profiles of cells or proliferative responses 
(460).  
In addition to the positive selection of memory CD4+ T-cells, the purity of naïve CD4+ T-cells, 
typically over 80%, may also be considered a weakness. Decreased cell purity can result in 
inferior results due to the contamination by CD14 monocytes (461). These cells had low levels 
of monocyte contamination, avoided with the enrichment technique, to ensure more accurate 
gene expression analysis. Contaminating populations were largely naïve and memory CD4+ T-
cells ensuring confidence that any resulting effects of IL-6 pre-exposure can be largely 
delineated to the CD4+ T-cell population. However, caution needs to be taken when interpreting 
data from naïve and memory CD4+ T-cells isolated in this way. 
Furthermore, in the case of CD8+ T-cells when naïve and memory cells are cultured together it 
has been shown that antigen experienced T-cells may drive the differentiation of naïve cells to 
result in synchronising behaviours of the cells which were shown to affect the transcriptional, 
metabolic and functional processes of the naïve cells (462). For this reason, it was important to 
isolate a highly pure population of cells. Cell sorting was not feasible for this study due to 
timing and cost. Large volumes of blood would be needed for the isolation of naïve CD4+ T-
cells which would take a long time to isolate via cell sorting in addition to the optimisation of 
a flow cytometry panel for their selection. Numerous cell isolations were required to obtain 
repeats in addition to analysis of different parameters following IL-6 pre-exposure, which 
meant this technique was too costly.  
Another weakness of the in vitro model is the length of cell culture. The length of IL-6 pre-
exposure was assessed after optimisation of culture media, culture with IL-6 and sIL-6R and 
the refreshment of cytokines. Due to this, these experiments all involved a culture period of 10 
days prior to stimulation. This has been shown to result in lower levels of cell viability hence 
if length of culture was titrated prior to the optimisation of these parameters these experiments 
may have yielded different conclusions. Furthermore, many of the optimisation experiments 
carried out in this Chapter had limited numbers of repeats which may also have affected the 
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conclusions drawn, however in many of the cases when differences occurred as a result of 
culture with IL-6 these differences were clear.  
Finally, the use of anti-CD3 and anti-CD28 antibodies for stimulation to mimic APC could be 
considered a weakness. The cytokine production by the APC is an important signal for T-cell 
effector function and this important component is missing from this reductionist in vitro model. 
Therefore, skewing of T-cells towards different T-helper cell subsets and hence effects on T-
cell cytokine production may not be seen. This will be further investigated in Chapter 4.  
3.4.5 Summary 
To conclude, in this Chapter an optimised in vitro model of IL-6 pre-exposure has been 
developed, which can be seen in Figure 23. This model involves the enrichment of CD4+ T-
cells from blood followed by isolation of naïve CD4+ T-cells using CD45RO MicroBeads. Cells 
are CFSE labelled prior to culture with varying concentrations of IL-6 and equimolar 
concentrations of sIL-6R for 3 days. After 3 days, cells are thoroughly washed to remove IL-6 
from the culture media and cells stimulated for a further 6 days with both a high stimulus and 
a low stimulus using anti-CD3 and anti-CD28 antibodies. This in vitro system will permit a 
detailed investigation into the consequences of prolonged pre-exposure to IL-6. This will be 
assessed by its ability to influence effector phenotype following TCR mediated activation in 
terms of proliferation, activation and cytokine production and resulting dynamic transcriptional 
effects, Chapter 4 and Chapter 5, respectively. 
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Figure 23. Optimised in vitro model of IL-6 pre-exposure of naïve CD4+ T-cells. CD4+ T-
cells are isolated by RosetteSep enrichment. Naïve CD4+ T-cells are further isolated by 
depletion of memory CD4+ T-cells using CD45RO microbeads. Naïve or memory CD4+ T-cells 
are labelled with a final concentration of 0.5μM CFSE and cultured for 3 days in TexMACS 
alone, TexMACS with 0.1ng/ml IL-6, TexMACS with 0.5ng/ml IL-6 or TexMACS with 
50ng/ml IL-6 all with equimolar sIL-6R. After 3 days cells are washed to remove IL-6 and sIL-
6R and cultured with 1μg/ml anti-CD3 and 5μg/ml anti-CD28 (high) or 0.5μg/ml anti-CD3 and 
1μg/ml anti-CD28 (low) for a further 6 days. Proliferation and activation markers are assessed 
by flow cytometry.  
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Chapter 4. Effects of IL-6 pre-exposure on naïve and memory CD4+ T-cell 
effector function 
 
4.1 Introduction  
It has been long understood that antigen-independent, cytokine mediated activation of T-cells 
can occur in vivo (463). A combination of cytokines, including IL-6, are able to induce the 
proliferation and effector function of CD4+ T-cells in the absence of TCR stimulation (463). 
Furthermore, evidence for the “sensitising” or “priming” of a number of different cells by a 
range of pro-inflammatory cytokines has been more recently described. Mesenchymal stem 
cells (MSCs) can be primed towards an anti-inflammatory phenotype by the presence of IL-1 
prior to stimulation (464). In contrast, neutrophils primed with GM-CSF, IFN-γ and TNF-α 
have increased inflammatory cytokine production (465). Cells of the adaptive immune system 
have also been shown to have this “pre-priming” potential as CD4+ T-cells have been shown to 
respond aberrantly to chronic TNF-α exposure by the attenuation of TCR signalling and the 
suppression of proliferation and cytokine production (466). These results suggest that immune 
cells have potential memory of the inflammatory environment, which can programme them 
towards altered effector phenotypes following activation.  
It has been clearly shown that IL-6 is present at high concentrations in RA patients at the time 
of disease presentation and it has been further shown that IL-6 can be found at high levels long 
before the clinical onset of arthritis (467-469). There has been no specific disease associated 
autoantigen which has been found to account for immune dysregulation in RA suggesting it is 
more of a pro-inflammatory than autoimmune disease. Given that naïve CD4+ T-cells are 
strikingly sensitive to IL-6 at the level of STAT-3 signalling, shown to be uniquely up regulated 
in early RA, here it is hypothesised that this is an important mechanism of antigen non-specific 
adaptive immune dysregulation early in the disease setting (427).  
In Chapter 3 an in vitro system was developed in order to recapitulate the chronic exposure of 
naïve and memory CD4+ T-cells to IL-6. In this in vitro model naïve and memory CD4+ T-cells 
are isolated before pre-exposure to varying concentrations of IL-6 for 3 days. IL-6 is then 
washed out of the system prior to TCR stimulation. High levels of IL-6 can be found in RA and 
it is likely that in vivo IL-6 is present at the time of stimulation, however; this reductionist 
approach allows the investigation of the extent to which IL-6 pre-exposure is mechanistically 
important to CD4+ T-cell effector function.  
This Chapter first assessed the ability of IL-6 and other pro-inflammatory and STAT-3 
signalling cytokines to induce the three key STAT-3 regulated genes found to be dysregulated 
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in early RA, to reveal how specific this effect is to IL-6. Next, the consequences of IL-6 pre-
exposure on the effector functions of naïve and memory CD4+ T-cells following TCR mediated 
activation were investigated.  
IL-6 signalling has profound effects on T-cell responses, specifically causing T-cell activation, 
inhibition of apoptosis, increased cell expansion, survival and infiltration (470-472). Due to 
this, the effect of IL-6 pre-exposure on naïve and memory CD4+ T-cell survival, activation and 
proliferation was measured. Several phenotypic surface markers was assessed following IL-6 
pre-exposure including CD25 and CD40L, which are upregulated early during the activation of 
CD4+ T-cells. In addition to these markers CXCR5 and latency associated peptide (LAP) 
expression were also analysed. LAP is the membrane bound form of TGF-β1, included as a 
marker of production of TGF-β, a difficult cytokine to measure via ELISA of supernatants 
or via intracellular cytokine staining. Based on previous work this marker has also been 
found to be strongly upregulated in response to strong stimulation via the TCR (Amy 
Anderson, Newcastle University, unpublished data) so this marker was included to assess if 
there was any influence of IL-6 pre-exposure. CXCR5 is the key chemokine receptor 
expressed on Tfh cells. IL-6 has been heavily implicated in the development of Tfh cells by 
the induction of IL-21. IL-6 also upregulates BCL-3 which has been shown to induce the 
master transcription factor of Tfh cells, BCL-6 (164). Expression levels of this gene have 
been shown to correlate with Tfh cell related genes such as ICOS and CXCR5. Hence, pre-
exposure of CD4+ T-cells to IL-6 may result in increased expression of Tfh cell markers. 
Furthermore, circulating Tfh cells have been found to be increased in early RA suggesting 
IL-6 pre-exposure may have a pathophysiological role in the development of these cells 
(473).  
The presence of IL-6 during TCR stimulation is linked to increased Th2 and decreased Th1 
differentiation (363, 474). IL-6 may also influence but is not the only cytokine required for 
commitment to the Th17 and Tfh cell lineages (364, 386) whilst trans signalling abrogates the 
induction of Tregs (371). Due to this complex role of IL-6 in T-helper cell differentiation the 
expression of master transcription factors for Th1, Th2, Th17 and Tregs was analysed as well 
as the effects of IL-6 pre-exposure on cytokine production and subsequent T-helper cell 
differentiation.  
All of these factors were assessed in order to determine the consequences of IL-6 pre-exposure 
on downstream CD4+ T-cell effector phenotype.   
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4.2 Aims and Objectives  
The aim of this chapter was, using the in vitro system developed in Chapter 3, to investigate 
the consequences of prolonged IL-6 pre-exposure upon naïve and memory CD4+ T-cell effector 
function following TCR mediated activation. In order to achieve this the proliferation and 
activation of cells was assessed post TCR stimulation. Cytokine production and transcription 
factor expression was assessed with IL-6 pre-exposure in addition to examining the influence 
of this pre-exposure on T-helper cell differentiation.  
The specific objectives of this chapter were: 
 Investigation into the specificity of IL-6 in the induction of the three key STAT-3 
regulated genes dysregulated in early RA 
 Determination of the consequences of sustained IL-6 pre-exposure on naïve and 
memory CD4+ T-cell effector function following TCR mediated activation, in terms 
of proliferation, activation and cytokine production. 
 Determination of whether the effect of IL-6 pre-exposure on naïve and memory CD4+ 
T-cell effector phenotype is related to the IL-6 pre-exposure dose or duration.  
 Exploration of the effect of chronic IL-6 pre-exposure of naïve and memory CD4+ T-
cells on subsequent transcription factor expression and T-helper cell differentiation. 
 
4.3 Results 
4.3.1 IL-6 induces STAT-3 target genes  
The previously described 12-gene transcriptional signature, which has the potential to 
discriminate early RA patients, contains a number of STAT-3 target genes, the most 
differentially expressed of these being BCL3, PIM1 and SOCS3 (431). Serum levels of IL-6 
were shown to correlate with expression of these genes as well as with levels of constitutively 
activated STAT-3 (427). I sought to assess whether, in an in vitro setting, IL-6 could induce the 
same combination of STAT-3 regulated genes and, if so, the extent to which this effect was 
specific to IL-6 or common to other pro-inflammatory cytokines. Total CD4+ T-cells were 
isolated from healthy donors by positive selection and incubated for 6 hours with a range of 
pro-inflammatory cytokines. RNA was isolated at each time point, reverse transcribed and the 
expression of BCL3, SOCS3 and PIM1 was examined by RT-PCR.  
Culture of CD4+ T-cells with a supra-physiological concentration of 50ng/ml IL-6 caused 
induction of  SOCS3 and PIM1 with induction around 10 fold and 2 fold, whereas there appears 
to be no induction of BCL-3 Figure 24. Culture of CD4+ T-cells with pro-inflammatory 
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cytokine TNF-α resulted in no induction of any of the STAT-3 mediated genes, Figure 24A, 
whereas IFN-α strongly induced PIM1 but had no effect on BCL-3, Figure 24C. The 
stimulation of CD4+ T-cells with other STAT-3 signalling pro-inflammatory cytokines (IL-21, 
IL-23, IL-27) resulted in a pattern of STAT-3 target gene induction more reminiscent of that of 
IL-6, with good induction of SOCS3 by IL-21 and IL-27 however only in the case of IL-21 was 
this consistent for all 3 genes examined, Figure 24. This suggests IL-21, in addition to IL-6, 
has the ability to generate the STAT-3 gene signature described in early RA.  
 
To summarise, IL-6 is a clear inducer of SOCS3 and PIM1 however failed to induce BCL-3 in 
this experiment. Other pro-inflammatory cytokines or STAT-3 cytokines were able to induce 
either SOCS3 or PIM1 with IL-21 reflecting similar induction to IL-6. Further investigation is 
needed into the effects of stimulation with IL-6 and IL-21. 
Figure 24. Fold induction of STAT-3 regulated genes in CD4+ T-cells stimulated with pro-
inflammatory cytokines. Freshly isolated CD4+ T-cells were cultured for 6 hours in TexMACS 
alone, or with 50ng/ml final concentrations of a range of cytokines including; IL-6 and 
equimolar sIL-6R, TNF-α, IL-21 (A), IL-27 (B), IFN-α and IL-23 (C). Following stimulation 
cells were harvested, RNA was isolated and expression of STAT-3 regulated genes BCL3, 
PIM1 and SOCS3 were assessed using TaqMan real time PCR. ΔCT values of each sample 
were determined by normalising to the housekeeping gene 18S. Fold induction was calculated 
by dividing 2-ΔCT of cytokine stimulated cells by 2-ΔCT of untreated cells, this is equivalent to 2-
ΔΔCT. Values from 3 (A), 2 (B) or 1 (C) biological replicates were plotted on a graph with bars 
representing mean values and error bars showing SEM  
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4.3.2 Viability of naïve and memory CD4+ T-cells following IL-6 pre-exposure  
The next aim of this Chapter was determine if pre-exposure to IL-6 could alter effector 
phenotype with the first aim to determine whether IL-6 pre-exposure could increase cell 
survival. Naïve and memory CD4+ T-cells were cultured with varying concentrations of IL-6 
and equimolar concentrations of sIL-6R and stimulated as per the in vitro model, Chapter 3.4.5. 
Viability was assessed by staining with DAPI for flow cytometry. The gating strategy for this 
analysis can be seen in Figure 5, Appendix.   
There was no clear difference in viability of naïve or memory CD4+ T-cells pre-exposed to IL-
6 following 6 days of TCR stimulation, with 80% viability for all conditions, Figure 25. This 
high viability suggests that viability is not a confounding factor in the subsequent functional 
outputs measured. Although IL-6 has been indicated to increase CD4+ T-cell viability, in this 
case IL-6 has no long lasting effects on naïve or memory CD4+ T-cell viability (470). 
Figure 25. Viability of naïve and memory CD4+ T-cells following pre-exposure to IL-6 and 
subsequent TCR stimulation. Freshly isolated naïve and memory CD4+ T-cells were cultured 
for 3 days in TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 50ng/ml IL-6 all with 
equimolar sIL-6R. After 3 days naïve (A and B) and memory (C and D) cells were washed 
and stimulated with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following 
stimulation cells were stained with DAPI for flow cytometry and assessment of viability. Viable 
cells were gated as DAPI-. Representative dot plots are shown for naïve (A) and memory CD4+ 
T-cells (C). Values from naïve (B) and memory CD4+ T-cells (D) from 5 biological replicates 
were plotted on a graph with bars showing median and error bars representing SEM.  
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4.3.3 IL-6 pre-exposure causes increased proliferative capacity following TCR stimulation 
Although there was no effect of IL-6 pre-exposure on cell viability the next aim was to assess 
whether pre-exposure to IL-6 could alter effector phenotype in terms of proliferative capacity. 
Naïve and memory CD4+ T-cells were isolated from LRS cones and cultured with varying 
concentrations of IL-6 and equimolar sIL-6R. Cells were washed and subsequently stimulated 
for 3 or 6 days with plate-bound anti-CD3 and soluble anti-CD28 at 1μg and 5μg respectively 
(termed “high stimulus”) and proliferation was measured by CFSE and the FlowJo proliferation 
tool. The gating strategy for all proliferation analyses can be seen in Figure 9, Chapter 2.9.5.  
High stimulus with anti-CD3 and anti-CD28 induces robust levels of proliferation at 6 days, 
with higher levels of proliferation seen in memory CD4+ T-cells compared to naïve CD4+ T-
cells with the percentage of cells dividing reaching levels between 10-25% or 10-17% 
respectively, Figure 26A and B. A clear increase in proliferation can be seen as a consequence 
of pre-exposure to increasing concentrations of IL-6, significant by non-parametric analysis of 
variance, p<0.05. However, Dunn’s posthoc analysis of IL-6 pre-exposed naïve and memory 
CD4+ T-cells compared to non-exposed cells revealed only pre-exposure to supra-physiological 
concentrations of IL-6 (50ng/ml) and equimolar sIL-6R causes significantly increased levels of 
proliferation compared to the non-pre-exposed cells, Figure 26.  
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As it is possible that the higher concentration stimulus may be inducing maximal levels of 
proliferation and thus masking the consequences of IL-6 pre-exposure the effect of IL-6 pre-
exposure on naïve and memory CD4+ T-cells was next explored following stimulation with 
0.5μg anti-CD3 and 1μg anti-CD28 (“low stimulus”). The low stimulus induced lower levels 
of proliferation compared to the high stimulus with the percentage of cells dividing ranging 
from 5-20%, Figure 27. Once again, there was a clear increase in proliferation of naïve and 
memory CD4+ T-cells as a consequence of pre-exposure to increasing concentrations of IL-6, 
significant by non-parametric ANOVA, p<0.05. As 0.5ng/ml IL-6 and equimolar sIL-6R is a 
Figure 26. Proliferation of naïve and memory CD4+ T-cells following pre-exposure to IL-
6 and 6-day high TCR stimulation. Freshly isolated CFSE labelled naïve (A) and memory 
(B) CD4+ T-cells were cultured for 3 days in TexMACS alone, with 0.1ng/ml, 0.5ng/ml or 
50ng/ml IL-6 all with equimolar sIL-6R. Cells were then washed and stimulated with; 1μg/ml 
anti-CD3 and 5μg/ml anti-CD28 (high stimulus) for a further 6 days. Cells were acquired on 
the flow cytometer. Cells were gated as singlets, lymphocytes and proliferating cells were 
identified as DAPI-. Proliferation was calculated using FlowJo, shown in Figure 9, Chapter 
2.9.5, with percentage divided indicating the precursor frequency of dividing cells and division 
index showing the average number of divisions, with representative plots of CFSE histograms 
from one donor shown in the left hand panel. Values from 5 biological replicates were plotted 
as graphs with points showing median and error bars representing SEM. Non-parametric 
analysis of variance (Friedman) demonstrated a significant effect in naïve and memory CD4+ 
T-cells irrespective of proliferation parameter (*p<0.05 in each case). Comparisons of 50ng/ml, 
0.5ng/ml and 0.1ng/ml IL-6 pre-exposed cells with non-pre-exposed cells were undertaken 
using Dunn’s post hoc pairwise analysis; *p<0.05. 
110 
 
concentration which mirrors the levels found in the upper limits of that seen in early RA 
patients, and as such was deemed more physiologically relevant, it was explored a priori 
whether this concentration could significantly increase proliferation compared to untreated 
cells. In a single Dunn’s posthoc test there was significant increase in proliferation of both naïve 
and memory CD4+ T-cells from the untreated condition, following pre-exposure to 0.5ng/ml 
IL-6 and equimolar sIL-6R with the low stimulus, Figure 27. However, Dunn’s posthoc 
analysis of all IL-6 pre-exposed naïve and memory CD4+ T-cells compared to non-exposed 
cells revealed only pre-exposure to supra-physiological concentrations of IL-6 (50ng/ml) and 
equimolar sIL-6R causes significantly increased levels of proliferation compared to the non-
pre-exposed cells, Figure 27. From these analyses, it can be seen that the proliferative capacity 
of CD4+ T-cells increases significantly 6 days post anti-CD3 and anti-CD28 stimulation in a 
manner that is dose-dependent with respect to IL-6 pre-exposure.  
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As an increase in proliferation was observed following pre-exposure to IL-6 and equimolar sIL-
6, the extent to which the observations described on proliferation were dependent on the 
presence of sIL-6R (and hence, potentially, the trans signalling mechanism) was next 
considered. Naïve CD4+ T-cells were isolated and cultured as previously described with varying 
concentrations of IL-6 with or without equimolar sIL-6R prior to TCR stimulation. In this 
experiment the low stimulus was used as this better represents the differences seen in 
proliferation with IL-6 pre-exposure. Again, there was increased proliferation with increasing 
concentrations of IL-6 pre-exposure seen with IL-6 and sIL-6R and this was also apparent in 
Figure 27. Proliferation of naïve and memory CD4+ T-cells following pre-exposure to IL-
6 and 6-day low TCR stimulation. Freshly isolated CFSE labelled naïve (A) and memory (B) 
CD4+ T-cells were cultured for 3 days in TexMACS alone, with 0.1ng/ml, 0.5ng/ml or 50ng/ml 
IL-6 all with equimolar sIL-6R. Cells were then washed and stimulated with; 0.5μg/ml anti-
CD3 and 1μg/ml anti-CD28 (low stimulus) for a further 6 days. Cells were acquired on the flow 
cytometer. Cells were gated as singlets, lymphocytes and proliferating cells were identified as 
DAPI-. Proliferation was calculated using FlowJo, shown in Figure 9, Chapter 2.9.5, with 
percentage divided indicating the precursor frequency of dividing cells and division index 
showing the average number of divisions, with representative plots from one donor shown in 
the left hand panel. Values from 5 biological replicates were plotted with points representing 
the median and error bars representing SEM. Non-parametric analysis of variance (Friedman) 
demonstrated a significant effect in naïve and memory CD4+ T-cells irrespective of 
proliferation parameter (*p<0.05 in each case). Comparisons of 0.5ng/ml IL-6 pre-exposed 
cells with non-pre-exposed cells were undertaken in a single Dunn’s posthoc pairwise analysis, 
p<0.05, ** p<0.005.  
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the absence of sIL-6R, significant by non-parametric ANOVA with p<0.05, Figure 28. . In a 
single Dunn’s posthoc test there was significant increase in proliferation of naïve CD4+ T-cells 
from the untreated condition only following pre-exposure to 0.5ng/ml IL-6 and equimolar sIL-
6R but this was not significant in the absence of sIL-6R, Figure 28. However, Dunn’s posthoc 
analysis of all IL-6 pre-exposed naïve CD4+ T-cells compared to non-exposed cells revealed 
pre-exposure to supra-physiological concentrations of IL-6 (50ng/ml) without the presence of 
equimolar sIL-6R causes significantly increased levels of proliferation compared to the non-
pre-exposed cells. It appears that without the addition of sIL-6R there is an increase in the 
number of cells dividing and the number of divisions compared to cells cultured with sIL-6R 
can only be seen at the highest concentration of IL-6, 50ng/ml compared to the untreated 
condition. However, the presence of the sIL-6R significantly increased levels of proliferation 
can be seen with 0.5ng/ml IL-6 pre-exposure, Figure 28A-B.   
Finally it was confirmed that proliferating cells were CD3+CD4+ T-cells, with less than 1% of 
cells in culture being monocytes, B-cells or NK cells, and no such contaminating cells were 
present in the diluted CFSE populations post-stimulation (Figure 14, Appendix).  
To summarise, the observed dose-dependent increases in proliferation relate specifically to of 
naïve and memory CD4+ T-cells. In addition, although increased proliferation appears to be 
seen with pre-exposure to IL-6 alone only when cultured with sIL-6R is a significant increase 
in proliferation seen, indicating a role for trans signalling.   
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4.3.4 Increased proliferative capacity is lost with reduced IL-6 pre-exposure  
As pre-exposure of naïve and memory CD4+ T-cells resulted in increased proliferative capacity 
it was next investigated to what extent the effect of IL-6 pre-exposure on increased proliferative 
capacity was dependent upon the duration of IL-6 pre-exposure. Naïve and memory CD4+ T-
cells, isolated from LRS cones, were cultured with varying concentrations of IL-6 and 
equimolar sIL-6R for 1 hour, 16 hours, 48 hours and 72 hours. At each of these points, cells 
were washed and stimulated as per the in vitro model, Chapter 3.4.5, and proliferation assessed 
after 6 days. 
Figure 28. Proliferation of naive CD4+ T-cells following pre-exposure to IL-6 with or 
without sIL-6R and subsequent TCR stimulation. Freshly isolated CFSE labelled naive 
CD4+ T-cells were cultured for 3 days in TexMACS alone, with 0.1ng/ml, 0.5ng/ml or 50ng/ml 
IL-6 all with (A and C) or without (B and D) equimolar sIL-6R. After 3 days cells were washed 
and stimulated with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following 
stimulation cells were acquired on the flow cytometer. Cells were gated as singlets, 
lymphocytes and proliferating cells were identified DAPI-. Proliferation was calculated using 
FlowJo, shown in Figure 9, Chapter 2.9.5, with division index showing the average number of 
divisions (A and B). and percentage divided indicating the precursor frequency of dividing 
cells (C and D), Values from 3 biological replicates were plotted with points showing median 
and error bars representing SEM. Non-parametric analysis of variance (Friedman) 
demonstrated a significant effect in both the presence or absence of sIL-6R (*p<0.05 in each 
case). Comparisons of 0.5ng/ml IL-6 pre-exposed cells with non-pre-exposed cells were 
undertaken in a single Dunn’s posthoc pairwise analysis, p<0.05. 
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The proliferative response after the usual 72 hours pre-exposure to IL-6 followed by 6 day 
stimulation shows dose-dependent increase in proliferation with increasing concentrations of 
IL-6 pre-exposure. This trend is still apparent after 48 hours pre-exposure to IL-6 followed by 
stimulation, however, the trend is completely abrogated with only 16 hours or 1 hour of IL-6 
pre-exposure, Figure 29. This pattern occurred in both naïve CD4+ T-cells and memory CD4+ 
T-cells, Figure 15-16, Appendix. A two-way ANOVA confirmed the interaction between pre-
exposure time and IL-6 concentration as significantly different, p<0.05, Figure 29. This 
highlights that the effect of IL-6 pre-exposure on proliferative capacity depends on its duration 
and becomes apparent only following more pro-longed pre-exposures.  
Overall, these experiments confirm the dependency of the effects seen on effector phenotype 
on the “chronicity” of IL-6 pre-exposure in vitro.   
4.3.5 IL-6 pre-exposure causes increased activation status following TCR stimulation  
After observing an increase in naïve and memory CD4+ T-cell proliferative capacity following 
pre-exposure to IL-6 the next parameter to be assessed was the effect of IL-6 pre-exposure on 
the expression of IL-6 signalling components and cell surface activation markers. To do this, 
naïve and memory CD4+ T-cells, isolated from LRS cones, were cultured with varying 
concentrations of IL-6 and equimolar sIL-6R prior to TCR stimulation, as previously described. 
Cell surface markers were assessed on day 6 post-TCR stimulation by staining with a panel of 
Figure 29. Proliferation of naive CD4+ T-cells following shortened pre-exposure to IL-6 
and subsequent TCR stimulation. Freshly isolated CFSE labelled naive CD4+ T-cells were 
cultured for 1 hour, 16 hours, 48 hours, or 72 hours in TexMACS alone, with 0.1ng/ml IL-6, 
0.5ng/ml IL-6 or 50ng/ml IL-6, all with equimolar sIL-6R. After exposure to IL-6 naïve CD4+ 
T-cells were washed and stimulated with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 
6 days. Following stimulation cells were acquired on the flow cytometer. Cells were gated as 
singlets, lymphocytes and then proliferating cells were DAPI-. Proliferation was calculated using 
FlowJo, shown in Figure 9, Chapter 2.9.5,  with percentage divided indicating the precursor 
frequency of dividing cells Values from 3 biological replicates were plotted with points showing 
median and error bars showing SEM, dotted line represents maximal proliferation of 
unstimulated cells. Significance was determined by two-way ANOVA, *p<0.05.   
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antibodies for phenotype or  activation for flow cytometry. For phenotype analyses gates were 
set employing the approach of setting gates on the starting population of CD4+ T-cells while 
for activation analyses gates were set based on unstained controls and in the case of CD40L 
with the use of FMO control, Figures 3-4, Appendix.  
The expression of phenotypic markers and IL-6 signalling components were assessed on naïve 
CD4+ T-cells following culture for 3 days with varying concentrations of IL-6 and equimolar 
sIL-6R and subsequent 6 day stimulation with 1μg/ml anti-CD3 and 10μg/ml anti-CD28. This 
level is different to the dose optimised in vitro model, Chapter 3.4.5 as it was carried out prior 
to determining optimal stimulation dose. It was found that post-TCR stimulation expression of 
CD25 doubled from baseline (Figure 14), whereas CD28 was dramatically decreased from 
baseline with no change in CD27 expression, Figure 30. In addition expression of IL-6R was 
reduced from baseline expression (Figure 14) whereas gp130 levels was increased from basal 
expression levels, Figure 30. Levels of expression do not appear to differ with differing 
concentrations of IL-6 showing the effect of IL-6 on the levels of these markers is lost following 
stimulation.  
The expression of activation markers were assessed on naïve CD4+ T-cells following culture as 
per the in vitro model, Chapter 3.4.5. Representative histograms for each marker can be seen 
in Figure 31, which show the intensity of expression of each molecule and the number of cells 
with this intensity. This shows that there is no difference in expression of LAP or CXCR5 but 
there is a clear increase in the s expression of CD40L In addition, for CD25 it appears that with 
Figure 30. Expression of phenotypic markers and IL-6 signalling receptors on naïve 
CD4+ T-cells following pre-exposure to IL-6 and subsequent TCR stimulation. Freshly 
isolated naïve CD4+ T-cells were cultured for 3 days in TexMACS alone, with 0.1ng/ml IL-6, 
0.5ng/ml IL-6 or 50ng/ml IL-6 all with equimolar sIL-6R. After 3 days cells were washed and 
stimulated with 1μg/ml anti-CD3 and 10μg/ml anti-CD28 for a further 6 days. Following 
stimulation cells were stained for cell surface markers for phenotype analysis. Cells were gated 
as singlets, lymphocytes and then CD4+ T-cells were identified as CD3+CD4+. N=1. 
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pre-exposure to IL-6 a greater number of cells express CD25 and those that express CD25 also 
express a higher level of CD25. Data from dot plots showing the percentage of cells positive 
for each marker was used to generate bar charts showing the percentage of cells positive for 
that marker, representative dot plots can be seen in Figure 17, Appendix.  
The percentages of cells positive for each marker was determined by dot plots, with 
representative plots in Figure 17, Appendix. Data from biological replicates was plotted as 
graphs for each marker. These show there was a significant effect with increasing 
concentrations of IL-6 pre-exposure for CD25 in naïve CD4+ T-cells and CD40L in both naïve 
and memory CD4+ T-cells, significant by non-parametric ANOVA with p<0.05, Figure 31. In 
a single Dunn’s posthoc test there was significant increase in the expression of CD25 and 
CD40L of naïve CD4+ T-cells from the untreated condition following pre-exposure to 0.5ng/ml 
IL-6 and equimolar sIL-6R. However, Dunn’s posthoc analysis of all concentrations of IL-6 
pre-exposure of naïve CD4+ T-cells compared to non-exposed cells revealed that for CD40L 
only pre-exposure to supra-physiological concentrations of IL-6 (50ng/ml) caused significantly 
increased expression of this molecule. For CD25 both 50ng/ml and 0.5ng/ml IL-6 pre-exposure 
resulted in significantly increased expression of this molecule. For memory CD4+ T-cells 
Dunn’s posthoc analysis of all concentrations of IL-6 pre-exposure compared to non-exposed 
cells revealed that for CD40L pre-exposure to supra-physiological concentrations of IL-6 
(50ng/ml) caused significantly increased expression of this molecule.  
In summary, increased expression of activation markers CD25 and CD40L can be seen with 
increasing concentrations of IL-6 pre-exposure, 6 days post TCR stimulation amongst naïve 
CD4+ T-cells, and these effects are not observed amongst memory CD4+ T-cells.  
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Figure 31. Expression of activation markers by naïve and memory CD4+ T-cells following 
pre-exposure to IL-6 and subsequent 6 day TCR stimulation. Freshly isolated naïve and 
memory CD4+ T-cells were cultured for 3 days in TexMACS alone, with 0.1ng/ml, 0.5ng/ml 
or 50ng/ml IL-6, all with equimolar sIL-6R. After 3 days cells were washed and stimulated 
with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days before staining for 
activation markers for flow cytometry. Cells were gated as singlets, lymphocytes and CD4+ 
T-cells were identified as CD3+CD4+. Expression of LAP (A), CXCR5 (B), CD40L (C) and 
CD25 (D) were measured for 3 (A), 5 (B), or 6 (C and D) biological replicates as percentage 
positive using dot plots and values plotted with bar representing the median and error bars 
representing SEM, the left panel shows naïve CD4+ T-cells and the middle panel shows 
memory CD4+ T-cells. The right panel shows representative histograms for untreated cells 
(pale blue shaded) and cells pre-exposed to 0.5ng/ml IL-6 (dark blue dashed line), showing 
intensities of expression of each molecule. Non-parametric analysis of variance (Friedman) 
demonstrated a significant effect for CD40L and CD25 in naïve CD4+ T-cells and for CD40L 
in memory CD4+ T-cells (**p<0.05 in each case). Comparisons of 0.5ng/ml IL-6 pre-exposed 
cells with non-pre-exposed cells were undertaken in a single Dunn’s posthoc pairwise analysis, 
* p<0.05, ** p<0.005.  
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4.3.6 Cytokine production following IL-6 pre-exposure  
Given that IL-6 pre-exposure resulted in clear functional and phenotypic consequences in terms 
of proliferation and activation the next step was to investigate whether IL-6 pre-exposure 
affected the cytokine production of naïve or memory CD4+ T-cells. Cytokine production by 
cells pre-exposed to IL-6 followed by 6-day stimulation with the low stimulus of 0.5μg/ml anti-
CD3 and 1μg/ml anti-CD28 was measured by two approaches. These included quantification 
of cytokines found in the supernatants of naïve CD4+ T-cell cultures by MSD plates and analysis 
of intracellular cytokine production by naïve and memory CD4+ T-cells upon restimulation with 
PMA and ionomycin. The gating strategy for this latter approach employed the use of BFA only 
controls and can be seen in Figure 6, Appendix. 
Firstly, MSD analysis of culture supernatants revealed substantial variation in cytokine 
production between experiments carried out with different donors, and none of the observed 
trends reached statistical significance. No clear relationship between IL-6 pre-exposure and 
cytokine production was observed, Figure 32.  
Overall, there is no clear relationship between IL-6 pre-exposure and cytokine production as 
measured in the supernatants of stimulated naïve CD4+ T-cells. 
Representative histograms from one donor for each cytokine detected by intracellular staining 
can be seen in Figure 33, which show the intensity of expression of each molecule and the 
number of cells with this intensity. This shows that there is no clear difference in expression of 
any cytokine in naïve CD4+ T-cells as 0.5ng/ml IL-6 pre-exposure.  
Data from dot plots for 5 donors showing the percentage of cells positive for each cytokine was 
used to generate bar charts in Figure 33, representative dot plots can be seen in Figure 18, 
Appendix. These show that cytokines detected by intracellular staining amongst the memory 
(but not naïve) sub-population of CD4+ T-cells, did reveal a relationship between IL-6 pre-
exposure and downstream cytokine production for IL-4 and IL-21 using non-parametric 
analysis of variance, p<0.05, Figure 33. However, significance was not seen using a single 
Dunn’s posthoc analyses for any cytokine with 0.5ng/ml IL-6 pre-exposure.  
Dunn’s posthoc analysis of all concentrations of IL-6 pre-exposed compared to non-exposed 
memory CD4+ T-cells revealed that for IL-4 and IL-21 only pre-exposure to supra-
physiological concentrations of IL-6 (50ng/ml) caused significantly increased expression. 
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Figure 32. Cytokine production of naïve CD4+ T-cells following pre-exposure to IL-6 
and subsequent TCR stimulation. Freshly isolated naïve CD4+ T-cells were cultured for 3 
days in TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 50ng/ml IL-6 all with 
equimolar sIL-6R. Naïve CD4+ T-cells were washed and stimulated with 0.5ug/ml anti-CD3 
and 1ug/ml anti-CD28 for 6 days. Following stimulation supernatants were harvested and 
cytokine levels measured by MSD including: IL-1β (A), IL-17 (B), IL-12 (C), IL-2 (D), TNF-
α (E), IL-13 (F), IL-4 (G), IL-10 (H), IL-6 (I), IFN-γ (J) and IL-8 (K). Values from 5 
biological replicates were plotted with the horizontal line representing the median of all 5 
experiments. The dotted line represents the detection threshold for the cytokine. Significance 
was determined by non-parametric analysis of variance (Friedman) with Dunn’s posthoc 
pairwise analyses. 
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Figure 33. Cytokine production of naïve and memory CD4+ T-cells following pre-exposure 
to IL-6 and subsequent TCR stimulation. Freshly isolated naïve and memory CD4+ T-cells 
were cultured for 3 days in TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 50ng/ml IL-
6 all with equimolar sIL-6R. After 3 days cells were washed and stimulated with 0.5μg/ml anti-
CD3 and 1μg/ml anti-CD28 for a further 6 days. Following stimulation cells were rested 
overnight and stimulated with PMA/ionomycin followed by intracellular staining for flow 
cytometry. Cells were gated as singlets, lymphocytes and then CD4+ T-cells were identified as 
CD3+CD4+. Expression of IFN-γ (A), IL-4 (B), IL-17 (C) and IL-21 (D) were measured for 5 
biological replicates as percentage positive using dot plots and values plotted with bar showing 
median and error bars representing SEM, the left panel shows naïve CD4+ T-cells and the 
middle panel shows memory CD4+ T-cells. The right panel shows representative histograms 
for untreated cells (pale blue shaded) and cells pre-exposed to 0.5ng/ml IL-6 (dark blue dashed 
line) showing intensities  of expression of each cytokine. Non-parametric analysis of variance 
(Friedman) demonstrated a significant effect for IL-4 and IL-21 in memory CD4+ T-cells 
(*p<0.05). Comparisons of 0.5ng/ml IL-6 pre-exposed cells with non-pre-exposed cells were 
undertaken in a single Dunn’s posthoc pairwise analysis.  
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To summarise, the wide variability in pro-inflammatory cytokine production observed in naïve 
CD4+ T-cells between biological replicates in these experiments hampers any confirmation of 
a relationship with IL-6 pre-exposure.  
4.3.7 IL-6 pre-exposure influences T-helper cell differentiation  
Due to the potential differences seen in cytokine production of memory CD4+ T-cells by 
intracellular staining, expression of transcription factors associated with effector differentiation 
was explored for association with IL-6 pre-exposure, Figure 34. Naïve and memory CD4+ T-
cells were pre-exposed to IL-6 followed by 6-day stimulation with the low stimulus of 0.5μg/ml 
anti-CD3 and 1μg/ml anti-CD28 and transcription factors were measured by intracellular 
staining. The gating strategy for this analysis employed the use of unstained controls can be 
seen in Figure 7, Appendix. 
Representative histograms from one donor for each transcription factor can be seen in Figure 
34, which show the intensity of expression of each molecule and the number of cells with this 
intensity. This shows that there is no clear difference in expression of any transcription factor 
in naïve CD4+ T-cells with 0.5ng/ml IL-6 pre-exposure.  
Data from dot plots for 5 donors showing the percentage of cells positive for each transcription 
factor was used to generate bar charts in Figure 34, representative dot plots can be seen in 
Figure 19, Appendix. These show that all transcription factors measured in memory CD4+ T-
cells and all except ROR-γt in naïve CD4+ T-cells displayed significant increase in expression 
with increasing concentrations of IL-6 pre-exposure as determined by non-parametric analysis 
of variance, p<0.05, Figure 34. In a single Dunn’s posthoc analyses only GATA-3 in naïve 
CD4+ T-cells and Foxp3 in memory CD4+ T-cells displayed significantly increased expression 
following 0.5ng/ml IL-6 pre-exposure.  
Dunn’s posthoc analysis of all concentrations of IL-6 pre-exposed compared to non-exposed 
cells revealed that for all cytokines in memory CD4+ T-cells and for all cytokines except ROR-
γt in naïve CD4+ T-cells pre-exposure to supra-physiological concentrations of IL-6 (50ng/ml) 
caused significantly increased expression. 
 
  
122 
 
  
Figure 34. Naïve and memory CD4+ T-cell transcription factor expression following 
pre-exposure to IL-6 and subsequent TCR stimulation. Freshly isolated naïve and 
memory CD4+ T-cells were cultured for 3 days in TexMACS alone, with 0.1ng/ml, 
0.5ng/ml or 50ng/ml IL-6, all with equimolar sIL-6R. After 3 days cells were washed and 
stimulated with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following 
stimulation cells were rested overnight followed by intracellular staining for flow 
cytometry. Cells were gated as singlets, lymphocytes and then CD4+ T-cells were identified 
as CD3+CD4+. Expression of T-bet (A), GATA-3 (B), ROR-γt (C) and Foxp3 (D) were 
measured for 5 biological replicates as percentage positive using dot plots and values 
plotted with bars showing the median and error bars representing SEM, the left panel shows 
naïve CD4+ T-cells and the middle panel shows memory CD4+ T-cells. The right panel 
shows representative histograms for untreated cells (pale blue shaded) and cells pre-
exposed to 0.5ng/ml IL-6 (dark blue dashed line) showing the intensity of expression of 
each transcription factor. Non-parametric analysis of variance (Friedman) demonstrated a 
significant effect for all transcription factors with the exception of ROR-γt in naïve CD4+ 
T-cells (*p<0.05 in each case). Comparisons of 0.5ng/ml IL-6 pre-exposed cells with non-
pre-exposed cells were undertaken in a single Dunn’s post hoc pairwise analysis *p<0.05. 
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Given the observed increase in transcription factors the possibility that pre-exposure to IL-6 
may influence subsequent T-helper cell differentiation was explored. Naïve and memory CD4+ 
T-cells were cultured with 0.5ng/ml IL-6 and equimolar sIL-6R as optimised in the in vitro 
model, Chapter 3.4.5, followed by culture in their respective cytokine conditions,  to induce 
differentiation of Th1, Th2, Th17 and Tfh. After 6 days of differentiation cells were rested 
before restimulation with PMA/ionomycin and stained for intracellular cytokines, employing 
an additional “BFA only” control for gating purposes, Figure 20-23, Appendix. 
Differentiation of naïve and memory CD4+ T-cells towards their respective T-helper subsets 
was confirmed by comparison of cytokine expression of these cells compared to control 
stimulated undifferentiated naïve, memory or whole CD4+ T-cells, Figure 35. Representative 
plots can be seen in Figures 20-23, Appendix. Naïve CD4+ T-cells differentiated towards a Th1 
phenotype had significantly increased production of IFN-γ, the key cytokine produced by Th1 
cells, compared to naïve CD4+ T-cells cultured without the addition of Th1 skewing cytokines. 
Cells skewed towards Th1 had no difference in production of IL-4 or IL-17 however production 
of IL21 was significantly increased compared to non-skewed cells, Figure 35A. Naïve CD4+ T-
cells differentiated towards Th2 cells showed no significant differences in cytokine production. 
The lack of increase in IL-4 suggests differentiation towards Th2 was not successfully achieved, 
Figure 35B. Memory CD4+ T-cells differentiated towards Th17 displayed significantly reduced 
production of IFN-γ and increased production of both IL-17 and IL-21 of cells compared to 
non-skewed memory CD4+ T-cells, confirming the differentiation of this cell subset, Figure 
35C. In contrast, CD4+ T-cells differentiated towards Tfh cell phenotype showed only a slight 
increase in IL-21 production which did not achieve statistical significance, and no difference in 
IFN-γ, IL-4 or IL-17 production, Figure 35D.  
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Figure 35. Cytokine production of CD4+ T-cells with or without differentiation towards 
T-helper cell subsets. Freshly isolated total CD4+ T-cells, naïve CD4+ T-cells or memory 
CD4+ T-cells were cultured for 3 days in TexMACS, IMDM +10% FCS or IMDM + SR 
respectively. After 3 days cells were washed and differentiated towards Th1 (A), Th2 (B), Th17 
(C) or Tfh (D) for 6 days. Following differentiation cells were rested for 1-4 days before 
stimulation with PMA/ionomycin and staining for intracellular cytokines for flow cytometry. 
Cells were gated as singlets, lymphocytes and then CD4+ T-cells were identified as CD3+CD4+. 
Representative histograms of cytokine expression shown for non-skewed cells (pink) and cells 
skewed towards T-helper subsets (blue) shows intensities of expression of each cytokine. 
Values for 6 biological replicates were determined using percentage positive dot plots and were 
plotted with bar showing median and error bars representing SEM. Significance was 
determined by two-way ANOVA and Bonferroni posthoc analyses ** p<0.05, ***p<0.001. 
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Next, naïve, memory or whole CD4+ T-cells were cultured in their respective differentiation 
cocktails following pre-exposure to 0.5ng/ml IL-6 and equimolar sIL-6R. Naïve CD4+ T-cells 
differentiated towards a Th1 phenotype had no difference in production of IL-4, IL-17 or IL-21 
but displayed increased ability to produce IFN-γ following pre-exposure to 0.5ng/ml IL-6 
compared to cells not exposed to IL-6, Figure 36A. Naïve CD4+ T-cells differentiated towards 
Th2 cells had no difference in cytokine production following exposure of cells to 0.5ng/ml IL-
6 compared to non-pre-exposed cells. Although decreased IFN-γ and IL-21 levels were seen 
with IL-6 pre-exposure of Th2 cells this, did not reach significance, Figure 36B. Moreover, 
memory CD4+ T-cells pre-exposed to 0.5ng.ml IL-6 prior to their differentiation into Th17 cells 
exhibited no difference in IFN-γ, IL-4 or IL-21 production but they did exhibit significantly 
decreased production of IL-17 compared to memory CD4+ T-cells not exposed to IL-6 prior to 
differentiation, Figure 36C. Finally, CD4+ T-cells pre-exposed to 0.5ng/ml IL-6 prior to 
differentiation towards Tfh cells had no difference in IFN-γ, IL-4 or IL-17 production, however 
these cells demonstrated a decrease in the production of IL-21 compared to non-pre-exposed 
Tfh cells, Figure 36D. 
  
126 
 
 
Figure 36. Cytokine production of T-helper cells differentiated following pre-exposure 
to IL-6. Freshly isolated total CD4+ T-cells, naïve CD4+ T-cells or memory CD4+ T-cells 
were cultured for 3 days in TexMACS, IMDM +10% FCS or IMDM + SR respectively, alone 
or with 0.5ng/ml IL-6 with equimolar sIL-6R. After 3 days cells were washed and 
differentiated towards Th1 (A), Th2 (B), Th17 (C) or Tfh (D) for 6 days. Following 
differentiation cells were rested for 1-4 days before stimulation with PMA/ionomycin and 
staining for intracellular cytokines for flow cytometry. Cells were gated as singlets, 
lymphocytes and then CD4+ T-cells were identified as CD3+CD4+. Representative histograms 
of cytokine expression shown for untreated cells (pale blue shaded) and cells pre-exposed to 
0.5ng/ml IL-6 (dark blue dashed line) show intensities of expression of each cytokine. Values 
from 6 biological replicates were determined using percentage positive dot plots and were 
plotted with bar showing median and error bars representing SEM. Significance was 
determined by two-way ANOVA and Bonferroni post hoc analyses; * p<0.05, **p<0.01. 
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To summarise the findings from this section, pre-exposure to IL-6 resulted in increased 
expression levels of the major transcription factors involved in T-helper cell differentiation in 
both naïve and memory CD4+ T-cells. Pre-exposure of naïve or memory CD4+ T-cells to IL-6 
does not affect the differentiation of either Th2 or Tfh cells but, as depicted in summary form 
in Figure 37, has the ability to influence Th1 and Th17 cell differentiation, which could have 
consequences on further function in the immune setting.  
Figure 37. Figure summarising main findings from Figure 36 in relation to effects of IL-
6 pre-exposure upon T-cell differentiation. Freshly isolated naïve CD4+ T-cells or memory 
CD4+ T-cells were cultured for 3 days in IMDM + 10% FCS or 10% SR respectively, alone 
or with 0.5ng/ml IL-6 with equimolar sIL-6R. After 3 days cells were washed and 
differentiated towards Th1 (A and C), Th17 (B and D) for 6 days. Following differentiation 
cells were rested for 1-4 days before being stimulated with PMA/ionomycin and stained for 
intracellular cytokines for flow cytometry. Cells were gated as singlets, lymphocytes and then 
CD4+ T-cells were identified as CD3+CD4+. Values from 6 biological replicates were 
determined using percentage positive dot plots (A and B) and were plotted with bar showing 
the median and error bars representing SEM (C and D). Significance was determined by 
Wilcoxon matched-pairs signed rank test * p=<0.05.  
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4.3.8 Cytokine analysis of culture supernatants 
IL-6 could affect T-cell effector function and phenotype either directly or indirectly through the 
induction of other factors. Many mediators were examined by MSD multiplex during IL-6 pre-
exposure. One factor IL-6 can induce is IL-2, which is of interest as this is a T-cell growth 
factor, which may be responsible for the effects seen with IL-6 pre-exposure. In order to rule 
out the effects observed are directly a consequence of IL-6, levels of IL-2 were measured in the 
culture supernatants during the 3 day IL-6 pre-exposure period. From this, it can be seen that 
the level of IL-2 in culture supernatants with 0.5ng/ml IL-6 was minimal and reflected the level 
of IL-2 in the untreated naïve CD4+ T-cells and the levels of IL-2 remained stable over the 3 
days of culture, Figure 38. Levels of IL-2 were substantially higher in the 50ng/ml IL-6 cultured 
naïve CD4+ T-cells over the 3 days of culture which may contribute to the altered effector 
function seen with this high concentration of IL-6. This suggests IL-2 is induced in response to 
supra-physiological levels of IL-6 exposure, however, at lower physiological concentrations 
seen in RA, there is no increased induction of IL-2 compared to untreated samples. This 
suggests that the effects on T-cells seen with 0.5ng/ml IL-6 are not indirectly due to enhanced 
IL-2 induction.  
4.4 Discussion  
In this chapter, the aim was to establish whether chronic pre-exposure of naïve and memory 
CD4+ T-cells to IL-6 could influence the function of effector CD4+ T-cells following TCR 
stimulation, by employing an in vitro system in which IL-6 was excluded at the point of TCR 
stimulation. The focus was to evaluate the consequences of IL-6 pre-exposure on CD4+ T-cell 
proliferation, activation, viability, cytokine production and T-helper differentiation. The effects 
of IL-6 on these parameters are summarised in Table 14. The current investigation is, to my 
Figure 38. Concentration of IL-2 in the supernatants of naïve CD4+ T-cells during 3 days 
pre-exposure to IL-6. Naïve CD4+ T-cells were cultured for 3 days with TexMACS alone, 
with 0.5ng/ml IL-6 or with 50ng/ml IL-6 with equimolar sIL-6R. Supernatants were harvested 
at 24 hours, 48 hours and 72 hours of culture and subject to MSD analysis. Values from 3 
biological replicates were plotted with bar representing mean and error bars representing SEM.  
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knowledge, the first to examine the degree to which long-lasting prior exposure of naïve CD4+ 
T-cells to IL-6 augments effector function downstream of subsequent TCR stimulation. 
Phenotypic consequences 
of IL-6 pre-exposure 
Naïve CD4+ T-cells Memory CD4+ T-cells 
Viability No effect No effect 
Proliferation Increased Increased 
Activation Increased CD25 and CD40L No effect 
Cytokines No effect No effect 
Transcription Factors Increased GATA-3  Increased Foxp3 
T-helper differentiations Increased IFN-γ in Th1 Decreased IL-17 in Th17 
The difference in response to IL-6 pre-exposure between naïve and memory CD4+ T-cells may 
be a result of the different expression of IL-6 receptors of these two subsets. The difference in 
response may reflect the functional characteristics of these cell subsets as memory CD4+ T-
cells are required for cytokine production and rapid response against antigen whereas naïve 
CD4+ T-cells generally do not produce cytokines and have not encountered cognate antigen in 
the periphery (475).  
4.4.1 Induction of STAT-3 target genes  
The 12-gene signature described in Chapter 1.3.12, which can identify a subset of RA patients, 
contains a significant number of STAT-3 inducible genes (431). STAT-3 is classically induced 
via ligation of the gp130 co-receptor. A number of IL-6 family cytokines members signal in 
this way to induce STAT-3, including IL-11, LIF, OSM, CNTF, CT-1, CLC, IL-27 and IL-31. 
In addition, STAT3 is also induced by other cytokines via alternative signalling mechanisms 
including IFNs, IL-2, IL-12, IL-10, IL-23, IL-21, G-CSF and leptin.  
In previously published work, several cytokines such as IL-4, IL-10, IL-17 and IL-23 as well 
as other serum mediators of STAT-3 (GCSF, leptin, IL-6R), were measured in the serum of 
early RA patients but found to be undetectable and/or unrelated to STAT-3 target gene 
expression. Furthermore, only IL-6 (and not the alternate pro-inflammatory cytokine TNF) was 
able to independently predict expression of the STAT-3 genes (431).  
Table 14. Overall effects of IL-6 pre-exposure on naïve and memory CD4+ T-cells. IL-6 
pre-exposure has no effects on viability or cytokine production however does increase cell 
proliferation and activation with effects on Th1 and Th17 differentiation.  
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Of the 3 genes explored in this chapter one of the genes, BCL-3 had no induction upon 
stimulation with any pro-inflammatory or STAT-3 cytokines. This may be due to a difference 
in time kinetics of this gene. Work carried out in the lab indicates that while maximal induction 
of SOCS3 occurs with 6 hours of cytokine stimulation the maximal induction of BCL-3 varies 
between 6-16 hours (Natasha West, Newcastle University). Therefore, further investigation into 
the time-kinetics of BCL-3 induction is required. Of the IL-6 family/STAT-3 utilising cytokines 
tested in the current experiments, only IL-21 was able to induce the STAT-3 target genes to a 
similar extent as IL-6. IL-21 signals via IL-21R to induce JAK1 and JAK3 and, similarly to IL-
6, subsequently to induce STAT-1 and STAT-3 with the balance of these determining cell 
functions (476). Like IL-6, IL-21 contributes to the inhibition of IFN-γ and Th1 differentiation 
but enhances Th17 and Tfh cells, although this is not the only cytokine necessary for their 
development (163, 477, 478). IL-6 has been shown to induce the production of IL-21 by CD4+ 
T-cells, which is necessary for indirect promotion of Ig production (298, 385). It is possible that 
circulating IL-21 may contribute to the STAT-3 signature described in early RA (479, 480); 
reliable measurement of the cytokine in serum has been attempted by our research group in the 
past but proved technically difficult, and this should be revisited in the light of these findings.  
4.4.2 Consequences of IL-6 pre-exposure on downstream effector function  
4.4.2.1 Proliferation  
The effect of IL-6 pre-exposure on proliferative capacity following stimulation was most 
evident in the naïve CD4+ T-cell subset. The presence of IL-6 has been heavily implicated in 
T-cell proliferation responses in previous studies. In animal models the deletion of IL-6R results 
in an impaired ability of T-cells to proliferate (481). In contrast, the excessive signalling of IL-
6 in mice drives accelerated CD4+ T-cell proliferation (403).  
Specifically, utilisation of the trans-signalling pathway by IL-6 has been shown to promote T-
cell proliferation in a number of contexts utilising animal models of disease, such as during 
colon cancer, in a TGF-β dependent manner (482). Further studies have also implicated the 
trans signalling pathway as playing a key role in the proliferation of hepatocytes and regulation 
of liver regeneration (483, 484). However, the in vitro finding that IL-6 pre-exposure effects 
upon downstream proliferative capacity does not require the presence of sIL-6R suggests the 
effect of this mechanism is not dependent on trans signalling in human cells. Despite this, the 
current work cannot be said to definitively link the observation to classical signalling alone. For 
example, it is possible that IL-6R shedding by CD4+ T-cells in response to classical IL-6 
signalling occurs, in turn permitting trans-signalling in the in vitro system.  
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For this study, both a high level of TCR stimulation and a lower “sub-optimal” level of stimulus 
were used. This was because a high level of stimulation may result in complete proliferation of 
all cells meaning an effect of IL-6 pre-exposure would be masked. The sub-optimal stimulus 
indeed proved more reliable for identifying dose effects in relation to IL-6 pre-exposure. 
Furthermore, the impurities seen in the naïve and memory CD4+ T-cell populations due to the 
isolation method chosen must be taken into account. Naïve CD4+ T-cells had a purity of >85% 
and so it could be possible that the contaminating cells could be playing a role in increased 
levels of proliferation seen. Equally memory CD4+ T-cells were typically only >60% pure with 
a high level of contamination from naïve CD4+ T-cells, this could suggest that in the memory 
population the small proportion of naïve CD4+ T-cells may be resulting in the effects seen.    
4.4.2.2 Activation and signalling receptors 
Phenotypic markers CD27, CD28, CD25 and CD40L were chosen in order to assess the 
expression of co-stimulatory molecules and markers of early CD4+ T-cell activation. CXCR5 
was chosen as a marker of Tfh cells, a subset which IL-6 has been heavily implicated in the 
development and LAP was also measured as a marker of TGF-β production for information on 
regulatory properties.  
It has previously been described that upon antigen exposure in vitro there is a progressive loss 
of CD28 followed also by the loss of CD27 (459). This is reflected in this Chapter as expression 
of CD28 of naïve CD4+ T-cells is decreased from baseline 6 days stimulation, Chapter 4.3.5. 
In contrast, the expression of CD27 on naïve CD4+ T-cells remains at a high level post 
stimulation. Based on the literature CD27 would also be expected to decrease following 
stimulation. One reason for its stability may be that loss of CD28 is described to occur before 
loss of CD27 so the time point sampled post-TCR stimulation may be too early to notice any 
change in expression. Alternatively, it may be due to the type and strength of stimulation. 
Stimulation of these cells was via anti-CD3 and anti-CD28 with no antigen present, it is possible 
that antigen exposure or the cytokine milieu produced by APCs is required for decreased CD27 
expression.  
Similarly, expression of IL-6R was shown to be down regulated following TCR stimulation, 
whereas the expression of gp130 appears to be upregulated following TCR stimulation, Chapter 
4.3.5. The down regulation of IL-6R upon stimulation is confirmed by other studies which 
report infiltrating effector cells shed the IL-6R upon stimulation via the TCR, correlating with 
increased sIL-6R levels (367, 368). The up-regulation of gp130 has been documented in smooth 
muscle cells upon stimulation with viral IL-6, a homologue of IL-6, or with IL-6 and sIL-6R in 
an autocrine stimulation loop, however, this has not been reported in CD4+ T-cells upon TCR 
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stimulation (231, 485). One explanation for its rapid upregulation could be the pleiotropic 
nature of this molecule means it is used by many different cytokines and its rapid turnover may 
reflect the necessity of this molecule in other signalling pathways following activation.  
Upon TCR stimulation of IL-6 pre-exposed CD4+ T-cells there is an increased expression of 
the activation markers CD25 and CD40L; as with the finding of increased proliferative capacity, 
the finding is most prominent in the naïve CD4+ T-cell sub-population. Following the discovery 
of IL-6, this cytokine described as a T-cell co-stimulatory molecule due to its ability to enhance 
proliferation when present alongside TCR stimulation, rather than as a “pre-programming” 
mediator as used in this study (486). This effect on proliferation is well characterised as 
independent of IL-2, however, here increased expression of CD25, the IL-2Rα, on naïve CD4+ 
T-cells suggests a possible role for IL-2. IL-2 is both produced and consumed by CD4+ T-cells 
and is a crucial cytokine in T-cell survival and proliferation (487). The increased expression of 
CD25 permits increased signalling via IL-2 as this molecule functions to increase the affinity 
of the IL-2R for its ligand (488). This increased level of IL-2 signalling may result in altered 
effector function. It is also possible that increased expression of CD25 acts to sequester IL-2 
and limit its availability to Tregs, as has been described in Teffs following antigen dependent 
activation (489). Furthermore, CD8+ T-cells expressing high levels of CD25 appear to 
proliferate more rapidly with a more pronounced effector phenotype (490). Due to this IL-2 has 
been measured in the supernatants of cultured T-cells to detect the importance of this cytokine 
in the effects seen as a result of IL-6 pre-exposure, Chapter 3.3 8.  
CD40L expression was increased following IL-6  pre-exposure and the ligation of this molecule 
with its receptor CD40 on DCs has been shown to result in the production of IL-6, potentially 
resulting in the creation of a positive feedback loop (491). The interaction of CD40-CD40L has 
also been shown to be critical for Th17 differentiation in vitro and in vivo as well as influencing 
the polarisation of Th1 and Th2 cells shown to play a role in pathogenesis of EAE and CIA 
(491, 492).  
CXCR5 is a marker present of Tfh cells, whose development is thought to require IL-6. 
Although IL-6 pre-exposure did not result in increased expression of this marker after 6 days 
stimulation literature has found IL-6 stimulation results in early and rapid upregulation of 
CXCR5 (493). Here, it was reportedly seen within the first 24 hours following antigen exposure 
so it may be possible that more of a difference would be apparent if phenotyping had been 
carried out at this earlier time point.  
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LAP is a membrane-bound form of TGF-β1, which is a marker of suppressive function. This 
molecule has been seen to be decreased in the presence of IL-6 in a STAT-3 dependent manner, 
by inhibition of Lrrc32, the glycoprotein that binds TGF-β to the membrane (494). In contrast, 
LAP has been reported to be strongly increased upon strong TCR stimulation (Amy Anderson, 
Newcastle University, unpublished data). Despite these findings, no difference in LAP 
expression was seen according to IL-6 pre-exposure and levels of this marker remained low 
throughout the 6 days of stimulation.  
Studies have indicated that both the presence of IL-6 alone or the presence of IL-6 with 
simultaneous TCR stimulation can mediate CD4+ T-cell survival by maintaining BCL-2 
expression and downregulating FasL to protect from AICD (472, 495, 496). Furthermore, mice 
with deficient IL-6 signalling have reduced numbers of T-cells (497), although others have 
found that IL-6Rα KO have no difference in apoptosis rates (481). Despite the documented role 
of IL-6 in cell survival in this study the pre-exposure of CD4+ T-cells to IL-6 had no effect on 
cell viability following stimulation. It may be that the effects of IL-6 on cell survival is an 
immediate effect and cannot be maintained when IL-6 is no longer present in the culture.  
4.4.2.3 Cytokines and differentiation 
It was also seen that the pre-exposure of naïve and memory CD4+ T-cells to IL-6 resulted in 
increased transcription factor expression (GATA-3 and FoxP3) and may alter cytokine 
production specifically in memory CD4+ T-cells following TCR stimulation, Chapter 4.3.7. 
Altered effector phenotypes were also observed under Th1 and Th17 skewing conditions, 
Chapter 4.3.8.  
IL-6 pre-exposure resulted in the increased expression of GATA-3 in naïve CD4+ T-cells and 
the increased expression of Foxp3 in memory CD4+ T-cells. IL-6 pre-exposure resulted in 
significant dose-dependent increase in transcription factor expression with increasing 
concentrations of IL-6 pre-exposure as determined by non-parametric analysis of variance, 
indicating that resting cells are more activated towards their pre-programmed phenotype when 
pre-exposed to IL-6. This effect is strongest in memory CD4+ T-cells which have already 
undergone activation and subsequent differentiation in vivo whereas naïve CD4+ T-cells have 
not undergone this process. Another possibility is that the increased expression of these markers 
with IL-6 pre-exposure is a result of increased activation and proliferation of these cells, as 
more cells are activated following pre-exposure to IL-6 there is a higher presence of these 
transcription factors. IL-6 has been shown to induce ROR-γt in mice, however, this requires the 
presence of TGF-β (498). The pre-exposure of cells to IL-6 also shows the ability to induce 
ROR-γt, however, this effect is specific to memory CD4+ T-cells.  
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The increased expression of transcription factors is also reflected in the increased cytokine 
production of memory CD4+ T-cells following IL-6 pre-exposure. In memory CD4+ T-cells 
pre-exposed to IL-6 there is significant dose-dependent increase in IL-4 and IL-21 expression 
with increasing concentrations of IL-6 pre-exposure as determined by non-parametric analysis 
of variance, which correspond to increased GATA-3, ROR-γt and with the increased CXCR5 
representing Tfh cells. In contrast, naïve CD4+ T-cells have no difference in cytokine 
production following IL-6 pre-exposure, however, this may be due to the fact that naïve CD4+ 
T-cells do not readily produce cytokines whereas memory CD4+ T-cells need to rapidly respond 
to antigen mediated activation with cytokine production in order to generate the immune 
response necessary to eliminate pathogens.  
When present at the time of stimulation IL-6 is known to influence the differentiation and hence 
cytokine production of CD4+ T-cells. Under these circumstances IL-6 has been shown to 
promote both IL-4 and IL-21 production in a STAT-3 dependent manner (361, 385, 499). The 
pre-exposure of memory CD4+ T-cells to IL-6 shows the increased production of IL-21 and IL-
4. Conversely, presence of IL-6 during stimulation  has been shown to inhibit IFN-γ production 
by inducing SOCS1, however, with IL-6 pre-exposure there was in fact an increase in IFN-γ. 
Due to the increased expression of transcription factors and cytokine production by cells pre-
exposed to IL-6 it was then explored whether cells pre-exposed to IL-6 prior to differentiation 
may result in altered cytokine production. This is this case of Th1 cells which display increased 
IFN-γ production and Th17 cells which show decreased IL-17 production. 
RA has historically been categorised as a Th1 mediated disease with IFN-γ being the dominant 
cytokine implicated. However, there has been no clear evidence for increased IFN-γ production 
in patients with the disease. The increased production of IFN-γ by Th1 cells pre-exposed to IL-
6 provides a mechanism of IFN-γ contribution to disease where levels although not particularly 
high result in a more pathogenic cell type and this could reflect the increased expression of T-
bet following IL-6 pre-exposure. Despite the suggestion of RA as a Th1 mediated disease the 
targeting of IFN-γ has been shown to be unsuccessful in RA 
With the emergence of Th17 cells came the suggested theory that RA was an inflammatory 
disease mediated by IL-17, however, IL-17 is not obviously increased in RA and the targeting 
of this cytokine is unsuccessful in the treatment of RA. Despite the increase in ROR-γt with IL-
6 pre-exposure there was decreased IL-17 production of Th17 cells pre-exposed to IL-6 prior 
to differentiation. In mice, IL-2 has been shown to inhibit the development of Th17 cells and 
as previously mentioned the increased expression of CD25 by IL-6 pre-exposed cells suggests 
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a role for this cytokine in potential pathogenic effects. Although this has been studied in mice 
it is possible that IL-2 also inhibits the development of human Th17 cells reflected in the 
decreased production of IL-17 seen with IL-6 pre-exposure.  
Despite no firm role for either subset in disease pathogenesis it is clear that the balance of these 
cells is pertinent to disease progression and this balance may be altered by the pre-exposure of 
CD4+ T-cells to IL-6. These conflicting stories although do suggest a T-cell specific role in 
disease and other T-cell mediators may be important.  
4.4.3 The effect of IL-2 in the IL-6 pre-exposure model 
In order to assess whether the effects of IL-6 pre-exposure seen on CD4+ T-cell phenotype were 
due to the direct effects of IL-6 or were due to an indirect effect via the induction of other 
mediators, cell culture supernatants of IL-6 exposed cells were analysed for the presence of 
cytokines which may impact downstream effector function. IL-6 is able to induce the 
production of IL-2 which is a key cytokine in the survival of CD4+ T-cells (500). It is possible 
that the effects of IL-6 pre-exposure on effector phenotype is due to the increased production 
of IL-2 by these cells which in turn has consequences on cell phenotype. However, it was seen 
that in culture supernatants of cells exposed to 0.5ng/ml IL-6 compared to untreated cells there 
was no significant increase in IL-2 levels in the culture at any time point over the 3 day culture. 
At the 50ng/ml concentration of IL-6 the levels of IL-2 are greatly increased. However, this is 
a supra-physiological concentration of IL-6 whereas more physiological concentrations appear 
to have no effect. This suggests that IL-2 is not responsible for the effects seen on naïve CD4+ 
T-cells following IL-6 pre-exposure. 
4.4.4 Summary  
In summary, here it is shown that pre-exposure to increasing concentrations of IL-6 and 
equimolar sIL-6R prior to TCR stimulation resulted in increased levels of proliferation and 
increased expression of activation markers and transcription factors in naïve and memory CD4+ 
T-cells. Although there was no clear effect of IL-6 pre-exposure on naïve CD4+ T-cell cytokine 
production following TCR stimulation, memory CD4+ T-cells display possible alterations in 
cytokine production. Furthermore, this priming event does appear to impact the cytokine 
production of cells differentiated towards Th1 and Th17 phenotypes, apparently favouring the 
differentiation of Th1 effector cells. Despite the numerous effects of IL-6 pre-exposure the 
effects on proliferation of naïve and memory CD4+ T-cells appears to be lost following shorter 
periods of IL-6 pre-exposure suggests these pathogenic effects require chronic stimulation with 
IL-6 and are not the result of transient IL-6 exposure. The findings suggest the possibility that 
“cytokine-programming” of CD4+ T-cells in the circulation may occur, whereby dysregulated 
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effector function becomes “imprinted” even when the subsequent antigen encounter/ TCR 
activation occurs in the absence of the cytokine in question. 
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Chapter 5. Effects of IL-6 pre-exposure on naïve and memory CD4+ T-cell 
gene expression 
 
5.1 Introduction  
One of the key objectives of the work outlined in this thesis was to investigate the molecular 
consequences of IL-6 pre-exposure on naïve and memory CD4+ T-cells. Given the clear 
differences in effector phenotype of CD4+ T-cells pre-exposed to IL-6 it was next important to 
investigate whether IL-6 pre-exposure had an effect on the transcriptional profile of these cells, 
an effect which will ultimately cause dysregulated effector function. Gene expression analysis 
is now commonplace and there is a wealth of CD4+ T-cell expression data available from 
numerous experimental contexts. However, the specific question of cytokine pre-exposure has 
not yet been addressed. 
IL-6 has been shown to affect the expression of a number of genes in CD4+ T-cells, such as the 
transcription factors BCL-6, c-Maf, GATA-3 and STAT-3 (298, 501-503). Others have also 
shown the ability of IL-6 to induce both IFN-γ and IL-4 mRNA expression (364, 474). Deinz 
et al. have explored the gene expression of mouse CD4+ T-cells at early time-points following 
TCR-stimulation in the presence of a supra-physiological concentration of 100ng/ml IL-6 
(385). This reveals differential expression of 132 genes, 16 hours following TCR-stimulation. 
The most striking induction is IL-21 with over 200-fold induction. Other notably induced genes 
included ROR-γ/α, ARID5b, ID2, BCL-3, CCR5, IL-4Rα, SOCS3 whereas a number of genes 
were also downregulated including CD4, IL-7R, STAT-4, FasL and RANKL.  
Furthermore, in RA patients that exhibit good clinical responses to anti IL-6R antibody 
tocilizumab there is a significantly reduced expression of ARID5a (504). This molecule has 
also been shown to govern the fate of naïve CD4+ T-cell effector function. IL-6 induces the 
expression of this molecule in mice CD4+ T-cells during Th17 differentiation in a STAT-3 
dependent manner.   
This work outlined in this Chapter will explore whether pre-exposure of naïve and/or memory 
CD4+ T-cells results in an upregulation of these previously defined IL-6 induced genes and 
what other genes are mediated by the presence of IL-6 but also pre-exposure of cells to IL-6 
followed by TCR-stimulation when IL-6 is no longer present in an effort to probe the situation 
in early RA.   
Naïve and memory CD4+ T-cells are both phenotypically and functionally distinct cell subsets 
and this is reflected in their difference in response to IL-6 pre-exposure, Chapter 4. Despite the 
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huge differences in naïve and memory phenotype and function these cell types are highly 
similar at the level of gene expression with 95% of genes overlapping (505). The differences in 
expression programmes largely reflect differences in effector function, migration and 
homeostasis. Differentially expressed genes between naïve and memory cells have been shown 
to exhibit enrichment of those harboured by risk loci for immune-mediated diseases generally 
implicating memory CD4+ T-cells in disease pathogenesis (506).  
The purpose of the work carried out in this Chapter was to test the hypothesis that IL-6 pre-
priming alters downstream transcriptional profiles, specifically in naïve CD4+ T-cells as these 
cells appear most sensitive to IL-6 at the level of STAT-3 signalling, Chapter 1.3.12. Gene 
expression analysis carried out in IL-6 pre-exposed naive and memory CD4+ T-cells, in parallel, 
will ascertain whether effects of IL-6 pre-exposure are more pronounced in the naïve sub-
population.  
5.2 Aims and objectives  
In the previous chapters, an in vitro model to mimic chronic IL-6 pre-exposure was established 
and the consequences of this pre-exposure on naïve and memory CD4+ T-cell effector function 
determined. Following IL-6 pre-exposure naive and memory CD4+ T-cells displayed increased 
cell proliferation and activation and altered cytokine production of memory CD4+ T-cells, in 
addition to altered cytokine profiles following T-helper cell differentiation. Employing the 
same in vitro model but utilising fresh blood from healthy donors rather than LRS cones, the 
overall aim of the work carried out in this chapter was to investigate the dynamic molecular 
consequences of pro-longed IL-6 pre-exposure on naïve and memory CD4+ T-cells, both before 
and after TCR stimulation.  
The specific objectives were: 
 To determine the transcriptional consequences of IL-6 exposure amongst naïve and 
memory CD4+ T-cells over a 72 hour period, and the extent to which these account for 
previously observed CD4+ T-cell deregulation in early RA. In doing so this will assess 
the relative transcriptional sensitivity of naïve and memory CD4+ T-cells to IL-6. 
 To determine the genes differentially induced during T-cell receptor stimulation, or 
differentially expressed 4 hours after stimulation, according to prior exposure to IL-6.  
 To examine the molecular pathways induced by IL-6 which may explain the differences 
in effector cell phenotype following IL-6 pre-exposure, described in Chapter 4.  
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5.3 Results 
5.3.1 Design of dynamic CD4+ T-cell transcriptome experiment  
To investigate the effects of IL-6 pre-exposure on the naïve and memory CD4+ T-cell 
transcriptome five healthy donors were recruited to derive cellular material for use in this 
experiment, with ages ranging between 24-40 and female to male ratio of 2:3, details can be 
seen in Table 3, Appendix. In each case, 120mls blood was drawn into citrate vacutainers. Naïve 
and memory CD4+ T-cells were isolated from fresh whole blood and the purity of these cells, 
determined using gating on whole CD4+ T-cells, Figure 2, Appendix, can be seen in Table 15. 
Purity of naïve CD4+ T-cells is consistently high however purity of memory CD4+ T-cells are 
much lower, with the majority of contaminants being CD45RA+ CD4+ T-cells, therefore caution 
should be taken when interpreting gene expression data for memory CD4+ T-cells.  
 
 
Following isolation naïve or memory CD4+ T-cells were then cultured for 3 days with 0.5ng/ml 
IL-6 and equimolar sIL-6R and during this period, RNA was extracted 6 hours and 72 hours 
post-IL-6 exposure.  The concentration of 0.5ng/ml IL-6 used in the transcriptional profiling of 
CD4+ T-cells was chosen as this was deemed to be both physiologically relevant and cause 
substantial consequences on CD4+ T-cell effector function, as seen in Chapter 4, in terms of 
proliferation, activation and T-helper cell differentiation.  
As in the in vitro model, cells were thoroughly washed before stimulation with 0.2μg/ml anti-
CD3 and 1μg/ml anti-CD28, optimised for citrate whole blood. Post-TCR stimulation RNA was 
extracted at 4 hours, 16 hours and 6 days. The time points chosen to take RNA for profiling 
were chosen in order to capture both early and late responses in gene expression as a result of 
Donor Purity of naïve CD4+ T-cells 
(CD45RA+ % of alive 
lymphocytes) 
Purity of memory CD4+ T-cells 
(CD45RO+ % of alive 
lymphocytes) 
1 89.3 80.9 
2 95.7 67.7 
3 93.7 65.4 
4 95.7 54.9 
Table 15. Purity of naïve and memory CD4+ T-cells used for subsequent microarray 
analysis. Purity was calculated for each healthy donor as the percentage of CD45RA or 
CD45RO in the alive lymphocyte population.  
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IL-6 exposure and TCR stimulation. The induction of STAT-3 regulated genes was found to be 
induced by IL-6 following 6 hours cytokine stimulation (Figure 24, Chapter 4.3.1) therefore 
this time point should reveal genes directly induced as a result of IL-6 stimulation. Following 
72 hour exposure to IL-6 and prior to TCR stimulation RNA was taken as this provides a 
baseline to assess which genes are deregulated by IL-6 at the point directly prior to stimulation. 
Time points post-TCR stimulation were 4 hours and 16 hours in order to capture both early and 
late changes in gene expression. The 6-day time point was also chosen to address whether there 
was altered gene expression at the time of altered effector phenotype and whether there were 
any long lasting consequences on gene expression of IL-6 pre-exposure. The experimental 
design is summarised in Figure 39.  
 
 
  
Figure 39. IL-6 Pre-exposure model for dynamic transcriptome experiment. Naïve and 
memory CD4+ T-cells were isolated from healthy donor blood drawn into citrate and were 
cultured for 3 days in TexMACS alone or with 0.5ng/ml IL-6 and equimolar sIL-6R. . After 
3 days cells were washed and stimulated with 0.2μg/ml anti-CD3 and 1μg/ml anti-CD28 for 
a further 6 days. RNA was taken at baseline, after 6 hours and 72 hours IL-6 exposure and 4 
hours, 16 hours and 6 days post-TCR stimulation. RNA was processed into double stranded 
cDNA, amplified to create cRNA and hybridised to Illumina Human HT-12 v4.0 microarray 
for genome expression profiling. In parallel, an aliquot of CFSE labelled naïve CD4+ T-cells 
were cultured as described and following 6 days stimulation acquired on the flow cytometer 
to analyse proliferation.  
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In order to ensure if inference about any relationship between dynamic gene expression and 
effector phenotype amongst CD4+ T-cells in this experiment was valid, the proliferative 
capacity of naïve and memory cells from each donor was assessed using residual cells. With 
the exception of donor 5, all donors appeared to show clear increases in proliferation between 
the untreated and 0.5ng/ml IL-6 pre-exposed naïve CD4+ T-cells, Figure 40A. As donor five 
did not appear to respond to TCR-stimulation nor to IL-6 pre-exposure this donor was excluded 
from the experiment resulting in 4 donors which showed good responses to IL-6 pre-exposure 
with fold induction between 2-8%, Figure 40B. RNA was extracted from these donors and 
microarray analysis was performed.  
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Figure 40. Proliferation of naïve CD4+ T-cells from healthy donors recruited for 
microarray. Freshly isolated naïve CD4+ T-cells from blood drawn into citrate were CFSE 
labelled and cultured for 3 days in TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 
50ng/ml IL-6 all with equimolar sIL-6R. After 3 days cells were washed and stimulated with 
0.2μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following stimulation cells were 
acquired on the flow cytometer. Proliferation was calculated using FlowJo with percentage 
divided indicating the precursor frequency of dividing cells (A) and fold change determined by 
the level of proliferation at 0.5ng/ml compared to the untreated condition (B).  
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5.3.2 Quality control of microarray data and pairwise analysis strategy  
Prior to performing differential gene analysis, data quality was assessed in R using the 
Bioconductor package (445, 507). An overview of the bioinformatics performed are outlined in 
Chapter 2.12. Briefly, box plots of raw data from all 4 donors were used to assess background 
intensities of all arrays, Figure 41A. Data was normalised both within array and between arrays 
as described by VST and RSN and box plots of normalised data were assessed, Figure 41B 
(446). Following normalisation all samples were deemed to be of good quality and were taken 
forward for further differential expression analysis. 
As all arrays passed this quality control stage, principle component analysis plots were 
generated which plot the measures that account for the largest amount of variance in the data 
set. Upon inspection of the PCA it was revealed that one of the donors, donor 4, appeared not 
to have responded to TCR stimulation, as all samples from this donor cluster around the 
baseline, 6-hour and 72-hour time pre-TCR stimulation time points of the other 3 donors, Figure 
42. The difference in gene expression of this donor is difficult to explain and it could not be 
definitively excluded that it may have resulted from experimental error as opposed to inter-
Figure 41. Boxplots showing intensities of all samples on microarray. Data quality was 
assessed in R using the Bioconductor package. Background intensities of all samples from 4 
donors were visualised as boxplots prior to normalisation (A) or following VST and RSN 
normalisation (B).  
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individual variability. For these reasons, samples from this donor have been excluded from 
downstream analyses. Naïve and memory CD4+ T-cells from the other 3 donors reveal that cells 
appear to cluster together based on time-point. Pre-stimulation samples cluster together and 
post-stimulation samples also cluster according to time point but also remain distinct from each 
other, Figure 42.  
 
The limma package (450) was used for differential gene expression analysis. This package uses 
a linear model where standard variances are moderated across genes allowing the shrinking of 
individual gene variance towards a pooled estimate; this allows for more stable inference where 
sample size is limited (508). The analysis also allowed multi-level comparisons to combine 
paired comparisons and comparisons between two independent groups, ultimately allowing for 
the variation between donors. In addition, around 30% of probes are non-specific and have 
sequences which match to more than one gene. Probes which can match to more than one gene 
can result in a doubling of signal intensity and cause false positive results. For this reason, these 
probes were removed from the analysis. Further analyses involved cross-sectional differential 
Figure 42. Principle component analysis of non-pre-exposed or IL-6 pre-exposed naïve 
CD4+ T-cells. Principle component analysis was carried out on gene expression data from the 
Illumina Human HT-12 v4.0 expression BeadChip array using the Bioconductor package in R 
software. The left hand plot represents the data with all 4 healthy donors included and the right 
hand plot represents the data following removal of donor number 4. Symbols represent the 
different time-points throughout culture with IL-6 and following TCR stimulation. Untreated 
naïve CD4+ T-cells are coloured red and IL-6 pre-exposed naïve CD4+ T-cells are coloured 
blue.  
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expression to identify genes differentially expressed at each time point in IL-6 pre-exposed cells 
compared to untreated cells and longitudinal differential induction analyses to identify genes 
differentially induced following TCR stimulation in IL-6 pre-exposed cells compared to 
untreated cells. These analyses are summarised in Figure 43. 
  
5.3.3 Effect of IL-6 pre-exposure on naïve and memory CD4+ T-cell gene expression prior 
to TCR stimulation  
The first analysis carried out was a cross sectional analysis to identify genes differentially 
expressed between the IL-6 exposed and non-exposed CD4+ T-cells amongst the three donors 
who passed quality control at the “6 hour post-IL-6” time-point in the dynamic transcriptome 
experiment described above in Chapter 5.3.2. Results were compared in naïve and memory 
Figure 43. Analyses conducted on the dynamic transcriptome experiment. Naïve or 
memory CD4+ T-cells were cultured alone (blue arrows) or with 0.5ng/ml IL-6 and equimolar 
sIL-6R (green arrows) followed by stimulation with 0.2μg/ml anti-CD3 and 1μg/ml anti-CD28. 
RNA was taken at time-points indicated. Cross-sectional analysis was performed at each time 
point to identify genes differentially expressed between untreated and IL-6 pre-exposed naïve 
and memory CD4+ T-cells (orange arrows). Longitudinal analysis was performed to identify 
genes differentially induced following TCR stimulation as a result of IL-6 pre-exposure (red 
arrows).  
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CD4+ T-cell subsets. Differentially expressed genes were identified using an adjusted p-value 
cut off of <0.05 and a log fold change (LFC) of 1.5. Genes were subject to multiple test 
correction using the Benjamini-Hochberg method (451). Differentially expressed genes are 
depicted as volcano plots in Figure 44A-B. Volcano plots are a visual representation of genes 
on the microarray, those that reach statistical significance in pairwise comparison of 
differentially expressed genes, according to their FC and corrected p-value thresholds, appear 
as red dots. The absolute numbers of differentially expressed genes (DEGs) identified in this 
way are displayed in Table 16, which also summarises the same information at other time-
points in the experiment. Corresponding gene lists can be found in the CD-ROM in the 
Appendix. 
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Time-point Naïve CD4+ T-cells Memory CD4+ T-cells 
6 hours post-IL-6 532 99 
72 hours post-IL-6 428 104 
4 hours post-TCR 233 10 
16 hours post-TCR 8 0 
6 days post-TCR 0 0 
Table 16. Number of differentially expressed genes between untreated and IL-6 pre-
exposed naïve and memory CD4+ T-cells at each time point. Differentially expressed genes 
were identified by cross sectional analysis of untreated and IL-6 exposed naïve and memory 
CD4+ T-cells from 3 biological replicates at each time point using paired t test with log fold 
change 1.5 and corrected p value cut off of <0.05.   
Figure 44. Volcano plots showing differentially expressed genes between untreated and 
IL-6 exposed naïve and memory CD4+ T-cells following 6 hours and 72 hours IL-6 
exposure. Differentially expressed genes were identified post multiple test correction by cross 
sectional analysis of untreated and IL-6 exposed naïve (A and C) and memory (B and D) CD4+ 
T-cells from 3 biological replicates following 6 hours and 72 hours exposure to 0.5ng/ml IL-6 
using paired t-test with log fold change 1.5 and corrected p value cut off of <0.05. STAT-3 
regulated genes found to be dysregulated in early RA are highlighted.  
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Exposure of naïve CD4+ T-cells to IL-6 and sIL-6R altered the expression of 532 genes by <1.5-
fold at 6 hours (adjusted p<0.05), with only 99 genes similarly modulated amongst the mature 
memory CD4+ T-cell counterparts, Figure 44, CD-ROM Gene lists 1A and 2A. This pattern was 
maintained at 72 hours with 428 and 104 genes in naïve and memory CD4+ T-cells, respectively, 
Figure 44, CD-ROM Gene lists 1B and 2B. This pattern was also present at 4 hours following 
IL-6 removal and TCR stimulation with 233 versus 10 genes and again at 16 hours post-TCR 
stimulation with differentially expressed genes only occurring in naïve CD4+ T-cells, Table 16, 
Gene lists 1C, 2C and 1D. The transcripts which were impacted in memory CD4+ T-cells 
corresponded for the most part to a subset of those impacted in naïve CD4+ T-cells, with very 
few genes differentially expressed in memory CD4+ T-cells alone at each time-point, Figure 
45. These data confirmed, at the transcriptional level, that naïve CD4+ T-cells are markedly 
more sensitive to sustained IL-6 exposure.  
 
 
A number of genes found to be differentially expressed following 6 hours or 72 hours IL-6 
exposure have been previously described as being up-or down-regulated by IL-6, these genes 
include ARID5A, ARID5B, ID2, BCL3, BCL6, STAT3, STAT4 and IL-21R (385). The 
differential expression of these genes whose expression is known to be affected by IL-6 
Figure 45. The overlap of differentially expressed genes between untreated and IL-6 pre-
exposed naïve and memory CD4+ T-cells at each time point. Venn diagrams indicate the 
differentially expressed genes identified by cross sectional analysis of untreated and IL-6 
exposed naïve and memory CD4+ T-cells from 3 biological replicates at each time point using 
paired t test with log fold change 1.5 and corrected p value cut off of <0.05. N=3.  
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confirms that naïve and memory CD4+ T-cells have been exposed to IL-6 in the in vitro model, 
with a significant dose to induce changes in gene expression.  
To explore the extent to which the IL-6 responsive genes observed in this Chapter corresponded 
to those we previously observed to be differentially expressed in total CD4+ T-cells of early RA 
patients compared to disease controls (431), DEGs at the 6 hour time-point amongst naïve and 
memory CD4+ T-cells in the current experiment were contrasted with the published dataset. A 
number of the DEGs identified were STAT-3 regulated genes, found to be components of a 12-
gene “signature” previously shown to robustly discriminate early RA from disease controls. 
These included BCL3, PIM1, SOCS3, SBNO2 and, uniquely in memory CD4+ T-cells, MUC1, 
Figure 44A and B. Furthermore, of an extended list of 96 genes found to be differentially 
expressed between early RA and non-RA controls before multiple test correction (see CD-ROM 
Supplementary Gene List (431)) 30 were also found to be differentially expressed in the IL-6 
exposed naïve CD4+ T-cells and 15 were found to be differentially expressed in IL-6 exposed 
memory CD4+ T-cells in the current study. The 15 genes found to be differentially expressed 
in memory CD4+ T-cells were the same as found in naïve CD4+ T-cells with the exception of 
MUC1 and SNORA10.  
Hypergeometric testing was then carried out on these gene lists which is a statistical test to 
determine the probability of successes (genes differentially expressed between early RA and 
disease controls) from the sample population (IL-6 exposed naïve or memory CD4+ T-cells). 
This level of overlap was significantly higher than would be expected by chance in the memory 
CD4+ T-cells with hypergeometric testing resulting in p-values of 2.22E-15. A smaller number 
of differentially expressed genes between untreated and IL-6 treated memory CD4+ T-cells 
overlap with DEGs found in early RA, however, this still remains significantly higher than 
would be expected by chance suggesting that although memory CD4+ T-cells are less sensitive 
to the effects of IL-6 they also contribute to the gene signature seen in early RA.  
5.3.4 CD4+ T-cell gene expression changes pre-TCR stimulation are partially maintained 
over 72 hours  
It was of interest to explore the extent to which dysregulation of genes identified after 6 hours 
IL-6 exposure was sustained after 72 hours of culture in this experimental set up, modelled, as 
it was to mimic “chronic” exposure to the cytokine. A pair-wise analysis of DEGs at 72 hours 
was therefore undertaken, analogous to that described above.  
The number of DEGs identified after 72 hours IL-6 exposure were 428 genes and 104 genes in 
naïve and memory CD4+ T-cells, respectively, Table 16. At this 72 hour time point differential 
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induction of STAT-3 regulated genes between untreated and IL-6 pre-exposed naïve CD4+ T-
cells are largely maintained from 6 hours including PIM1, SOCS3, SBNO2 and MUC1 which 
is now found in both naïve and memory CD4+ T-cells, Figure 44C. Although naïve CD4+ T-
cells gain differential expression of MUC1, they appear to lose differential expression of BCL3 
at this time point, despite this gene having a log fold change over 1.5 the adjusted p value does 
not reach significance. On the other hand, the memory CD4+ T-cells only maintain differential 
expression of MUC1, SOCS3 and SBNO2, Figure 44D.   
Again, in previously published data by Pratt et. al. of the 96 DEGs found between early RA and 
non-RA patients, 18 of these genes were found to be differentially expressed as a result of IL-
6 pre-exposure in naïve CD4+ T-cells compared to 11 of these genes found to be differentially 
expressed by IL-6 pre-exposure in memory CD4+ T-cells at 72 hours. Once more, this level of 
overlap is significantly higher than would be expected by chance with hypergeometric testing 
resulting in p-values of 9.59E-09 for naïve CD4+ T-cells and 8.99E-10 for memory CD4+ T-
cells. The dynamic profiles of genes significantly dysregulated at both 6 hours and 72 hours in 
naïve CD4+ T-cells can be seen in Figure 46, with genes previously observed to be differentially 
expressed in early RA indicated. Despite a number of DEGs in memory CD4+ T-cells as a result 
of 72 hours IL-6 exposure overlapping with genes identified by Pratt et al as differentially 
expressed in early RA, a higher number of DEGs in naïve CD4+ T-cells as a result of 72 hours 
IL-6 exposure overlap with these previously identified DEGs in early RA, further suggesting 
that naïve CD4+ T-cells are the crucial cell type responding to IL-6 signalling.  
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The top 10 differentially expressed genes following 72 hours exposure to IL-6 in naïve CD4+ 
T-cells are summarised in Table 17. Of these genes 5 were chosen for validation and further 
investigation in Chapter 6 to explore whether these genes were differentially expressed in 
disease conditions. The induction of these genes, termed the “IL-6 pre-TCR signature”, was 
assessed in naïve CD4+ T-cells  following 72 hours exposure to IL-6 by real-time PCR, Figure 
47. All genes showed increased expression following IL-6 treatment compared to untreated 
cells and this increase reached significance for BCL-6, SBNO2 and REXO2. Full gene lists can 
be seen in CD-ROM Gene List 1B and 2B.  
 
  
Figure 46. Dynamic profiles of differentially expressed genes between untreated and IL-6 
exposed naïve CD4+ T-cells following 6 hours or 72 hours. Fold-expression in IL-6 exposed 
cells is depicted relative to that in non-exposed cells at 6 hours (t1) and 72 hours (t2) with log 2 
fold change >1.5 and corrected p<0.05 for inclusion. Genes previously observed to be 
differentially expressed (DE) in early RA (eRA) are indicated (heavy lines), and specific STAT-
3 targets labelled (solid lines). 
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Gene Symbol Illumina ID Log Fold Change P-value 
BCL6* ILMN_1737314 2.745663468 3.385E-13 
REXO2* ILMN_1749009 1.035768851 7.174E-10 
AF038185 ILMN_1833858 1.640052332 7.506E-10 
LRP8* ILMN_1724533 1.669138016 7.506E-10 
PRG4 ILMN_1780349 2.125162982 8.759E-10 
FAM113B ILMN_1712431 1.634692162 2.46E-09 
ID2 ILMN_1793990 1.959497127 2.057E-08 
SBNO2* ILMN_1808811 1.850223353 6.21E-08 
C10orf10* ILMN_1767556 1.612132122 1.404E-07 
SULT1B1 ILMN_1733443 1.306667282 4.41E-07 
5.3.5 Gene expression changes post-TCR stimulation  
Next, genes differentially expressed between the untreated and IL-6 pre-exposed naïve and 
memory CD4+ T-cells at the time-points post TCR stimulation was assessed, including 4 hours, 
16 hours and 6 days. When examining differential gene expression at time points following 
TCR stimulation there were substantially fewer DEGs found after 4 hours and 16 hours and no 
Table 17. Top 10 differentially expressed genes in naïve CD4+ T-cells following 72 hours 
IL-6 exposure. Genes shown are the top 10 differentially expressed genes with the strongest p 
values with their respective log fold changes and Illumina IDs. Genes highlighted with * 
represent those genes used for further validation of the IL-6 pre-TCR signature in Chapter 6. 
Figure 47. Validation of “IL-6 pre-TCR signature” genes in naïve CD4+ T-cells following 
72 hours IL-6 exposure. Naïve CD4+ T-cells from 5 healthy donors were cultured with 
0.5ng/ml IL-6 and equimolar sIL-6R for 72 hours and RNA was extracted. 5 genes shown to be 
differentially expressed following 72 hours IL-6 exposure were assessed by real-time PCR, (A) 
2-ΔCT were plotted for untreated and IL-6 treated and (B) fold induction was calculated by 
dividing 2-ΔCT of IL-6 treated cells by 2-ΔCT of untreated cells, this is equivalent to 2-ΔΔCT. 
Significance was determined by two-way analysis of variants with Bonferroni posthoc pairwise 
analyses: ***p<0.0001.   
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DEGs found 6 days following TCR stimulation or 16 hours following TCR stimulation in 
memory CD4+ T-cells, Table 16.  
4 hours post-TCR stimulation there were 233 DEGs in naïve CD4+ T-cells compared to only 
10 DEGs in memory CD4+ T-cells, Table 16. The full list of genes can be seen in CD-ROM 
Gene List 1C and 2C. 
The top 10 differentially expressed genes after 72 hours exposure to IL-6 followed by 4 hour 
TCR stimulation in naïve CD4+ T-cells are summarised in Table 18. Of these genes, four were 
chosen for investigation in Chapter 6 to explore whether these genes were differentially 
expressed in disease conditions. These genes are termed the “IL-6 post-TCR signature” and 
their induction was assessed, following 72 hours exposure to IL-6 followed by 4 hour TCR 
stimulation, by real-time PCR, Figure 48. The induction of CST7 and GPT2 was significantly 
increased by pre-exposure to IL-6 followed by TCR stimulation however there was no induction 
of GSTO1. In contrast RRAD appeared to show a decrease following IL-6 pre-exposure. 
 
Gene Symbol Illumina ID Log Fold Change P-value 
GSTO1* ILMN_2227573 -1.021102282 2.67199E-06 
RRAD* ILMN_2186137 1.318849708 2.67199E-06 
GPT2* ILMN_1684158 1.432891356 2.67199E-06 
ISM1 ILMN_1772869 -0.97596656 6.1381E-06 
RASA1 ILMN_1725312 -0.79472334 6.1381E-06 
CST7* ILMN_1679826 1.849028026 6.49498E-06 
C1orf22 ILMN_1663068 -0.985021927 1.07571E-05 
ARC ILMN_1711120 1.053244701 2.86219E-05 
TMEM194A ILMN_3228822 -0.751914657 0.000169431 
CBS ILMN_1804735 1.306365759 0.003820756 
 
 
Table 18. Top 10 differentially expressed genes in naïve CD4+ T-cells after 72 hours IL-6 
pre-exposure followed by 4 hours TCR stimulation. Genes shown are the top 10 differentially 
expressed genes with the strongest p values with their respective log fold changes and illumina 
IDs. Genes highlighted with * represent those genes used for further validation of the IL-6 post-
TCR signature in Chapter 6. 
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The DEGs 4 hours post-TCR stimulation are highly similar between naïve and memory CD4+ 
T-cells with only one of the genes (ANK3) differentially expressed in memory CD4+ T-cells 
not found to be differentially expressed in naïve CD4+ T-cells. The full list of these genes can 
be seen in the CD-ROM in the Appendix, Gene list 1C and 2C. Furthermore, only 2 of the 123 
DEGs identified as a consequence of IL-6 pre-exposure in naïve CD4+ T-cells 4 hours post TCR 
stimulation were overlapping with the genes previously found by Pratt et. al. to be dysregulated 
between early RA and non-RA, but not found higher than would be expected by chance. This 
indicates altered response to TCR stimulation, which is enhanced in naïve CD4+ T-cells 
compared to memory CD4+ T-cells. The absence of any DEGs at both 16 hours post-stimulation 
and 6 days post-stimulation indicates no longer lasting consequences on gene expression as a 
result of IL-6 pre-exposure.  
5.3.6 Gene expression changes over time  
A striking observation from the analysis hereto had been the apparent absence of genes 
differentially expressed in cross sectional analyses at 16 hours or 6 days, Table 16. To allay 
concern that the pairwise analyses undertaken might be insufficiently sensitive to identify all 
genes whose dynamic profiles differed significantly as a result of IL-6 pre/non-exposure, 
especially following TCR stimulation, the next analyses carried out was a longitudinal analysis, 
as shown in Figure 43. This longitudinal analysis was carried out with the aim of identifying 
Figure 48. Validation of “IL-6 post-TCR signature” genes in naïve CD4+ T-cells following 
72 hours IL-6 exposure. Naïve CD4+ T-cells from 5 healthy donors were cultured with 
0.5ng/ml IL-6 and equimolar sIL-6R for 72 hours, washed and stimulated with 0.2μg/ml anti-
CD3 and 1μg/ml anti-CD28 for 4 hours and RNA was extracted. 4 genes shown to be 
differentially expressed following 72 hours IL-6 exposure and subsequent 4 hour TCR 
stimulation were assessed by real-time PCR, (A) 2-ΔCT were plotted for untreated and IL-6 
treated and (B) fold induction was calculated by dividing 2-ΔCT of IL-6 treated cells by 2-ΔCT of 
untreated cells, this is equivalent to 2-ΔΔCT. Significance was determined by two-way analysis 
of variants with Bonferroni posthoc pairwise analyses: **p<0.001, ***p<0.0001.  
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those genes differentially induced by TCR stimulus at the 4 hour, 16 hour and 6 day post-TCR 
time-points relative to the 72 hour pre-TCR time-point. The number of differentially induced 
genes at each of these time-points relative to the 72 hour pre-TCR time point can be seen in 
Table 19.  
 
Post-TCR time-
point 
DEG in untreated naïve 
CD4+ T-cells 
DEG in IL-6 pre-exposed naïve 
CD4+ T-cells 
4 hours 4318 4457 
16 hours 1209 1496 
6 days 5641 5325 
 
Similar to the cross sectional analysis between untreated and IL-6 exposed cells, there were 
fewer differentially regulated genes at the 16 hour time-point compared to the 4 hour time point 
however after 6 days stimulation there are much greater numbers of differentially expressed 
genes. This longitudinal analysis revealed many genes differentially induced at time-points 
post-TCR stimulation in both untreated naïve CD4+ T-cells and a similar number of genes 
differentially induced in IL-6 pre-exposed naïve CD4+ T-cells. This highlights that there are 
gene expression changes post TCR stimulation as a result of IL-6 pre-exposure, however, a 
pair-wise test of differential expression is not sensitive enough to detect these changes, as 
shown in Table 16.  
Genes whose dynamic profiles differed as a result of TCR stimulation at the 4 hour time point 
post TCR stimulation compared to the 72 hour pre-TCR time-point are depicted in Figure 49. 
There were 1576 genes up regulated and 1674 genes down regulated irrespective of IL-6 pre-
incubation. However, in IL-6 pre-exposed naïve CD4+ T-cells there were 646 genes uniquely 
induced by TCR stimulation and 556 genes uniquely repressed. These lists include some of 
those found to be differentially expressed in the cross sectional analysis between untreated and 
IL-6 pre-exposed cells 4 hours post-TCR stimulation, including CST7, ARC, CBS and 12 
others. Other notable genes induced at this time point include SOCS3, SBNO2, PRG4, REXO2, 
Table 19. Genes differentially induced in naïve CD4+ T-cells post-TCR stimulation 
relative to 72 hours IL-6 exposure pre-TCR stimulation. Genes were identified which were 
differentially induced between the 72 hour time point pre-TCR stimulation and all time points 
post-TCR stimulation in both untreated and IL-6 pre-exposed naïve CD4+ T-cells for 3 
biological replicates.  
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C10orf10 and ARID5B, genes found to be differentially expressed by presence of IL-6 pre-
TCR stimulation. Only 3 probes were found to be down regulated in untreated cells but up 
regulated by IL-6 pre-exposure. Two of these probes corresponded to the master transcription 
factor of Tfh cells, BCL6. The full list of genes for each time-point can be found in CD-ROM 
Gene lists 3A-F. 
 
Furthermore, there were many genes found to be induced by TCR stimulation in both the 
untreated and IL-6 pre-exposed naïve and memory CD4+ T-cells. These overlapping genes 
between untreated and IL-6 pre-exposed cells were more abundant at 4 hours and 6 days post-
TCR stimulation than genes which are unique to untreated or IL-6 pre-exposed cells. Moreover, 
despite having fewer genes induced at 4 hours post-TCR stimulation there is a higher number 
of genes induced by TCR stimulation in both untreated and IL-6 pre-exposed memory CD4+ T-
cells at 6 days post stimulation.  
5.3.7 Pathways differentially induced by IL-6 pre-exposure  
Ingenuity Pathway Analysis (IPA) software (Qiagen, Germany) was used to analyse particular 
DEG lists identified in Chapter 5.3.3-6, in order to derive the key biological processes 
Figure 49. Upset plot of the intersections between gene sets differentially induced 4 hours 
following TCR stimulation relative to pre-TCR stimulation at 72 hours in naïve CD4+ T-
cells as a consequence of IL-6 exposure. Differentially expressed genes were determined in 
both untreated and IL-6 pre-exposed cells between 72 hours pre-TCR stimulation and 4 hours 
post-TCR stimulation for 3 biological replicates with log 2 FC >1.5 and corrected p<0.05. The 
bar chart on the left indicates the number of genes up- or down- regulated in untreated of IL-
6/sIL-6R pre-exposed naïve CD4+ T-cells. The upper bar chart depicts the number of genes in 
each intersection, as summarised in the lower panel. 
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represented and gain insight into the underlying biology. Pathway analysis identifies related 
proteins, cellular processes or signalling pathways that are statistically associated with the 
differences in gene expression between two samples. It requires prior knowledge of biological 
processes and their interactions and in the cases of GO and KEGG exploit knowledge in public 
repositories.  
The gene lists first subjected to pathway analysis were those identified in Chapter 5.3.3 in cross 
sectional differential expression analysis at 6-hour, 72-hour post-IL-6 exposure and 4 hour post-
TCR stimulation to reveal the pathways differentially expressed as a consequence of IL-6, these 
lists can be found in the CD-ROM in Appendix, Gene Lists 1A-C. At all times points, STAT-3 
was predicted to be a regulator confirming the role of STAT-3 mediated signalling in the IL-6 
pre-exposure model.  
Biological functions of DEGs obtained with IL-6 pre-exposure compared to non-pre-exposure 
followed by 4-hour TCR stimulation of naïve CD4+ T-cells included cellular movement, cell 
death and survival, cellular development and cell growth and proliferation, Figure 50. 
Canonical pathways identified at this time point include TCR signalling and many pathways 
involved in the metabolism of nucleotides suggestive of increased activation status, which 
correlates with the aberrant effector phenotype described in Chapter 4.   
There were few/no DEGs found in cross sectional analysis between untreated and IL-6 pre-
exposed CD4+ T-cells at time-points 16 hours and 6 days post-TCR stimulation, however, a 
large number of genes were found to be differentially induced by TCR stimulation in 
longitudinal analysis described in Chapter 5.3.6. IPA analysis was then carried out on genes 
found to be differentially induced at the 4 hour, 16 hour and 6 day post-TCR time-points relative 
to the 72hr pre-TCR time-point for both untreated and IL-6 pre-exposed naïve CD4+ T-cells to 
identify pathways differentially induced by IL-6 pre-exposure at later time-points post TCR 
stimulation.  
The IPA analysis on genes differentially induced uniquely with IL-6 pre-exposure at 4 hours 
post-TCR compared to 72 hours pre-TCR revealed decreased lymphocyte apoptosis and 
decreased lymphocyte migration with p-value of 1.23E-32 and z-score of -2.676 or p value 
8.04E-16 and z-score -2.345 respectively. In contrast, these pathways were not identified in 
genes uniquely induced in untreated naïve CD4+ T-cells with decreased quantities of T-helper 
cells identified with p-value 1.58E-05 and z-score of -2.507. 
IPA analysis on genes differentially induced uniquely in IL-6 pre-exposed naïve CD4+ T-cells 
at 16 hours post TCR stimulation compared to 72 hours pre-TCR stimulation revealed increased 
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cell adhesion, cell movement and increased quantity of leukocytes with p-values of 5.65E-05, 
1.56E-04 and 1.38E-05 respectively and z-scores of 2.047, 1.567 and 2.182 respectively. In 
addition to these differentially induced biological functions predicted upstream regulators of 
this pathway were suggested to be TCR stimulation and IL-6 stimulation and the STAT-3 
pathway was also significantly upregulated at this time-point post-TCR stimulation, providing 
reassurance that the effects seen are a result of IL-6 mediated STAT-3 signalling. 
This is in contrast to genes differentially induced uniquely in non-pre-exposed naïve CD4+ T-
cells at 16 hours post-TCR stimulation compared to 72 hours pre-TCR stimulation which were 
included decreased cell viability and decreased T-cell proliferation.  
Finally, following 6-day post-TCR stimulation genes which were uniquely differentially 
induced at this time-point relative to the 72-hour time-point as a result of IL-6 pre-exposure 
were analysed. IPA analysis found these genes to be involved in decreased immune response 
of cells and increased cell death of connective tissue cells with p-values of 6.28E-03 and 4.76E-
04 respectively and z-scores of -2.670 and 1.650 respectively, suggesting potential pathogenic 
effects of IL-6 pre-exposure. On the other hand, pathways differentially induced uniquely in 
non-pre-exposed naïve CD4+ T-cells 6 days post-TCR stimulation involved decreased cell 
survival with a p-value of 4.21E-04 and a z-score of -2.008. In addition, to increased cell death, 
joint inflammation was also described as a pathway increased in non-pre-exposed naïve CD4+ 
T-cells 6 days post-TCR stimulation with a p-value of 2.12E-06 and z-score of 1.901. The 
increased joint inflammation pathway contained 41 genes ,of which only 4 genes were found 
to result in the activation of this pathway, whereas the effect could not be predicted for the 
remaining 37 genes.   
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Figure 50. Pathway analysis of differentially expressed genes in naive CD4+ T-cells as a 
result of IL-6 pre-exposure and 4 hours TCR stimulation. DEG lists from cross sectional 
differential expression analysis of IL-6 pre-exposed naïve CD4+ T-cells at 4 hours post-TCR 
stimulation for 3 biological replicates were subject to IPA analysis. This analysis revealed 
numerous genes involved in pathways relating to cell proliferation, movement and survival (A) 
There were 18 genes found to be differentially up-regulated (pink) or down-regulated (blue) 
between untreated and IL-6 pre-exposed naïve CD4+ T-cells which were associated with 
lymphocyte proliferation (B). The consequence of the expression of the molecule on the 
proliferation pathway is indicated by the colour of the line with orange being activation of 
proliferation, yellow being inconsistent with the state of the pathway and grey indicating that 
the effect on the pathway could not be predicted.   
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5.4 Discussion   
The aims of this Chapter were to investigate how the effector phenotype of naïve and memory 
CD4+ T-cells following IL-6 pre-exposure was regulated by differential gene expression in 
these cells. A microarray of RNA extracted at several time points post-IL-6 exposure and post-
TCR stimulation was undertaken which revealed a number of genes differentially expressed as 
a result of IL-6 pre-exposure. A number of the genes differentially expressed in the presence of 
IL-6 in both naïve and memory CD4+ T-cells overlap with genes previously found by Pratt et 
al. to discriminate early RA from disease controls. IL-6 pre-exposure also has consequences on 
gene expression following 4-hour TCR stimulation, however, no genes can be found in cross-
sectional analyses at 16 hours or 6 days post-TCR stimulation. In a longitudinal analysis of the 
later time-points post-TCR stimulation many genes were found to be differentially induced 
uniquely by IL-6 relative to the 72-hour pre-TCR stimulation time-point. Many of the genes 
found to be differentially induced by IL-6 pre-exposure are those involved in proliferation, cell 
development and survival, which reinforce the consequences on phenotype seen in Chapter 4. 
Interestingly, naïve CD4+ T-cells have a much higher number of differentially expressed genes 
following IL-6 pre-exposure compared to memory CD4+ T-cells. This is consistent with data 
suggesting naïve CD4+ T-cells are more sensitive to IL-6 pre-exposure compared to memory 
CD4+ T-cells, Figure 8, Chapter 1.3.12. However, although memory CD4+ T-cells have a 
lower number of differentially expressed genes following IL-6 pre-exposure a large proportion 
of these overlap with previously identified RA signature genes indicating that the influence of 
IL-6 upon both circulating subsets probably contributes to the previously described 
discriminatory gene signature.   
5.4.1 Design of dynamic CD4+ T-cell transcriptome experiment  
Profiling the transcriptome represents a valuable means of understanding biological processes. 
Many high throughput sequencing technologies have been developed to profile cell gene 
expression including microarray and RNA sequencing. The microarray is a popular and 
relatively low cost technique providing reliable data on relative gene expression in a particular 
cell population. One disadvantage of this method is its dependence on probes designed using 
prior knowledge of the target organism’s genome; low abundance transcripts or splice variants 
are not always captured. In addition, issues regarding probe sensitivity and specificity have 
arisen, with a number of probes able to cross-hybridise with unintended targets across the 
genome, these probes were removed from the analysis in this Chapter.  
In contrast, RNA-seq is where transcripts are directly sequenced to quantify absolute and 
relative gene expression. This technique is fast with high sensitivity and does not require prior 
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knowledge of transcripts. RNA-seq is now the favoured method of gene expression analysis. 
The work in this thesis was designed and undertaken during the time of transition from 
microarray to RNA-seq. The considerations of cost and analytical challenge, historically 
causing researchers to favour microarray have largely been overcome making it conceivable 
that RNA-seq may have been favoured if the study were designed again. Due to the fact that 
splice variant information was not required and the abundant in-house understanding of the 
Illumina microarray technology the decision was made to use the microarray technique for 
genetic analysis. 
Although there are clear differences in RNA seq and microarray technology with RNA seq 
providing a more dynamic range for DEG identification (509) microarrays are still robust and 
reliable tools for differential gene expression analysis with studies describing strong overlap of 
DEGs between the two techniques (510). Transcript abundance between the different gene 
expression technologies are highly correlated and 80% of genes differentially expressed by 
microarray were detected by sequencing (511).  Differences occur when high intensity probes 
are identified with only small sequence counts, this may be due to the background hybridisation 
of probes which was accounted for in our analysis, with others stating that concordance depends 
on treatment and transcript abundance (512).  
Misinterpretations of data can occur due to the presence of contaminating cell populations. In 
cell isolations using positive selection monocytes are often contaminating cell populations in 
CD4+ T-cell isolations due to their expression of CD4 which has the potential to influence DEG 
lists (461). Although positive selection was reviewed to have no significant influence on gene 
expression (513) our study favoured negative selection of naïve CD4+ T-cells which resulted in 
over 90% purity with few contaminating monocytes or B-cells. Despite highly pure naïve CD4+ 
T-cells the memory CD4+ T-cell populations have lower purity with contaminating populations, 
mainly naive CD4+ T-cells, due to this the data should be interpreted with caution.  
Another issue which may confound microarray analysis is both the sample processing and the 
delays from blood draw to cell separation. This variable affects many cell types and has been 
shown to decrease expression of certain genes even between 1-3 hours, however, lymphocyte 
transcriptomes are stable for longer in contrast to monocytes (514, 515). Therefore, all 
isolations were carried out immediately following blood draw with as much efficiency as 
possible.    
In summary, although newer sequencing technologies now exist the careful experimental 
design and good quality control data obtained using the microarray approach provide 
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confidence in the integrity of the data. This has provided an extensive data set enriched for 
genes differentially expressed as a result of IL-6 pre-exposure.  
5.4.2 Gene expression analysis  
In the first stages of quality control, Chapter 5.3.2, it was shown that donor 4 appeared not to 
respond in terms of gene expression in the same way as donors 1-3 to TCR stimulation. This 
donor did appear to respond to stimulation in the CFSE proliferation assay with a fold change 
of three, due to this it is possible that there was an experimental error that occurred during 
experimental set up that resulted in the cells from which RNA was taken were not stimulated.  
5.4.2.1 Gene expression changes with IL-6 exposure 
A number of genes found to be differentially expressed following exposure to IL-6 at 6 hours 
or 72 hours, were those previously described as being up- or down- regulated by IL-6 such as 
ARID5B, ID2, BCL3, BCL6, STAT3, STAT4 and the IL-21R (385). The full list of DEGs can 
be found in Genes lists 1A and B and 2A and B, Appendix. In addition to the induction of 
ARID5B, in both naïve and memory CD4+ T-cells, an important paralog of this gene ARID5A 
was differentially expressed following IL-6 exposure specifically in naïve CD4+ T-cells. This 
gene has recently been shown to regulate naïve CD4+ T-cell fate in an IL-6 dependent manner 
by the selective stabilisation of STAT-3 resulting in the differentiation of cells into 
inflammatory cells, particularly Th17 cells (345). This indicates the role of IL-6 pre-exposure 
in development of a more pathogenic pro-inflammatory effector cell. 
A notable finding was the striking induction of BCL6 both with IL-6 exposure prior to TCR 
stimulation and its upregulation following 4 hours TCR stimulation compared to its 
downregulation in untreated cells. This confirms the importance of IL-6 as a key driver of Tfh 
cells, however no difference was seen in Tfh differentiation with IL-6 pre-exposure, Chapter 4 
(162).  
Many genes previously described as being induced by IL-6 were not observed as differentially 
expressed in this study including IL-21, CCR5, ROR-γ/α, CD4, STAT-4 and FasL. This may 
be due to the difference in experimental set up, which in this study involves the prolonged 
exposure of naïve CD4+ T-cells to IL-6 for 72 hours whereas in other studies may have different 
lengths of IL-6 stimulation or involve the presence of IL-6 at the time of stimulation. Another 
factor is the concentration of IL-6 used which in this study was 0.5ng/ml as this was deemed to 
be more physiological compared to others which use supra-physiological concentrations of 
100ng/ml. The simultaneous stimulation of cells with both IL-6 and via their TCR may be 
needed to result in the differential expression of these genes and the prolonged exposure to IL-
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6 prior to stimulation may mean this is not seen. One potential limitation of this system is that 
IL-6 is only added at the beginning of culture and not refreshed therefore effects may be lost 
after 72 hours.  
In addition to the expression of previously identified IL-6 regulated genes a number of STAT-
3 regulated genes were identified which overlap with genes previously found by Pratt et al. in 
total CD4+ T-cells to distinguish untreated early RA patients from disease controls (431). These 
include BCL3, PIM1, SBNO2 and MUC1 and the presence of these genes was significantly 
higher than would be expected by chance providing validation that the gene signature seen in 
these patients may be driven by IL-6 (431), highlighting the importance of this cytokine in 
disease the indicating the relevance of IL-6 pre-exposure in this disease setting.  
5.4.2.2 Gene expression changes post TCR stimulation 
With the exception of donor 4, which was excluded from differential gene expression analysis, 
when principle component analysis was carried out upon remaining samples TCR-mediated 
activation was a strong principle component identifier. This is likely to be due to extensive 
transcriptional changes documented upon activation. Wang et al. identified 1463 genes with 
significant expression changes following activation with anti-CD3 and anti-CD28 beads over 
0-72 hours in CD4+ T-cells and 3793 genes in CD3+ T-cells (516). Among these genes were 
immune response genes, cytokines and receptors. Many of these genes were also found to be 
differentially expressed in response to TCR stimulation here including CD69, CD83, BCL6 in 
untreated naïve CD4+ T-cells at 4 hours and ITGAL, ICOS and CTLA4 in both untreated and 
IL-6 pre-exposed naïve CD4+ T-cells at 4 hours. This provides reassurance that cells have 
responded as expected to TCR stimulation.  
In particular, Hess et al., using a microarray containing 5016 cDNA clones, reported many 
genes induced during early, intermediate and late phases of anti-CD3 and anti-CD28 activation, 
15, 25 and 156 genes respectively making a total of 196 DEGs with more genes differentially 
induced as time from activation increased (517). Data presented in this Chapter is similar with 
the number of differentially induced genes is much higher after 6 days stimulation compared to 
16 hours post stimulation. Of the 196 genes, 10 genes were found in this Chapter to be induced 
by TCR stimulation, including JAK1, IL10RA and PSMA3. Diehn et al. also profiled gene 
expression changes following anti-CD3 and anti-CD28 stimulation at 7 time points between 0-
48 hours finding 2926 genes differentially expressed by 3-fold (518). Many of the genes 
induced include cytokines, cell adhesion molecules, effector molecules, cell cycle and 
proliferation molecules as well as metabolic elements such as glycolysis.  
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Data presented here show lower numbers of DEGs, in the range of 20-421 DEGs, in response 
to TCR mediated stimulation. A reason for this difference may be in part down to the proportion 
of responding cells in the system. Following TCR stimulation, as indicated by the proliferation 
graphs, Chapter 5.3.1, only up to 5% of untreated cells and 10-20% of IL-6 pre-exposed cells 
are dividing in the final population. As a result, the non-activated cells will be causing a dilution 
in the signal from the responsive cells, which may lower the differences in fold changes between 
untreated and IL-6 pre-exposed cells. The proportion of responding cells investigated by Diehn 
et al. was not included in analysis, however, is potentially higher than the number seen in this 
study due to the stronger stimulus used. Diehn et al. stimulated cells with anti-CD3 and anti-
CD28 coated beads at a ratio of 1:1 which is a much stronger stimulus then the relatively low 
stimulation concentration of anti-CD3 and anti-CD28 used in this Chapter. Another reason for 
this difference may be the type of culture medium used, the in vitro model presented in this 
thesis applies the use of serum free medium which may result in differences in gene expression 
post-TCR stimulation. 
The lower number of DEGs identified is supported in the literature as Allison et al. showed that 
the affinity and dose of the TCR stimulation will govern the magnitude of response, with 
stronger TCR signals resulting in higher amounts of phosphorylated ERK, enhancer acetylation 
and activation markers in CD4+ T-cells (519). In the experiment presented in this Chapter, 
however, the level of TCR stimulation was optimised as being 0.2μg/ml anti-CD3 and 1μg/ml 
anti-CD28, significantly lower than optimised in the in vitro model, Chapter 3.4.4. This was in 
order to optimise the model for use of whole blood drawn in citrate anti-coagulant, as opposed 
to LRS cones used in the in vitro model. As a result, the relatively low stimulus may have 
resulted in a lower magnitude response of the naïve and memory CD4+ T-cells. It is possible 
that with a higher concentration of stimulus the greater response would have allowed the 
identification of more DEGs mediated by IL-6 pre-exposure, particularly at later time-points 
post-TCR stimulation. At day 6 where it was shown in Chapter 4 that cells have increased 
proliferative capacity and differential activation marker and transcription profiles cells did not 
have any differentially expressed genes with IL-6 pre-exposure using the cross sectional paired 
t-test to identify differentially expressed genes, Chapter 5.3.3. These differences can be 
detected by differential gene induction in untreated and IL-6 pre-exposed cells, Chapter 5.3.6, 
suggesting that the paired differential expression test is not sensitive enough to detect 
significant changes in cross sectional analysis, potentially due to the high level of multiple test 
correction. This indicates that although there are no significant differentially expressed genes 
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at later time points post-TCR gene expression changes are still occurring which impact on the 
effector function of the CD4+ T-cell.  
5.4.2.3 Pathways highlighted by IL-6 pre-exposure 
The pathways identified in this Chapter as being significantly up or down regulated in naïve 
CD4+ T-cells pre-exposed to IL-6 involve increased survival, maturation, migration and 
proliferation of lymphocytes, which reflects the aberrant phenotype of IL-6 pre-exposed naïve 
CD4+ T-cells seen in Chapter 4. Further pathways identified at 6 days post-TCR stimulation 
with IL-6 pre-exposure involve the decreased immune response of cells and increased cell death 
of connective tissue cells. This fits in with the pathology of rheumatoid arthritis whose CD4+ 
T-cells have been well described in the literature as being phenotypically exhausted and less 
responsive to stimulation (111, 520). In contrast, the pathways found to be significantly up or 
down regulated in untreated naïve CD4+ T-cells involved decreased cell viability and decreased 
T-cell proliferation reflecting the phenotype of untreated naïve CD4+ T-cells, Chapter 4. 
Pathways involving joint inflammation were found to be upregulated in untreated naïve CD4+ 
T-cells 6 days post-TCR stimulation which does not fit in with IL-6 pre-exposure causing more 
pathogenic phenotype, however, only 4 of the 41 genes were shown to confidently up-regulate 
this pathway with all other genes having no predicted effect. Therefore, this pathway cannot be 
confidently described as upregulated in untreated naïve CD4+ T-cells.   
Finally, there were more DEGs identified in naïve compared to memory CD4+ T-cells as a 
consequence of IL-6 pre-exposure, Table 16. The greater transcriptional response to IL-6 seen 
in naïve CD4+ T-cells is consistent with the notion that these cells have increased sensitivity to 
circulating IL-6 which may relate to the expression of gp130 signalling receptor as previously 
described in Chapter 3.3.1.  
It has been shown that inflammatory cytokines, such as TNF, can alter the levels of DNA 
methyltransferases causing altered methylation of specific promoters, which underlie cellular 
dysregulation in cardiomyocytes (521). A similar mechanism may also be possible with IL-6 
with studies showing that IL-6 has the ability to increase DNA methyltransferase expression 
and activity (522, 523). This alteration of DNA methyltransferases may occur in CD4+ T-cells 
mediating the methylation of promoter regions of cell cycle regulatory genes to result in 
enhanced proliferative capacity.   
5.4.3 Summary  
In summary, here it is shown that IL-6 pre-exposure causes differential gene expression in CD4+ 
T-cells that is most abundant in naïve cells, indicating increased transcriptional sensitivity to 
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the cytokine in this sub-population. The differentially expressed genes following IL-6 pre-
exposure strongly reflect those genes found to be differentially expressed in early RA patients, 
providing independent validation of the relevance of IL-6 signalling in early RA pathogenesis. 
There was also a distinctive set of genes differentially expressed 4 hours post-TCR stimulation 
in cells pre-exposed to IL-6 which were involved in cell proliferation and growth, suggesting 
IL-6 pre-exposure programmes CD4+ T-cells with an enhanced proliferative capacity following 
activation.  
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Chapter 6. Effects of IL-6 pre-exposure in relation to rheumatoid arthritis 
 
6.1 Introduction  
Work outline in previous chapters has demonstrated that chronic pre-exposure of healthy 
control naïve and memory CD4+ T-cells to physiological concentrations of IL-6 and equimolar 
sIL-6R has consequences on effector cell phenotype and gene expression following TCR 
stimulation. Specifically IL-6 pre-exposure results in increased proliferative capacity, 
activation marker and transcription factor expression of both naïve and memory CD4+ T-cells. 
IL-6 pre-exposure of memory CD4+ T-cells results in altered cytokine production whereas pre-
exposure of naive CD4+ T-cells has no influence on cytokine production following TCR 
stimulation. When differentiated towards T-helper cell subsets the pre-exposure of naïve CD4+ 
T-cells to IL-6 results in increased IFN-γ production of Th1 cells whereas the pre-exposure of 
memory CD4+ T-cells results in the inhibition of IL-17 production from Th17 cells. These 
effects of IL-6 pre-exposure on effector phenotype have been shown to be mediated by a subset 
of genes both pre- and post- TCR-stimulation involved in cell development, survival and 
proliferation and many of the genes found upon IL-6 exposure overlap with genes previously 
described as dysregulated in early RA.  
These findings were of interest, particularly when considered alongside previously published 
observations regarding the CD4+ T-cell phenotype in early and established RA. It has been 
reported that in RA inflammation drives naïve CD4+ T-cell proliferation, evidenced by the 
reduced levels of TREC, promoting the differentiation of atypical progeny, which are hypo-
responsive to ex vivo stimulation (108). Furthermore, there is strong evidence to suggest the 
acceleration of immunosenescence in RA (524). Naïve CD4+ T-cells have restricted diversity 
and clonal burst and the replicative stress experienced by these cells may lead to pathogenic 
senescent subsets which have reduced thresholds of activation and are supported by the optimal 
conditions of the synovial micro-environment. Evidence for the immunosenescence of effector 
subsets of CD4+ T-cells is shown by reduced cell cycle duration, reduced numbers of cells 
dividing and fewer number of divisions per dividing cells of ex vivo stimulated CD4+ T-cells 
from undifferentiated arthritis patients which progress to RA compared to those patients which 
progress to non-RA disease groups (114). A reason for this apparent immunosenescence may 
be the cells have already encountered IL-6 in vivo in the periphery and subsequent TCR 
stimulation secondary lymphoid organs so that when stimulated ex vivo they have decreased 
responsiveness. The IL-6 pre-exposure in vitro model is based on primary stimulation of naïve 
168 
 
CD4+ T-cells following IL-6 exposure, the restimulation of cells may show reduced ability to 
activate and proliferate compared to cells that have not been exposed to IL-6.  
Based on these findings there may be reason to believe that the phenotype of naïve CD4+ T-
cells stimulated via the TCR following IL-6 pre-exposure, mimicking what is seen in early RA, 
may recapitulate the altered proliferative phenotype described in RA. Defining the relevance of 
these findings to the pathogenesis of early RA remains an important question to address. 
6.2 Aims and objectives  
In light of the above, the over-arching aim of the work carried out in this Chapter is to explore 
the extent to which the consequences of IL-6 pre-exposure determined by the in vitro model are 
recapitulated amongst early RA patients in terms of IL-6 receptor expression, proliferative 
capacity of CD4+ T-cells and dynamic gene expression following TCR stimulation. 
The observations outlined in this thesis raise the hypothesis that increased levels of circulating 
IL-6 in RA patients will result in aberrant effector phenotype and gene expression of CD4+ T-
cells of early RA patients. Due to this, the work carried out in this chapter aims to investigate 
how these findings are correlated with the situation in naïve and memory CD4+ T-cells obtained 
from early rheumatoid arthritis patients. To do this CD4+ T-cells of untreated early RA patients 
were assessed in terms of cell surface marker expression, proliferation and gene expression. 
Findings were compared to those in cells from healthy controls as well as from patients with 
clinically suspect arthralgia (CSA) – defined in this study as those positive for ACPAs who 
have yet to manifest clinical signs of RA. 
Specifically, the objectives were: 
 To measure the expression of gp130 and IL-6R on the surface of CD4+ T-cell subsets 
in early arthritis patients and healthy controls and identify any correlation with disease 
phenotype or clinical characteristics. 
 To compare the proliferative response of CD4+ T-cells from early untreated RA 
patients, CSA patients and healthy controls following TCR stimulation. The extent to 
which observations in CD4+ T-cells of patients mirror those in healthy cells pre-
exposed to IL-6 (Chapter 4) will be assessed.  
 Similarly, to compare the expression pattern of a specific set of IL-6 pre/post-TCR 
signature genes identified in Chapter 5 (found to be differentially induced by IL-6 pre- 
and post-TCR stimulation) between CD4+ T-cells from healthy donors, CSA and early-
untreated RA patients. 
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6.3 Results  
6.3.1 Expression of gp130 and IL-6R on CD4+ T-cell subsets of early arthritis clinic 
attendees 
In Chapter 3.3.1-2, gp130 and IL-6R expression levels on isolated naïve CD4+ T-cells or CD4+ 
T-cells of patients from the NEAC were assessed. This revealed maximal expression of gp130 
on true naïve CD4+ T-cells compared to central memory and even further reduced levels on 
effector memory CD4+ T-cells, Figure 12. Examination of the IL-6R revealed the lowest 
expression on true naïve CD4+ T-cells and highest expression on central memory CD4+ T-cells 
with moderate levels on effector memory CD4+ T-cells, Figure 12B.  
Here, as in Chapter 3.3.1, expression of gp130 and IL-6R were assessed on true naïve CD4+ T-
cells. It was investigated whether any clinical parameters could account for the expression of 
gp130 or IL-6R. The first analysis to be undertaken was the expression of gp130 and IL-6R 
stratified by disease diagnosis, Figure 51. Gating strategy can be seen in Figure 8, Appendix 
and representative plots Figure 12, Chapter 3. The level of expression of both gp130 and IL-
6R did not correlate with disease diagnosis, with no difference seen in expression of either 
marker in EAC attendees compared to healthy controls. Next, it was assessed whether gp130 
and IL-6R expression were correlated with C-reactive protein (CRP), a measure of 
inflammation, or CD25 expression, a marker of cell activation. This shows that there is no 
significant correlation of gp130 or IL-6R expression levels with CRP, Figure 52. Furthermore, 
there was no correlation of gp130 or IL-6R expression with CD25, Figure 53. This is in contrast 
to previous work showing CD25 negative cells have higher expression of both gp130 and IL-
6R (455). 
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Figure 51. Expression of gp130 and IL-6R on true naïve CD4+ T-cells of early arthritis 
patients according to disease diagnosis. Whole blood of 8 early RA (eRA), 8 other 
inflammatory (OI), 10 non-inflammatory (NI) and 4 healthy controls (HC) was stained for flow 
cytometry with a panel of antibodies to detect cell surface expression of gp130 (A) and IL-6R 
(B). CD4+ T-cells were identified as CD3+CD4+ and from this population true naïve cells were 
identified as CD45RA+CD62L+. Values were determined using percentage positive dot plots 
plotted with median values indicated by the horizontal line.  
Figure 52. Expression of gp130 and IL-6R on true naïve CD4+ T-cells of early arthritis 
patients plotted against CRP levels. Whole blood of 8 early RA (eRA), 8 other inflammatory 
(OI), 10 non-inflammatory (NI) was stained for flow cytometry with a panel of antibodies to 
detect cell surface expression of gp130 (A) and IL-6R (B). CD4+ T-cells were identified as 
CD3+CD4+ and from this population true naïve cells were identified as CD45RA+CD62L+. 
Values were determined using percentage positive dot plots and plotted with a line of linear 
regression added, gp130: r2 0.04417 and IL-6R: r2 0.001291.   
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In summary, the level of expression of the IL-6 signalling receptors did not correlate with 
disease diagnosis or with level of CRP or CD25 expression.     
6.3.2 Response of CD4+ T-cells from early arthritis clinic attendees to TCR stimulation  
Pre-exposure of naïve and memory CD4+ T-cells to IL-6 results in increased levels of 
proliferation following TCR stimulation, Chapter 4.3.2. As early rheumatoid arthritis patients 
have high levels of IL-6 in serum it was hypothesised that levels of proliferation of CD4+ T-
cells from early RA patients would be similar to levels seen in IL-6 pre-exposed healthy control 
cells and also be greater than that from healthy controls. In a deviation from previous Chapters 
proliferation of total (as opposed to naïve) CD4+ T-cells from early RA patients were assessed 
due to the relatively limited amount of blood able to be obtained from these patients which 
would not allow for isolation of naïve CD4+ T-cells. Total CD4+ T-cells were isolated CFSE 
labelled and stimulated immediately ex vivo with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 
for 6 days. After 6 days, proliferation was assessed by flow cytometry.  
CD4+ T-cells from early RA patients proliferate to a similar extent to healthy controls, with no 
difference in the number of cells dividing or the number of divisions, Figure 54. This suggests 
that in early RA T-cells have a similar ability to proliferate in response to TCR stimulation as 
healthy controls. The level of IL-6 in the serum of the early RA patients and healthy controls 
whose CD4+ T-cells were used for proliferation analysis was also assessed, Figure 54C.  Serum 
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Figure 53. Expression of gp130 and IL-6R on naïve CD4+ T-cells of healthy controls 
plotted against expression of CD25. Naïve CD4+ T-cells isolated from 12 healthy controls 
were stained for flow cytometry with a panel of antibodies to detect cell surface expression of 
CD25, gp130 (A) and IL-6R (B). CD4+ T-cells were identified as CD3+CD4+ and from this 
population naïve cells were identified as CD45RA+. Values were determined using percentage 
positive dot plots and plotted with a line of linear regression added, gp130: r2 0.1940 and IL-
6R: r2 0.009466.  
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levels of IL-6 range from 0-70pg/ml, lower than the concentrations used in the in vitro model 
of IL-6. IL-6 levels also shows dichotomy in with 3 of the early RA patients having higher 
levels of IL-6 compared to 3 early RA patients and healthy controls. Despite levels of IL-6 
being increased in a number of early RA patients compared to healthy controls, there was no 
correlation between the level of circulating IL-6 and the proliferation of CD4+ T-cells.  
 
  
Figure 54. Proliferation of CD4+ T-cells of early rheumatoid arthritis patients compared to 
healthy controls. Total CD4+ T-cells isolated from 6 early RA (eRA) patients and 5 healthy 
controls (HC) were CFSE labelled and stimulated for 6 days with 0.5μg/ml anti-CD3 and 1μg/ml 
anti-CD28. After 6 days cells were harvested and ran on the flow cytometer. Proliferation was 
calculated using FlowJo with percentage divided indicating the precursor frequency of dividing 
cells (A), division index showing the average number of divisions (B). Serum IL-6 from 6 early 
RA patients and 2 HC was measured by MSD (C) and levels of IL-6 were plotted against level 
of proliferation (D). Significance was determined by Mann Whitney U test. A line of linear 
regression added r2 0.1917.  
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Additionally, CSA patients were recruited to assess levels of proliferation at the early stages of 
disease pathogenesis. In this instance naïve CD4+ T-cells were isolated from these patients as 
more blood was able to be obtained. These cells were then CFSE labelled and cultured for 3 
days in the presence or absence of 0.5ng/ml IL-6 followed by 6 day stimulation with 0.2μg/ml 
anti-CD3 and 1μg/ml anti-CD28. Here, it can be seen that CSA patients have differing 
responses to stimulation with some having high levels of proliferation and some having only 
very low levels of proliferation, Figure 55A-B. Levels of proliferation do appear to be 
marginally higher than that of healthy controls stimulated with the same concentration of anti-
CD3 and anti-CD28 seen in Chapter 5.3.1. The level of IL-6 in the serum of CSA patients 
whose naïve CD4+ T-cells were used for proliferation analysis was also assessed, however as 
there were only 3 patients this showed no correlation between serum IL-6 levels and CD4+ T-
cell proliferation, Figure 55C.   
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Figure 55. Proliferation of naïve CD4+ T-cells of CSA patients compared to healthy 
controls. Naive CD4+ T-cells isolated from 3 CSA patients and 5 healthy controls (HC) were 
CFSE labelled cultured for 3 days in absence or presence of 0.5ng/ml IL-6 with equimolar sIL-
6R. After 72 hours cells were washed and stimulated for 6 days with 0.2μg/ml anti-CD3 and 
1μg/ml anti-CD28. After 6 days cells were harvested and ran on the flow cytometer. 
Proliferation was calculated using FlowJo with percentage divided indicating the precursor 
frequency of dividing cells (A), division index showing the average number of divisions (B). 
Serum IL-6 from each CSA patient was measured by MSD and correlated with level of 
proliferation. Significance was determined by Mann Whitney U test.  
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Finally, in order to assess the ability of patient CD4+ T-cells to respond to further IL-6 exposure 
naïve CD4+ T-cells from CSA patients were pre-exposed to 0.5ng/ml IL-6 and equimolar sIL-
6R for 3 days, as in the in vitro model, prior to TCR stimulation. It can be seen that naïve CD4+ 
T-cells from CSA patients do not respond to IL-6 in the same manner of healthy controls with 
no increase in the level of proliferation after 6 days TCR stimulation, Figure 56. Although there 
is a hint that exposure to IL-6 or prior activation in vivo may “blunt” the responsiveness of cells 
to IL-6 (smaller percent divided in healthy donors compared to other groups), meaning CSA 
CD4+ T-cells have different response to IL-6 compared to healthy control cells, no firm 
conclusions can be drawn from this limited dataset.   
 
In summary, based on the data presented, CD4+ T-cells from early RA patients appear to have 
a similar ability to proliferate as healthy controls. Furthermore, the level of serum IL-6 in these 
patients showed no correlation with level of proliferation.  
6.3.3 Basal gene expression of early arthritis clinic attendees   
In Chapter 5.3.3, a number of genes were determined to be differentially expressed between 
untreated and IL-6 pre-exposed naïve CD4+ T-cells 72 hours post-IL-6 exposure. As early RA 
patients are hypothesised to have already been chronically pre-exposed to high levels of IL-6 
in serum it was proposed that levels of expression of the genes found to be differentially 
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Figure 56. Effect of IL-6 pre-exposure on CSA naïve CD4+ T-cells. Naive CD4+ T-cells 
isolated from 3 CSA patients and 5 healthy controls (HC) were CFSE labelled cultured for 3 
days in absence or presence of 0.5ng/ml IL-6 with equimolar sIL-6R. After 72 hours cells were 
washed and stimulated for 6 days with 0.2μg/ml anti-CD3 and 1μg/ml anti-CD28. After 6 days 
cells were harvested and ran on the flow cytometer. Proliferation was calculated using FlowJo 
with percentage divided indicating the precursor frequency of dividing cells. Values were 
plotted with median values indicated by the horizontal line. Significance was determined by 
non-parametric analysis of variance (Kruskal-Wallis), p<0.05.  
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induced/repressed by IL-6 would be up- or down- regulated in rheumatoid arthritis patients 
respectively compared to healthy controls.  
In order to assess whether this is the case CD4+ T-cells were isolated from 5 CSA patients, 5 
early RA patients, 5 established RA patients and 5 healthy controls and RNA extracted at 
baseline. As a positive control, RNA was extracted from naïve CD4+ T-cells pre-exposed to 
0.5ng/ml IL-6 for 72 hours, to confirm that the selection of these genes were valid. From the 
list of 267 genes identified as differentially expressed following 72 hours exposure to IL-6, 5 
genes were chosen to be assessed in disease subgroups. These genes were chosen as they had 
the high log fold changes but also had strong p values and included BCL6, SBNO2, REXO2, 
LRP8 and c10orf10. The dynamic profiles of these genes highlight their strong induction by 
IL-6 after 72 hours IL-6 pre-exposure, Figure 57.  
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Expression of all genes were significantly induced in healthy donors with IL-6 exposure 
compared to non-exposure, Figure 58A, as depicted in Figure 47B. There was a trend for 
increased expression of BCL6, SBNO2, REXO2 and c10orf10 in early RA compared to healthy 
controls but only BCL6 and REXO2 reached statistical significance. Expression levels were 
similar for all genes between CSA patients and healthy controls whereas expression levels in 
established RA appeared higher than healthy controls for BCL6, SBNO2 and c10orf10 but 
lower than healthy controls for LRP8 and no change with REXO2.   
Figure 57. Dynamic profiles of differentially expressed IL-6 pre-TCR signature genes 
after 72 hours exposure to IL-6. Differentially expressed genes were identified post multiple 
test correction by cross sectional analysis of untreated and IL-6 exposed naïve CD4+ T-cells 
following 72 hours exposure to 0.5ng/ml IL-6 using paired t-test with LFC 1.5 and p-value 
cut off of <0.05. Graph shows the five IL-6 pre-TCR gene signature chosen in Chapter 5 based 
on strong p-value and high log fold change. Graph representative of three donors. 
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Figure 58. Expression of 72 hour IL-6 induced genes in healthy controls and EAC patient 
CD4+ T-cells. CD4+ T-cells were isolated from 5 CSA patients, 5 early RA patients (eRA), 5 
established RA patients (estRA) and 5 healthy controls (HC) and RNA extracted at baseline. 
For a positive control, naïve CD4+ T-cells were cultured with 0.5ng/ml IL-6 and equimolar sIL-
6R for 72 hours and RNA extracted. (A) Fold induction of each gene with IL-6 stimulation. 
Expression of BCL6 (B), SBNO2 (C), REXO2 (D), LRP8 (E) and c10orf10 (F) were assessed 
using TaqMan real time PCR. Values were plottted with bars showing mean and error bars 
representing SEM. Non-parametric analysis of variance (Kruskal-Wallis) showed significant 
effect in gene expression irrespective of disease group (*p<0.05 in each case ). Comparisons of 
healthy controls with arthritis disease groups were undertaken as depicted (ns; not significant; 
*p<0.05, Dunn’s post hoc pairwise analysis).   
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As the genes shown in Figure 58 were those genes found to be differentially expressed at 72 
hours with IL-6 exposure in naïve CD4+ T-cells (Chapter 5), the level of IL-6 in the serum 
would be expected to correlate with the expression of these genes. To investigate whether this 
was the case the level of IL-6 in serum of patients was determined and plotted against gene 
expression, Figure 59. Although there was a trend for a positive correlation between serum IL-
6 levels and gene expression for all of the genes analysed this correlation only reaches statistical 
significance for BCL6 and SBNO2. This suggests that the expression of these genes in CD4+ 
T-cells of CSA, early RA and established RA patients may be driven by the presence of IL-6. 
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Figure 59. Expression of 72 hour IL-6 induced genes in EAC patient CD4+ T-cells 
correlates with serum IL-6. CD4+ T-cells were isolated from CSA patients, early RA patients, 
established RA patients and healthy controls and RNA extracted at baseline. Serum IL-6 from 
each patient was measured by MSD and correlated with expression of BCL6 (A), SBNO2 (B), 
REXO2 (C), LRP8 (D) and c10orf10 (E) which were assessed using TaqMan real time PCR. 
Significance was determined by linear regression; * p=<0.05. BCL6: r2 = 0.5382, SBNO2: r2 = 
0.4158, REXO2: r2 = 0.1762, LRP8: r2 = 0.2436, c10orf10: r2 = 0.3941.CSA n=5, eRA n=5, 
estRA n=5. 
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6.3.4 Gene expression of early arthritis clinic attendees after 4-hour TCR stimulation  
In Chapter 5.3.4 there were 123 genes differentially expressed between untreated and IL-6 pre-
exposed naïve CD4+ T-cells following 4 hours TCR stimulation. To assess whether these 
differentially expressed genes were also differentially expressed between RA patients 
compared to healthy controls, five genes from the list of 123 were chosen. The genes chosen 
include CST7, GPT2 and RRAD as these had the highest induction in terms of log fold change 
and strongest p values. In contrast, GSTO1 was chosen as this was one of the most differentially 
expressed genes according to IL-6 pre-exposure, however, in contrast to the other genes this 
gene was strongly repressed by IL-6 pre-exposure. The dynamic profiles of these genes 
highlight their strong induction by IL-6 after 72 hours IL-6 pre-exposure, Figure 60. Naïve 
CD4+ T-cells were isolated from 5 CSA patients, 5 early RA patients, 5 established RA patients 
and 5 healthy controls. As a positive control, naïve CD4+ T-cells were pre-exposed to 0.5ng/ml 
IL-6 for 72 hours. All naïve CD4+ T-cells were then stimulated with 0.2μg/ml anti-CD3 and 
1μg/ml anti-CD28 and RNA extracted after 4 hours stimulation.  
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There was one early RA donor with abnormally high CT values for the housekeeping gene 
POL2RPB1, which resulted in altered expression of all genes and as a result, this individual 
was removed from the analysis.  
The pre-exposure of naïve CD4+ T-cells with 0.5ng/ml IL-6 for 72 hours prior to 4 hours TCR 
stimulation resulted in the increased induction of CST7 and GPT2 compared to healthy controls, 
however, IL-6 pre-exposure had no effect on expression of RRAD with similar levels as 
untreated healthy controls, Figure 61A, as also depicted in Figure 48B. This is inconsistent with 
the microarray data in Chapter 5.3.4, in which RRAD had strong induction following IL-6 pre-
Figure 60. Dynamic profiles of differentially expressed IL-6 post-TCR signature genes 
after 4-hour TCR stimulation. Differentially expressed genes were identified post multiple 
test correction by cross sectional analysis of untreated and IL-6 pre-exposed naïve CD4+ T-
cells following 72 hours pre-exposure to 0.5ng/ml IL-6 and subsequent 4 hours TCR 
stimulation using paired t-test with log fold change 1.5 and p-value cut off of <0.05. Graph 
shows the four IL-6 post-TCR gene signature chosen in Chapter 5 based on strong p-value 
and high log fold change. Graph representative of three donors. 
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exposure. GSTO1, which was strongly repressed by IL-6 pre-exposure in Chapter 5.3.4, also 
appeared to have not been altered in response to IL-6 pre-exposure.  
Furthermore, there was no clear difference in expression of CST7 or GPT2 between disease 
groups or healthy controls. There appeared to be a trend for highest expression of RRAD in 
CSA patients, followed by early RA with lower levels in established RA and healthy controls, 
although this trend was not statistically significant. As GSTO1 was revealed from the 
microarray as being down regulated as a consequence of IL-6 pre-exposure it would be expected 
to be decreased in early RA compared to healthy controls as circulating serum IL-6 levels are 
increased in early RA compared to healthy controls. However, there is no change in expression 
across disease groups or between healthy controls and it does not appear to decrease with IL-6 
pre-exposure. Furthermore, the serum concentrations of IL-6 from these patients did not 
correlate with expression of these genes, data not shown.   
To summarise 2 of the 4 genes found to be differentially expressed as a result of IL-6 pre-
exposure following 4 hour stimulation in the microarray experiment shown in Chapter 5 were 
found to be differentially expressed between healthy controls and IL-6 pre-exposed healthy 
controls using a TaqMan validation assay. However, none of the genes assessed appeared to 
differ in expression between disease groups or healthy controls.   
 
184 
 
 
Figure 61. Expression of genes differentially expressed following IL-6 pre-exposure and 
4-hour TCR stimulation in healthy controls and EAC patient naïve CD4+ T-cells. Naïve 
CD4+ T-cells were isolated from 5 CSA patients, 5 early RA patients (eRA), 5 established RA 
patients (estRA) and 5 healthy controls (HC). Cells were stimulated with 0.2μg/ml anti-CD3 
and 1μg/ml anti-CD28 for 4 hours and RNA extracted. For a positive control naïve CD4+ T-
cells were cultured with 0.5ng/ml IL-6 and equimolar sIL-6R for 72 hours followed by 4 hour 
stimulation with 0.2μg/ml anti-CD3 and 1μg/ml anti-CD28 and RNA extracted. (A) Fold 
induction of each gene with IL-6 stimulation. Expression of CST7 (B), GPT2 (C), RRAD (D) 
and GSTO1 (E) were assessed using TaqMan real time PCR. Values were plotted with bars 
representing mean and error bars representing SEM. Non-parametric analysis of variance 
(Kruskal-Wallis) showed no significant effect in differences in gene expression between the 
groups. Comparisons of healthy controls with arthritis disease groups were undertaken as 
depicted (ns; not significant; Dunn’s post hoc pairwise analysis).  
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6.4 Discussion  
In this Chapter, the aim of the work carried out was to investigate the potential relevance of the 
findings in relation to the IL-6 pre-exposure model, presented in previous chapters, to early RA 
pathogenesis. To do this I explored the extent to which properties of circulating CD4+ T-cells 
from early RA and/or CSA patients mimicked those of healthy donor cells pre-exposed to IL-6 
in vitro. CD4+ T-cells from early RA patients were assessed in terms of their IL-6 signalling 
receptors and their response to TCR stimulus at the level of gene expression and proliferative 
response. This Chapter reveals that early arthritis CD4+ T-cells are no different to healthy 
controls in terms of their gp130 and IL-6R expression, irrespective of disease phenotype, or 
response to TCR stimulation. In addition, CD4+ T-cells from CSA patients appear to have 
marginally increased levels of proliferation compared to healthy controls, however, they appear 
to be unable to respond to further IL-6 stimulation. There was increased expression of two genes 
in early RA CD4+ T-cells, which were found to be induced by IL-6 exposure pre-TCR 
stimulation in vitro; however, there was no difference in expression of genes differentially 
induced by IL-6 pre-exposure post-TCR stimulation.  
6.4.1 Expression of IL-6 signalling receptors in early RA  
It was shown in Chapter 3.3.1 that in CD4+ T-cells from EAC patients naïve CD4+ T-cells have 
higher expression of gp130 whereas memory CD4+ T-cells have higher expression of IL-6R.  
This was further confirmed in naïve CD4+ T-cells isolated from healthy donors in Chapter 
4.3.1. This suggests high expression of gp130 on naïve CD4+ T-cells is a potential mechanism 
of increased sensitivity of these cells to IL-6 signalling. Based on these findings it was 
investigated whether the differential expression of gp130 may account for the STAT-3 gene 
signature or the high level of pSTAT-3 expression discriminatory for RA in early arthritis.  
In this Chapter, no differential expression of IL-6R or gp130 between healthy controls and 
different disease phenotypes was observed. This observation correlates with previous studies 
which show that IL-6R expression of CD4+ T-cells and serum levels of sgp130 and sIL-6R are 
equal across disease diagnoses (427). In addition, peripheral blood CD4+ T-cells from non-RA 
inflammatory arthritis patients appear similarly sensitive as early RA patients to circulating IL-
6 indicating there is no differential responsiveness of these cells to IL-6 between disease groups. 
This suggests a mechanism other than differential receptor expression is responsible for the 
increased pSTAT-3 seen in early RA.   
In vivo CRP is a measure of inflammation and correlates with increasing IL-6 levels. As such 
with increasing CRP decreasing levels of receptor expression would potentially be expected. 
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However, expression levels of gp130 and IL-6R were found to have no correlation with markers 
of inflammation, such as CRP.  
The presence of CD25 expression on CD4+ T-cells has also been shown to correlate with 
differential expression of IL-6R and gp130 (455). High expression of IL-6R and gp130 has 
been seen in CD25-CD4+ T-cells and the increased expression of CD25 has been shown to 
correlate with the downregulation of expression of gp130. In this Chapter it was seen that with 
higher expression of CD25 there was no difference in the expression of gp130. In this thesis, 
CD25 was used as a marker of activation rather than a marker of Treg presence hence may 
represent a decrease in IL-6 signalling with increasing levels of cell activation. However, in the 
case of Tregs this downregulation of IL-6 signalling may be important for the maintenance of 
these cells as IL-6 signalling has been shown to abrogate Foxp3. It has also been described that 
IL-6 signalling results in the resistance of CD25-CD4+ effector T-cells to Treg mediated 
suppression a potential pathogenic mechanism of IL-6, which may also be mediated by IL-6 
pre-exposure.   
To summarise, these is no difference in IL-6 signalling receptors between early RA and healthy 
or disease controls. Furthermore, there is no correlation between expression of these receptors 
with inflammatory markers or CD25 expression.  
6.4.2 Proliferation of early RA CD4+ T-cells  
There is much evidence supporting the dysregulation of CD4+ T-cells in RA. The repertoire of 
naïve and memory CD4+ T-cells is markedly contracted in RA compared to healthy controls 
indicating an abnormality in repertoire formation (525). In addition to the less diverse repertoire 
RA patients also have fewer T-cell receptor excision circles (TREC) which correlated inversely 
with inflammation, demonstrating decreased influx of newly generated T-cells or increased cell 
turnover (107, 108). A decrease in telomere length, most prominent in naïve CD4+ T-cells also 
suggests increased self-replication which occurs very early in disease, even possibly pre-dating 
disease onset although this does not correlate with disease duration (107). These findings 
suggest that homeostatic proliferation of CD4+ T-cells is dysregulated in RA. Further evidence 
suggests in healthy individuals homeostatic proliferation requires MHC II whereas in RA this 
is not the case and is dependent on membrane bound TNF-α (526).  
Despite the increased self-replication suggested by shortened telomeres, many studies have 
documented the impaired proliferative response of RA CD4+ T-cells. This has been shown by 
the reduced proliferation of CD4+ T-cells with active RA in culture with autologous MLR 
though proliferation can be partially restored by IL-2 (112, 113). CD4+ T-cells from patients 
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with RA stimulated with PHA or anti-CD3 also resulted in a larger number of non-responsive 
cells and impaired magnitude of response (111). Further investigation reveals cell cycle 
duration, number of cells dividing and number of cell divisions are all reduced in RA whereas 
the time to transition from G0 to G1 was increased (114). As well as reduced proliferation RA 
CD4+ T-cells have been shown to have increased CD25, PD-1, CTLA-4 but decreased CD69, 
OX40 and IL-2 expression (520). These features are indicative of an exhausted phenotype and 
immunosenescence of CD4+ T-cells in RA.  
The impaired proliferative response of RA CD4+ T-cells conflicts with the data presented in 
this chapter, which show similar levels of proliferation compared to healthy controls, Figure 
54. The difference in proliferation seen may be due to the use of different cell populations or 
difference of patient groups used for the study of proliferation. For example, many of these 
papers involved the stimulation of CD4+ T-cells in a PBMC culture and the presence of other 
cells in this system may be contributing to the suppression of CD4+ T-cell proliferation. In this 
Chapter, total CD4+ T-cells were purified prior to anti-CD3 and anti-CD28 stimulation which 
limits the number of confounding factors in this system. A number of papers also involved the 
recruitment of patients presenting with arthritis flare and patients on a range of 
immunomodulatory treatments. This contrasts with the patients used in this Chapter, which 
were drug naïve early RA patients, which may explain the difference of the ability of CD4+ T-
cells to proliferate.  
The similar levels of proliferation of early RA patients and healthy controls is contrary to the 
effect predicted as a result of IL-6 pre-exposure evidenced by increased proliferation, Chapter 
4.3.3. One explanation for this is that the IL-6 stimulus used in the in vitro model is much 
greater than the levels seen in disease. Although this was optimised in Chapter 4 to be the 
concentration which was found at physiologically relevant levels to disease while still resulting 
in differences to effector phenotype this concentration may not reflect actual physiological 
functional levels and the levels of IL-6 in the serum of these patients was found not to correlate 
with the level of proliferation of CD4+ T-cells. This may be because these patients have already 
developed active disease so have high levels of inflammation and a range of other cytokines 
may be present. Another reason for this may be due to the high levels of sgp130 found in the 
serum of early RA patients, which acts as an inhibitor of the IL-6 signalling pathway. Despite 
100-500pg/ml being physiologically measurable, it may be that once the IL-6-sIL-6R complex 
binds to sgp130 this pathway is turned off resulting in functionally lower levels. In addition, 
the CD4+ T-cells from these patients will have already encountered antigen in vivo hence will 
have already undergone activation. Furthermore, work in Chapter 4 was carried using naïve 
188 
 
CD4+ T-cells whereas in early RA patients total CD4+ T-cells were used for measurement of 
proliferation. Due to the differences in sensitivity to IL-6 seen between naïve and memory CD4+ 
T-cells differences in response to IL-6 between naïve and total CD4+ T-cells would be expected 
which may in part explain the lack of difference seen between early RA and healthy controls.  
The limited number of early RA patients recruited for proliferation analysis in this Chapter 
mean this data has low statistical power with the possibility of overestimating effect size 
meaning that it is not possible to draw firm conclusions regarding the proliferative capacity of 
early RA CD4+ T-cells (527). For this data to have more statistical power more patients would 
need to be recruited which was not possible in the time frame of this project. Analysis of ex 
vivo CD4+ T-cells carried out previously with the group (Amy Anderson, unpublished data). 
show increased expression of ki-67 in RA CD4+ T-cells compared to healthy controls further 
indicating increased CD4+ T-cell proliferation in early RA, Figure 62. This increase in ki67 
expression in ex vivo CD4+ T-cells from early RA patients would suggest CD4+ T-cells from 
early RA do have increased proliferative capacity which may result from pre-exposure to IL-6 
in vivo. 
 
Finally, CSA patients, representing the “pre-RA” state appear to have a trend for higher 
percentage of dividing cells and have slightly higher number of divisions. However, as 
previously mentioned this only represents a limited number of patients. Due to the rarity of 
these patients presenting in the clinic the recruitment of these patients was slow and ideally 
more patients would be recruited for further investigation. 
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Figure 62. Early RA patient CD4+ T-cells express higher ki67 than healthy controls. 
PBMC were isolated from peripheral blood of healthy controls (HC) and early drug-naïve RA 
patients (eRA). Ki67 expression in CD4+ T-cells was assessed by flow cytometry. *** p<0.001 
calculated with Mann Whitney test. HC n = 48; eRA n = 25. Figure from Dr Amy Anderson, 
Newcastle University. 
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The reason for a trend for increased CD4+ T-cell proliferation in CSA and not in early RA 
compared to healthy controls, may be that CSA patients have not developed as severe joint 
inflammation. At this pre-RA stage there may be less other pro-inflammatory cytokines present 
and cells may be in a less activated state meaning the effects of IL-6 can be more closely seen. 
Another reason for the difference in proliferation between CSA and early RA patients may be 
due to the different cell types used. As in the in vitro model naïve CD4+ T-cells were used for 
analysis of the proliferation in CSA patients. These cells will be undergoing primary stimulation 
compared to early RA CD4+ T-cells which contain previously in vivo stimulated memory CD4+ 
T-cells. The restimulation of these memory CD4+ T-cells may account for their reduced 
proliferation compared to naïve CD4+ T-cells of CSA patients. Further characterisation of CSA 
and early RA CD4+ T-cell proliferation is required to further elucidate the effect of IL-6 in these 
cells.  
When CSA naïve CD4+ T-cells pre-exposed to IL-6 for 3 days were TCR stimulated there was 
only limited effect of IL-6 on the levels of cell proliferation.  One possible explanation for this 
is that these patients may have higher basal levels of IL-6 which will serve as the “pre-exposure” 
stage. Another potential reason for the unresponsiveness of these cells to IL-6 pre-exposure is 
their high level of activation. Immediately following TCR stimulation cells have decreased 
expression of IL-6R and gp130 and the decrease in expression of these receptors may explain 
their apparent insensitivity to further IL-6 stimulation, however, the expression of these 
receptors on CSA CD4+ T-cells was not measured. The levels of IL-6 in the serum of these 
patients was assessed and a trend was seen for increasing concentrations of IL-6 with higher 
levels of proliferation of naïve CD4+ T-cells. This mirrors the effect of IL-6 pre-exposure on 
naïve CD4+ T-cell proliferation in the in vitro model (Chapter 4).  
6.4.3 IL-6 mediated gene expression in early RA CD4+ T-cells  
In this Chapter it was seen that basal CD4+ T-cells isolated from early RA patients had increased 
expression of a number of genes up-regulated by prolonged exposure to IL-6 identified using 
an in vitro model (Chapter 5). Early RA patients have been shown to have differential 
expression of STAT-3 regulated genes which correlate with serum IL-6 levels (431). The 
presence of these chronic IL-6 regulated genes further suggests high levels of IL-6 in the 
circulation of these patients mediating differential gene expression. It was also seen that there 
was a trend for the increased expression of certain genes differentially expressed as a 
consequence of IL-6 pre-exposure followed by TCR stimulation although this did not reach 
significance.  
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The genes that were chosen for real-time PCR analysis were chosen on the basis of log fold 
change and p value. However, there were 267 genes differentially expressed in naïve CD4+ T-
cells following 72-hours chronic exposure to IL-6 compared to the untreated condition and 123 
genes differentially expressed following IL-6 pre-exposure and then 4-hours TCR stimulation 
compared to non-pre-exposed cells. Time restrictions meant more genes could not be further 
investigated, however, it is possible that many more genes may be differentially expressed in 
early RA compared to healthy controls both pre- and post- TCR stimulation and this would be 
an interesting field of further investigation. 
All genes investigated involved the culture of healthy controls with 0.5ng/ml IL-6 with or 
without TCR stimulation as a positive control to confirm that expression of these genes are 
altered as a consequence of IL-6 pre-exposure providing technical validation of the system. All 
genes were significantly induced by 72 hours culture with IL-6 compared to untreated healthy 
controls suggesting a direct role for IL-6 in expression of these genes, Figure 58.  
Genes found in Chapter 5.3.4 to be differentially expressed by prolonged IL-6 exposure were 
found to show a trend for increased expression in early RA patients compared to healthy 
controls, with two of these genes reaching statistical significance. On the other hand expression 
of these genes in CSA patients were similar to that of healthy controls which was unexpected 
as changes in gene expression would be expected to correlate with the enhanced level of 
proliferation seen. Expression levels of these genes in established RA vary and are generally 
higher than healthy controls but lower than early RA, indicating treatment may alter IL-6 levels. 
These results conflict with proliferation which was seen to be similar to healthy controls in early 
RA CD4+ T-cells but increased in CSA patients compared to controls. This suggests that the 
genes selected for validation were not directly relevant to proliferative response of CD4+ T-
cells.  
In contrast, no strong conclusions can be drawn from the expression of genes induced 4 hours 
post-TCR stimulation. As the positive control for this experiment, IL-6 pre-exposed naïve CD4+ 
T-cells followed by 4 hour TCR stimulation, only resulted in the differential expression of only 
2 out of the 4 genes shown to be differentially expressed 4 hours post-TCR stimulation with IL-
6 pre-exposure, this experiment requires further validation, Figure 61.    
This in vitro system is a reductionist approach to a highly complex in vivo situation and assumes 
a prior IL-6 pre-exposure period is occurring in vivo, which needs to be confirmed by analysis 
of IL-6 levels in serum. Realistically the in vivo situation is much more complex with many 
other cytokines and other soluble mediators, such as sgp130, which may alter the ability of IL-
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6 to induce subsequent gene expression following TCR stimulation. More optimisation of this 
complex model would be required in order to delineate the effects of IL-6 pre-exposure on early 
RA gene expression. Alternatively, sampling the population at baseline and subsequently 4 
hours post-TCR stimulation to assess the expression of genes at each time-point would provide 
the relative induction of each gene for both the untreated and IL-6 pre-exposed cells. This 
analysis would take into account potential differences in basal gene expression, which may be 
different in early RA compared to healthy controls, despite similar levels of final expression.  
To summarise early RA patients have increased expression of a number of genes identified 
following prolonged exposure to IL-6 and potential induction of genes differentially induced 
post-TCR stimulation highlighting IL-6 pre-exposure as an event in early RA.  
6.4.4 Summary  
In conclusion, this Chapter demonstrates that early RA patients have high levels of expression 
of a number of genes shown to be differentially expressed as a result of IL-6 pre-exposure in 
vitro. This confirms the up-regulation of IL-6 mediated STAT-3 signalling in early RA. Some 
of the consequences of IL-6 pre-exposure on healthy control naïve and memory CD4+ T-cells 
can be seen to be reflected in the phenotype of early RA CD4+ T-cells, such as increased Ki67 
and increased expression of IL-6 induced genes. This is consistent with an important role for 
IL-6 mediated STAT-3 signalling early in the pathogenesis of RA.  
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Chapter 7. General discussion and future work 
 
The work outlined in this thesis extends upon previous findings which highlight IL-6 mediated 
STAT-3 signalling as an important event in the earliest stages of RA pathogenesis; which, 
through transcriptional imprinting may programme aberrant effector responses of naïve and/or 
memory CD4+ T-cells (427, 431).  
7.1 Differential expression of IL-6 signalling receptors 
It was previously suggested that naïve CD4+ T-cells were more sensitive to circulating IL-6 
than their memory CD4+ T-cell counterparts, evidenced by their strong correlation between 
circulating IL-6 levels and activated phosphorylated STAT-3 (427). The assessment of 
expression of IL-6 receptors on CD4+ T-cell subsets revealed maximal  expression of the β 
subunit, signalling  receptor gp130 on naïve CD4+ T-cells compared to both central and effector 
memory CD4+ T-cells. In contrast, IL-6R, the α subunit, was shown to be lowest on naïve CD4+ 
T-cells and highest on central memory CD4+ T-cells, those which display reduced sensitivity 
to IL-6. These observations suggest that expression of IL-6 receptor subunits could be linked 
to the antigen experience of the T-cell, providing further insight to previous descriptions of 
receptor expression (368, 528).  
As previously described the sIL-6R can be found in excess of IL-6 in circulation, therefore 
increased expression of gp130 of naïve CD4+ T-cells provides a potential mechanism for 
increased IL-6 trans signalling (rather than classical signalling) as the mediator of STAT-3 
signalling in these cells. The trans signalling pathway of IL-6 has been linked to the pathogenic 
features of the IL-6 signalling pathway and has been shown to play an important role in the 
development of numerous immune-mediated inflammatory diseases, suggesting that in early 
RA naïve CD4+ T-cells may be driving pathogenic cell types with consequences relevant to RA 
pathogenesis (291, 456, 529). 
The absence of sIL-6R during IL-6 pre-exposure resulting in similar levels of proliferation 
following TCR stimulation, hamper the hypothesis that IL-6 pre-exposure is mediated by IL-6 
trans signalling. Therefore further investigation into the contributions of classical and trans 
signalling, by blocking of membrane bound IL-6R or partial blocking of gp130, in the effects 
of IL-6 exposure should be further explored.   
7.2 IL-6 pre-exposure results in pathogenic phenotype 
The presence of IL-6 and also its presence during activation has been shown to mediate effects 
such as decreased cell death, enhanced proliferation and numerous consequences on T-helper 
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cell differentiation (530). This is the first study to show that cytokine “priming” of naïve CD4+ 
T-cells in the circulation, often predating the clinical onset of RA, has the ability to programme 
hyper-proliferation, activation and a propensity towards Th1 differentiation upon subsequent 
antigen encounter, even when this occurs in the tissue where IL-6 may no longer dominate 
(531). Despite the known effect of IL-6 on cell survival, an influence of IL-6 pre-exposure on 
cell viability was not observed, Chapter 4.3.1, suggesting the effect of this cytokine on cell 
survival requires the presence of IL-6.  
Increased proliferation seen with IL-6 pre-exposure may contribute to the hyper-proliferative 
phenotype of CD4+ T-cells in early RA leading to accumulation of cells within the joint. 
Increased activation of these cells may contribute to the recruitment and activation of further 
immune cell subsets. The increased production of IFN-γ from Th1 cells may drive the activation 
of inflammatory M1 macrophages which further drive inflammation and joint destruction. The 
effects of IL-6 pre-exposure on T-helper differentiation opposes the reported roles of IL-6 upon 
T-helper differentiation however these may depend upon continuous availability of IL-6 during 
stimulation and the presence of other mediators such as. TGF-β (364, 474, 532). Despite the 
debate surrounding these cytokines in the involvement of RA, IL-6 pre-exposure may 
potentially alter the balance of these subsets with important implications for disease 
progression.  
7.3 IL-6 pre-exposure reveals significant changes in gene expression 
The observation of increased sensitivity of naïve CD4+ T-cells was further confirmed at the 
transcriptional level. Furthermore, the transcriptional profile of IL-6 exposed naïve CD4+ T-
cells showed striking similarity to those genes previously observed to be differentially 
expressed between early RA and non-RA patients, providing strong evidence that IL-6 is a key 
driver of this gene signature in early RA (427, 431). Furthermore, the genes found to be 
differentially expressed post-TCR stimulation in IL-6 pre-exposed naïve CD4+ T-cells 
compared to untreated naïve CD4+ T-cells were enriched for those involved in pathways such 
as lymphocyte proliferation and survival, which reflect the hyper-proliferating effector 
phenotype of these cells.  
The consequences of IL-6 pre-exposure on effector phenotype and gene expression post-TCR 
stimulation highlight the possibility of cellular pre-programming via cytokine exposure as an 
important event in the inflammatory process. The prolonged exposure of CD4+ T-cells to pro-
inflammatory cytokines such as IL-6 may have the ability to cause cellular programming with 
consequences specifically relevant in the early disease setting. A potential mechanism for this 
event could be that prolonged exposure to cytokines may result in epigenetic changes, such as 
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DNA methylation, whereby the expression of certain genes is altered therefore affecting the 
proteins which are transcribed. This has the ability to unmask potential disease relevant 
expression quantitative trait loci (eQTLs), therefore influencing disease development or 
progression.  
7.4 Relevance of IL-6 pre-exposure in CD4+ T-cells from early RA  
No significant differences were seen in the phenotype of early RA CD4+ T-cells compared to 
healthy controls. In contrast, preliminary data from a limited number of CSA patients, who have 
joint pain but no obvious signs of inflammation, appear to proliferate to a slightly higher level 
than healthy controls and this level appears to show correlation with serum levels of IL-6. It is 
possible that the cytokine milieu is more complex in early RA and other circulating cytokines 
may be confounding the effects of IL-6 pre-exposure (531). However, it is also possible that in 
early RA the CD4+ T-cells have experienced a far longer period of chronic pre-exposure and 
subsequent activation. These CD4+ T-cells in early RA may then in fact be “exhausted” due to 
the increased level of cycling in vivo, indicated by the increased expression of ki67 in early RA 
patient CD4+ T-cells. This may explain why no difference in proliferative capacity can be seen 
upon ex vivo stimulation. It may also be the case that this exhaustion has not yet reached its 
peak in CSA.  
The model of IL-6 pre-exposure optimised in this thesis highlights the potential of an 
inflammatory cytokine, such as IL-6, as a surrogate autoantigen in those pre-disposed to RA, 
with a particularly prominent role for this mechanism in seronegative RA where disease 
relevant mechanisms of pathogenesis remain elusive, Figure 63. Those individuals genetically 
pre-disposed to RA, via HLA haplotype or a combination of SNPs, may undergo an 
environmental triggers such as an infection, resulting in the increased production of IL-6. In 
certain individuals this increased production of IL-6 may not be regulated, possibly due to SNPs 
affecting the IL-6 region or the hypo-methylation of the IL-6 promoter. This prolonged period 
of IL-6 exposure has the potential to programme naïve CD4+ T-cells in the periphery, via 
transcriptional imprinting. Following their migration to lymph nodes or lymphoid follicles in 
the joint these cells may be activated via the TCR following a second hit/ trigger and these cells 
have an aberrant effector phenotype where hyper-proliferation, activation and IFN-γ production 
drive inflammation, immune cell recruitment and activation and joint destruction.  
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This model may provide a potential experimental method of treatment stratification. The use of 
therapies which target IL-6 depend upon its well known role as a pro-inflammatory mediator in 
established disease (533). It is now being realised that IL-6 has a complex mechanism of 
signalling and a uniquely important role in early disease and as such this therapeutic strategy 
should now be reconsidered (221, 534, 535). The proliferation and activation of CD4+ T-cells 
both in absence and presence of IL-6 pre-exposure can be assessed alongside circulating IL-6 
levels to identify a particular “endotype” of patients, those for which IL-6 signalling blockade 
would prove to be maximally effective in treating disease. This provides potential justification 
for the treatment of such patients, with high circulating IL-6 levels, early in disease and 
potentially even prior to disease onset, with a biologic therapy such as IL-6 blockade as a first 
line treatment. This early stage of disease may be the correct phase at which this treatment 
Figure 63. Model of IL-6 pre-exposure in vivo. Chronic exposure to high levels of circulating 
IL-6, as seen in early RA, has the potential to programme naïve CD4+ T-cells in the periphery. 
These cells will then migrate to the lymph nodes or to lymphoid follicles in the joints where 
these cells are subsequently stimulated via the TCR. Following stimulation these cells then 
respond aberrantly with increased proliferation and high levels of activation, such as CD25 
and CD40L. Together this has the potential to exacerbate disease, providing a mechanism of 
antigen independent immune dysregulation. 
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should be used. Treatment with biologics at the correct disease stage, prior to joint degradation, 
means that other pathways in addition to inflammatory pathways will be targeted. For example, 
temporary IL-6 signal blockade during the preclinical phase of RA, tailored to target the trans 
signalling pathway, could reverse transcriptional imprinting in a time-dependent manner and 
alter disease progression (536). The targeting of disease relevant cellular dysregulation in a 
particular disease endotype provides the potential for a more tolerogenic rather than merely 
anti-inflammatory effect, with the potential to induce drug free remission.   
7.5 Future work  
The work outlined in this thesis opens up several areas for further investigation. 
7.5.1 Validation of the “post-TCR signature” 
Validation of the “4-hour post-TCR gene signature” following IL-6 pre-exposure is necessary 
before further analysis of these genes in arthritis patients can be carried out. The presence of 
the “4-hour post-TCR gene expression signature” was determined in Chapter 6.3.4 by real-time 
PCR analysis of pre-selected highly differentially expressed genes. Levels of expression of 
these genes were determined for several stages of disease and compared with healthy controls 
but no differences in expression of these genes was seen between these groups. Other candidate 
genes, such as those specifically identified as being involved in proliferative responses, would 
be worth investigating in these patient groups. To identify these genes for example TaqMan 
low density array (TLDA) or nanostring could be carried out on CD4+ T-cells of subgroups of 
arthritis patients to determine the expression of all 123 differentially expressed genes found in 
naïve CD4+ T-cells. These are techniques to identify specific genes of interest by the binding 
to corresponding probes. The expression of these genes could be measured in a number of early 
RA patients following 4 hour TCR-stimulation to determine the level of overlap of gene 
expression of early RA compared to IL-6 pre-exposed cells. This list could then be narrowed 
down to the most differentially expressed genes between early RA and healthy controls to 
produce an “IL-6 driven post-TCR gene signature”.  
7.5.2 Role of IL-6 in CSA   
The preliminary data showing a potential correlation of circulating IL-6 levels with levels of 
proliferation of CSA CD4+ T-cells, Chapter 6.3.2, highlights the role of IL-6 in the very earliest 
stages of RA. This is potentially important as it provides possible identification of a disease 
endotype in which IL-6 signalling is particularly important in disease pathogenesis. This then 
provides justification for the use of IL-6 targeting therapies in this group of individuals. This 
finding needs to be confirmed and further investigation is required to investigate the 
contribution of this mechanism at this early stage of disease.  
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7.5.3 Potential relevance of IL-2 signalling 
 IL-2 is a key cytokine in T-cell maintenance which supports proliferation and survival. IL-2 is 
produced by T-cells in response to TCR stimulation, with levels proportional to the strength of 
stimulation. IL-6 has also been shown to induce the production of IL-2 from T-cells which can 
then be used by the cells with rapid and steady turnover. Therefore, the role of IL-2 in the IL-6 
pre-exposure model requires further investigation. The consequences of IL-6 pre-exposure may 
occur as a direct result of IL-6 signalling or may occur indirectly by secondary signalling by 
IL-2 as IL-2 signalling causes the decreased expression of gp130 to prevent further IL-6 
signalling. In order to address this possibility levels of IL-2 in the supernatants of IL-6 pre-
exposed naïve CD4+ T-cells was assessed in Chapter 4.3.8, and it was seen that levels of IL-2 
are not increased significantly in the 0.5ng/ml IL-6 pre-exposed cells compared to untreated 
cells.. Due to the quick turnover of this cytokine and the dependence of CD4+ T-cells on this 
cytokine for survival. The influence of IL-2 in particular upon observations attributed to IL-6 
cannot be entirely excluded. The addition of an IL-2 blocking antibody will reveal how 
dependent the IL-6 pre-exposure model is on the presence of IL-2.  
7.5.4 Contributions of classical and trans signalling to the processes of IL-6 pre-exposure 
The expression of the gp130 signalling receptor on CD4+ T-cell subsets, Chapter 3.3.1, and its 
correlation with sensitivity to IL-6 signalling implicates the trans signalling pathway as the 
primary mechanism of the IL-6 pre-exposure effect. In contrast, in Chapter 4.3.3 the 
contributions of the classical and trans signalling pathways were briefly reviewed in terms of 
proliferative responses of naïve CD4+ T-cells. This revealed that even in the absence of sIL-6R 
increases in proliferation following IL-6 pre-exposure and subsequent TCR stimulation were 
still observed. Further work may therefore aim to assess the relative contributions of each of 
these signalling mechanisms to the consequences of IL-6 pre-exposure This could be assessed 
experimentally with the use of molecules such as sgp130Fc to specifically block the trans 
signalling pathway (264).  
7.5.5 Effector resistance to Treg suppression  
There is mixed evidence as to whether there is impaired function of Treg cells in RA. However, 
in several inflammatory diseases effector cells have been shown to become resistant to 
suppression by Tregs. A role for IL-6 mediated STAT-3 signalling has been outlined in these 
diseases and work highlighting the importance of the STAT-1/STAT-3 balance as a predictive 
biomarker of early RA further implicates the signalling pathway in early disease. Data presented 
herein indicates cells pre-exposed to IL-6 display increased levels of proliferation and activation 
displaying an increased propensity for pro-inflammatory cytokine production upon 
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differentiation under Th1 skewing conditions. This raises the hypothesis that elevated 
circulating IL-6 in the earliest phase of RA leads to STAT-3 mediated transcriptional pre-
programming of antigen inexperienced naïve CD4+ T-cells which, upon TCR stimulation, 
results in an effector phenotype resistant to Treg suppression. To test this hypothesis, healthy 
control Teff cells could be pre-exposed to IL-6 followed by co-cultured with allogenic Tregs in 
a suppression assay to assess the capacity of these cells to be suppressed. The ability of these 
cells to proliferate as well as expression of activation markers would be assessed to determine 
their resistance to suppression. It would be of further interest to carry out similar experiments 
using naïve CD4+ T-cells from early RA and tocilizumab treated RA patients to assess the 
relevance of this mechanism of IL-6 pre-exposure in disease pathogenesis. This may yield 
insight into a novel mechanism of immune tolerance loss in early RA. These readouts may then 
be a valuable tool in defining an “endotype” of early RA for those whom IL-6 signalling 
blockade may prove most effective in treating disease and potentially even inducing drug-free 
remission.  
7.6 Summary  
In conclusion a model to test the consequences of cytokine pre-exposure and their ability to 
pre-programme naïve and memory CD4+ T-cells has been developed. These findings indicate 
that pre-exposure of cells to IL-6 pre-programmes cells to respond aberrantly when faced with 
subsequent TCR stimulation. This aberrant response includes increased proliferation and 
activation and increased pro-inflammatory cytokine production on Th1 differentiation, 
providing a more pathogenic phenotype. My findings require further study, but could have 
implications both for pathogenic understanding of this heterogeneous disease, and for designing 
optimal IL-6 targeting strategies for its management.  
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Figure 1. Gating strategy for total CD4+ T-cell purity analysis. Total CD4+ T-cells were 
stained with purity panel of antibodies prior to acquisition on the flow cytometer. Cells were 
gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-A to gate lymphocytes. 
CD4+ T-cells were gated as CD3+CD4+.  
Figure 2. Gating strategy for naïve CD4+ T-cell purity analysis. Naïve CD4+ T-cells were 
stained with purity panel of antibodies prior to acquisition on the flow cytometer. Cells were 
gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-A to gate lymphocytes. 
CD4+ T-cells were gated as CD3+CD4+ and naïve CD4+ T-cells identified as CD4+CD45RA+. 
Gates were set based on the expression of CD45RA on whole CD4+ T-cells and transferred to 
naïve and memory populations. 
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Figure 3. Gating strategy for phenotype analysis of naïve and memory CD4+ T-cells. 
Naïve or memory CD4+ T-cells were stained with phenotype panel of antibodies prior to 
acquisition on the flow cytometer. Cells were gated on SSC-A v SSC-W to exclude debris 
followed by SSC-A v FSC-A to gate lymphocytes. CD4+ T-cells were gated as CD3+CD4+. 
Gates of phenotypic markers were set based on the expression of the marker on whole CD4+ 
T-cells and transferred to naïve and memory populations. 
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Figure 4. Gating strategy for activation analysis of naïve and memory CD4+ T-cells. 
Naïve and memory CD4+ T-cells were stained with activation panel of antibodies prior to 
acquisition on the flow cytometer. Cells were gated on SSC-A v SSC-W to exclude debris 
followed by SSC-A v FSC-A to gate lymphocytes. Cells were further gated on DAPI- cells 
and CD4+ T-cells were gated as CD3+CD4+. Gates were set based on the unstained 
populations and transferred to fully stained populations. In the case of CD40L an FMO 
control was used. 
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Figure 5. Gating strategy for viability of naïve and memory CD4+ T-cells. Naïve or 
memory CD4+ T-cells were stained with DAPI and Annexin V prior to acquisition on the flow 
cytometer. Cells were gated on SSC-A v FSC-A to gate lymphocytes. Viable cells were DAPI-
Annexin V- , gated based on clear positive and negative populations. 
Figure 6. Gating strategy for intracellular cytokine staining of naïve and memory CD4+ 
T-cells. Naïve and memory CD4+ T-cells were stained with intracellular cytokine panel of 
antibodies prior to acquisition on the flow cytometer. Cells were gated on SSC-A v SSC-W 
to exclude debris followed by gating viable zombie aqua negative cells and SSC-A v FSC-
A to gate lymphocytes. CD4+ T-cells were gated as CD3+CD4+. Gates were set based on the 
BFA only controls and transferred to naïve PMA/ionomycin stimulated populations. 
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Figure 7. Gating strategy for transcription factor staining of naïve and memory CD4+ 
T-cells. Naïve and memory CD4+ T-cells were stained with transcription factor panel of 
antibodies prior to acquisition on the flow cytometer. Cells were gated on SSC-A v SSC-
W to exclude debris followed by gating on viable zombie aqua negative cells and SSC-A 
v FSC-A to gate lymphocytes. CD4+ T-cells were gated as CD3+CD4+. Gates were set on 
an unstained population and transferred to fully stained naïve and memory populations. 
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Figure 8. Gating strategy for whole blood phenotype staining of naïve and memory CD4+ T-
cells. Whole blood was stained with a panel of antibodies prior to acquisition on the flow cytometer. 
Cells were gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-A to gate 
lymphocytes. CD4+ T-cells were gated as CD3+CD4+. True naïve CD4+ T-cells were identified as 
CD45RA+CD62L+, central memory CD4+ T-cells were identified as CD45RA-CD62L+ and effector 
memory CD4+ T-cells were identified as CD45RA-CD62L-. Gates were set based on the expression 
of IL-6R and gp130 on internal negative controls and transferred to naïve and memory populations. 
207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Expression of IL-6R on CD4+ T-cell subsets of early arthritis patients. Whole 
blood of early RA patients was stained for flow cytometry with a panel of antibodies to detect 
cell surface expression of IL-6R, using the IL-6R-CFS antibody recognising the 17506 clone. 
Cells were gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-A to gate 
lymphocytes. CD4+ T-cells were identified as CD3+CD4+ and from this population true naïve 
cells were identified as CD45RA+CD62L+, central memory cells identified by CD45RA-
CD62L+ and effector memory cells identified as CD45RA-CD62L-. Horizontal bars represent 
the median value and significance was determined by non-parametric analysis of variance 
(Kruskal-Wallis) with Dunn’s posthoc pairwise analyses: ***p<0.0001. N=27. 
 
Figure 10. Surface marker expression of IL-6 treated and IL-6 with equimolar sIL-6R 
treated naïve CD4+ T-cells following 3 day culture. Freshly isolated naïve CD4+ T-cells were 
cultured for 3 days in TexMACS with 50ng/ml IL-6 or with 50ng/ml with equimolar sIL-6R. 
After 3 days cells were stained for cell surface markers for flow cytometry. Cells were gated as 
singlets, lymphocytes and then CD4+ T-cells were identified as CD3+CD4+, naïve CD4+ T-cells 
were identified as CD4+CD45RA+ and memory CD4+ T-cells identified as CD4+CD45RA-. 
 N= 1.  
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Figure 11. Expression of cell surface markers over 3 days culture with increasing 
concentrations of IL-6. Freshly isolated naïve CD4+ T-cells were cultured for 3 days in 
TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6, 5ng/ml or 50ng/ml IL-6 all with 
equimolar sIL-6R. Cells were stained with phenotype panel of antibodies prior to acquisition 
on the flow cytometer. Cells were gated on SSC-A v SSC-W to exclude debris followed by 
SSC-A v FSC-A to gate lymphocytes. CD4+ T-cells were gated as CD3+CD4+. N=1 
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Figure 12. Cytokine production of naïve CD4+ T-cells after 3 days exposure to 
increasing concentrations of IL-6. Freshly isolated naïve CD4+ T-cells were cultured for 
3 days in TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6, 5ng/ml or 50ng/ml IL-6 all 
with equimolar sIL-6R. After 3 days supernatants were harvested and IFN, IL-10, IL-5 and 
IL-17 ELISA carried out. Results only obtained for IL-10. N=3. 
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Figure 14. Examination of cell subsets in naïve CD4+ T-cell proliferation assay. 
Freshly isolated CFSE labelled naive CD4+ T-cells were cultured for 3 days with, 0.5ng/ml 
IL-6 with equimolar sIL-6R. After exposure to IL-6 naïve CD4+ T-cells were washed and 
stimulated with 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following 
stimulation cells were stained with naïve purity panel of antibodies and acquired on the 
flow cytometer. Data analysed on FlowJo to give % of cells divided.  
Figure 13. Percentage of viable cells over 6-day culture alone or with IL-6. Freshly 
isolated naïve CD4+ T-cells were cultured for 6 days in TexMACS alone or with 50ng/ml 
IL-6. Cells were stained with DAPI and Annexin V prior to acquisition on the flow 
cytometer. Cells were gated on SSC-A v FSC-A to gate lymphocytes. Viable cells were 
DAPI-Annexin V- .  
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Figure 15. Proliferation of naive CD4+ T-cells following different lengths of pre-
exposure to IL-6 and subsequent TCR stimulation. Freshly isolated CFSE memory naive 
CD4+ T-cells were cultured for 1 hour (A), 16 hours (B), 48 hours (C) or 72 hours (D) in 
TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 50ng/ml IL-6 all with equimolar sIL-
6R. After exposure to IL-6 naïve CD4+ T-cells were washed and stimulated with  a high 
stimulus; 1μg/ml anti-CD3 and 5μg/ml anti-CD28 or a low stimulus of 0.5μg/ml anti-CD3 
and 1μg/ml anti-CD28 for a further 6 days. Following stimulation cells were acquired on the 
flow cytometer. Data analysed on FlowJo to give % of cells divided. Mean values were 
plotted with error bars representing SEM. Significance of each cell type and stimulus was 
determined by non-parametric analysis of variance (Friedman) with Dunn’s posthoc pairwise 
analyses for individual IL-6 concentrations. N=3. 
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Figure 16. Proliferation of memory CD4+ T-cells following different lengths of pre-
exposure to IL-6 and subsequent TCR stimulation. Freshly isolated CFSE memory naive 
CD4+ T-cells were cultured for 1 hour (A), 16 hours (B), 48 hours (C) or 72 hours (D) in 
TexMACS alone, with 0.1ng/ml IL-6, 0.5ng/ml IL-6 or 50ng/ml IL-6 all with equimolar sIL-
6R. After exposure to IL-6 naïve CD4+ T-cells were washed and stimulated with  a high 
stimulus; 1μg/ml anti-CD3 and 5μg/ml anti-CD28 or a low stimulus of 0.5μg/ml anti-CD3 and 
1μg/ml anti-CD28 for a further 6 days. Following stimulation cells were acquired on the flow 
cytometer. Data analysed on FlowJo to give % of cells divided. Mean values were plotted with 
error bars representing SEM. Significance of each cell type and stimulus was determined by 
non-parametric analysis of variance (Friedman) with Dunn’s posthoc pairwise analyses for 
individual IL-6 concentrations. N=3. 
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Figure 17. Activation marker expression of naive CD4+ T-cells following 3 days pre-
exposure to IL-6 and subsequent 6 day TCR stimulation. Freshly isolated CFSE labelled 
naive CD4+ T-cells were cultured for 3 days in TexMACS alone or with 0.5ng/ml IL-6 with 
equimolar sIL-6R. Naïve CD4+ T-cells were washed and stimulated with a low stimulus of 
0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following stimulation cells were 
stained with activation marker panel of antibodies and acquired on the flow cytometer. Cells 
were gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-A to gate 
lymphocytes. CD4+ T-cells were gated as CD3+CD4+. 
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Figure 18. Cytokine production of naive CD4+ T-cells following 3 days pre-exposure to 
IL-6 and subsequent 6 day TCR stimulation. Freshly isolated CFSE naive CD4+ T-cells 
were cultured for 3 days in TexMACS alone or with 0.5ng/ml IL-6 with equimolar sIL-6R. 
After exposure to IL-6 naïve CD4+ T-cells were washed and stimulated with a low stimulus 
of 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. Following stimulation cells 
were stained with intracellular cytokine panel of antibodies and acquired on the flow 
cytometer. Cells were gated on SSC-A v SSC-W to exclude debris followed by SSC-A v FSC-
A to gate lymphocytes. CD4+ T-cells were gated as CD3+CD4+. 
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Figure 19. Transcription factor expression of naive CD4+ T-cells following 3 days pre-
exposure to IL-6 and subsequent 6 day TCR stimulation. Freshly isolated CFSE naive 
CD4+ T-cells were cultured for 3 days in TexMACS alone or with 0.5ng/ml IL-6 with 
equimolar sIL-6R. After exposure to IL-6 naïve CD4+ T-cells were washed and stimulated 
with a low stimulus of 0.5μg/ml anti-CD3 and 1μg/ml anti-CD28 for a further 6 days. 
Following stimulation cells were stained with intracellular cytokine panel of antibodies and 
acquired on the flow cytometer. Cells were gated on SSC-A v SSC-W to exclude debris 
followed by SSC-A v FSC-A to gate lymphocytes. CD4+ T-cells were gated as CD3+CD4+. 
216 
 
 
 
  
Figure 20. Cytokine production of CD4+ T-cells with or without differentiation towards 
Th1. Freshly isolated naïve CD4+ T-cells were cultured for 3 days in TexMACS. After 3 days 
cells were washed and differentiated towards Th1 in IMDM +10% FCS for 6 days. Following 
differentiation cells were rested for 1-4 days before stimulation with PMA/ionomycin and 
staining for intracellular cytokines for flow cytometry. Cells were gated as singlets, 
lymphocytes and then CD4+ T-cells were identified as CD3+CD4+. The top panel shows Th1 
cells stimulated with BFA for controls, the second panel shows naïve CD4+ T-cells without 
skewing towards Th1, the third panel shows untreated Th1 cells and the bottom panel shows 
Th1 cells following IL-6 pre-exposure. 
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Figure 21. Cytokine production of CD4+ T-cells with or without differentiation towards 
Th2. Freshly isolated naïve CD4+ T-cells were cultured for 3 days in TexMACS. After 3 days 
cells were washed and differentiated towards Th2 in IMDM +10% FCS for 6 days. Following 
differentiation cells were rested for 1-4 days before stimulation with PMA/ionomycin and 
staining for intracellular cytokines for flow cytometry. Cells were gated as singlets, 
lymphocytes and then CD4+ T-cells were identified as CD3+CD4+. The top panel shows Th2 
cells stimulated with BFA for controls, the second panel shows naïve CD4+ T-cells without 
skewing towards Th2, the third panel shows untreated Th2 cells and the bottom panel shows 
Th2 cells following IL-6 pre-exposure. 
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Figure 22. Cytokine production of CD4+ T-cells with or without differentiation towards 
Th17. Freshly isolated memory CD4+ T-cells were cultured for 3 days in TexMACS. After 3 
days cells were washed and differentiated towards Th17 in IMDM +10% SR for 6 days. 
Following differentiation cells were rested for 1-4 days before stimulation with 
PMA/ionomycin and staining for intracellular cytokines for flow cytometry. Cells were gated 
as singlets, lymphocytes and then CD4+ T-cells were identified as CD3+CD4+. The top panel 
shows Th17 cells stimulated with BFA for controls, the second panel shows memory CD4+ 
T-cells without skewing towards Th17, the third panel shows untreated Th17 cells and the 
bottom panel shows Th17 cells following IL-6 pre-exposure. 
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Figure 23. Cytokine production of CD4+ T-cells with or without differentiation towards 
Tfh. Freshly isolated CD4+ T-cells were cultured for 3 days in TexMACS. After 3 days cells 
were washed and differentiated towards Tfh for 6 days. Following differentiation cells were 
rested for 1-4 days before stimulation with PMA/ionomycin and staining for intracellular 
cytokines for flow cytometry. Cells were gated as singlets, lymphocytes and then CD4+ T-
cells were identified as CD3+CD4+. The top panel shows Tfh cells stimulated with BFA for 
controls, the second panel shows CD4+ T-cells without skewing towards Tfh, the third panel 
shows untreated Tfh cells and the bottom panel shows Tfh cells following IL-6 pre-exposure. 
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Experiment Condition Total RNA 260:280 
Figure  Total CD4 
cytokine stimulation 
Donor 1 
1hr Untreated 95.5 1.97 
 1hr IL-6 108 1.95 
 1hr TNF 105.5 1.93 
 1hr IFN 121 1.96 
 1hr IL-21 109.7 1.93 
 6hr Untreated 117.7 1.93 
 6hr IL-6 115.3 1.96 
 6hr TNF 114.2 1.99 
 6hr IFN 111.2 1.99 
 6hr IL-21 93.6 1.96 
 24hr Untreated 102.3 2.01 
 24hr IL-6 108.8 2.01 
 24hr TNF 101 1.99 
 24hr IFN 102.3 1.98 
 24hr IL-21 98.7 1.98 
Figure  Total CD4 
cytokine stimulation 
donor 2 
1hr Untreated 2.9 1.95 
 1hr IL-6 30.6 1.89 
 1hr TNF 26.7 1.89 
 1hr IL-21 27.2 1.83 
 1hr IL-23 23.4 2.09 
 1hr IL-27 21.8 2.07 
 6hr Untreated 24.6 1.98 
 6hr IL-6 20.5 2.08 
 6hr TNF 26.6 1.99 
 6hr IL-21 17.6 2.41 
 6hr IL-23 15.8 2.13 
 6hr IL-27 24.4 1.7 
 24hr Untreated 31.7 1.79 
 24hr IL-6 31.1 1.77 
 24hr TNF 24.9 1.66 
 24hr IL-21 29.7 1.84 
 24hr IL-23 26.6 1.78 
 24hr IL-27 35.7 1.86 
Figure  total CD4 
cytokine stimulation 
donor 3 
6hr Untreated 24.6 1.98 
 6hr IL-6 20.5 2.08 
 6hr TNF 26.6 1.99 
 6hr IL-21 17.6 2.41 
 6hr IL-23 15.8 2.13 
 6hr IL-27 24.4 1.7 
Figure  total CD4 
cytokine stimulation 
donor 4 
1hr Untreated 25.2 1.99 
 1hr IL-6 32.6 1.85 
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 1hr TNF 21.2 1.99 
 1hr IL-21 38.6 1.82 
 1hr IL-23 47.5 1.72 
 1hr IL-27 40.9 1.74 
 6hr Untreated 28.2 1.89 
 6hr IL-6 28.9 2 
 6hr TNF 26.7 2.02 
 6hr IL-21 20.8 2.11 
 6hr IL-23 39.5 1.7 
 6hr IL-27 37.7 1.78 
 
 
 
 
Experiment Condition  Total RNA 260:280 
Donor 1 Naïve CD4+ 
T-cells 
Basal 57.3 1.99 
 6hr Untreated 107.8 1.58 
 6hr IL-6  65.4 1.8 
 72hr Untreated 95.2 1.58 
 72hr IL-6 78.9 1.75 
 4hr Untreated 117.2 1.59 
 4hr IL-6 91 1.76 
 16hr Untreated 70.7 1.85 
 16hr IL-6 80.5 1.78 
 6 day Untreated 68 1.84 
 6 day IL-6 92.1 1.96 
Donor 1 Memory 
CD4+ T-cells 
Basal  86.3 1.96 
 6hr Untreated  106.9 1.81 
 6hr IL-6 135.7 1.66 
 72hr Untreated 124.8 1.63 
 72hr IL-6 89.2 1.91 
 4hr Untreated 104 1.68 
 4hr IL-6 67.6 1.98 
 16hr Untreated  109.5 1.67 
 16hr IL-6 118.4 1.64 
 6 day Untreated 159.2 2.02 
 6 day IL-6 252.6 2.06 
Donor 2 Naïve CD4+ 
T-cells 
Basal 70.1 1.67 
 6hr Untreated 43.3 1.91 
 6hr IL-6 49.7 1.91 
Table 1. Amount of RNA and 260:280 ratios from cytokine stimulated total CD4+ T-cells. 
CD4+ T-cells were stimulated with various pro-inflammatory cytokines to analyse STAT-3 
target gene induction in Figure 24. 
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 72hr Untreated 42.5 1.91 
 72hr IL-6 45.5 1.9 
 4hr Untreated 126.8 1.52 
 4hr IL-6 57.2 1.89 
 16hr Untreated 98.2 1.58 
 16hr IL-6 50.1 1.89 
 6 day Untreated 89.1 1.94 
 6 day IL-6 130.9 1.89 
Donor 2 Memory 
CD4+ T-cells 
Basal 55.2 1.92 
 6hr Untreated 70.4 1.91 
 6hr IL-6 81.1 1.78 
 72hr Untreated 71.6 1.69 
 72hr IL-6 53 1.93 
 4hr Untreated  60 2.19 
 4hr IL-6 77.8 1.83 
 16hr Untreated 87.2 1.87 
 16hr IL-6 89.7 1.74 
 6 day Untreated 316.8 2.02 
 6 day IL-6 394.8 2.01 
Donor 3 Naïve CD4+ 
T-cells 
Basal  85.8 1.78 
 6hr Untreated 71.5 1.82 
 6hr IL-6 64.9 1.99 
 72hr Untreated 47.8 2.09 
 72hr IL-6 128.2 1.61 
 4hr Untreated 71 1.88 
 4hr IL-6 59.6 1.95 
 16hr Untreated  98.6 1.62 
 16hr IL-6 65 1.84 
 6 day Untreated 196.7 1.85 
 6 day IL-6 431.7 1.98 
Donor 3 Memory 
CD4+ T-cells 
Basal  13.1 1.82 
 6hr Untreated 23.6 1.53 
 6hr IL-6 55.6 1.51 
 72hr Untreated 22 1.54 
 72hr IL-6 33.1 1.47 
 4hr Untreated 47.9 1.48 
 4hr IL-6 34.1 1.67 
 16hr Untreated 59.8 1.54 
 16hr IL-6 28.8 1.65 
 6 day Untreated 18.6 2.02 
 6 day IL-6 61.8 1.98 
Donor 4 Naive CD4+ 
T-cells 
Basal 54.4 1.71 
 6hr Untreated 35.3 1.81 
 6hr IL-6 93.1 1.55 
 72hr Untreated 90.2 1.54 
 72hr IL-6 41.2 1.67 
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 4hr Untreated 42.8 1.64 
 4hr IL-6 70.8 1.57 
 16hr Untreated 96.2 1.54 
 16hr IL-6 48.2 1.72 
 6 day Untreated 65.5 1.43 
 6 day IL-6 26.2 1.49 
Donor 4 Memory 
CD4+ T-cells 
Basal 114.4 1.72 
 6hr Untreated 94.5 1.85 
 6hr IL-6 113.9 1.79 
 72hr Untreated 93.7 1.76 
 72hr IL-6 80.2 1.89 
 4hr Untreated 99.5 1.77 
 4hr IL-6 68.7 1.73 
 16hr Untreated 127.1 1.7 
 16hr IL-6 72.3 1.69 
 6 day Untreated 87.7 1.82 
 6 day IL-6 31.1 1.69 
 
 
 
 
 
 
 
 
 
 
Healthy donors for microarray  Age Sex 
Donor 1  40 Male 
Donor 2 25 Male 
Donor 3 24 Male 
Donor 4 37 Female 
Donor 5 38 Female 
Table 3. Characteristics of healthy donor samples used for microarray. Age and sex of 
healthy donors whose blood was taken for use in microarray.   
Table 2. Amount of RNA and 260:280 ratios from naïve and memory CD4+ T-cells 
samples for microarray. Naïve and memory CD4+ T-cells were isolated from healthy donors 
prior to culture as per the in vitro model with RNA taken at multiple experimental time-points. 
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